[
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_0",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: GUIDELINES FOR PREVENTING]\nHEALTH-CARE-ASSOCIATED PNEUMONIA, 2003\nRecommendations of CDC and the Healthcare Infection Control Practices \n Advisory Committee \nAccessible version: https://www.cdc.gov/infection-control/hcp/pneumonia-prevention/index.html \nPrepared By:\nOfelia C. Tablan, M.D.1\nLarry J. Anderson, M.D.2\nRichard Besser, M.D.3\nCarolyn Bridges, M.D.2\nRana Hajjeh, M.D.3\n1Division of Healthcare Quality Promotion, National Center for Infectious Diseases , CDC\n2Division of Viral and Rickettsial Diseases, NCID, CDC\n3Division of Bacterial and Mycotic Diseases, NCID, CDC\nThe material in this report originated in the National Center for Infectious Diseases, James M. Hughes, M.D., Director,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "GUIDELINES FOR PREVENTING",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 0,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_1",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Division of Healthcare Quality Promotion, Denise M. Cardo, M.D., Director, and the Division of Bacterial and Mycotic \nDiseases, Mitchell L. Cohen, M.D., Director.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "GUIDELINES FOR PREVENTING",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 1,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_2",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: HEALTHCARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE]\nChair: Robert A. Weinstein, M.D., Cook County Hospital, Chicago, Illinois\nCo-Chair: Jane D. Siegel, M.D., University of Texas Southwestern Medical Center, Dallas,\n  Texas\nExecutive Secretary: Michele L. Pearson, M.D., CDC, Atlanta, Georgia\nMembers: Raymond Y.W. Chinn, M.D., Sharp Memorial Hospital, San Diego, California; Alfred DeMaria, Jr., \nM.D., Massachusetts Department of Public Health, Jamaica Plains, Massachusetts; Elaine L. Larson, R.N., Ph.D.,\nColumbia University School of Nursing, New York, New York; James T. Lee, M.D.,Ph.D., Veterans Affairs\nMedical Center, University of Minnesota, St. Paul, Minnesota; Ramon E. Moncada, M.D.,Coronado Physician’s",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTHCARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 2,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_3",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Medical Center Coronado, California; William A. Rutala, Ph.D.; University of North Carolina School of\nMedicine, Chapel Hill, North Carolina; William E. Scheckler, M.D.; University of Wisconsin Medical School,\nMadison, Wisconsin; Beth H. Stover, Kosair Children’s Hospital, Louisville, Kentucky; Marjorie Underwood,\nMt. Diablo Medical Center, Concord, California.\nLiaison Representatives: Loretta L. Fauerbach, M.S., CIC, Association for Professionals of Infection Control and \nEpidemiology, Inc., Shands Hospital at University of Florida, Gainesville, Florida; Sandra L. Fitzler, R.N., \nAmerican Healthcare Association, Washington, D.C.; Dorothy M. Fogg, R.N., B.S.N., M.A., Association of \nperiOperative Registered Nurses, Denver, Colorado; Stephen F. Jencks, M.D., M.P.H., Center for Medicare and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTHCARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 3,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_4",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Medicaid Services, Baltimore, Marynalnd; Chiu S. Lin, Ph.D., Food and Drug Administration, Rockville, \nMaryland; James P. Steinberg, Society for Healthcare Epidemiology of America, Inc., Crawford Long Hospital, \nAtlanta, Georgia; Michael L. Tapper, M.D., Advisory Committee for the Elimination of Tuberculosis, Lennox Hill \nHospital, New York, New York.\n1",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTHCARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 4,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_5",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 2\nCONTENTS]\nSummary .............................................................................................................................3\nIntroduction .........................................................................................................................4\nKey terms used in the guidelines ....................................................................................... 5\nAbbreviations used in the guidelines ..................................................................................5\nPart I.  Background\nHealth-care-associated bacterial pneumonia ...........................................................7\nHealth-care-associated legionnaires disease .........................................................25",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 5,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_6",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Health-care-associated pertussis ...........................................................................32\nHealth-care-associated aspergillosis......................................................................36\nHealth-care-associated viral infections..................................................................42\nHealth-care-associated respiratory syncytial virus infection..................................43\nHealth-care-associated parainfluenza infection......................................................47\nHealth-care-associated adenovirus infection..........................................................48\nHealth-care-associated influenza............................................................................50",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 6,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_7",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Severe acute respiratory syndrome.........................................................................55\nPart II. Recommendations\nCategorization of recommendations.......................................................................56\nPrevention and control of health-care-associated bacterial pneumonia..................57\nPrevention and control of health-care-associated legionnaires disease...................68\nPrevention and control of health-care-associated pertussis.....................................75\nPrevention and control of health-care-associated aspergillosis...............................79\nPrevention and control of health-care-associated respiratory syncytial virus,\n parainfluenza and adenovirus infections....................................................84",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 7,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_8",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "parainfluenza and adenovirus infections....................................................84\nPrevention and control of health-care-associated influenza....................................90\nSevere acute respiratory syndrome..........................................................................95\nPart III. Performance indicators...........................................................................................95\nReferences............................................................................................................................96\nAppendix............................................................................................................................179\n3\nSummary\nThis report updates, expands, and replaces the previously published CDC \"Guideline for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 8,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_9",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "3\nSummary\nThis report updates, expands, and replaces the previously published CDC \"Guideline for\nPrevention of Nosocomial Pneumonia”. The new guidelines are designed to reduce the incidence\nof health-care-associated pneumonia and other severe, acute lower respiratory tract infections in\nacute-care hospitals and in other health-care settings (e.g., ambulatory and long-term care\ninstitutions) and other facilities where health care is provided. \nAmong the changes in the recommendations to prevent bacterial pneumonia, especially\nventilator-associated pneumonia, are the preferential use of oro-tracheal rather than naso-\ntracheal tubes in patients who receive mechanically assisted ventilation, the use of noninvasive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 9,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_10",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tracheal tubes in patients who receive mechanically assisted ventilation, the use of noninvasive\nventilation to reduce the need for and duration of endotracheal intubation, changing the\nbreathing circuits of ventilators when they malfunction or are visibly contaminated, and (when\nfeasible) the use of an endotracheal tube with a dorsal lumen to allow drainage of respiratory\nsecretions; no recommendations were made about the use of sucralfate, histamine-2  receptor\nantagonists, or antacids for stress-bleeding prophylaxis. For prevention of health-care-associated\nLegionnaires disease, the changes include maintaining potable hot water at temperatures not\nsuitable for amplification of Legionella spp., considering routine culturing of water samples from",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 10,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_11",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "suitable for amplification of Legionella spp., considering routine culturing of water samples from\nthe potable water system of a facility’s organ-transplant unit when it is done as part of the\nfacility’s comprehensive program to prevent and control health-care-associated Legionnaires\ndisease, and initiating an investigation for the source of Legionella spp. when one definite or one\npossible case of laboratory-confirmed health-care-associated Legionnaires disease is identified\nin an inpatient hemopoietic stem-cell transplant (HSCT) recipient or in two or more HSCT\nrecipients who had visited an outpatient HSCT unit during all or part of the 2-10 day period\nbefore illness onset. In the section on aspergillosis, the revised recommendations include the use",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 11,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_12",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "before illness onset. In the section on aspergillosis, the revised recommendations include the use\nof a room with high-efficiency particulate air filters rather than laminar airflow as the protective\nenvironment for allogeneic HSCT recipients, and the use of high-efficiency respiratory-protection\ndevices (e.g., N95 respirators) by severely immunocompromised patients when they leave their\nrooms when dust-generating activities are ongoing in the facility. In the respiratory syncytial\nvirus (RSV) section, the new recommendation is to determine, on a case-by-case basis, whether to\nadminister monoclonal antibody (palivizumab) to certain infants and children aged <24 months\nwho were born prematurely and are at high risk for severe RSV infection. In the section on",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 12,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_13",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "who were born prematurely and are at high risk for severe RSV infection. In the section on\ninfluenza, the new recommendations include the addition of oseltamivir (to amantadine and\nrimantadine) for prophylaxis of all patients without influenza illness and oseltamivir and\nzanamivir (to amantadine and rimantadine) as treatment for patients who are acutely ill with\ninfluenza in a unit where an influenza outbreak is recognized.\nIn addition to the revised recommendations, the guideline contains new sections on pertussis and\nlower respiratory tract infections caused by adenovirus and human parainfluenza viruses, and\nrefers readers to the source of updated information about prevention and control of severe acute\nrespiratory syndrome.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "2\nCONTENTS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 13,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_14",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 4\nINTRODUCTION]\nBecause of the high morbidity and mortality associated with health-care-associated pneumonia,\nseveral guidelines for its prevention and control have been published. The first CDC Guideline for\nPrevention of Nosocomial Pneumonia was published in 1981 and addressed the main infection-\ncontrol problems related to hospital-acquired pneumonia at the time: the use of large-volume\nnebulizers that were attached to mechanical ventilators and improper reprocessing (i.e., cleaning\nand disinfection or sterilization) of respiratory-care equipment. The document also covered the\nprevention and control of hospital-acquired influenza and respiratory syncytial virus (RSV)\ninfection.\nIn 1994, the Healthcare Infection Control Practices Advisory Committee (HICPAC) (then known",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 14,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_15",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "In 1994, the Healthcare Infection Control Practices Advisory Committee (HICPAC) (then known\nas the Hospital Infection Control Practices Advisory Committee) revised and expanded the CDC\nGuideline for Prevention of Nosocomial Pneumonia to include Legionnaires disease and pulmonary\naspergillosis (1). HICPAC advises the secretary of Health and the directors of CDC and the\nNational Center for Infectious Diseases about the prevention and control of health-care-associated\ninfections and related adverse events. The 1994 guideline addressed concerns related to preventing\nventilator-associated pneumonia (VAP) (e.g., the role of stress-ulcer prophylaxis in the causation\nof pneumonia and the contentious roles of selective gastrointestinal decontamination and periodic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 15,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_16",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of pneumonia and the contentious roles of selective gastrointestinal decontamination and periodic\nchanges of ventilator tubings in the prevention of the infection). The document also presented\nmajor changes in the recommendations to prevent and control hospital-acquired pneumonia due to\nLegionnella spp. and aspergilli. \nIn recent years, demand has increased for guidance on preventing and controlling pneumonia and\nother lower respiratory tract infections in health-care settings other than the acute-care hospital,\nprobably resulting in part from the progressive shift in the burden and focus of health care in the\nUnited States away from inpatient care in the acute-care hospital and towards outpatient and long-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 16,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_17",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "United States away from inpatient care in the acute-care hospital and towards outpatient and long-\nterm care in other health-care settings. In response to this demand, HICPAC revised the guideline\nto cover these other settings. However, infection-control data about the acute-care hospital setting\nare more abundant and well analyzed compared with those from long-term care, ambulatory, and\npsychiatric facilities and other health-care settings. \nThis publication is the complete three-part document, Parts II and III of which have been published\nrecently (2). Part I of the document provides the background for the recommendations and\nincludes a discussion of the epidemiology, diagnosis, pathogenesis, modes of transmission, and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 17,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_18",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "includes a discussion of the epidemiology, diagnosis, pathogenesis, modes of transmission, and\nprevention and control of the infections. Part I can be an important resource for educating health-\ncare personnel. Because education of health-care personnel is the cornerstone of an effective\ninfection control program, health-care agencies should give high priority to continuing infection-\ncontrol educational programs for their staff members. Part II contains the consensus HICPAC\nrecommendations for the prevention of the following infections: bacterial pneumonia, Legionnaires\ndisease, pertussis, invasive pulmonary aspergillosis (IPA), lower respiratory tract infections caused\nby RSV, parainfluenza and adenoviruses, and influenza. Lower respiratory tract infection caused",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 18,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_19",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "by RSV, parainfluenza and adenoviruses, and influenza. Lower respiratory tract infection caused\nby Mycobacterium tuberculosis is not addressed in this document, however; it is covered in a\n5\nseparate publication (3). HICPAC recommendations address such issues as education of health-\ncare personnel about the prevention and control of health-care-associated pneumonia and other\nlower respiratory tract infections, surveillance and/or reporting of diagnosed cases of infections,\nprevention of person-to-person transmission of each disease, and reduction of host risk for\ninfection. Part III provides suggested performance indicators to assist infection-control personnel\nin monitoring the implementation of the guideline recommendations in their facilities.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 19,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_20",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "in monitoring the implementation of the guideline recommendations in their facilities.\n    The document was prepared by CDC; reviewed by experts in infection control, intensive-care\nmedicine, pulmonology, respiratory therapy, anesthesiology, internal medicine, and pediatrics; and\napproved by HICPAC. The recommendations are endorsed by the American College of Chest\nPhysicians, American Health Care Association, Association for Professionals of Infection Control\nand Epidemiology, Infectious Diseases Society of America, Society for Healthcare Epidemiology\nof America, and Society of Critical Care Medicine.\nKey Terms Used In the Guidelines\nProtective environment (PE) is a specialized patient-care area, usually in a hospital, with a positive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 20,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_21",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "air flow relative to the corridor (i.e., air flows from the room to the outside adjacent space). The\ncombination of high-efficiency particulate air (HEPA) filtration, high numbers (>12) of air changes\nper hour (ACH), and minimal leakage of air into the room creates an environment that can safely\naccommodate patients with a severely compromised immune system (e.g., those who have\nreceived allogeneic hemopoietic stem-cell transplant [(HSCT]).\nImmunocompromised patients are those patients whose immune mechanisms are deficient because\nof immunologic disorders (e.g., human immunodeficiency virus [HIV] infection, congenital\nimmune deficiency syndrome, chronic diseases [e.g.,diabetes mellitus, cancer, emphysema, or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 21,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_22",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "immune deficiency syndrome, chronic diseases [e.g.,diabetes mellitus, cancer, emphysema, or\ncardiac failure], or immunosuppressive therapy [e.g., radiation, cytotoxic chemotherapy, anti-graft-\nrejection medication, steroids]). Immunocompromised patients who are identified as high-risk\npatients have the greatest risk for infection and include persons with severe neutropenia (i.e., an\nabsolute neutrophil count [ANC] of < 500 cells/mL) for prolonged periods of time, recipients of\nallogeneic HSCT, and those who receive the most intensive chemotherapy (e.g., patients with\nchildhood acute myelogenous leukemia).\nAbbreviations Used In the Guidelines\nACIP\nAdvisory Committee on Immunization Practices\nANC \nabsolute neutrophil count\nBAL\nbroncho-alveolar lavage\nCSF \ncerebrospinal fluid\nCOPD",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 22,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_23",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "ANC \nabsolute neutrophil count\nBAL\nbroncho-alveolar lavage\nCSF \ncerebrospinal fluid\nCOPD \nchronic obstructive pulmonary disease\nDFA\ndirect fluorescein-conjugated antibody\nDNA\ndeoxyribonucleic acid\n6\nDTP \ndiphtheria, tetanus and pertussis\nDTaP \ndiphtheria and tetanus toxoids and acellular pertussis\nEOP\nearly-onset pneumonia\nFDA \nFood and Drug Administration\nGCSF \ngranulocyte colony-stimulating factor\nGVHD\ngraft-versus-host disease\nHEPA\nhigh-efficiency particulate air \nHICPAC \nHealthcare Infection Control Practices Advisory Committee\nHIV \nhuman immunodeficiency virus\nHME \nheat-moisture exchanger\nHPIV\nhuman parainfluenza virus\nHSCT\nhemopoietic stem-cell transplant\nICU\nintensive care unit\nIGIV\nimmune globulin intravenous\nIHPS\ninfantile hypertrophic pyloric stenosis\nIPA",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 23,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_24",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "IGIV\nimmune globulin intravenous\nIHPS\ninfantile hypertrophic pyloric stenosis\nIPA\ninvasive pulmonary aspergillosis\nLAF\nlaminar airflow\nLAIV\nlive attenuated influenza vaccine\nLOP\nlate-onset pneumonia\nLTCFs\nlong-term care facilities\nNH\nnursing home\nNHAP\nnursing home-associated pneumonia\nNIV\nnoninvasive ventilation\nNNIS\nNational Nosocomial Infection Surveillance\nNPPV\nnoninvasive positive-pressure ventilation\npBAL\nprotected broncho-alveolar lavage\nPE\nprotective environment\nPCR\npolymerase chain reaction\nPSB\nprotected-specimen brush \nRNA\nribonucleic acid\nRSV\nrespiratory syncytial virus\nSARS\nsevere acute respiratory syndrome\nSDD\nselective decontamination of the digestive tract\nSOP\nstanding orders program\nTMP-SMZ\ntrimethoprim-sulfamethoxazole\nVAP\nventilator-associated pneumonia\n7",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 24,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_25",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "standing orders program\nTMP-SMZ\ntrimethoprim-sulfamethoxazole\nVAP\nventilator-associated pneumonia\n7\nPART I.    ISSUES ON PREVENTING HEALTH-CARE-ASSOCIATED\nPNEUMONIA, 2003",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "4\nINTRODUCTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 25,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_26",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA]\nI.  EPIDEMIOLOGY\nThe epidemiology of health-care-associated pneumonia varies considerably according to\nthe type of health-care setting.\nA.   Hospital-Associated (Nosocomial) Pneumonia\nPneumonia has accounted for approximately 15% of all hospital-associated infections and\n27% and 24% of all infections acquired in the medical intensive-care unit (ICU) and coronary care\nunit, respectively (4-6).  It has been the second most common hospital-associated infection after\nthat of the urinary tract (4;7).  The primary risk factor for the development of hospital-associated\nbacterial pneumonia is mechanical ventilation (with its requisite endotracheal intubation) (8).  The",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 26,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_27",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "CDC’s National Nosocomial Infection Surveillance System (NNIS) reported that in 2002, the\nmedian rate of VAP per thousand ventilator-days in NNIS hospitals ranged from 2.2 in pediatric\nICUs to 14.7 in trauma ICUs (9).  In other reports, patients receiving continuous mechanical\nventilation had 6-21 times the risk of developing hospital-associated pneumonia compared with\npatients who were not receiving mechanical ventilation (10-12).  Because of this tremendous risk,\nin the last two decades, most of the research on hospital-associated pneumonia has been focused\non VAP.  Other major risk factors for pneumonia have been identified in various studies; most of\nthese conditions usually coexist with mechanical ventilation in the same critically ill patients.  These",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 27,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_28",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "include a primary admitting diagnosis of burns, trauma, or disease of the central nervous system;\nthoraco-abdominal surgery; depressed level of consciousness; prior episode of a large-volume\naspiration; underlying chronic lung disease; >70 years of age; 24-hour ventilator-circuit changes;\nfall-winter season; stress-bleeding prophylaxis with cimetidine with or without antacid;\nadministration of antimicrobial agents; presence of a nasogastric tube; severe trauma; and recent\nbronchoscopy (8;11;13-25).\nThe fatality rates for hospital-associated pneumonia in general, and VAP in particular, are\nhigh.  For hospital-associated pneumonia, attributable mortality rates of 20%-33% have been\nreported; in one study, VAP accounted for 60% of all deaths due to hospital-associated infections",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 28,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_29",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "reported; in one study, VAP accounted for 60% of all deaths due to hospital-associated infections\n(10;13;23;26-28).   In studies in which invasive techniques were used to diagnose VAP, the crude\nmortality rates ranged from 4% in patients with VAP but without antecedent antimicrobial therapy\n(29) to 73% in patients with VAP caused by Pseudomonas or Acinetobacter spp. (30), and\nattributable mortality rates ranged from 5.8% to 13.5% (31;32).  These wide ranges in crude and\nattributable mortality rates strongly suggest that a patient’s risk of dying from VAP is affected by\nmultiple other factors, such as the patient's underlying disease(s) and organ failure, antecedent\nreceipt of antimicrobial agent(s), and the infecting organism(s) (16;23;29-34).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 29,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_30",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "receipt of antimicrobial agent(s), and the infecting organism(s) (16;23;29-34).\nAnalyses of pneumonia-associated morbidity have shown that hospital-associated\npneumonia can prolong ICU stay by an average of 4.3-6.1 days and hospitalization by 4-9 days \n(26;28;29;31;33;35;36).  An estimate of the direct cost of excess hospital stay due to VAP is\n8\n$40,000 per patient (33).\nB.   Nursing Home (NH)-Associated Pneumonia (NHAP)\n In long-term care facilities (LTCFs) such as NHs, pneumonia is the first or second most\ncommon infection (after those of the urinary tract) acquired by patients (37;38), and accounts for\n13-48% of all nursing home-associated infections (39;40).  Its seasonal variation mirrors that of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 30,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_31",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "13-48% of all nursing home-associated infections (39;40).  Its seasonal variation mirrors that of\ninfluenza, suggesting that influenza plays a major role in the occurrence of pneumonia in the\nelderly (41).  NHAP is associated with a high mortality rate.  The case-fatality rate of pneumonia in\nNH residents is reported to be from 6% to 23% (37;38;42;43).\nII.  DIAGNOSIS\nHealth-care-associated pneumonia, especially VAP, is difficult to diagnose.  Traditional\ncriteria for diagnosis have been fever, cough, and development of purulent sputum, in combination\nwith radiologic evidence of a new or progressive pulmonary infiltrate, leukocytosis, a suggestive\nGram's stain, and growth of bacteria in cultures of sputum, tracheal aspirate, pleural fluid, or blood",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 31,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_32",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(44-47).  Although clinical criteria together with cultures of sputum or tracheal specimens may be\nsensitive for bacterial pathogens, they are highly nonspecific, especially in patients with VAP\n(46;48-51); conversely, culture of blood has a very low sensitivity (52).\nIn 1992, a group of investigators recommended standardized methods for diagnosing\npneumonia in clinical research studies of VAP (53-55).  These methods involved bronchoscopic\ntechniques, e.g., quantitative culture of protected specimen brush (PSB) specimen (56-65),\nbronchoalveolar lavage (BAL) (57;66-72), and protected BAL (pBAL) (73;74).  The reported\nsensitivities and specificities of these methods have ranged between 70% to 100% and 60% to",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 32,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_33",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "sensitivities and specificities of these methods have ranged between 70% to 100% and 60% to\n100%, respectively, depending on the tests or diagnostic criteria to which they were compared \n(57;75;76).  Because these techniques are invasive, they can cause complications such as\nhypoxemia, bleeding, or arrhythmia (51;58;70;77-79).  Quantitative culture of endotracheal\naspirate (80;81) and non-bronchoscopic procedures that utilize blind catheterization of the distal\nairways, e.g., nonbronchoscopic-pBAL (66;82) and nonbronchoscopic-PSB (65;83;84), were\ndeveloped  later and were shown to approximate the sensitivity and specificity of bronchoscopic\ntechniques (81).\nSubsequently, in a randomized, controlled, multicenter study in France, it was shown that",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 33,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_34",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Subsequently, in a randomized, controlled, multicenter study in France, it was shown that\nin comparison with non-invasive (qualitative cultures of endotracheal aspirate) tests, invasive\nbronchoscopic technique (PSB or pBAL) for the microbiologic diagnosis of pneumonia was\nassociated with fewer deaths by the 14th day after pneumonia onset, earlier improvement from\norgan dysfunction, and less antibiotic use (50).\nPneumonia in residents of NHs is also difficult to diagnose because of unavailability of\ndiagnostic tests (especially rapid viral diagnostic tests), the general inability of the patients to\nprovide sputum specimens, and the difficulty of interpreting sputum cultures and chest radiographs\n(85).\nIII.  ETIOLOGIC AGENTS\nA.  Hospital-Associated Pneumonia",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 34,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_35",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(85).\nIII.  ETIOLOGIC AGENTS\nA.  Hospital-Associated Pneumonia\nThe reported distribution of etiologic agents causing hospital-associated pneumonia varies\n9\namong institutions and settings primarily because of differences in patient populations, diagnostic\nmethods employed, and definitions used (29;44;56-59;86-90).  In general, however, bacteria have\nbeen the most frequently isolated pathogens.  In most studies, very few anaerobic bacteria and\nviruses were reported, partly because anaerobic and viral cultures were not performed routinely in\nthe reporting facilities.  Similarly, cultures of bronchoscopic specimens from patients with VAP \nhave rarely yielded anaerobes (25;56;57;59;60;73;91).  The bacterial pathogens that have been",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 35,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_36",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "have rarely yielded anaerobes (25;56;57;59;60;73;91).  The bacterial pathogens that have been\nmost frequently associated with nosocomial pneumonia in studies of critically ill and/or\nmechanically ventilated patients in intensive-care units are Gram-negative bacilli (e.g.,\nPseudomonas aeruginosa, Proteus spp., and Acinetobacter spp.) and Staphylococcus aureus\n(56;90). \nThe causative microbial agents of nosocomial pneumonia, including VAP, however, can\nvary depending on the length of time the patient has spent in the ICU and/or received mechanically\nassisted ventilation.  VAP has been classified into either early-onset pneumonia (EOP), if\npneumonia develops within 96 hours of the patient’s admission to an ICU or intubation for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 36,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_37",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pneumonia develops within 96 hours of the patient’s admission to an ICU or intubation for\nmechanical ventilation, and late-onset pneumonia (LOP), if pneumonia develops after 96 hours of\nthe patient’s admission to an ICU or intubation for mechanical ventilation.  This categorization can\nbe helpful to clinicians in initiating empiric antimicrobial therapy for cases of pneumonia, when the\nresults of microbiologic diagnostic testing are not yet available.  EOP has been associated usually\nwith non-multi-antimicrobial-resistant microorganisms such as Escherichia coli, Klebsiella spp.,\nProteus spp., S. pneumoniae, H. influenzae, and oxacillin-sensitive S. aureus (92).  On the other\nhand, LOP has been associated with Pseudomonas aeruginosa, oxacillin-resistant S. aureus, and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 37,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_38",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hand, LOP has been associated with Pseudomonas aeruginosa, oxacillin-resistant S. aureus, and\nAcinetobacter spp.-- strains that are usually multi-antibiotic-resistant (92). \nB.  NHAP\n Like cases of community-acquired pneumonia in the elderly, most cases (up to 79%) of\nNHAP have undetermined etiologies primarily because definitive etiologic diagnosis usually is not\nrigorously pursued (37;85).  However, a review of several studies documenting the etiologic\nagents of endemic NHAP reported the identification of: S. pneumoniae in 0-39%, S. aureus in 0-\n33%,  H. influenzae in 0-19% of cases, and aerobic Gram-negative bacilli in 0-55% of cases (85)\n(although culture isolation of Gram-negative bacilli from respiratory tract of patients with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 38,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_39",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(although culture isolation of Gram-negative bacilli from respiratory tract of patients with\npneumonia may be confounded by the prevalence of these bacilli as respiratory-tract colonizers of\nNH residents).  Although Legionella spp. and Chlamydia pneumoniae are not reported very often\nas etiologic agents (85;93), they have caused outbreaks in LTCFs (94-96).  On the other hand,\nMycoplasma pneumoniae has not been a significant pathogen in NHs (93).  Viruses such as\ninfluenza and RSV have caused outbreaks in NHs and have been linked with the occurrence of \npneumonia during these outbreaks (97).\nIV.  PATHOGENESIS\nBacteria may invade the lower respiratory tract by micro- or bolus-aspiration of\noropharyngeal organisms, inhalation of aerosols containing bacteria, or, less frequently, by",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 39,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_40",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "oropharyngeal organisms, inhalation of aerosols containing bacteria, or, less frequently, by\nhematogenous spread from a distant body site.  Bacterial translocation from the gastrointestinal\ntract had been hypothesized as a mechanism for infection; however, its occurrence in patients with\nhealth-care-associated pneumonia has not been shown.  Of the plausible routes, micro-aspiration is\n10\nbelieved to be the most important for both health-care-associated and community-acquired\npneumonia.  In studies using radioisotope tracers, 45% of healthy adults were found to aspirate\nduring sleep (98).  Persons with abnormal swallowing, such as those who have depressed\nconsciousness, respiratory tract instrumentation and/or mechanically assisted ventilation,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 40,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_41",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "consciousness, respiratory tract instrumentation and/or mechanically assisted ventilation,\ngastrointestinal tract instrumentation or diseases, or who have just undergone surgery, especially\nthoracic and/or abdominal surgery, are particularly likely to aspirate (12;13;16;25).\nThe high incidence of Gram-negative bacillary pneumonia in hospitalized patients appears\nto be the result of factors that promote colonization of the pharynx by Gram-negative bacilli and\nthe subsequent entry of these microorganisms into the lower respiratory tract (47;99-103). \nAlthough aerobic Gram-negative bacilli are recovered infrequently or are found in small numbers in\npharyngeal cultures of healthy persons (99;104), colonization dramatically increases in patients",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 41,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_42",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pharyngeal cultures of healthy persons (99;104), colonization dramatically increases in patients\nwith acidosis, alcoholism, azotemia, coma, diabetes mellitus, hypotension, leukocytosis,\nleukopenia, pulmonary disease, or endotracheal or nasogastric tubes in place, and in patients given\nantimicrobial agents (47;102;103;105).\nOropharyngeal or tracheobronchial colonization by Gram-negative bacilli begins with the\nadherence of the microorganisms to the host's epithelial cells (101;106-108).  Adherence may be\naffected by multiple factors related to the bacteria (e.g., presence of pili, cilia, or capsule, or\nproduction of elastase or mucinase), host cell (e.g., surface proteins and polysaccharides), and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 42,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_43",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "production of elastase or mucinase), host cell (e.g., surface proteins and polysaccharides), and\nenvironment (e.g., pH and presence of mucin in respiratory secretions) (100;101;106;109-118). \nStudies indicate that certain substances (e.g., fibronectin) can inhibit the adherence of Gram-\nnegative bacilli to host cells (109;111;119).  Conversely, certain conditions (e.g., malnutrition,\nsevere illness, or post-operative state) can increase adherence of gram-negative bacteria\n(100;109;113;118;120).\n In addition to the oropharynx, the stomach has been postulated to be an important\nreservoir of organisms that cause health-care-associated pneumonia (16;121-125), although the\nexact role of the stomach in the causation of health-care-associated pneumonia, specifically VAP,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 43,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_44",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "exact role of the stomach in the causation of health-care-associated pneumonia, specifically VAP,\nhas been critically investigated and debated (126-129).  It appears, however, that the stomach's\nrole may vary depending on the patient's underlying condition(s) and on the prophylactic or\ntherapeutic interventions that the patient receives (122;130-134).  In healthy persons, few bacteria\nentering the stomach survive in the presence of hydrochloric acid at pH<2 (135).  However, when\ngastric pH increases from the normal levels to >4, microorganisms are able to multiply to high\nconcentrations in the stomach (133;135-138).  This can occur in patients with advanced age (136),\nachlorhydria (135), ileus, or upper gastrointestinal disease, and in patients receiving enteral",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 44,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_45",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "achlorhydria (135), ileus, or upper gastrointestinal disease, and in patients receiving enteral\nfeeding, antacids, or histamine-2 (H-2) antagonists (122;133;134;138).  The contribution of other\nfactors (e.g., duodeno-gastric reflux and the presence of bile) to gastric colonization in patients\nwith impaired intestinal motility also has been suggested (132).\nThe relative importance of oropharyngeal colonization over that of gastric colonization in\nthe development of VAP has been strongly suggested in two studies. In one study, recovery of the\netiologic agents of VAP by culture isolation occurred in the following sequence: from the\noropharynx initially, then from the tracheo-bronchi and/or stomach (139).  In the other study,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 45,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_46",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "oropharynx initially, then from the tracheo-bronchi and/or stomach (139).  In the other study,\nmechanically ventilated patients who received selective oro-pharyngeal decontamination without\nconcurrent decontamination of the stomach had a 60% lower risk of VAP compared to those who\ndid not have such a treatment (140).\n11\nThe importance of aspiration of bacteria found in dental plaques in the causation of health-\ncare-associated pneumonia has been invoked by studies in which cultures of dental plaques have\nyielded pathogenic microorganisms that are prevalent etiologic agents of pneumonia (141;142).\nBacteria can also gain entry into the lower respiratory tract of patients through inhalation\nof aerosols generated primarily by contaminated nebulization devices.  In the past, outbreaks of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 46,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_47",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of aerosols generated primarily by contaminated nebulization devices.  In the past, outbreaks of\nnosocomial respiratory tract infections including pneumonia (143;144) as well as other infections\n(145) were related to the use of contaminated large-volume nebulizers (i.e., humidification devices\nthat produced large amounts of aerosol droplets <4 :m in size via ultrasound, spinning disk, or\nVenturi mechanism).  Inhalation of contaminated aerosol is particularly hazardous for intubated\npatients because endotracheal tubes provide direct access to the lower respiratory tract.  In\ncontrast to nebulizers that were used as humidification devices for ventilated  patients, bubble-\nthrough or wick humidifiers primarily increase the water-vapor (or molecular-water) content of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 47,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_48",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "through or wick humidifiers primarily increase the water-vapor (or molecular-water) content of\ninspired gases during mechanical ventilation.  Although heated bubble-through humidifiers\ngenerate aerosol droplets, they do so in quantities that may not be clinically important (146;147);\nwick humidifiers do not generate aerosols.\nRarely, bacterial pneumonia can result from hematogenous spread of infection to the lung\nfrom another infection site, e.g., pneumonia resulting from purulent phlebitis or right-sided\nendocarditis.\nV.  RISK FACTORS AND CONTROL MEASURES\nPotential risk factors for health-care-associated bacterial pneumonia have been examined in\nseveral large studies.  Although specific risk factors may differ slightly between study populations,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 48,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_49",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "they can be grouped into the following general categories:1) factors that enhance colonization of\nthe oropharynx and/or stomach by microorganisms, e.g., administration of antimicrobial agents,\nadmission to the ICU, or presence of underlying chronic lung disease; 2) conditions favoring\naspiration into the respiratory tract or reflux from the gastrointestinal tract (e.g., initial or repeat\nendotracheal intubation; insertion of nasogastric tube; supine position; coma; surgical procedures\ninvolving the head, neck, thorax, or upper abdomen; and immobilization due to trauma or illness);\n3) conditions requiring prolonged use of mechanical ventilatory support with potential exposure to\ncontaminated respiratory devices and/or contact with contaminated or colonized hands, mainly of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 49,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_50",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "contaminated respiratory devices and/or contact with contaminated or colonized hands, mainly of\nhealth-care personnel; and 4) host factors such as extremes of age, malnutrition, and severe\nunderlying conditions, including immunosuppression (13;15;18;20;23;25;47;148-150).\nA.  Oropharyngeal, Tracheal, and Gastric Colonization\nThe association between a patient’s predisposition to Gram-negative bacillary pneumonia\nand bacterial colonization of the patient’s oropharynx (45;99), trachea (133), or stomach\n(122;138) prompted attempts by researchers to prevent the infection by various means, mainly by\nlocal and/or systemic antimicrobial prophylaxis.\nOropharyngeal and/or tracheal colonization\nLocal bacterial interference and aerosolized antimicrobial agents",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 50,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_51",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Local bacterial interference and aerosolized antimicrobial agents\nEarly studies centered on utilization of the phenomenon of local bacterial interference \n(151;152) or  prophylactic aerosolization of antimicrobial agent(s) (153;154).  Bacterial\ninterference (with alpha-hemolytic streptococci) was successfully used by some investigators to\n12\nprevent oropharyngeal colonization by aerobic Gram-negative bacilli (151).  However, the efficacy\nof this method for general use has not been evaluated.  In small studies, aerosolization of\nantimicrobial agents has been shown to eradicate common Gram-negative bacillary pathogens from\nthe upper respiratory tract and/or decrease the incidence of Gram-negative-bacillary pneumonia",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 51,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_52",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "the upper respiratory tract and/or decrease the incidence of Gram-negative-bacillary pneumonia\n(153) or VAP (155); however, no effect on patient mortality rate has been shown (153) and\nsuperinfection occurred in some patients receiving the therapy (153;154;156;157).  The use of\nintratracheal colistin was shown to significantly decrease the incidence of gram-negative bacillary\nand polymicrobial pneumonia in critically ill patients who were compared to historic controls\n(158).  There was, however, no effect on mortality, and although no increase was detected in the\nnumber of cases infected with colistin-resistant microorganisms, the follow-up period was\nrelatively short.\nSelective oropharyngeal decontamination with antimicrobial agents",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 52,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_53",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "relatively short.\nSelective oropharyngeal decontamination with antimicrobial agents\nRecently, a study was conducted to determine the effect of selectively modulating the\nbacterial colonization of the oropharynx only (without modulating the gastric and intestinal\ncolonization and without the concomitant use of systemic antimicrobial agent[s]) (140).  The use\nof a topical prophylactic preparation containing gentamicin, colisitin, and vancomycin resulted in\nthe eradication of oropharyngeal and tracheal colonizers in 75% of the study patients (vs 0 and 9%\nof 2 groups of controls), prevented acquisition of new oropharyngeal colonizers in 90% of treated\npatients (vs 41% and 37% of untreated patients), and lowered the incidence of VAP (10%) in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 53,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_54",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients (vs 41% and 37% of untreated patients), and lowered the incidence of VAP (10%) in\nstudy patients (compared to 59% and 63% in two groups of control patients) (140).  However, the\nuse of the topical preparation was not associated with shorter duration of ventilation or ICU stay\nor longer survival in study patients.\nOropharyngeal cleaning and decontamination with an antiseptic agent\nTwo clinical studies (one in ICU with temporal controls and another in a multi-nursing-\nhome setting using random controls) have shown a decrease in rates of pneumonia, including VAP,\nupon implementation of a comprehensive oral-hygiene program for patients or residents,\nrespectively (159;160).  The oral hygiene programs consisted of frequent toothbrushing and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 54,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_55",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "respectively (159;160).  The oral hygiene programs consisted of frequent toothbrushing and\nmouth-swabbing with an antiseptic agent; and in the ICU, frequent suctioning of the mouth and\nsubglottic areas of patients receiving mechanically assisted ventilation.  More randomized,\ncontrolled studies are needed to determine the role of a comprehensive oral-hygiene program in the\nprevention of VAP or NHAP.  However, in the interim, it is prudent for health-care facilities to\nimplement such a program.\nOral chlorhexidine rinse in adult patients undergoing cardiac surgery  \nRecently, the antiseptic chlorhexidine gluconate (0.12%) was used successfully as a peri-\noperative oral rinse to decrease the overall incidence of nosocomial respiratory tract infections in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 55,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_56",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients who underwent cardiac surgery (161).  However, its use for preventing health-care-\nassociated pneumonia in other groups of patients at high risk for this infection has not been\nevaluated.\nOropharyngeal and Gastric Colonization \n“Selective” Decontamination of the Digestive Tract (SDD)\nSDD is one of the most studied strategies designed to prevent lower respiratory tract\ninfection in critically ill and/or mechanically ventilated patients by preventing bacterial colonization\nof the digestive tract (162-193).  SDD is aimed at preventing oropharyngeal and gastric\n13\ncolonization with aerobic Gram-negative bacilli and Candida spp., without altering the digestive\ntract’s anaerobic flora.  Various SDD regimens include a combination of locally administered",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 56,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_57",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tract’s anaerobic flora.  Various SDD regimens include a combination of locally administered\nnonabsorbable antimicrobial agents, such as polymyxin or colistin, and an aminoglycoside\n(tobramycin, gentamicin, or, rarely, neomycin) or a quinolone (norfloxacin or ciprofloxacin),\ncoupled with either amphotericin B or nystatin.  Several times a day, the local antimicrobial\npreparation is applied as a paste to the oropharynx and, except in one study (187), given orally or\nvia the nasogastric tube for gastric decontamination.  In addition, however, in many studies, a\nsystemic (i.e., intravenous) antimicrobial agent such as cefotaxime or trimethoprim (TMP) is\nadministered to the patient, thus rendering the regimen nonselective for the oropharynx (187) or\noropharynx and stomach.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 57,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_58",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "oropharynx and stomach.\nAlthough most clinical trials (162-165;167-174;176;177;182-184;187;189-193), including\nseveral meta-analyses (178;185;188), have demonstrated a decrease in the rates of hospital-\nassociated respiratory infections with the use of SDD, these studies have been difficult to assess\nbecause they differ in study design and population, and many have had short follow-up periods.  In\naddition, except in a few reports (166;169;180;182-184;186), in most of the studies, \nnonbronchoscopic methods were used to diagnose pneumonia.\nSDD has not been shown to decrease significantly the duration of mechanical ventilation or\nICU stay; however, a decrease in overall antimicrobial use was shown in a few studies",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 58,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_59",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "ICU stay; however, a decrease in overall antimicrobial use was shown in a few studies\n(163;173;179;182;187;189;191;192), and in two meta-analyses and a primary study, a decrease in\nmortality was shown in two groups of patients, i.e., critically ill surgical patients and those who\nreceived both systemic and local prophylactic antibiotics (188;190;193).\nThe cost of preventing VAP or mortality with the use of SDD has been estimated: in order\nto prevent one case of hospital-associated pneumonia or one death due to hospital-associated\npneumonia, 6 (range: 5-9) or 23 (range:13-39) patients, respectively, would have to be given SDD\n(185).\n SDD will probably be found cost-effective for use on subsets of ICU patients, such as",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 59,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_60",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(185).\n SDD will probably be found cost-effective for use on subsets of ICU patients, such as\ntrauma and/or critically ill surgical patients.  However, there are concerns about the potential for\nincreased bacterial antimicrobial resistance and superinfection with multi-drug resistant pathogens\nin patients (29;163;165;166;168;182;194).\nSucralfate, H-2 receptor antagonists, antacids, and stress-bleeding prophylaxis\nThe administration of antacids and/or H-2 receptor antagonists for prevention of stress\nbleeding in critically ill, postoperative, or mechanically ventilated patients has been associated with\ngastric bacterial overgrowth (123;137;138;195) and increased risk for pneumonia\n(16;123;134;196-198).  Sucralfate, a cytoprotective agent that has little effect on gastric pH and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 60,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_61",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(16;123;134;196-198).  Sucralfate, a cytoprotective agent that has little effect on gastric pH and\nmay have bactericidal properties of its own, has been suggested as a substitute for antacids and H-\n2 receptor antagonists (199-201).  The results of clinical trials comparing the risk of pneumonia in\npatients receiving sucralfate with that in patients given H-2 receptor antagonists and/or antacids\nhave been variable.  Early studies suggested that the use of sucralfate (compared to H-2 receptor\nantagonists and/or antacids) decreased the risk of pneumonia in ICU patients receiving\nmechanically assisted ventilation (123;134;198;199;202).  More recent studies, however, failed to\ndemonstrate the advantage of using sucralfate (203-205).  In addition, another study has suggested",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 61,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_62",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "demonstrate the advantage of using sucralfate (203-205).  In addition, another study has suggested\nthat patients with acute respiratory distress syndrome who are administered sucralfate may even be\nat a greater risk of developing VAP compared to those who are not (206).\n14\nAcidified enteral feeding\nBecause enteral feeding can increase gastric pH (207) and result in gastric colonization,\nacidification of enteral solutions has been advocated to prevent gastric and tracheal colonization in\npatients receiving such treatment (208).  The absence of  “pathogenic” bacteria from the stomachs\nof patients given acidified enteral feeding has been shown; however, the effect on the incidence of\npneumonia has not been evaluated (208;209). \nContinuous versus intermittent enteral feeding",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 62,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_63",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pneumonia has not been evaluated (208;209). \nContinuous versus intermittent enteral feeding\nContinuous enteral feeding of mechanically ventilated patients, a common practice in ICUs,\nhas been associated with increased gastric pH (133;210), subsequent gastric colonization with\nGram-negative bacilli (21;210;211), and a high incidence of pneumonia (21); whereas intermittent\nenteral feeding has been associated with lower gastric pH and lower rates of pneumonia (211). \nHowever, in a cross-over study of intermittent enteral feeding of patients who had just had\ncontinuous enteral feeding, intermittent feeding had no lowering effect on gastric pH or gastric\nmicrobial colonization (212).  In another study that compared intermittent and continuous enteral",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 63,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_64",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "microbial colonization (212).  In another study that compared intermittent and continuous enteral\nfeeding, intermittent feeding resulted in decreased gastric pH during the “off-feeding” interval;\nhowever, the oropharyngeal and tracheal colonization rates and the incidence of VAP were similar\nin patients who received either treatment (213).  More studies are needed to determine the effect\nof intermittent enteral feeding on the incidence of pneumonia.\nB.  Aspiration of Oropharyngeal and Gastric Flora and Nasal-Sinus Secretions\nClinically important aspiration usually occurs in patients who have one or more of the\nfollowing conditions: a depressed level of consciousness; dysphagia due to neurologic or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 64,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_65",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "following conditions: a depressed level of consciousness; dysphagia due to neurologic or\nesophageal disorders; an endotracheal (naso- or oro-tracheal), tracheostomy, or enteral (naso- or\noro-gastric) tube in place; and receipt of enteral feeding (13;98;214-220).\nPlacement of an enteral tube may increase nasopharyngeal colonization, cause reflux of\ngastric contents, or allow bacterial migration via the tube from the stomach to the upper airway\n(216;218;221-223).  Gross contamination of the enteral solution during its preparation (224-226)\nmay lead to gastric colonization with gram-negative bacilli.\nPrevention of pneumonia in such patients may be difficult; however, placing the patient in a\nsemi-upright position (by elevating the head of the bed at an angle of 30o-45o) has been beneficial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 65,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_66",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "semi-upright position (by elevating the head of the bed at an angle of 30o-45o) has been beneficial\n(227), probably by preventing aspiration (223).  Gastric contents that were labeled with radioactive\nmaterial were aspirated via the gastro-esophageal route when patients were treated in the supine\nposition (222;223;228).  In two other studies of patients receiving mechanically assisted\nventilation, significantly higher percentages (i.e., 23% and 36%) of patients who were supine\ndeveloped pneumonia compared with 5% and 11% of those who were semi-upright, either during\nthe first 24 hours of receipt of mechanically assisted ventilation (23) or during their receipt of both\nmechanically assisted ventilation and enteral feeding (227), respectively.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 66,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_67",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "mechanically assisted ventilation and enteral feeding (227), respectively. \nOn the other hand, other measures that theoretically might be beneficial have yielded either\nnegative or equivocal results in studies involving small numbers of patients: the use of flexible,\nsmall-bore nasogastric tubes did not reduce the incidence of gastroesophageal reflux or\nmicroaspiration (229); and placement of the enteral tube below the stomach (e.g., in the jejunum)\nhad variable effects on the rate of aspiration (230-233) and the incidence of pneumonia (234-236).\nDirect correlations have been reported between naso-tracheal (rather than oro-tracheal)\n15\nintubation and the occurrence of nosocomial maxillary sinusitis (237;238) and high incidence of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 67,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_68",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "15\nintubation and the occurrence of nosocomial maxillary sinusitis (237;238) and high incidence of\npneumonia (238).  These findings suggest that the entry site for endotracheal intubation may affect\nthe incidence of VAP.\nC.  Mechanically Assisted Ventilation and Endotracheal Intubation\nThe increased risk for pneumonia in intubated, mechanically ventilated patients is partly due\nto the carriage of oropharyngeal microorganisms via passage of the endotracheal tube into the\ntrachea during intubation, as well as to depressed host defenses secondary to the patient's severe\nunderlying illness (13;16;25;239).  In addition, bacteria can aggregate on the surface of the\nendotracheal tube over time and form a glycocalyx (i.e., biofilm) that protects the bacteria from",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 68,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_69",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "endotracheal tube over time and form a glycocalyx (i.e., biofilm) that protects the bacteria from\nantimicrobial agents or host defenses (240).  Some investigators believe that these bacterial\naggregates may become dislodged by ventilation flow, tube manipulation, or suctioning and\nsubsequently embolize into the lower respiratory tract and cause focal pneumonia (241;242).\nDrainage of subglottic secretions\nIn the intubated patient, leakage around the cuff of the endotracheal tube allows bacteria-\nladen secretions (which pool below the glottis and above the endotracheal-tube cuff) direct access\nto the lower respiratory tract (243;244).  The effect of using an endotracheal tube that has a\nseparate dorsal lumen which allows drainage (i.e., removal by suctioning) of the subglottic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 69,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_70",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "separate dorsal lumen which allows drainage (i.e., removal by suctioning) of the subglottic\nsecretions has been compared to that of a conventional endotracheal tube (245-248).  In the first\nstudy in ICU patients, intermittent (i.e., hourly) subglottic secretion drainage was associated with a\nlower incidence (13% vs 29%) as well as a delayed onset (16.2 + 11 days vs 8.3  + 5 days) of VAP\n(246).  Subsequent studies corroborated these findings: lower VAP incidence:14/76 (18.4%) vs\n25/77 (32.5%) (248), and 3/49 (4%) vs 12/56 (16%) (247); and delayed onset of VAP: 12.0 + 7.1\ndays vs 5.9 + 2.1 days (248), and + 2.3 days vs 2.9 + 1.2 days (247); albeit the decrease in VAP\nincidence was not statistically significant: 8/160 (5%) vs 15/183 (8.2%) in one study of patients",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 70,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_71",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "incidence was not statistically significant: 8/160 (5%) vs 15/183 (8.2%) in one study of patients\nwho had undergone cardiac surgery (245). \nAlthough these randomized, controlled studies showed the beneficial effect of suctioning of\nsubglottic secretions on the incidence of VAP, none showed a corresponding effect on mortality,\nlength of stay in the ICU, or duration of mechanical ventilation.  And, although a decision-model\ncost-effectiveness analysis has shown that as a VAP-prevention strategy, the use of endotracheal\ntubes that allow aspiration of subglottic secretions may result in savings, the study was\nhypothetical and based on data extrapolated from several studies instead of one study (249).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 71,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_72",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hypothetical and based on data extrapolated from several studies instead of one study (249). \nLarger randomized controlled studies with cost-benefit analysis are needed to determine the exact\nrole of the use these tubes in the overall scheme to prevent VAP and improve secondary outcomes. \nNoninvasive ventilation (NIV): Noninvasive positive-pressure ventilation (NPPV):\nNIV of patients in acute respiratory failure due to various causes is emerging as a\npotentially more advantageous method of delivering positive-pressure ventilation than\nendotracheal tube placement (250-255).  NPPV has been shown to reduce the need for, and\nduration of, intubation, and has resulted in improved survival, particularly in patients with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 72,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_73",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "duration of, intubation, and has resulted in improved survival, particularly in patients with\nhypercapnic acute respiratory failure due to exacerbation of chronic obstructive pulmonary\ndisease (COPD) (251;252;256;257).  In several studies, the use of NPPV resulted in a decreased\nrisk for pneumonia (254;256-260).  In one of these studies, the incidence of pneumonia was three\ntimes lower (4 [18%] of 50) in those who received NPPV than in those (11 [60%] of 50) who\n16\nreceived the conventional treatment (i.e., intubation and mechanically-assisted ventilation) (258).\nRepeat Endotracheal Intubation\nRepeat insertion of the endotracheal tube soon after it is removed from a patient who is\ntaken off ventilatory support has been shown to be a risk factor for pneumonia (149).  Using NIV",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 73,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_74",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "taken off ventilatory support has been shown to be a risk factor for pneumonia (149).  Using NIV\ninstead may help reduce the risk (261).  \nD.  Cross-Colonization Via Hands of Personnel\nPathogens causing health-care-related pneumonia, such as Gram-negative bacilli and S.\naureus, are ubiquitous in health-care settings, especially in intensive- or critical-care areas\n(262;263).  Transmission of these microorganisms to patients frequently occurs via health-care\npersonnel's hands that become contaminated or transiently colonized with the microorganisms\n(264-269).  Procedures such as tracheal suctioning and manipulation of ventilator circuit or\nendotracheal tubes increase the opportunity for cross-contamination (269;270).  The risk of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 74,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_75",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "endotracheal tubes increase the opportunity for cross-contamination (269;270).  The risk of\ncross-contamination can be reduced by using aseptic technique and sterile or disinfected\nequipment when appropriate and eliminating pathogens from the hands of personnel\n(11;269;271;272).\nIn theory, handwashing is an effective way of removing transient bacteria from the hands\n(271;272); however, in general, personnel compliance with handwashing has been poor (273-\n277).  New guidelines for hand hygiene that promote the use of alcohol-based antiseptic\npreparations may result in increased personnel compliance and decreased incidence of hand-\ntransmitted infections (278).\nGloving also helps prevent cross-contamination (279).  Routine gloving (in addition to",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 75,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_76",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Gloving also helps prevent cross-contamination (279).  Routine gloving (in addition to\ngowning) was associated with a decrease in the incidence of health-care-related RSV infection\n(280) and infections occurring in the ICU (281).  Gloves, however, can be colonized by\npathogens prevalent in the health-care setting (282), and outbreaks have been traced to health-\ncare personnel who did not change gloves after contact with one patient and before providing care\nto another (283).  In addition, gloved hands may get contaminated via leaks in the gloves (284). \nThus, personnel should use gloves properly and decontaminate their hands after gloves are\nremoved (278;279).\nE.  Contamination of Devices Used on the Respiratory Tract",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 76,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_77",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "removed (278;279).\nE.  Contamination of Devices Used on the Respiratory Tract\nDevices used on the respiratory tract for respiratory therapy (e.g., nebulizers, endotracheal\ntubes), diagnostic examination (e.g., bronchoscopes or spirometers), or administration of\nanesthesia are potential reservoirs or vehicles for infectious microorganisms (11;285-287). \nRoutes of transmission may be from device to patient, from one patient to another, or from one\nbody site to the lower respiratory tract of the same patient via hand or device (143;147;286-297). \nContaminated reservoirs of aerosol-producing devices, e.g., nebulizers, can allow the growth of\nhydrophilic bacteria that may be subsequently aerosolized during device use (143;144;292).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 77,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_78",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hydrophilic bacteria that may be subsequently aerosolized during device use (143;144;292). \nGram-negative bacilli (e.g., Pseudomonas spp. or Flavobacterium spp.;  Legionella spp.) and\nnontuberculous mycobacteria can multiply to high concentrations in nebulizer fluid (291;298-300)\nand increase the device user's risk of acquiring pneumonia (143;144;147;291;292;301-303).\nProper cleaning and sterilization or disinfection of reusable equipment are important\ncomponents of a program to reduce infections associated with devices used for respiratory\n17\ntherapy, pulmonary diagnostic tests, or delivery of anesthesia (286;288-290;292;304-308).  Most\ndevices or parts of devices used on the respiratory tract have been categorized as semicritical in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 78,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_79",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "devices or parts of devices used on the respiratory tract have been categorized as semicritical in\nthe Spaulding classification system for appropriate sterilization or disinfection of medical devices\nbecause they come into direct or indirect contact with mucous membranes but do not ordinarily\npenetrate body surfaces (see Appendix), and the associated infection risk following the use of\nthese devices in patients is less than that associated with devices that penetrate normally sterile\ntissues (309).  Thus, after they are thoroughly cleaned, they can be subjected to high-level\ndisinfection by either using liquid chemical disinfectants that are cleared by the Food and Drug\nAdministration (FDA) for use on medical instruments (310) or by pasteurization at >70oC for 30\nminutes (310-315).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 79,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_80",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "minutes (310-315).\nSterile water is preferred to tap or unsterilized distilled water for rinsing off residual liquid\nchemical disinfectant from a respiratory device that has been chemically disinfected for reuse,\nbecause tap or distilled water may harbor microorganisms that can cause pneumonia\n(298;299;316-318).  However, when rinsing with sterile water is not feasible, rinsing with tap\nwater or filtered water (water passed through 0.2: filter), followed by an alcohol rinse and\nforced-air drying, may be done (310).  Forced-air drying has been shown to markedly lower the\nlevel of microbial contamination of stored endoscopes, most likely by removing the wet\nenvironment favorable for bacterial growth (319;320).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 80,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_81",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "environment favorable for bacterial growth (319;320).\n1.  Mechanical Ventilators, Breathing Circuits, Humidifiers, Heat-Moisture Exchangers, and\nIn-Line Nebulizers \na.  Mechanical Ventilators.   The internal machinery of mechanical ventilators used for respiratory\ntherapy has not been reported as an important source of bacterial contamination of inhaled gas. \nThus, routine sterilization or high-level disinfection of the internal machinery is considered\nunnecessary. \nb.   Breathing circuits, humidifiers, and heat-moisture exchangers.  Most U.S. hospitals use\nventilators that provide inspired-gas humidification with either bubble-through or wick\nhumidifiers.  Because bubble-through humidifiers produce insignificant amounts of aerosol and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 81,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_82",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "humidifiers.  Because bubble-through humidifiers produce insignificant amounts of aerosol and\nwick humidifiers produce no aerosol, they do not pose an important risk for pneumonia in patients\n(146;321).  In addition, bubble-through humidifiers are usually heated to temperatures that reduce\nor eliminate bacterial pathogens (321;322).  In general, however, sterile water is still used to fill\nthese humidifiers (323) because of the potential presence in tap or distilled water, of\nmicroorganisms (e.g., Legionella spp.) that are more heat-resistant than other bacteria\n(302;306;317).\nThe potential risk for pneumonia in patients using mechanical ventilators with heated\nbubble-through humidifiers primarily results from the formation of condensate in the inspiratory-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 82,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_83",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "bubble-through humidifiers primarily results from the formation of condensate in the inspiratory-\nphase tubing of unheated ventilator circuits due to the difference in the temperatures of the\ninspiratory-phase gas and ambient air.  The condensate and tubing can rapidly become\ncontaminated, usually with bacteria that originate from the patient's oropharynx (324).  In a study\nby Craven et al., 33% of inspiratory circuits were colonized with bacteria from patients'\noropharynx within 2 hours, and 80% within 24 hours, of use (324).  Spillage of the contaminated\ncondensate into the patient's tracheobronchial tree can occur with procedures during which the\ntubing may be moved (e.g., suctioning, adjusting the ventilator setting, or feeding or giving\n18",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 83,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_84",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tubing may be moved (e.g., suctioning, adjusting the ventilator setting, or feeding or giving\n18\nhygienic care to the patient) and may increase the patient’s risk for pneumonia (324).  Thus, in\nmany health-care facilities, personnel are trained to prevent such spillage and drain and discard the\nfluid periodically.  Microorganisms contaminating ventilator-circuit condensate can be transmitted\nto other patients via hands of the health-care personnel handling the fluid, especially if the\npersonnel fail to decontaminate their hands after handling the condensate.\nThe role of ventilator-tubing changes in preventing pneumonia in patients using\nmechanical ventilators with bubble-through humidifiers has been investigated for many years.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 84,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_85",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "mechanical ventilators with bubble-through humidifiers has been investigated for many years. \nInitial studies of in-use contamination of mechanical ventilator circuits with humidifiers have\nshown that neither the rate of bacterial contamination of inspiratory-phase gas nor the incidence\nof pneumonia was significantly increased when tubing was changed every 24 hours rather than\nevery 8 or 16 hours (325).  Craven et al. later showed that changing the ventilator circuit every 48\nhours rather than 24 hours did not result in an increase in contamination of the inspiratory-phase\ngas or tubing of the ventilator circuits (326).  In addition, ventilatory circuit changes every 24\nhours rather than every 48 hours was shown to be a risk factor for VAP in a study of ICU patients",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 85,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_86",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hours rather than every 48 hours was shown to be a risk factor for VAP in a study of ICU patients\nwho were receiving mechanically assisted ventilatory support (16).  Later reports suggested that\nthe risk for pneumonia did not increase when the interval for circuit change was prolonged\nbeyond 48 hours (327;328).  Hess et al. showed no increase in the incidence of VAP and a\nsavings of more than $110,000 per year in materials and personnel salaries when breathing circuits\nwere changed every seven days rather than every 48 hours (329).  Dreyfuss et al. reported that\nwhen the circuits were never changed for the duration of use by a patient, the risk of pneumonia\n(8 [29%] of 28) was not higher than when the circuits were changed every 48 hours (11 [31%] of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 86,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_87",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(8 [29%] of 28) was not higher than when the circuits were changed every 48 hours (11 [31%] of\n35) (330).  More recently, Kollef et al. showed that the risk of acquiring pneumonia in patients\nwhose breathing circuits were left unchanged indefinitely for the duration of  their receipt of\nmechanical ventilation (unless the circuit was observed to be grossly contaminated) was not\nhigher than in those whose breathing circuits were changed routinely every 7 days (331).  And,\nFink et al. found that patients whose circuits were changed every 2 days had >3 times the risk of\nacquiring VAP compared to those whose circuits were changed every 7 or 30 days (332). \nThese findings indicate that the previous CDC recommendation to change ventilator",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 87,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_88",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "These findings indicate that the previous CDC recommendation to change ventilator\ncircuits routinely on the basis of duration of use should be changed to one that is based on visual\nand/or known contamination of the circuit.  This change in recommendation is expected to result\nin large savings in device use and personnel time for U.S. health-care facilities\n(323;326;327;331).\nCondensate formation in the inspiratory-phase tubing of a ventilator breathing circuit can\nbe decreased by elevating the temperature of the inspiratory-phase gas with a heated wire in the\ninspiratory-phase tubing .  However, in one report, three cases of endotracheal or tracheostomy\ntube blockage by dried patient secretions were attributed to the decrease in the relative humidity",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 88,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_89",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tube blockage by dried patient secretions were attributed to the decrease in the relative humidity\nof inspired gas that results from the elevation of the gas temperature (333).  Therefore, users of\nheated ventilator tubing should be aware of the advantages and potential complications of using\nheated tubing.\nCondensate accumulation can also be eliminated by using a heat-moisture exchanger\n(HME) (334-337).  An HME recycles heat and moisture exhaled by the patient and eliminates the\nneed for a humidifier.  In the absence of a humidifier, no condensate forms in the inspiratory-\nphase tubing of the ventilator circuit.  Thus, bacterial colonization of the tubing is prevented; and\n19\nperiodic, routine changing of the tubing is not necessary (270).  An HME, however, increases the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 89,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_90",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "19\nperiodic, routine changing of the tubing is not necessary (270).  An HME, however, increases the\ndead space and resistance to breathing (338), may leak around the endotracheal tube, and may\nresult in drying of sputum (339) and blockage of the tracheo-bronchial tree (340;341).  Its effect\non the work of breathing (338;342) and the ventilatory drive may cause increased inspiratory\nneuromuscular activity from the patients, which, if sustained during acute respiratory failure, may\nlead to inspiratory muscle fatigue (342).  Thus, consideration of the economic advantages of the\nuse of an HME should be balanced with its possible negative respiratory effects (342).  \nIn 1998, Cook et al. reviewed five randomized, controlled studies comparing HMEs and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 90,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_91",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "In 1998, Cook et al. reviewed five randomized, controlled studies comparing HMEs and\nheated humidifiers; the main outcome variable was pneumonia (343).  A significantly lower\nincidence of pneumonia in the HME patient group was shown in one study (344), a tendency\ntowards lower incidence of pneumonia in the HME group was seen in three other studies\n(339;341;345), and no difference in risk was seen in the only study in which PSB was used as a\nconfirmatory method for diagnosing pneumonia (346).  In a later study, Kollef et al. found no\ndifference in the risk of VAP between a group of patients on whom HMEs were used and a\ncomparable group with heated humidifiers (347).\nRecently, an HME with an active humidifier (i.e., external heat and moisture added at the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 91,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_92",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Recently, an HME with an active humidifier (i.e., external heat and moisture added at the\npatient side of the HME) was designed to offset the device’s negative effects (i.e., drying of\npatient’s secretions and increased resistance to airflow) (348;349).  However, studies assessing its\neffects on prevention of pneumonia have not been done.\nc.  Small-Volume (In-Line) and Hand-held Medication Nebulizers.  Small-volume (in-line)\nmedication nebulizers that are inserted in the inspiratory circuit of mechanical ventilators and\nhand-held liquid-medication nebulizers can produce bacterial aerosols (292).  If in-line nebulizers\nbecome contaminated by condensate in the inspiratory tubing of the breathing circuit, they can",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 92,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_93",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "become contaminated by condensate in the inspiratory tubing of the breathing circuit, they can\nincrease the patient's risk of pneumonia because the nebulizer aerosol is directed through the\nendotracheal tube and bypasses many of the normal host defenses against infection (324).  Hand-\nheld small-volume medication nebulizers have been associated with health-care-associated\npneumonia, including Legionnaires disease, as a result of their contamination with medications\nfrom multidose vials (350-354) or with Legionella-contaminated tap water used for rinsing and\nfilling the reservoir (306).  Thus, when nebulized liquid medications are used, unit-dose vials are\npreferable to multi-dose vials.  If multidose medication vials are used, the persons who handle,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 93,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_94",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "preferable to multi-dose vials.  If multidose medication vials are used, the persons who handle,\ndispense, and store such medications should closely follow the medications’ manufacturers’\ndirections to prevent equipment and medication contamination.\n2.  Suction Catheters\n Endotracheal suction catheters can introduce microorganisms into a patient's lower\nrespiratory tract.  Currently, two types of suction-catheter systems are used in U.S. hospitals: the\nopen single-use catheter system and the closed multi-use catheter system.  The closed-suction\nsystem has the potential advantages of decreased environmental contamination as well as lower\ncosts, especially if it can be corroborated that, notwithstanding the manufacturer-recommended",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 94,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_95",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "costs, especially if it can be corroborated that, notwithstanding the manufacturer-recommended\ndaily catheter changes, the catheter can remain unchanged for an indefinite period without\nincreasing the patient’s risk of VAP (355).  However, studies that compared the effect of the open\nsingle-use catheter system and that of the closed multi-use catheter system on the incidence of\nVAP have yielded equivocal results.  Two studies showed no difference in the incidences of VAP\nin the two patient groups (356;357) while a third study showed the VAP incidence rate to be\n20\nlower (7.32 per 1,000 patient-days) in patients with the closed suction system than (15.89 per\n1,000 patient-days) in those who had the open system (358).  More studies are needed to",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 95,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_96",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1,000 patient-days) in those who had the open system (358).  More studies are needed to\ndetermine the effect of the type of suction system on the incidence of VAP.\n3.  Resuscitation Bags, Ventilator Spirometers and Temperature Probes\nReusable resuscitation bags are particularly difficult to clean and dry between uses;\nmicroorganisms in secretions or fluid left in the bag may be aerosolized or sprayed into the lower\nrespiratory tract of the patient on whom the bag is used; in addition, contaminating\nmicroorganisms may be transmitted from one patient to another via hands of staff members (359-\n363).  Ventilator spirometers and temperature probes have been associated with outbreaks of\nGram-negative bacillary respiratory tract colonization and pneumonia resulting from patient-to-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 96,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_97",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Gram-negative bacillary respiratory tract colonization and pneumonia resulting from patient-to-\npatient transmissin of microorganisms (294;295;364;365).  Devices such as these require\nsterilization or high-level disinfection between uses on different patients.  Education of physicians,\nrespiratory therapists, and nursing staff about the appropriate care and handling of these devices\n(in addition to appropriate hand decontamination between patients) is essential. \n4.  Anesthesia Equipment \nThe contributory role of anesthesia equipment in outbreaks of health-care-associated\npneumonia was reported before hospitals implemented routine after-use cleaning and\ndisinfection/sterilization of reusable components of anesthesia-equipment that may become",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 97,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_98",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "disinfection/sterilization of reusable components of anesthesia-equipment that may become\ncontaminated with pathogens during use (366;367). \na.  Anesthesia machine.  The internal components of anesthesia machines (e.g., the gas sources\nand outlets, gas valves, pressure regulators, flow meters, and vaporizers) are not considered\nimportant sources of bacterial contamination of inhaled gases (368).  Thus, routine sterilization or\nhigh-level disinfection of the internal machinery is considered unnecessary.\nb.  Breathing system or patient circuit.  The breathing system or patient circuit through which\ninhaled and/or exhaled gases flow to and from a patient can become contaminated with\nmicroorganisms that may originate from the patient's oropharynx or trachea. The breathing system",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 98,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_99",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "microorganisms that may originate from the patient's oropharynx or trachea. The breathing system\nincludes the tracheal tube or face mask, inspiratory and expiratory tubing, y-piece, CO2 absorber\nand its chamber, the anesthesia ventilator bellows and tubing, humidifier, adjustable pressure-\nlimiting valve, and other devices and accessories.  Recommendations for in-use care, maintenance,\nand reprocessing (i.e., cleaning and disinfection or sterilization) of the components of the\nbreathing system have been published (369;370).  In general, reusable components of the\nbreathing system that directly touch the patient's mucous membranes (e.g., face mask or tracheal\ntube) or become readily contaminated with the patient's respiratory secretions (e.g., y-piece,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 99,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_100",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tube) or become readily contaminated with the patient's respiratory secretions (e.g., y-piece,\ninspiratory and expiratory tubing and attached sensors) are cleaned and subjected to high-level\ndisinfection or sterilization between patients.  The other parts of the breathing system (e.g.,\ncarbon dioxide absorber and its chamber) for which an appropriate and cost-effective schedule of\nreprocessing has not been firmly determined (371) are changed, cleaned, and sterilized or\nsubjected to high-level disinfection periodically, according to published guidelines (310;369;370)\nand manufacturers' instructions.\nUsing high-efficiency bacterial filters at various positions in the patient circuit (e.g., at the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 100,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_101",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Using high-efficiency bacterial filters at various positions in the patient circuit (e.g., at the\ny-piece or on the inspiratory and expiratory sides of the patient circuit) has been advocated  (369)\nand shown to decrease contamination of the circuit (372-374).  However, the efficacy of bacterial\nfilters in preventing health-care-associated pneumonia has not been shown (375-378).\n21\n5.  Pulmonary function testing equipment\n In general, pulmonary function testing devices (e.g., spirometers, peak flow meters) have\nnot been considered an important source of bacterial contamination of inhaled gas (379;380). \nHowever, because of concern about possible carry-over of bacteria from an infectious user of the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 101,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_102",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "However, because of concern about possible carry-over of bacteria from an infectious user of the\ndevice to the next patient-user(s) (381), placement of bacterial filters that remove exhaled bacteria\nbetween the patient and the testing equipment has been advocated (382).  Randomized controlled\nstudies have not been done to evaluate the efficacy of these filters in preventing health-care-\nassociated pneumonia (383). \nWhereas high-level disinfection of spirometer tubing and mouthpieces was recommended\nin the past because these spirometer parts could become contaminated with secretions during\npatient use (379), recent routine use of filters has obviated the need for such disinfection.  Instead,\nthe mouthpiece and the filter are changed between uses by different patients (384).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 102,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_103",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "the mouthpiece and the filter are changed between uses by different patients (384).\nF.  Post-operative State\nA preoperative risk index for predicting postoperative pmeumonia was recently developed\nfrom a study of 160,805 patients who underwent major noncardiac surgery, and validated using\nanother pool of 155,266 surgical patients.  The following significant risk factors were identified:\ntype of surgery (abdominal aortic aneurysm repair, thoracic surgery, and emergency surgery); use\nof general anesthesia; age >60 years; totally dependent functional status; weight loss greater than\n10%; steroid use for chronic conditions; recent history of alcohol use; history of chronic\nobstructive pulmonary disease; smoking within one year of surgery; impaired sensorium; history",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 103,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_104",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "obstructive pulmonary disease; smoking within one year of surgery; impaired sensorium; history\nof cerebrovascular accident with residual neurologic deficit; low (<8mg/dL) or high (>22 mg/dL)\nblood urea nitrogen level; and receipt of more than 4 units of blood before surgery (385).  These\nfindings echo those from previous studies of risk factors for postoperative pulmonary\ncomplications, and underscore the major role of a patient’s underlying health status in the\noccurrence of post-operative pneumonia (18;386).  \nInterventions aimed at reducing the postoperative patient's risk for pneumonia and other\npulmonary complications have been developed; most measures have been geared towards clearing\nsecretions and increasing lung expansion (387-391).  These include deep breathing exercises,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 104,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_105",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "secretions and increasing lung expansion (387-391).  These include deep breathing exercises,\nchest physiotherapy, use of incentive spirometry and continuous positive airway pressure by face\nmask.  The results of studies looking at the effect of each of these maneuvers on the occurrence of\npostoperative pneumonia, bronchitis, or atelectasis are difficult to compare and interpret because\nof the relatively small numbers of patients per study; the differences in study design, endpoints,\npatient populations and surgical procedures; and the potential confounding effects of other forms\nof treatment (e.g., antibiotic administration, stress-ulcer prophylaxis) received by the study\npatients (387-397).  A common finding among several studies, however, is the association",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 105,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_106",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients (387-397).  A common finding among several studies, however, is the association\nbetween incentive spirometry and deep breathing exercises on one hand, and a lower incidence of\npostoperative pulmonary complications (including atelectasis, bronchitis, and clinically diagnosed\npneumonia) on the other hand (387-389;391-397).\nG.  Other Prophylactic Measures\n1.  Immunomodulation  \na.  Pneumococcal vaccination.  Although pneumococci are not a major cause of health-care-\nassociated pneumonia, they have been identified as etiologic agents of serious health-care-associated\npulmonary infection and bacteremia (398-401), and have caused outbreaks in NHs (402).  The\n22\nfollowing factors render patients at high risk for complications from pneumococcal infections: >65",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 106,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_107",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "following factors render patients at high risk for complications from pneumococcal infections: >65\nyears of age, chronic cardiovascular or pulmonary disease, diabetes mellitus, alcoholism, cirrhosis,\ncerebro-spinal fluid (CSF) leaks, immunosuppression, functional or anatomic asplenia, or HIV\ninfection. \nStrains of drug-resistant S. pneumoniae have become increasingly common in the United\nStates and in other parts of the world (403).  In certain areas of the US, approximately 35% of\ninvasive isolates have intermediate (MIC= 0.1-1.0 ug/ml) susceptibility or high-level (MIC >2 ug/ml)\nresistance to penicillin (404).  Because many of the penicillin-resistant strains of pneumococci are also\nresistant to other antimicrobial agents (e.g., erythromycin, trimethoprim-sulfamethoxazole [TMP-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 107,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_108",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "resistant to other antimicrobial agents (e.g., erythromycin, trimethoprim-sulfamethoxazole [TMP-\nSMZ], and extended-spectrum cephalosporins), therapeutic management of invasive penumococcal\ninfections (e.g., pneumonia) becomes difficult and expensive.\nThe 23-valent vaccine is cost-effective and protective against invasive pneumococcal disease\nwhen administered to immunocompetent persons aged >5 years, and although not as effective for\nimmunocompromised patients as for immunocompetent persons, its potential benefits and safety\njustify its use on this group of patients (405;406).  The Advisory Committee on Immunization\nPractices (ACIP) recommends the administration of the vaccine to the following: a)\nimmunocompetent persons >65 years of age, persons aged >2-64 years who have chronic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 108,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_109",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "immunocompetent persons >65 years of age, persons aged >2-64 years who have chronic\ncardiovascular disease (e.g., congestive heart failure or cardiomyopathy), chronic pulmonary disease\n(e.g., COPD or ermphysema, but not asthma), diabetes mellitus, alcoholism, chronic liver disease\n(cirrhosis), or CSF leaks; persons aged >2-64 years who have functional or anatomic asplenia; and\npersons aged >2-64 who are living in special environments or social settings; and b) \nimmunocompromised persons aged >2 years with HIV infection, leukemia, lymphoma, Hodgkin’s\ndisease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome, or\nother conditions associated with immunosuppression, such as solid-organ or human-stem-cell",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 109,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_110",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "other conditions associated with immunosuppression, such as solid-organ or human-stem-cell\ntransplantation, and persons receiving immunosuppressive chemotherapy, including long-term\nsystemic corticosteroids (405).\nBecause the 23-valent vaccine does not protect children aged <2 years, the age group with the\nhighest rate of invasive (e.g., bacteremia, meningitis) and noninvasive pneumococcal disease (i.e.,\ncommunity-acquired pneumonia, acute otitis media, and sinusitis), a 7-valent pneumococcal\npolysaccharide protein-conjugate vaccine has been recommended for use in all children aged <2 years\nand for children aged 24-59 months who are at increased risk for pneumococcal disease (e.g., children\nwith sickle cell disease, HIV infection, and other immunocompromising or chronic medical",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 110,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_111",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "with sickle cell disease, HIV infection, and other immunocompromising or chronic medical\nconditions).  ACIP recommends that the vaccine be considered for all children aged 24-59 months,\nwith priority given to children aged 24-35 months, children who are descendants of Alaska natives,\nAmerican Indians, and African-Americans, and children who attend group day-care centers (407).\nIn order to improve vaccination coverage rates among adults, in March 2000, the ACIP\npublished recommendations for the use of the Standing Orders Program (SOP), under which nurses\nand pharmacists are authorized to administer vaccinations according to an institution- or physician-\napproved protocol, without an examination of the patient by a physician (408).  To further facilitate",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 111,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_112",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "the implementation of the SOP, in October 2002, the Centers for Medicare and Medicaid Services\npublished an interim final rule that removes the physician-signature requirement from the Conditions\nof Participation for Medicare and Medicaid in participating hospitals, LTCFs, and home health\nagencies (where it is allowed under local and state laws) i.e., in these institutions, pneumococcal and\n23\ninfluenza vaccines may be administered to a Medicare or Medicaid patient without a written order\nfrom the patient’s physician (409).\nBecause two-thirds or more of patients with serious pneumococcal disease have been\nhospitalized at least once within 4 years before their pneumococcal illness, offering pneumococcal",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 112,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_113",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hospitalized at least once within 4 years before their pneumococcal illness, offering pneumococcal\nvaccine in health-care facilities, e.g., at the time of patient discharge or facility visit, should contribute\nsubstantially to preventing the disease (405;410).\nb.  Use of immune globulin or granulocyte colony-stimulating factor.   Intravenous immune globulin\n(given at 400 mg/kg body weight, once a week) was shown in one study to be efficacious in reducing\nthe overall incidence of nosocomial infections, including gram-negative bacillary pneumonia, in post-\noperative patients (411).  However, its cost-effectiveness in the prevention of health-care-associated\npneumonia has not been studied.\nThe use of hyperimmune globulin (100 mg/kg) against exotoxin A, Klebsiella spp., and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 113,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_114",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The use of hyperimmune globulin (100 mg/kg) against exotoxin A, Klebsiella spp., and\nPseudomonas aeruginosa has not been shown to prevent infections due to these microorganisms\n(412).\nGranulocyte colony-stimulating factor (GCSF) increases the immune response of\ngranulocytopenic patients to infections.  It has been administered to patients with chemotherapy-\ninduced febrile neutropenia (413-415) and to those with acute traumatic brain injury or cerebral\nhemorrhage (416) to decrease the incidence of health-care-associated infections in general.  However,\nmore studies are needed to determine specifically its efficacy in preventing pneumonia.\nc.  Use of glutamine-enriched enteral feeding.   Deficiency of glutamine, an essential amino acid that",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 114,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_115",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "is needed for adequate lymphocyte and enterocyte function, may develop in times of severe illness,\nand contribute greatly to depression of the immune response and increased gut permeability.  The\nintravenous administration of glutamine has been shown to help maintain integrity of the intestines\n(417) and glutamine-enriched enteral feeding was associated with lower incidences of VAP and\nbacteremia in multiple-trauma patients (418).  However, more studies are needed to define the role, if\nany, of glutamine administration in the prevention of VAP.\n   \n2.  Administration of Antimicrobial Agents \na.  Prophylactic systemic antimicrobial administration.  Studies that evaluated the effect of systemic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 115,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_116",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "administration of an antimicrobial agent on the prevention of health-care-associated pneumonia have\nhad conflicting results (419;420).  In addition, prophylaxis with systemic antibiotics can potentially\ncause the emergence of and superinfection with antimicrobial-resistant microorganisms.  More studies\nare needed to resolve this issue.\nb.  Periodic scheduled change in the class of antimicrobial agents used for empiric therapy of\ninfections.  Kollef et al. showed that the incidence of VAP in the ICU caused by antibiotic-resistant\nGram-negative bacilli decreased significantly when a scheduled change was made in the class of\nantimicrobial agents (i.e., from a third-generation cephalosporin to a quinolone) used for empiric",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 116,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_117",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "antimicrobial agents (i.e., from a third-generation cephalosporin to a quinolone) used for empiric\ntherapy of suspected Gram-negative bacillary infections in patients undergoing cardiac surgery (421). \nThe authors attributed this finding to the quinolone’s prevention of the emergence of infections that\nwere not suppressed previously by the cephalosporin.  However, they also noted the possibility that\nthe decrease in the rate of VAP may have been due to other factors not measured in the study. In a\nvery similar study, Gruson et al. showed a decrease in the incidence of VAP caused by multi-resistant\nmicroorganisms after they instituted a strategy of antibiotic-use control in the medical ICU as follows:\n24",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 117,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_118",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "24\n1) restriction of the use of cefetazidime and ciprofloxacin for empiric or definitive therapy; 2) rotation\nof antimicrobial agents for use in the unit; and 3) supervision and control of antibiotic use by\ndesignated personnel (422).  The use of this approach specifically to prevent health-care-associated\npneumonia needs further evaluation. \n3.  Turning or Rotational Therapy\nTurning or rotational therapy is used to prevent pulmonary and other complications of\nprolonged immobilization or bed rest as occur in patients with acute stroke, critical illness, head injury\nor traction, blunt chest trauma, and/or mechanically assisted ventilation (423-429).  In the last two\ndecades, automated beds or cushions have been used to provide turning therapy to immobilized",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 118,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_119",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "decades, automated beds or cushions have been used to provide turning therapy to immobilized\npatients.  These equipment fall into 2 general classes based on the turning angle: the “kinetic” bed\n(i.e., one that achieves a 62o-angle turn), and the continuous lateral rotational therapy (CLRT) bed\n(i.e., one that turns <40° along its longitudinal axis).  Among the hypothesized benefits of using these\nbeds are improved drainage of secretions within the lungs and lower airways, increased tidal volume,\nand reduction of venous thrombosis and its sequela, pulmonary embolization (430;431).\nCook et al. reviewed five randomized controlled studies that evaluated the efficacy of CLRT\nin preventing pneumonia (342;423;425-427;429).  Although all five studies showed a lower incidence",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 119,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_120",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "in preventing pneumonia (342;423;425-427;429).  Although all five studies showed a lower incidence\nof pneumonia in patients placed on CLRT compared to those on standard beds, only the study by\nFink et al. showed a significant difference between the two rates ( i.e., 7/51 [14%] vs 19/48 [40%],\nrespectively, RR=0.35, 95% CI: 0.16-0.75) (427).  In addition, in all the studies, one or more patients\nin the CLRT group had to discontinue treatment because of discomfort, chest pain, or difficulty\nmaintaining IV access, and in all the studies, the diagnosis of pneumonia was based on clinical criteria\nand cultures of endotracheal aspirates.\nA more recent study also has shown the association of turning therapy and lower incidence of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 120,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_121",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "A more recent study also has shown the association of turning therapy and lower incidence of \npneumonia (432); however, a decrease in patient mortality was not shown in this or other previous\nstudies (425-427;429;432).  One other study reported no beneficial effect on incidence of pneumonia,\nlength of ICU stay, or duration of mechanical ventilation (433).\nTurning therapy is expensive; Kirschenbaum et al. estimated CLRT to cost a patient $100-\n150/day.  In the report by Cook et al., four patients would  have to be on CLRT instead of the\nstandard bed in order to prevent one case of health-care-associated pneumonia (342).  Cost-\neffectiveness studies that utilize more specific diagnostic tests for pneumonia should be done before\nCLRT becomes routine therapy.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED BACTERIAL  PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 121,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_122",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE]\nLegionnaires disease is a multi-system illness, with pneumonia, caused by Legionella spp.  In\ncontrast, Pontiac fever is a self-limited influenza-like illness, without pneumonia, that is associated\nwith Legionella spp. (434).\nI.  EPIDEMIOLOGY\nNumerous outbreaks of health-care-associated Legionnaires disease have been reported and\nhave provided the opportunity to study the epidemiology of epidemic legionellosis.  In contrast, the\nepidemiology of sporadic (i.e., non-outbreak-related) health-care-associated Legionnaires disease has\nnot been well elucidated.  However, data suggest that when one case is recognized, the presence of\nadditional cases should be suspected.  Of 196 cases of health-care-associated Legionnaires disease",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 122,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_123",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "additional cases should be suspected.  Of 196 cases of health-care-associated Legionnaires disease\nreported in England and Wales during 1980-1992, 69% occurred during 22 institutional outbreaks\n(defined as two or more cases occurring at an institution during a 6-month period) (435).  Nine\npercent of cases occurred >6 months before or after an institutional outbreak.  Another 13% were in\nfacilities where other sporadic cases (but no outbreaks) were identified.  Only 9% occurred at\ninstitutions where no outbreaks or additional sporadic cases were identified.\nThe overall proportion of health-care-associated pneumonia due to Legionella spp. in North\nAmerica has not been determined, although individual health-care institutions have reported ranges of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 123,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_124",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "0%-14% (436-438).  During an outbreak, the proportion of health-care-associated pneumonia due to\nLegionnaires disease may be as high as 50%.   Because diagnostic tests for Legionella spp. infection\nare not routinely performed on all patients with health-care-associated pneumonia in most U.S.\nhealth-care facilities, these ranges probably underestimate the incidence of Legionnaires disease (439). \nLegionella spp. are commonly found in various natural and man-made aquatic environments\n(440;441) and may enter hospital water systems in low or undetectable numbers (442;443).  Cooling\ntowers, evaporative condensers, heated potable-water-distribution systems within health-care\nfacilities, and locally produced distilled water can provide a suitable environment for these",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 124,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_125",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "facilities, and locally produced distilled water can provide a suitable environment for these\nmicroorganisms to multiply.  Factors known to enhance colonization and amplification of Legionella\nspp. in man-made water environments include temperatures of 25-42oC (444-448), stagnation (449),\nscale and sediment (445), and the presence of certain free-living aquatic amoebae that are capable of\nsupporting intracellular growth of Legionella spp. (450;451).\nA person's risk for acquiring legionellosis following exposure to contaminated water depends\non a number of factors, including the type and intensity of exposure and the exposed person's health\nstatus (452-455).  Persons with severe immunosuppression from organ transplantation or chronic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 125,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_126",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "status (452-455).  Persons with severe immunosuppression from organ transplantation or chronic\nunderlying illnesses (e.g., hematologic malignancy or end-stage renal disease) are at markedly\nincreased risk for legionellosis (452;454;456-461).  Persons with diabetes mellitus, chronic lung\ndisease, or non-hematologic malignancy; those who smoke cigarettes; and the elderly are at\nmoderately increased risk (434).  Health-care-associated Legionnaires disease also has been reported\nin patients infected with the HIV (462;463) as well as among neonates and older patients at children's\nhospitals; the latter cases account for 24% of reported pediatric cases of Legionnaires disease (464-\n467). \nUnderlying disease and advanced age are not only risk factors for acquiring Legionnaires",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 126,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_127",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "467). \nUnderlying disease and advanced age are not only risk factors for acquiring Legionnaires\ndisease but also for dying from the illness.  In a multivariate analysis of 3,524 cases reported to CDC\n26\nfrom 1980 through 1989, immunosuppression, advanced age, end-stage renal disease, cancer, and\nhealth-care-associated acquisition of disease were each independently associated with a fatal outcome\n(454).\n \nThe mortality from Legionnaires disease declined markedly between 1980 and 1998: from\n34% to 12% for all cases, from 46% to 14% for nosocomial cases, and from 26% to 10% for\ncommunity-acquired cases (468).  It is not clear whether this decline reflects changes in empiric\ntherapy for community- and health-care-associated pneumonia, or detection of milder cases of\nLegionnaires disease.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 127,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_128",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Legionnaires disease.\nII.  DIAGNOSIS\nThe clinical spectrum of disease due to Legionella spp. is broad and ranges from\nasymptomatic infection to rapidly progressive pneumonia.  Legionnaires disease cannot be\ndistinguished clinically or radiographically from pneumonia caused by other agents (469-471), and\nevidence of infection with other respiratory pathogens does not rule out the possibility of concomitant\nLegionella spp. infection (472;473). \nThe diagnosis of legionellosis may be confirmed by any one of the following: isolation of\nLegionella sp. from culture(s) of respiratory secretions or tissues, microscopic visualization of the\nbacterium in respiratory secretions or tissue by immunofluorescent microscopy, or, for legionellosis",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 128,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_129",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "due to L. pneumophila serogroup 1, detection of L. pneumophila serogroup-1 antigens in urine by\nradioimmunoassay or ELISA, or observation of a fourfold rise in L. pneumophila serogroup-1\nantibody titer to $1:128 in paired acute and convalescent serum specimens by use of an indirect\nimmunofluorescent antibody test (IFA) (474-477).  A single elevated antibody titer does not confirm\na case of Legionnaires disease because IFA titers $1:256 are found in 1%-16% of healthy adults\n(478-481).\nBecause the above tests complement each other, performing each test when Legionnaires\ndisease is suspected increases the probability of confirming the diagnosis.  However, because none of\nthe laboratory tests is 100% sensitive, the diagnosis of legionellosis is not ruled out even if one or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 129,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_130",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "more of the tests are negative (474).  Of the available tests, the most specific is culture isolation of\nLegionella sp. from any respiratory tract specimen (474).\n Since the 1990s, the selection of diagnostic tests for Legionnaires disease has changed\ndramatically (468).  The urine antigen has become the most frequent test by which reported cases of\nLegionnaires disease are detected.  Diagnosis by culture and by direct fluorescent antibody and\nserologic testing decreased significantly.  The consequence of this change is that cases of\nLegionnaires disease caused by species and serogroups other than L. pneumophila serogroup 1 have\nbeen rarely reported.  This may allow undetected transmission of these microorganisms.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 130,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_131",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "been rarely reported.  This may allow undetected transmission of these microorganisms.\nTherefore, when the diagnosis of Legionnanires’ disease is being considered, patients should\nbe tested with both the urine antigen test and cultures of appropriate respiratory specimens.  The use\nof both tests allows rapid diagnosis of infections due to L. pneumophila serogroup 1 and detection\nand collection of isolates of all Legionella species and serogroups (468).\nIII.  MODES OF TRANSMISSION\nInhalation of aerosols of water contaminated with  Legionella spp. is believed to be the\nprimary mechanism of entry of these microorganisms into a patient's respiratory tract (434).  In\n27\nseveral hospital outbreaks, patients were considered to have been infected from their exposure to",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 131,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_132",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "several hospital outbreaks, patients were considered to have been infected from their exposure to\ncontaminated aerosols generated by cooling towers, showers, faucets, respiratory therapy equipment,\nand room-air humidifiers (291;306;471;482-488).  In other studies, aspiration of contaminated\npotable water or pharyngeal colonizers has been proposed as the mode of transmission to certain\npatients (486;489-492).  Person-to-person transmission has not been observed.\nIV.  DEFINITION OF HEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE\nThe incubation period for Legionnaires disease is generally 2-10 days (493); thus, for\nepidemiologic purposes in this document, laboratory-confirmed legionellosis that occurs in a patient",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 132,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_133",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "who has spent $10 days continuously in a health-care facility prior to onset of illness is considered\ndefinite health-care-associated Legionnaires disease, and laboratory-confirmed infection that occurs\nin a patient who has spent 2-9 days in a health-care facility before onset of illness is considered\npossible health-care-associated infection.\nV.  PREVENTION AND CONTROL MEASURES\nA.  Prevention of Legionnaires Disease in Health-Care Facilities with No Identified Cases\n(Primary Prevention)\nIt is essential that health-care facilities with no cases of health-care-associated legionellosis\nformulate prevention strategies in accordance with each facility’s specific situation.  Therefore, these\nstrategies may vary by institution, depending on the immunologic status of the patients, the design",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 133,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_134",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "strategies may vary by institution, depending on the immunologic status of the patients, the design\nand construction of the facility, resources available for implementation of the prevention strategies,\nand state and local regulations.\nThere are at least two schools of thought regarding the most appropriate and cost-effective\napproach to prevent health-care-associated legionellosis, especially in facilities where no cases or only\nsporadic cases of the illness are detected.  However, a study comparing the cost-benefit ratios of\nthese strategies has not been done.\nThe first approach is based on periodic, routine culturing of water samples from the health-\ncare facility’s potable water system, for Legionella spp. (494;495).  If any sample is culture-positive,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 134,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_135",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "diagnostic testing for Legionnaires disease is recommended for all patients with health-care-\nassociated pneumonia and the tests are made available to clinicians, either in-house or through a\nreference laboratory.  In-house testing is recommended in particular for facilities with transplant\nprograms (495).  When >30% of the samples obtained are culture-positive for Legionella spp., the\nfacility's potable water system is decontaminated.  This approach is based on the premise that no cases\nof health-care-associated legionellosis can occur in the absence of Legionella spp. from the potable\nwater system, and, conversely, once Legionella spp. are cultured from the water, cases of health-\ncare-associated legionellosis may occur (489;496).  Proponents of this strategy indicate that when",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 135,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_136",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "care-associated legionellosis may occur (489;496).  Proponents of this strategy indicate that when\nphysicians are informed that the potable water system of the facility is culture-positive for Legionella\nspp., they are more inclined to conduct the necessary tests for legionellosis (497).  A potential\nadvantage of this approach is the lower cost of culturing a limited number of water samples, if the\ntesting is done infrequently, compared with the cost of routine laboratory diagnostic testing for\nlegionellosis in all patients with health-care-associated pneumonia in facilities that have had no cases\nof health-care-associated legionellosis.\n28\nThe main argument against this approach is that in the absence of cases, the relationship",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 136,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_137",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "28\nThe main argument against this approach is that in the absence of cases, the relationship\nbetween the results of water cultures and the risk of legionellosis remains undefined.  The bacterium\nhas been frequently present in hospital water systems (498), often without being associated with\nknown cases of disease (317;437;499).  In a study of 84 hospitals in Quebec, 68% were found to be\ncolonized with Legionella spp., and 26% were colonized at >30% of sites sampled; however, cases of\nLegionnaires disease were rarely reported from these hospitals (317).  Interpretation of the results of\nroutine culturing of water may be confounded by variable culture results from sites sampled within a\nsingle water system and by fluctuations in the concentration of Legionella spp. in the same site",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 137,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_138",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "single water system and by fluctuations in the concentration of Legionella spp. in the same site\n(500;501).  In addition, the risk of illness following exposure to a given source may be influenced by\na number of factors other than the presence or concentration of microorganisms; these include the\ndegree to which contaminated water is aerosolized into respirable droplets, the proximity of the\ninfectious aerosol to potential host, the susceptibility of the host, and the virulence properties of the\ncontaminating microbial strain (502;503).  Thus, data are insufficient to assign a level of risk for\ndisease even on the basis of the number of colony-forming units detected in samples from the hospital\nenvironment.  By routinely culturing water samples, many health-care facilities will have to be",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 138,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_139",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "environment.  By routinely culturing water samples, many health-care facilities will have to be\ncommitted to water-decontamination programs to eradicate Legionella spp.  Because of this problem,\nroutine monitoring of water from the hospital's potable water system and from aerosol-producing\ndevices, although instituted in some health-care facilities and in certain locality (494;495), has not\nbeen recommended universally (504).\nThe second approach to prevent and control health-care-associated legionellosis is by\n a) maintaining a high index of suspicion for legionellosis and appropriately using diagnostic tests for\nlegionellosis in patients with health-care-associated pneumonia who are at high risk of developing the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 139,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_140",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "disease and dying from the infection (437;505); b) initiating an investigation for a facility source of\nLegionella spp., which may include culturing of facility water for Legionella spp. upon identification\nof one case of definite or two cases of possible health-care-associated Legionnaires disease; c)\nroutinely maintaining cooling towers and potable-water systems, and filling nebulization devices only\nwith sterile fluid (e.g., sterile water or aerosol medication); and d) circulating potable water at\ntemperatures not conducive to the amplification of Legionella spp. (i.e., storing and distributing cold\nwater below 20oC (68oF) and storing hot water above 60oC (140oF) and circulating it at a  minimum\nreturn temperature of 51oC [124oF]) (504;506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 140,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_141",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "return temperature of 51oC [124oF]) (504;506).\nAt present, diagnostic testing for legionellosis is underutilized.  In one large study, only 19%\nof hospitals routinely performed testing for legionellosis among patients at high risk for health-care-\nassociated Legionnaires disease (439;457).  The establishment of formal testing protocols in health-\ncare facilities can improve the recognition of cases of health-care-associated legionellosis and\nfacilitate focused, cost-effective interventions to reduce transmission.\nCulturing of the facility water system for Legionella spp. may be appropriate if performed to\nevaluate the suspected source of infection as part of an outbreak investigation, to assess the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 141,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_142",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "evaluate the suspected source of infection as part of an outbreak investigation, to assess the\neffectiveness of water treatment or decontamination protocols, or to evaluate the potential for\ntransmission in health-care facilities with patients at exceedingly high risk of developing Legionniares’\ndisease (e.g., HSCT recipients).  Because HSCT recipients are at much higher risk for disease and\ndeath from legionellosis compared to most other patients (439;456;457;507), periodic routine\nculturing for Legionella spp. in water samples from the transplant unit’s potable-water supply can be\ndone (508) as part of a comprehensive strategy to prevent Legionnaires disease in transplant units. \n29\nHowever, the optimal method (frequency, number of sites) for environmental surveillance cultures in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 142,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_143",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "However, the optimal method (frequency, number of sites) for environmental surveillance cultures in\ntransplant units has not been determined, and the cost-effectiveness of this strategy has not been\nevaluated (507).  In addition, because of the absence of data regarding a “safe” concentration of\nLegionella spp. in potable water, the goal of an environmental surveillance for Legionella spp. in\ntransplant units, if undertaken, should be to maintain water systems with no detectable Legionella\nspp.  More importantly, however, clinicians must 1) maintain a high index of suspicion for\nlegionellosis in HSCT recipients who develop health-care-associated pneumonia and 2) perform\ndiagnostic testing (i.e., culture and urine antigen testing) for legionellosis in all HSCT recipients who",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 143,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_144",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "develop health-care-associated pneumonia, even when environmental surveillance cultures do not\nyield Legionella spp.\nIn the Guidelines for the Prevention of Opportunistic Infections in HSCT Recipients, the\nCDC, Infectious Diseases Society of America, and the American Society of Blood and Marrow\nTransplantation recommend decontaminating the potable-water system of the transplant unit when\nLegionella spp. are detected in its water.  In addition, and until Legionella spp. are eradicated from\nthe water supply, they recommend that a) HSCT recipients should be restricted from taking showers\nusing the unit water; b) sponge baths should be given to patients using water that is not contaminated\nwith Legionella spp.; c) faucet water in patient rooms or outpatient clinics should not be used so as",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 144,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_145",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "not to create infectious aerosols, and d) water that is free of Legionella spp., e.g., sterile water,\nshould be used by transplant recipients for drinking, tooth brushing, or flushing of nasogastric tubes\n(485;490;507;509).\nMeasures aimed at creating an environment that is not conducive to survival or multiplication\nof Legionella spp. have been used in facilities where cases of health-care-associated legionellosis have\nbeen identified.  These measures include routine maintenance of potable water at >51oC (124°F) or\n<20oC (68oF) at the tap (in localities where it is allowed by state law) or chlorination of heated water\nto achieve 1-2 mg/L free residual chlorine at the tap, especially in areas where immunosuppressed and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 145,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_146",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "other high-risk patients are located (504;510-516).  If the temperature setting of 51°C is permitted,\nscalding becomes a possible hazard; one method of preventing scalding is to install preset\nthermostatic mixing valves. Where buildings cannot be retrofitted, periodically increasing the\ntemperature to at least 66°C (150°F) at the point of use (i.e., faucets) or chlorination followed by\nflushing can be used to control the growth of Legionella spp. (511;513;514).  Systems should be\ninspected annually to ensure that thermostats are functioning properly.  Hot or cold water systems\nthat incorporate an elevated holding tank should be inspected and cleaned annually, and lids should fit\ntightly to exclude foreign material.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 146,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_147",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tightly to exclude foreign material.\nB.  Prevention of Legionnaires Disease in Health-Care Facilities with Identified Cases\n(Secondary Prevention)\nThe indications for a full-scale environmental investigation to search for and subsequently\ndecontaminate identified environmental sources of Legionella spp. in health-care settings remain to be\nelucidated and probably vary from one health-care facility to another.  In facilities where as few as 1-3\nhealth-care-associated cases have been identified over a period of up to several months, intensified\nsurveillance for Legionnaires disease has frequently detected numerous additional cases\n(457;483;486;512;517;518).  This suggests the need for a low threshold for initiating an",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 147,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_148",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(457;483;486;512;517;518).  This suggests the need for a low threshold for initiating an\ninvestigation following the identification of health-care-associated, laboratory-confirmed cases of\n30\nlegionellosis.  However, when developing a strategy to respond to such an identification, infection-\ncontrol personnel should consider the level of risk for acquisition of, and mortality from, Legionella\nspp. infection at their particular facility.\nThe Guidelines for the Prevention of Opportunistic Infections in HSCT Recipients recommend\nthat in a health-care facility with an HSCT program, the performance of a thorough investigation to\nidentify the source(s) of Legionella spp. (and the subsequent disinfection, decontamination, and/or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 148,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_149",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "identify the source(s) of Legionella spp. (and the subsequent disinfection, decontamination, and/or\nremoval of the identified source(s) of Legionella spp.) should be done even when only one definite or\none possible case of laboratory-confirmed health-care-associated Legionnaires disease is identified in\nan inpatient HSCT recipient or in two or more HSCT recipients who had visited an outpatient HSCT\nunit during all or part of the 2-10 day period before illness onset (507).\nAn epidemiologic investigation of the source of Legionella spp. involves several important\nsteps, including 1) retrospective review of microbiologic and medical records, 2) active surveillance\nto identify all recent or ongoing cases of legionellosis, 3) identification of potential risk factors for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 149,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_150",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection (including environmental exposures, such as showering or use of respiratory-therapy\nequipment) by line listing of cases; analysis by time, place, and person; and comparison with\nappropriate controls, 4) collection of water samples from environmental sources implicated by the\nepidemiologic investigation and from other potential sources of aerosolized water, and 5) subtype-\nmatching between Legionella spp. isolated from patients and environmental samples (488;519-521). \nThe latter step can be crucial in supporting epidemiologic evidence of a link between human illness\nand a specific source (522-524).\nIn facilities where the cooling towers are found to be contaminated, measures that have been\npreviously published should be used for decontamination (504;506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 150,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_151",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "previously published should be used for decontamination (504;506).\nIn facilities where the heated-water system has been identified as the source of the organism,\nemergency decontamination of the system has been achieved by pulse (one-time) thermal disinfection\nor superheating (504;513;514;516;525).  In thermal decontamination, the hot water temperature is\nraised to 71°-77°C (160°-170°F) and maintained at that level while each outlet around the system is\nprogressively flushed (526).  A minimum flush time of 5 minutes has been recommended; however,\nthe optimal flush time is not known, and longer flush times may be necessary.  The number of outlets\nthat can be flushed simultaneously depends on the capacity of the water heater and the flow capability",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 151,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_152",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of the system.  Appropriate safety procedures to prevent scalding are essential; thus, when possible,\nflushing should be performed when the building occupants are fewest or least likely to utilize water\n(e.g., on nights and weekends).  For systems where thermal shock treatment is not possible, shock\nchlorination may provide an alternative (457;504;512-514;525;527).  There is, however, less\nexperience with this method of decontamination, and corrosion of metals in the system may result\nfrom exposures to high levels of free chlorine.  Chlorine should be added, preferably overnight, to\nachieve a free chlorine residual of at least 2 mg/L (2 ppm) throughout the system.  This may require\nchlorination of the water heater or tank to levels of 20-50 mg/L (20-50 ppm).  The pH of the water",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 152,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_153",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "chlorination of the water heater or tank to levels of 20-50 mg/L (20-50 ppm).  The pH of the water\nshould be maintained between 7.0 and 8.0.  Once the decontamination is complete, recolonization of\nthe hot-water systems is likely to occur unless the proper temperatures are maintained or a procedure\nsuch as continuous supplemental chlorination is continued (504;513).\nFollowing either of these procedures, most health-care facilities maintain heated water with a\nminimum return temperature of >51oC (where allowed by state law) or <20oC at the tap or chlorinate\nheated water to achieve 1-2 mg/L free residual chlorine at the tap (437;489;500;504;511-514;528). \n31\nAdditional measures, such as physical cleaning or replacement of hot water storage tanks, water",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 153,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_154",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "31\nAdditional measures, such as physical cleaning or replacement of hot water storage tanks, water\nheaters, faucets, and showerheads and removal of dead legs in the water-distribution system, may be\nnecessary because scale and sediment may accumulate and protect organisms from the biocidal\neffects of heat and chlorine (445;514).  Alternative methods for controlling and eradicating\nLegionella spp. in water systems, such as treatment of water with chlorine dioxide, heavy metal ions\n(i.e., copper/silver ions), ozone, or ultraviolet light  have limited the growth of Legionella spp. under\nlaboratory or operating conditions (515;529-542).  However, more data are needed regarding the\nlong-term efficacy of these methods (543).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 154,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_155",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "long-term efficacy of these methods (543).\nRecent, renewed interest in the use of chloramines has arisen primarily because of concerns\nabout adverse health effects associated with by-products of currently used disinfectants (544).  When\nmonochloramine is used for disinfection, the formation of by-products including trihalomethanes and\nhaloacetic acids is minimized.  In addition, however, monochloramine reaches distal points in a water\nsystem and penetrates into bacterial biofilms better than does free chlorine (545).  A recent study\nindicated that 90% of hospital outbreaks of Legionnaires disease that were associated with potable\nwater system could have been prevented if monochloramine rather than free chlorine had been used",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 155,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_156",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "water system could have been prevented if monochloramine rather than free chlorine had been used\nfor residual disinfection (546).  In another study that retrospectively compared the incidences of\nnosocomial Legionnaires disease among hospitals in central Texas, no cases were noted in facilities\nlocated in municipalities with monochloramine-treated water (547).  And, a survey of 166 US\nhospitals revealed that in hospitals supplied with municipal water that was disinfected with\nmonochloramine, sporadic cases or outbreaks of facility-acquired Legionnaires disease were less\nlikely to occur (548).  However, additional data are needed about the effectiveness of using\nmonochloramine before a recommendation can be made for its routine use as a disinfectant in health-\ncare-facility water systems.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 156,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_157",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "care-facility water systems. \nBecause of a) the high costs of conducting an environmental investigation and eradicating\nLegionella spp. from sources in health-care facilities (526;549), and b) host-related differences in\npatient risk for acquiring and dying from legionellosis, the decision to search for and eradicate\nLegionella spp. from sources in a facility should be based, to a large extent, on the type of patient\npopulation served by the facility.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "25\nHEALTH-CARE-ASSOCIATED LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 157,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_158",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 32\nHEALTH-CARE-ASSOCIATED PERTUSSIS]\nPertussis is a highly infectious acute respiratory tract infection caused by Bordetella pertussis\nand typically characterized by progressive, repetitive, and paroxysmal cough that usually lasts for 6-8\nweeks.  Whooping cough, post-tussive vomiting, and episodes of cyanosis or apnea also may occur,\nusually in children.  In some cases, a chronic cough may persist for several months.\nI.  EPIDEMIOLOGY\nB. pertussis is most noted for causing serious disease during infancy and early childhood\n(550;551).  The morbidity (e.g., pneumonia, seizures, encephalopathy, and prolonged\nhospitalization) and mortality due to pertussis had decreased dramatically after routine childhood",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 158,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_159",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hospitalization) and mortality due to pertussis had decreased dramatically after routine childhood\nimmunization against pertussis was implemented (552).  However, the disease has not been\neliminated, and in the last two decades, the reported incidence of pertussis, including pertussis in\nadults (both young and elderly), adolescents and older children, has increased (553-561).  It is\nestimated that 1-2 in 1,000 adolescents and adults contract pertussis each year (562).  These infected\nadolescents and adults often serve as reservoirs for pertussis in young infants who are unimmunized\nor incompletely immunized (563).  Pertussis in adults may result in pneumonia, urinary incontinence,\nor sinusitis (564).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 159,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_160",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "or sinusitis (564).\nOutbreaks of pertussis in health-care settings may follow the introduction of the infection\ninto the facility by admission of infant(s) with pertussis.  This may occur during a community\noutbreak of pertussis, which is often associated with increased hospitalizations and deaths in young\nchildren.  Adults with cough, including health-care personnel or visitors, can also be a major source\nof pertussis in the health-care setting (562;565-570), especially because they can shed the\nmicroorganism for prolonged periods before the infection is detected or diagnosed.\nII.  DIAGNOSIS\nThe classic clinical characteristics of pertussis in infants, i.e., catarrh and paroxysmal cough\nfollowed by prolonged convalescence, are usually distinguishable from those of other respiratory",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 160,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_161",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "followed by prolonged convalescence, are usually distinguishable from those of other respiratory\ntract infections after several weeks of cough.  However,  the clinical presentation of pertussis in the\npreviously immunized person (older child, adolescent, or adult) is often, although not always,\natypical (561).  The illness may be mild but protracted.  Patients may have a prolonged cough lasting\nfor several weeks, without the classic “whoop” (571;572).\nLaboratory diagnosis of pertussis is difficult (573).  Of the different laboratory tests that have\nbeen developed, the best method for confirmation of pertussis remains culture isolation of B.\npertussis from nasopharyngeal secretions (574).  The other laboratory tests (i.e., direct fluorescein-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 161,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_162",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "conjugated antibody [DFA] tests, polymerase chain reaction [PCR] assays, and serologic assays)\neither have not been standardized or validated for general use (PCR and serologic tests), or have low\nsensitivity and specificity (DFA tests).\nDFA tests have been used widely for screening purposes, but some tests have had low\nsensitivity (38%) and specificity (up to 85% cross-reactivity with normal nasopharyngeal flora) for\ndiagnosing pertussis (573-576) and require a high level of technical care and experienced personnel\nfor accurate interpretation of results.  A newer DFA test that uses mouse monoclonal antibody was\nshown initially to have 65% sensitivity and 99% specificity when compared to culture (577);\n33",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 162,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_163",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "shown initially to have 65% sensitivity and 99% specificity when compared to culture (577);\n33\nhowever, when it was utilized in an outbreak investigation in 1999, its sensitivity and specificity were\nonly at <30% and 20%, respectively (578).\nPCR assays have been more sensitive than other tests (e.g., they can remain positive for 1-7\ndays longer than culture isolation tests) in patients who have received antimicrobial therapy for\npertussis (579;580).  In one study, the number of PCR-positive samples was 2.4-fold higher than the\nnumber of culture-positive specimens (581).  The sensitivity of PCR, however, may decrease with an\nincrease in patient’s age: in one report, the sensitivities of PCR in patients with <10 days of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 163,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_164",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "increase in patient’s age: in one report, the sensitivities of PCR in patients with <10 days of\nsymptoms were 70%, 50%, and 10% in the age groups <1 year, 1-4 years, and >5 years, respectively\n(582).  The main disadvantages of PCR are the lack of a standardized technique that has been\nvalidated among laboratories and the likelihood of false-positive results (583).  Thus, it has been\nsuggested that as much as possible, whenever a PCR assay is used to diagnose a suspected case of\npertussis, a culture of the patient’s nasopharyngeal secretions should be performed at the same time,\nfor confirmation (578;584).\nSerologic assays for pertussis show potential to be a good diagnostic tool.  Even single-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 164,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_165",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Serologic assays for pertussis show potential to be a good diagnostic tool.  Even single-\nsample determination of titers of IgG and IgA to various pertussis antigens can be highly sensitive\nmostly during the convalescent stage of the disease (576).  For example, a combination of IgG anti-\npertussis toxin and IgA anti-filamentous hemagglutinin enzyme-immunoassay testing (using age-\nspecific reference values) had an estimated sensitivity of 81%-89% in diagnosing pertussis from a\nsingle serum sample taken 5-10 weeks after symptoms had started (585).  Standardized serologic\ntests for pertussis, however, are not available for clinical use in the United States, and only one state\nhealth department laboratory has a standardized technique in use at the present time (578;586).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 165,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_166",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "health department laboratory has a standardized technique in use at the present time (578;586).\n \nIII.  MODES OF TRANSMISSION\nPertussis is transmitted during close contact with an infected person, probably most\ncommonly by direct deposition of B. pertussis on the uninfected person’s respiratory mucosa, from\nlarge droplets generated by the infected person’s cough or sneeze.  Autoinoculation may also occur\nwhen infectious secretions are picked up on hands (directly from the infected person or indirectly\nfrom fomites contaminated with the infected person’s bacteria-laden secretions) and deposited onto\nthe respiratory mucosa.  Patients can also be infected with B. pertussis when their nasal mucosa is",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 166,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_167",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "the respiratory mucosa.  Patients can also be infected with B. pertussis when their nasal mucosa is\ntouched by contaminated hands of other persons (e.g., health-care personnel), or by contaminated\nobjects.\nIn one study, B. pertussis deoxyribonucleic acid (DNA) was recovered from air samples from\nfilters placed as far as 4 meters from the bedside of a patient with pertussis (587).  Transmission of\npertussis by the airborne route, however, i.e., via droplet nuclei carried by air currents over long\ndistances, has not been shown.\nIV.  CONTROL MEASURES\nVaccination of infants and children against pertussis (even after the infant or child has had\npertussis) has been effective in reducing the impact of pertussis worldwide.  In the United Sates,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 167,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_168",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pertussis) has been effective in reducing the impact of pertussis worldwide.  In the United Sates,\ncurrent recommendations for childhood vaccination include the use of diphtheria and tetanus toxoids\nand acellular pertussis (DTaP) vaccine (588;589).\nIn recent years, the impetus for universal or selective vaccination of adults with pertussis\nantigens has become stronger with the development of DTaP (590) and the greater realization by the\n34\nmedical community and the public, of the high prevalence of cases of pertussis in adults and\nadolescents and its impact on the transmission of the infection (561).  The occurrence of outbreaks\nof pertussis in highly immunized populations of children aged 11-12 years (591) and adults has",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 168,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_169",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of pertussis in highly immunized populations of children aged 11-12 years (591) and adults has\ncorroborated the finding that vaccine-induced immunity weakens considerably within 6-10 years\nafter vaccination (592) and suggests that booster immunizations for older children, adolescents and\nadults may be necessary for the control of pertussis (593;594).  However, the safety and efficacy of\nbooster vaccinations in adults and children older than 7 years are still under study (578).\nIn health-care institutions that have had pertussis outbreaks, combinations of control\nmeasures have been utilized (565;567).  Successful programs have had several elements in common:\na prevailing high index of suspicion for pertussis infection; performance of diagnostic testing on",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 169,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_170",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "a prevailing high index of suspicion for pertussis infection; performance of diagnostic testing on\npersons with symptoms suggestive of pertussis; prompt initiation of antimicrobial treatment of\nproven and suspected cases of infection and prophylaxis of exposed patients and health-care\npersonnel; granting of administrative leave (from work) status to health-care personnel with\nsuspected pertussis until after they complete 5 days of antimicrobial therapy for pertussis; and\nimplementation of droplet precautions in addition to standard precautions (565;567).  Droplet and\nstandard precautions include: a) placing a patient with suspected or proven pertussis in a private\nroom or placing a patient with proven pertussis in a room with other patients with proven pertussis",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 170,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_171",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "room or placing a patient with proven pertussis in a room with other patients with proven pertussis\nand no other infection; b) wearing a surgical mask when entering the room of a person with\nsuspected or proven pertussis and/or when performing procedures and patient-care activities that are\nlikely to generate sprays of respiratory secretions; c) decontaminating hands with soap and water\nwhen hands are visibly soiled, or with an alcohol-based hand rub when hands are not visibly soiled,\nafter touching respiratory secretions or secretion-contaminated items, whether or not gloves are\nworn (and if gloves are worn, immediately after they are removed) and between patient contacts\n(278); d) using clean, nonsterile gloves when touching respiratory secretions and contaminated items",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 171,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_172",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "or before touching mucous membranes, and removing gloves promptly after use, before touching\ncontaminated items and environmental surfaces, and before going to another patient; e) wearing a\nclean, nonsterile gown during procedures or patient-care activities that are likely to soil clothing or\nskin with respiratory secretions, and removing a soiled gown as promptly as possible; and f) handling\nused patient-care equipment soiled with respiratory secretions in a manner that prevents skin and\nmucous membrane exposures, contamination of clothing, and transfer of the microorganism to other\npatients and environments (279).\nThe use of a prophylactic antimicrobial agent, most notably erythromycin, for household",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 172,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_173",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The use of a prophylactic antimicrobial agent, most notably erythromycin, for household\ncontacts of patients with pertussis has been effective in preventing culture-positive pertussis (595). \nChemoprophylaxis is most effective if administered within 3 weeks of the onset of cough in the index\ncase (578).  In an earlier review of 14 studies that evaluated the use of erythromycin for preventing\nsecondary transmission of pertussis to close contacts of primary cases, Dodhia and Miller concluded\nthat the protection afforded by such chemoprophylaxis is at best, modest and inferior to that from\nadministering whole-cell vaccine; however, some of the contacts in the studies started taking\nprophylaxis more than 3 weeks after cough onset in the index case (596).  Adverse events, such as",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 173,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_174",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "prophylaxis more than 3 weeks after cough onset in the index case (596).  Adverse events, such as\nnausea, vomiting, and abdominal pain, were reported in association with erythromycin intake in three\nof the studies (596).  In addition to these reports, post-exposure prophylaxis with erythromycin in\nneonates has been associated with the development of infantile hypertrophic pyloric stenosis (IHPS)\n(597;598).  In one study, infants given erythromycin in the first 2 weeks of life had an 8-fold\n35\nincreased risk for IHPS compared with infants not exposed to erythromycin (598).  These findings\nsuggest that erythromycin should be given with caution to very young infants (i.e., those <2 weeks\nof age).  The American Academy of Pediatrics recommends that physicians who prescribe",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 174,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_175",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of age).  The American Academy of Pediatrics recommends that physicians who prescribe\nerythromycin to newborn infants should inform parents about the potential risks of IHPS\ndevelopment and signs of IHPS (599). \nNevertheless, erythromycin remains the drug of choice for treatment of and\nchemoprophylaxis for pertussis in persons who are not hypersensitive to the drug (578;599-601).  In\ntwo outbreaks occurring in the health-care setting, health-care personnel with prolonged coughing\nthat was possibly pertussis were treated with erythromycin for 14 days, and those with proven or\nprobable pertussis were given a 5-day sick leave during the first 5 days of therapy (565;566).  In one\ncenter, a case of nosocomial pertussis occurred in one of 61 erythromycin-treated health-care",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 175,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_176",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "center, a case of nosocomial pertussis occurred in one of 61 erythromycin-treated health-care\npersonnel; this necessitated treatment of all (exposed) unit personnel with a second course of another\nantibiotic for 10 days (566).  In the other center, only one case of  nosocomial  pertussis was\nidentified--in an infant who was not able to complete the prescribed course of prophylaxis with\nerythromycin (565). \nOther macrolides have been found to be active against B. pertussis in vitro (602) and have\nbeen used successfully for its eradication; however, data on their clinical efficacy are sparse.  In one\nreport, clarithromycin for 7 days (at 500 mg twice a day for adults or 15 mg/kg/day in divided doses",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 176,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_177",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "for children) and azithromycin for 5 days resulted in the eradication of the microorganism (603).  In\nanother study, treatment of infants and young children with azithromycin for 3 days (at 10\nmg/kg/day) or 5 days (at 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2-5) resulted in the\neradication of B. pertussis from 94% and 100% of nasopharyngeal cultures on days 7 and 14,\nrespectively, after initiation of treatment (604).  The incidence of IHPS in infants aged <2 weeks\ntreated with azithromycin or clarithromycin is unknown.\nFor persons with hypersensitivity and/or intolerance to erythromycin, TMP-SMZ for 14 days\n(at one double-strength tablet twice a day for adults and 8 mg/kg/day TMP, 40 mg/kg/day",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 177,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_178",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(at one double-strength tablet twice a day for adults and 8 mg/kg/day TMP, 40 mg/kg/day\nsulfamethoxazole (SMZ) in 2 divided doses for children) has been successfully used for therapy\n(605) and has been the second-line drug for chemoprophylaxis (567;578;599).\n During institutional outbreaks of pertussis, additional measures have been used to help\ncontrol the transmission of B. pertussis: a) exclusion of health-care personnel who have symptoms of\nupper respiratory tract infection from the care of infants and other high-risk patients, including\nimmunocompromised persons such as HSCT recipients; and b) limiting visitors to only those who do\nnot have symptoms of a respiratory tract infection and are aged >14 years (565).  Although the exact",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 178,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_179",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "role of each of these measures in preventing the transmission of pertussis has not been determined,\ntheir use for control of outbreaks seems prudent.  In one outbreak, the administration of acellular\npertussis vaccine to health-care personnel was used safely as an adjunct to chemoprophylaxis (606). \nAt present, however, there is no pertussis vaccine licensed for use in adults in the U.S.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "32\nHEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 179,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_180",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS]\nI.  EPIDEMIOLOGY\n Aspergillus spp. are ubiquitous fungi, commonly occurring in soil, water, and decaying\nvegetation.  Aspergillus spp. have been cultured from unfiltered air, ventilation systems,\ncontaminated dust dislodged during hospital renovation and construction, horizontal surfaces, food,\nornamental plants (607), and recently, water from hospital water system (608).\n A. fumigatus and A. flavus are the most frequently isolated Aspergillus spp. in patients with\nproven aspergillosis (609-611).  Aspergillosis, most notably IPA, has been recognized increasingly as\na cause of severe illness and mortality in immunocompromised patients, e.g., patients undergoing",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 180,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_181",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "a cause of severe illness and mortality in immunocompromised patients, e.g., patients undergoing\nchemotherapy and/or organ transplantation (including receipt of HSCT or solid-organ transplant)\nand patients with advanced HIV infection, specifically those with CD4 counts of <50/cu mm (610-\n623).  In addition, patients with chronic lung disease such as chronic granulomatous disease (624) or\nwho are receiving prolonged high-dose corticosteroid therapy also are susceptible to aspergillosis\n(625).  Outbreaks of IPA have occurred mainly in severely neutropenic patients, especially those in\nHSCT units (615;621;626-631).  Although IPA has been reported in recipients of solid-organ\ntransplants (e.g., heart, kidney, liver, or lung), its incidence in these patients is lower than in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 181,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_182",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "transplants (e.g., heart, kidney, liver, or lung), its incidence in these patients is lower than in\nrecipients of HSCT (610;625;632-637).\nThe reported attributable mortality from IPA has varied according to patient risk groups. \nMortality rates of up to 94% in recipients of allogeneic HSCT, 13%-80% in patients with aplastic\nanemia and leukemia (including non-allografted, intensely treated neutropenic patients with multiple\nmyeloma), >80% in HIV-infected persons, and 68-100% in solid-organ transplant patients have been\nreported (610;615;616;621;638-640).  The lower mortality rates observed in some series are\nprobably due to a less specific case-definition of IPA.\nII.  PATHOGENESIS\nPulmonary aspergillosis is acquired primarily by inhalation of the fungal spores.  In severely",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 182,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_183",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Pulmonary aspergillosis is acquired primarily by inhalation of the fungal spores.  In severely\nimmunocompromised patients, primary Aspergillus spp. pneumonia results from local lung tissue\ninvasion (623;641;642).  Subsequently, the fungus may disseminate via the bloodstream to involve\nmultiple other deep organs (609;623;643).  A role for nasopharyngeal colonization with Aspergillus\nspp. as an intermediate step before invasive pulmonary disease has been proposed but remains to be\nelucidated (644;645).  Likewise, colonization of the lower respiratory tract by Aspergillus spp.,\nespecially in patients with preexisting lung disease such as COPD, cystic fibrosis, or inactive\ntuberculosis, was reported to predispose patients to invasive pulmonary or disseminated infection",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 183,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_184",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "tuberculosis, was reported to predispose patients to invasive pulmonary or disseminated infection\n(609;623;646); however, more recent data have not shown the correlation (647). \nHost defenses against Aspergillus spp. involve the mobilization of both macrophages and \ngranulocytes (648).  Alveolar macrophages, by inhibiting germination of fungal conidia, serve as the\nfirst line of defense against airborne pulmonary aspergillus infections.  After aspergilli germinate and\ntheir hyphae invade pulmonary tissue, neutrophils, by secreting microbicidal oxidative metabolites\nthat can damage the fungal hyphae, become the main effector cells involved.  Thus, prolonged,\nsevere neutropenia is a risk factor for IPA (649).  And, because a) corticosteroids suppress",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 184,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_185",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "severe neutropenia is a risk factor for IPA (649).  And, because a) corticosteroids suppress\nmonocyte/macrophage function that includes the release of both oxidative and non-oxidative\nmetabolites, and b) cyclosporine and  tacrolimus (either of which is used in combination with\n37\ncorticosteroids in organ-transplant recipients) inhibit gamma interferon which activates macrophages,\ntheir use in organ-transplant recipients increases the recipients’ risk of aspergillosis.  Low CD4\nlymphocyte count, as occurs in patients with severe and/or end-stage HIV infection, decreases the\nantifungal activity of granulocytes, and chronic granulomatous disease inhibits granulocyte\nrespiratory burst oxidase activity, resulting in impaired microbicidal phagocytosis.\n   \nIII.  DIAGNOSIS",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 185,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_186",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "III.  DIAGNOSIS\nDiagnosing pneumonia due to Aspergillus spp. is often difficult (612).  Clinical signs and\nsymptoms, such as fever, chest pain, cough, malaise, weight loss, and dyspnea are highly variable and\nnonspecific, and chest x-ray findings can vary from single or multiple nodules with or without\ncavitation, to widespread infiltrates (650).  The definitive diagnosis of pulmonary aspergillosis\nrequires both histopathologic demonstration of branching, septate, nonpigmented hyphae in lung\ntissue and isolation of the microorganism in culture.  Histologic identification in the absence of a\npositive culture gives only a probable diagnosis, because aspergillus hyphae are identical to those of\nFusarium spp., Scedosporium spp., and many other non-pigmented molds.  The examination of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 186,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_187",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Fusarium spp., Scedosporium spp., and many other non-pigmented molds.  The examination of \nBAL fluid by smear (53%-64% sentisivity, 97%-99% specificity, and 75%-84% positive predictive\nvalue for IPA), culture (23%-40% sentisivity, 90% specificity, and 24.% positive predictive value for\nIPA), may be helpful in  some cases (651;652).\n By itself, culture isolation of Aspergillus spp. from respiratory tract specimens of patients\nmay indicate colonization (653).  However, when Aspergillus spp. is grown from the sputum of a\nfebrile, neutropenic patient with a new pulmonary infiltrate, it is highly likely that the patient has\npulmonary aspergillosis (654;655).  Routine blood cultures are remarkably insensitive for detecting\nAspergillus spp. (656).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 187,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_188",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Aspergillus spp. (656).\nAbnormalities detected by computerized tomography (CT) scanning often precede those\ndetected by plain chest radiograph (657).  In neutropenic patients, the most distinctive lesions are\nsmall nodules surrounded by a zone of low attenuation, termed the \"halo sign\" (658-661).  Over\ntime, the nodules may cavitate, resulting in the \"crescent sign,” a thin air crescent near the edge of\nthe nodule.\nTesting for antibodies against Aspergillus spp. has seldom proved helpful in diagnosing\ninvasive aspergillosis in neutropenic patients.  However, recent results from lung transplant\nrecipients suggest that this procedure might be a useful adjunct to other methods of diagnosis (662). \nTechniques have been developed to detect aspergillus galactomannan antigen in serum or urine of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 188,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_189",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Techniques have been developed to detect aspergillus galactomannan antigen in serum or urine of\ninfected patients (663-665)  A sandwich enzyme immunoassay, available in many European\ncountries, has been reported to have a sensitivity of 67-100% and a specificity of 81-99% for\ndetection of galactomannan in serum; however, it is not clear whether this test will allow earlier\ndiagnosis of disease (666-669).  The variable results obtained by using antibody or antigen assays for\nconfirmation of IPA (670) suggest that more studies are needed to determine the appropriate and\ncost-effective clinical applications of these tests (671). \nIV.  RISK FACTORS\nFactors related to the host immune status, as well as various environmental exposures, are",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 189,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_190",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Factors related to the host immune status, as well as various environmental exposures, are\nassociated with increased risk of IPA.  Severe (absolute neutrophil count [ANC] <500 per cubic\nmillimeter) and prolonged (>2 weeks) neutropenia is the most important host risk factor for IPA\n38\n(615;649).  In addition, deficits in neutrophil function are also associated with IPA; these occur in\npatients with chronic granulomatous disease (624), patients receiving supraphysiologic doses of\ncorticosteroids, or patients who develop graft-versus-host disease (GVHD) (619;629;672).  Because\nHSCT recipients experience the most severe degree of neutropenia, they constitute the population at\nhighest risk for developing invasive aspergillosis (639;673).  The tendency of HSCT recipients to",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 190,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_191",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "highest risk for developing invasive aspergillosis (639;673).  The tendency of HSCT recipients to\ncontract severe neutropenia is associated with the type of graft they receive.  While both autologous\n(615) and allogeneic HSCT transplant recipients are severely neutropenic for up to 4 weeks after\ntransplantation, allogeneic transplant recipients may, in addition, develop acute or chronic GVHD\n(674).  The latter may occur up to several months after the procedure; and the disease and/or its\ntherapy (often with high doses of corticosteroids and other immunosuppressive agents) may result in\nsevere neutropenia (675).\nRecently, a shift in the onset of IPA occurring post transplantation has been observed: IPA",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 191,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_192",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Recently, a shift in the onset of IPA occurring post transplantation has been observed: IPA\nnow frequently occurs late (>40 days) after receipt of  HSCT, i.e., during the period when acute\nGVHD occurs, rather than during the earlier period of neutropenia (611;629;674-676).\n In addition to the host’s immune system status, other factors related to the organ-\ntransplantation procedure may be associated with an increased risk of IPA.  Lung-transplant\nrecipients may be at increased risk of IPA because of post-transplantation impairment of local\ndefenses in the bronchial airways (677). \nHospital-based outbreaks of IPA often have been associated with activities that result in an\nincrease in the count of airborne spores of Aspergillus spp. in the hospital environment, such as",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 192,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_193",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "increase in the count of airborne spores of Aspergillus spp. in the hospital environment, such as\noccurs during building demolition, construction, and/or renovation (626;678-685).  Other hospital\nenvironmental sources that have been associated with IPA outbreaks include bird droppings in air\nducts supplying high-risk patient areas (686) and contaminated fireproofing material or damp wood\n(626).  Recently, hospital water was suggested as a possible vehicle for transmission of aspergilli. \nAspergillus spp. were cultured from hospital water and water structures; and  A. fumigatus isolated\nfrom one patient who died of invasive aspergillosis had a random-amplified-polymorphic-DNA\nprofile that was similar to that of isolates obtained from water samples from the patient’s hospital",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 193,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_194",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "room (608).  Larger, controlled studies, however, are needed to determine the role of water in the\ntransmission of aspergillosis.\nAttempts by researchers to identify the health-care environmental source(s) of airborne\nAspergillus spp. by establishing an association between the occurrence of IPA cases and either a) the\nrecovery of Aspergillus spp. from the air or b) an increased concentration of Aspergillus spores  in\nthe air have met with difficulties (687;688).  Often, a correlation between patient and environmental\nisolates could not be demonstrated (628), and on the rare occasion that some patient and\nenvironmental isolates were identical, not all the case-isolates could be matched with those from the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 194,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_195",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "environment (689).  The difficulties are due in part to air-sampling problems, the vast genetic\ndiversity of Aspergillus isolates (690), and the limitations of the various subtyping methods for\nmolds.  Molecular typing techniques, i.e., karyotyping (691) and DNA endonuclease profiling (now\navailable for A. fumigatus) (692;693), have been developed and may aid substantially in identifying\noutbreak sources.\nOur current understanding of the transmission of aspergilli in cases of IPA is based mostly on\ninformation gathered from outbreak investigations.  However, outbreaks of IPA are rare, and the\nmajority of IPA cases occur sporadically.  In addition, since little is known about the incubation\n39",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 195,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_196",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "39\nperiod of IPA, it is very possible that infections identified in the health-care facility are acquired\noutside the hospital.  This may occur prior to admission (i.e., during the ambulatory-care period)\nwhen patients are still receiving treatment for the underlying disease (outside the hospital setting), or\nafter discharge, during the periods of acute and chronic GVHD that occur many months after\ntransplantation (629;694).\nV.  CONTROL MEASURES\nA.  Prevention of Patient Exposure to Aspergilllus spp.\nMost prevention studies have focused on IPA acquired in the hospital setting.  However, in\ndeveloping strategies to prevent IPA in HSCT recipients, infection-control personnel have to\nconsider the patient’s exposures to the fungus not only during the immediate post-transplantation",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 196,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_197",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "consider the patient’s exposures to the fungus not only during the immediate post-transplantation\nperiod in the hospital, but also during a later period when the patient, especially the allogeneic HSCT\nrecipient, may again develop severe neutropenia.  Preventing patient exposures to Aspergillus spp.\noutside the hospital is difficult; but health-care providers can focus on decreasing the patient’s\nexposure to dusty environments and reducing or eliminating obvious sources or reservoirs of\nAspergillus spp., e.g., by removing plants and flowers from rooms where high-risk patients reside or\nreceive medical treatment  (e.g., in ambulatory-care settings) (507;695).\n In the hospital setting, the provision of a PE to house the severely immunocompromised",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 197,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_198",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "In the hospital setting, the provision of a PE to house the severely immunocompromised\npatient, especially the allogeneic HSCT recipient, has been the cornerstone of prevention of IPA and\nother airborne infections.  Although the exact configuration and specifications of the PE may vary\nbetween hospitals, this patient-care area is built to minimize fungal spore counts in air by maintaining\na) central or point-of-use high-efficiency particulate air (HEPA) filtration, b) high rates of room-air\nchanges (>12 per hour), c) directed airflow, incoming at one side of the room and outgoing on the\nopposite side of the room, d) positive room-air pressure relative to the corridor or anteroom, and e)\nwell-sealed rooms (619;678;696-705).  In the 1970s and 1980s, a PE usually was a room with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 198,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_199",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "well-sealed rooms (619;678;696-705).  In the 1970s and 1980s, a PE usually was a room with\nlaminar airflow (LAF) consisting of a bank of filters along an entire wall through which air is pumped\nby blowers into the room at a uniform velocity (90 + 20 feet/minute), forcing the air to move in\nparallel streams or a laminar pattern (706).  The air usually exits at the opposite end of the room, and\nultra-high air-change rates (100-400 per hour) are achieved.  The net effects are essentially sterile air\nin the room, minimal air turbulence, minimal opportunity for microorganism build-up, and a\nconsistently clean environment (619).\n The use of rooms with LAF was effective in decreasing the risk of nosocomial aspergillosis",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 199,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_200",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The use of rooms with LAF was effective in decreasing the risk of nosocomial aspergillosis\nduring the post-transplantation period  in HSCT recipients (619) and in controlling outbreaks of\naspergillosis related to hospital construction (678;681).  However, a resultant reduction in patient\nmorbidity and/or mortality with such a costly and difficult-to-maintain system has not been shown\nconclusively (707).  The past preference for LAF in PE for allogeneic HSCT recipients with aplastic\nanemia and HLA-identical sibling donors stemmed from the association of the use of regular rooms\nwith a patient mortality rate that was about four times higher than that in patients treated in rooms\nwith LAF (696;708;709).  Since the late 1990s, however, the survival of HSCT recipients with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 200,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_201",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "with LAF (696;708;709).  Since the late 1990s, however, the survival of HSCT recipients with\naplastic anemia has far exceeded that reported in the 1980s, and no randomized- control study has\nbeen done to determine whether the use of  PE with LAF for these patients would result in further\nimprovement in survival.  Furthermore, placement of HSCT recipients in a PE with LAF (or HEPA\nfilters) cannot protect the patients against late-occurring invasive aspergillosis (676) and has not\n40\nbeen evaluated in solid-organ transplant recipients.  Thus, at present, the cost-benefit ratio of\nutilizing PE with LAF, even for allogeneic HSCT recipients, may not justify its routine use.\nThe benefit of routinely placing immunocompromised patients other than allogeneic HSCT",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 201,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_202",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The benefit of routinely placing immunocompromised patients other than allogeneic HSCT\nrecipients in PE has not been shown either (705).  Less expensive alternative systems with lower\nrates of air changes per hour (but maintained at >12 per hour) have been used in some centers\n(699;703;706;710;711).\nPreventing exposure to aspergillus spores in the health-care facility also involves prevention\nof exposure to hospital demolition, construction, renovation, and dust-generating cleaning activities\n(679;685).  Recommended measures have been published (506;507;679;685).  In summary, during\nconstruction or renovation, facility planners should a) intensify efforts to seal off patient care units\nthat house those at high risk for invasive aspergillosis (i.e., severely immunocompromised patients)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 202,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_203",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "and keep potentially spore-bearing air from the construction or renovation site from infiltrating the\nrooms or areas where severely immunocompromised patients are housed (712;713); b) clean newly\nconstructed or renovated areas before allowing severely immunocompromised patients to enter\nthem, c) minimize aerosolization of Aspergillus spores during unit cleaning by using vacuums with\nHEPA filters, and cloth wipes and mop heads that have been pre-moistened with an FDA-approved\nhospital disinfectant (714), and d) allow HSCT recipients to leave the PE only for essential\nprocedures that cannot be performed in the patient rooms, and when the patients do leave the PE,\ninstruct them to wear high-efficiency masks in areas near building construction or renovation (715).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 203,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_204",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Although the N95 respirator is untested specifically for its efficacy in reducing exposure to\nApergillus spp. in hospital construction or renovation areas, it can reduce reliably any aerosol\nexposure by 90%, with correct fit testing and training of its user (3;716).\nA topical fungicide, copper-8-quinolinolate, may be helpful in reducing the environmental\nfungal spore burden: it was applied on environmental surfaces contaminated with Aspergillus spp. to\nhelp control a reported outbreak (717) and incorporated in paint or fireproofing material of a newly\nconstructed facility (681).\nB. Chemoprophylaxis\nBecause of the difficulty of preventing patient exposures to Aspergillus spp. in the\nenvironment, chemoprophylaxis with antifungal agents has been employed in an effort to decrease",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 204,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_205",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "environment, chemoprophylaxis with antifungal agents has been employed in an effort to decrease\nthe patient’s risk of IPA (718;719).  However, its cost-effectiveness remains controversial.\nIn trials with historical controls, the use of low-dose amphotericin B (up to 0.25 mg/kg/day)\nprophylaxis or oral fluconazole was associated with reduced deaths from aspergillosis in HSCT or\nlung-transplant recipients (720;721).  In one study, low-dose amphotericin reduced early systemic\nfungal infections and improved patient survival (although the latter effect was not directly related to\nthe prevention of fungal infection) (722).  However, numerous anecdotal reports of breakthrough\ninvasive aspergillosis occurring while patients are on low-dose parenteral amphotericin B suggest",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 205,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_206",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "invasive aspergillosis occurring while patients are on low-dose parenteral amphotericin B suggest\nthat this form of prophylaxis may be only partially effective.  Lipid-based formulations of\namphotericin B, although less nephrotoxic than amphotericin B, are significantly more expensive and\nhave not been shown to provide effective prophylaxis against IPA (723).  Studies on the efficacy of\nnebulized amphotericin B administered by inhalation as prophylaxis for IPA have yielded variable\nresults (724-726).  Two recent studies suggested that itraconazole oral suspension can offer\nprotection against deep fungal infections (including aspergillosis) that is equal to that from oral\n41\namphotericin B (727) and greater than that from oral fluconazole (728).  However, two meta-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 206,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_207",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "41\namphotericin B (727) and greater than that from oral fluconazole (728).  However, two meta-\nanalyses have found no efficacy with the use of azole antifungal agents (e.g., itraconazole,\nfluconazole) or low-dose intravenous amphotericin B for chemoprophylaxis against IPA in patients\nwith malignant disease who have severe neutropenia (729;730).  In light of these equivocal findings,\nit has been recommended that when HSCT recipients’ respiratory specimens are culture-positive for\nAspergillus sp., a presumptive diagnosis of acute IPA should be made and preemptive and\naggressive treatment (e.g., with intravenous amphotericin) should be started (507).\nRelapse of invasive aspergillosis, including IPA, has occurred after HSCT receipt in about",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 207,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_208",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Relapse of invasive aspergillosis, including IPA, has occurred after HSCT receipt in about\n33% of patients who had previous aspergillosis (731).  Some centers have used either prophylactic\nintravenous amphotericin B and surgical removal of potentially infected parts of the lung prior to the\ntransplantation, or intravenous amphotericin or itraconazole until the resolution of neutropenia;\nhowever, the effectiveness of these measures needs further evaluation (672;732-736).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "36\nHEALTH-CARE-ASSOCIATED ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 208,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_209",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 42\nHEALTH-CARE-ASSOCIATED VIRAL PNEUMONIA]\nViruses can be an important and often underestimated cause of health-care-associated\npneumonia (737-740).  In one prospective study of endemic health-care-associated infections,\napproximately 20% of patients with pneumonia had viral infections (738).  Despite advances in\ndiagnosis and treatment of viral respiratory infections, most cases remain undiagnosed and many\npatients in health-care facilities remain at high risk for developing severe and sometimes fatal viral\ninfections (737;741-750).  The potential for prolonged patient hospitalization and its attendant\nincreased health-care costs (751-753), the high risk for serious complications of infection for some",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "42\nHEALTH-CARE-ASSOCIATED VIRAL PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 209,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_210",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients, and the occurrence of nosocomial outbreaks (754;755) underscore the importance of\nimplementing measures to prevent the transmission of respiratory viruses in health-care facilities.\nHealth-care-associated viral respiratory infections 1) usually follow community outbreaks\nthat occur during particular periods every year (755-759), 2) affect healthy and ill persons\n(743;744;751;760-763), and 3) are usually introduced into health-care facilities by patients,\npersonnel, or visitors who have acute infections (764).  A number of viruses, including adenoviruses,\ninfluenza virus, measles virus, parainfluenza viruses, RSV, rhinoviruses, and varicella-zoster virus,\ncan cause health-care-associated pneumonia (744;755;764-772).  However, adenoviruses, influenza",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "42\nHEALTH-CARE-ASSOCIATED VIRAL PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 210,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_211",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "can cause health-care-associated pneumonia (744;755;764-772).  However, adenoviruses, influenza\nviruses, parainfluenza viruses, and RSV account for most (70%) cases of health-care-associated \npneumonia due to viruses (773).\n This section focuses on the principles and approaches to control health-care-associated \nadenovirus, parainfluenza, and RSV infections.  Prevention of health-care-associated influenza is\ndiscussed in another section in this document; infections due to other respiratory viral pathogens are\naddressed in another publication (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "42\nHEALTH-CARE-ASSOCIATED VIRAL PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 211,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_212",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION]\nI.  EPIDEMIOLOGY\nRSV is most noted for causing serious disease during infancy and early childhood. RSV\nbronchiolitis has been documented as the leading cause of hospital admissions for infants <1 year of\nage (774).  However, infection with RSV confers only limited protective immunity; thus, persons can\nbe repeatedly infected and develop serious disease throughout life (751;775;776).  The most\ncommon manifestation of infection is a mild to moderately severe upper respiratory tract illness, but\nserious lower respiratory tract disease, e.g., pneumonia or bronchiolitis, can develop in some\npersons, especially infants, children, and persons with compromised cardiac, pulmonary, or  immune",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 212,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_213",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "persons, especially infants, children, and persons with compromised cardiac, pulmonary, or  immune\nsystems (743;745;752;763;766;777-779).  RSV infection in recipients of HSCT has been associated\nwith mortality rates of  >50% (779).\nRSV transmission in health-care settings usually occurs during yearly community outbreaks\nof RSV infection (between December and March in the North American Continent) and are\nassociated with marked increases in hospitalizations and deaths from pneumonia and bronchiolitis in\nyoung children (774;780;781).  During community outbreaks of RSV infection, children with\nsymptoms of lower respiratory tract disease who are admitted to health-care facilities often are\ninfected with RSV and can introduce RSV into the health-care facility (754;782).  RSV-infected",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 213,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_214",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infected with RSV and can introduce RSV into the health-care facility (754;782).  RSV-infected\npersonnel and visitors can also introduce RSV into health-care facilities.\nII.  DIAGNOSIS\nThe clinical characteristics of RSV infection are often indistinguishable from those of other\nviral respiratory tract infections, although an increase in cases of bronchiolitis in young children is\nhighly suggestive of a community outbreak of RSV infection (783;784).  During laboratory-\ndocumented community outbreaks of RSV infection, pneumonia or bronchiolitis in a young child can\nbe assumed to be caused by RSV for infection control purposes.  However, suspicion of RSV\ninfection in the neonate, the immunosuppressed patient, and the elderly can be confounded.  The",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 214,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_215",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection in the neonate, the immunosuppressed patient, and the elderly can be confounded.  The\nRSV-infected neonate can present not so much with respiratory symptoms as with nonspecific\nsymptoms and signs such as poor feeding, increased irritability and apnea, bradycardia, and difficulty\nbreathing (766;785).  The RSV-infected elderly patient can present with exacerbation of underlying\ncardiac or pulmonary disease and may not be suspected of having a respiratory infection (751;786). \nThe immunosuppressed patient can remain infected and shed virus for prolonged periods of time\nwithout symptoms (743;787).\nLaboratory methods available to diagnose RSV and other viral respiratory infections include\ntraditional tissue culture, shell-vial tissue culture, antigen detection assays, PCR assays, and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 215,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_216",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "traditional tissue culture, shell-vial tissue culture, antigen detection assays, PCR assays, and\nserologic assays.  The optimal method for diagnosing infection varies with the patient’s age\n(777;788;789).  In general, diagnostic assays are effective in detecting acute infection in infants and\nyoung children, but are relatively insensitive in older children and adults.  For example, in infants <6\nmonths of age, virus detection by tissue-culture isolation, antigen detection, or PCR studies is\nsubstantially more sensitive than that by serologic tests (i.e., tests to detect a rise in antibody titer\nbetween acute- and convalescent-phase serum specimens) (790;791).  In previously infected persons\nand in older children and adults, virus detection is progressively less sensitive; and in adults,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 216,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_217",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "and in older children and adults, virus detection is progressively less sensitive; and in adults,\n44\nserologic studies are substantially more sensitive than virus detection (789;792).  The PCR assay for\nviral RNA is generally more sensitive than either tissue culture isolation or antigen detection (792-\n794).\nWhen specimens are handled appropriately, tissue culture isolation is highly sensitive and\nspecific for detecting infection in infants and young children.  Whereas standard viral-isolation\nstudies take days to weeks to detect RSV, the newer shell-vial isolation system can detect RSV\nwithin 24 to 48 hours (795;796).\nThe most rapid way to detect RSV infection (i.e., in <24 hours) is by antigen-detection using",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 217,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_218",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The most rapid way to detect RSV infection (i.e., in <24 hours) is by antigen-detection using\nimmunofluorescence, ELISA, or radioimmunoassay.  The reported sensitivity and specificity of these\ntests, however, can vary between 80% and 95% and may even be lower in actual practice (764;797-\n801).\nIII.  MODES OF TRANSMISSION\nRSV is transmitted during close contact with infected persons, probably most commonly by\nautoinoculation of infectious secretions that are picked up on hands (directly from the infected\nperson or indirectly from fomites contaminated with the infected person’s virus-laden secretions) and\ndeposited onto the conjunctiva or respiratory mucosa; and also by droplet spread, i.e., direct",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 218,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_219",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "deposited onto the conjunctiva or respiratory mucosa; and also by droplet spread, i.e., direct\ndeposition of RSV on a person’s conjunctiva or respiratory mucosa, from large droplets generated\nby an infected person’s cough or sneeze (782;802-804).  Patients can also be infected with RSV\nwhen contaminated objects or hands of other persons (e.g., health-care personnel) touch their\nconjunctiva or respiratory mucosa.  RSV can remain viable on environmental surfaces for up to 6\nhours, sufficiently long to allow its transmission via fomites (803).  In studies of RSV outbreaks in\nhealth-care facilities, it is often possible to identify multiple strains of RSV, indicating that multiple\nsources introduce the virus into the facility (760;762;805;806).  During community outbreaks, RSV-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 219,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_220",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "sources introduce the virus into the facility (760;762;805;806).  During community outbreaks, RSV-\ninfected patients, health-care personnel, and visitors are all potential sources of the virus (807). \nInfected infants, however, are probably the most effective sources of RSV because they shed high\ntiters of the virus for prolonged periods and require very frequent close contact with their care\ngivers, and therefore, present a greater chance of contaminating other persons or their environment\nwith infectious respiratory secretions (808).  Health-care personnel may become infected after\nexposure in the community or in the health-care facility, and in turn, infect patients, other health-care\npersonnel, or facility visitors (767;809).  Patients with suppressed immune systems can remain",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 220,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_221",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "personnel, or facility visitors (767;809).  Patients with suppressed immune systems can remain\ninfectious for prolonged periods of time and be positive for RSV intermittently.\nIV.  CONTROL MEASURES\nVarious combinations of control measures ranging from the simple to the complex have been\neffective in preventing RSV infection and controlling RSV transmission in health-care facilities\n(280;749;809-817).  Successful programs have had two elements in common: implementation of\nstandard and contact precautions (279) and adherence by health-care personnel to these precautions. \nThese precautions include a) hand decontamination with soap and water or an alcohol-based hand\nrub after touching respiratory secretions or secretion-contaminated items, whether or not gloves are",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 221,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_222",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "worn, immediately afer gloves are removed, and between patient contacts (278); b) gloving (with\nclean, nonsterile gloves) upon entering an infected patient’s room or before handling patients, their\nrespiratory secretions or contaminated items, and removing gloves promptly (and decontaminating\n45\nhands) after use, before handling other items or environmental surfaces, and before going to another\npatient; c) gowning (with a clean, nonsterile gown) during procedures or patient-care activities that\nare likely to cause soiling of clothing or skin with respiratory secretions, and removing a soiled gown\nas promptly as possible; d) masking and wearing an eye protector during procedures and patient-care",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 222,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_223",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "as promptly as possible; d) masking and wearing an eye protector during procedures and patient-care\nactivities that are likely to generate sprays of respiratory secretions; and e) handling used patient-care\nequipment soiled with respiratory secretions in a manner that prevents skin and mucous membrane\nexposures, contamination of clothing, or transfer of the virus to other patients and environments\n(279).  Other precautions include a) placing patients with proven or suspected RSV infection in\nprivate rooms or cohorting such patients either by their clinical signs and symptoms or by rapid\nlaboratory testing for RSV (749); and b) limiting patient movement and transport from the room to\nthose for essential purposes only.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 223,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_224",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "those for essential purposes only.\nAdditional measures may be indicated to control ongoing transmission of RSV in health-care\nsettings or prevent transmission to patients at high risk for serious complications of infections (e.g.,\nthose with compromised immune, cardiac, or pulmonary systems).  The following additional control\nmeasures have been used in various combinations: a) pre-admission screening of patients for RSV\ninfection by rapid laboratory diagnostic tests to facilitate patient placement and prevent exposure of\nhigh-risk patients; b) cohorting of personnel; c) exclusion of health-care personnel who have\nsymptoms of respiratory tract infection from the care of patients at high risk of severe or fatal RSV",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 224,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_225",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection, e.g., infants, immunocompromised persons such as HSCT recipients, persons in advanced\nstages of HIV infection, or persons on prolonged corticosteroid therapy; d) limiting visitors to only\nthose who do not have symptoms of a respiratory tract infection; and e) postponing elective\nadmission of patients at high risk for complications from RSV infection\n(749;764;810;813;815;818;819).  Although the exact role of each of these measures in preventing\nRSV transmission has not been determined, their use for controlling outbreaks and protecting\npatients who are at the greatest risk for serious disease is prudent.\nRecently, two products, immune globulin intravenous (IGIV) with a high titer of RSV",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 225,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_226",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Recently, two products, immune globulin intravenous (IGIV) with a high titer of RSV\nneutralizing antibody, and an intramuscular preparation of a humanized mouse monoclonal antibody\nthat neutralizes RSV (palivizumab), have been licensed by the FDA and recommended for the\nprevention of hospitalizations for RSV lower respiratory tract disease in selected children aged <24\nmonths who were born prematurely at <35 weeks gestational age and infants who have chronic lung\ndisease (820).  Palivizumab also is indicated for children with chronic lung disease who have >2 of\nthe following risk factors: child care attendance, school-aged siblings, exposure to environmental\npollutants, congenital abnormality of airways, and severe neuromuscular disease.  Palivizumab,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 226,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_227",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pollutants, congenital abnormality of airways, and severe neuromuscular disease.  Palivizumab,\nwhich is administered in 5 monthly injections of 15 mg/kg during the RSV season, is the preferred\nproduct because of its ease of administration, safety, and effectiveness (820;821).\n  FDA licensure for the use of palivizumab in other groups of children is under consideration. \nThese children include those who are <24 months of age who have hemodynamically significant\ncyanotic or acyanotic congenital heart disease, including infants <12 months of age who have\ncongenital heart disease and are most likely to benefit from immunoprophylaxis, i.e., those receiving\nmedication to control congestive heart failure, those with moderate to severe pulmonary artery",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 227,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_228",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "medication to control congestive heart failure, those with moderate to severe pulmonary artery\nhypertension, and those with cyanotic heart disease (for which RSV-IGIV is contraindicated) (820).\nThe role for prophylactic palivizumab administration in other high-risk populations, e.g.\nthose with cystic fibrosis or immune compromise, has not yet been determined.  It has been\n46\nsuggested that RSV-IGIV could be a substitute for standard IGIV in children with severe\nimmunodeficiencies who are receiving monthly infusions of standard IGIV (820).\nPaliviumab and RSV-IGIV have been shown to prevent hospitalizations for RSV lower\nrespiratory tract disease (821-825); however, their effectiveness in controlling outbreaks of RSV",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 228,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_229",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "respiratory tract disease (821-825); however, their effectiveness in controlling outbreaks of RSV\ninfection in health-care settings, although suggested in one report (826), needs further study.  In\naddition, the high cost of these products makes their use impractical for control or prevention of\nhealth-care-facility outbreaks.  Cost-benefit studies of the prophylactic treatment have had varying\nconclusions: one study suggested that the preparations are cost-beneficial when given as\nrecommended in the infant and young child; the other suggested otherwise (827;828).  A third study\npointed out that various factors, i.e., changes in the incidence of RSV infection, cost of\nhospitalization for RSV infection, and cost of palivizumab, may affect the “incremental” cost-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 229,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_230",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hospitalization for RSV infection, and cost of palivizumab, may affect the “incremental” cost-\neffectiveness of palivizumab (829).  Thus, in the setting of a health-care-associated RSV outbreak, it\nis prudent for attending clinicians to review the status of each hospitalized child and consider the\nadministration of prophylactic RSV antibody preparation to those for whom such prophylaxis is\notherwise recommended.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "43\nHEALTH-CARE-ASSOCIATED  RSV INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 230,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_231",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS]\nI.  EPIDEMIOLOGY\nAll four serotypes of human parainfluenza viruses (HPIV 1-4) are associated with a similar\nrange of respiratory tract illnesses, including upper respiratory tract disease (e.g., a cold and/or sore\nthroat) and serious lower respiratory tract illness (e.g., croup, pneumonia, and bronchiolitis) (830). \nTaken together, the four serotypes of HPIV account for nearly as many cases of respiratory tract\ndisease in children as does RSV (830-834).  HPIV disease is most common in children, but as with\nRSV, infection confers only limited protective immunity, and persons can become infected and ill\nrepeatedly throughout life (835).  Although the four serotypes cause similar illnesses, the frequency",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 231,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_232",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of occurrence and other epidemiologic features of the illnesses differ from each other\n(830;831;836;837).  HPIV-1 is the leading cause of croup in children; and HPIV-2 is a common\ncause of croup in children.  HPIV-3 is less frequently associated with croup than with bronchiolitis\nand pneumonia.  HPIV-4 is infrequently detected presumably because it rarely causes severe disease. \nSince the early 1970s, the observed peaks in the number of detected cases of HPIV-1 infections in\nthe United States have occurred in the fall of odd-numbered years; the peaks in HPIV-2 infections\nhave occurred yearly in autumn; and peaks in HPIV-3 infections have occurred in late spring and\nearly summer (830;835-837).  The seasonal pattern for HPIV-4 infections has not been defined",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 232,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_233",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "early summer (830;835-837).  The seasonal pattern for HPIV-4 infections has not been defined\nbecause of the infection’s infrequent detection and the paucity of studies about the infection.\nII.  DIAGNOSIS\nThe patterns of sensitivity of the various laboratory tests for diagnosing HPIV infections\nsimulate those for RSV infections.  The sensitivity of serologic tests is low in infants <6 months of\nage and high in older children and adults, whereas the sensitivity of virus detection by tissue-culture\nisolation or antigen-detection assays is high in infants and young children and low in adults (838-\n840).  PCR assays appear to be the most sensitive test for detection of infection in infants and young\nchildren (793;841), and was shown recently to be more sensitive than viral culture and antigen",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 233,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_234",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "children (793;841), and was shown recently to be more sensitive than viral culture and antigen\ndetection in adults (842).\nIII.  MODES OF TRANSMISSION \nThe modes of transmission of HPIVs have not been well studied but are likely to be similar to\nthose of RSV, i.e., by direct and indirect contact and by large-droplet transmission.  The viruses are\nprobably transmitted most often when HPIV-contaminated hands or objects touch a susceptible\nperson’s eyes, nose, or possibly mouth.  Hands or objects can be contaminated directly from\nsecretions of infected persons or by fomites previously contaminated by secretions from infected\npersons.  Droplet transmission may possibly occur when HPIV-laden secretions generated by cough",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 234,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_235",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "persons.  Droplet transmission may possibly occur when HPIV-laden secretions generated by cough\nor sneeze from an infected person are directly deposited onto a susceptible person’s conjunctivae,\nnose, or possibly mouth.\nIV.  CONTROL MEASURES   \nThe control measures described in the preceding section on RSV Infection, also are\napplicable for prevention and control of HPIV infections in health-care settings.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "47\nHEALTH-CARE-ASSOCIATED HUMAN PARAINFLUENZA VIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 235,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_236",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION]\nI.  EPIDEMIOLOGY \nAdenovirus infections occur predominantly in childhood and cause acute upper respiratory\nillness (843).  Infections may be asymptomatic (844) and infected individuals may shed the virus for\nmonths or even years (845;846).  Respiratory disease caused by adenovirus is most prevalent in late\nwinter, spring, and early summer (844), but has been observed year-round.  Forty-nine species of\nadenovirus are known to cause human infection, although not all species cause respiratory illnesses\n(846).  Adenovirus infection of the respiratory tract can lead to symptoms of pharyngitis (844;847),\nbronchitis (844), croup (844), or pneumonia (844;848-851).  Adenoviruses may also invade the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 236,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_237",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "bronchitis (844), croup (844), or pneumonia (844;848-851).  Adenoviruses may also invade the\ngastrointestinal tract and cause diarrhea (852), or the conjunctiva and cause conjunctivitis\n(844;847;853;854).  More serious complications leading to higher morbidity and mortality rates can\noccur in immunocompromised patients (855-858), premature infants (857), and patients with\nunderlying pulmonary or cardiac disease (844;859).  These patients may shed the virus for extended\nperiods of time during which they are likely to infect other high-risk patients (857;860;861). \nAdenovirus can also remain latent within lymphatic tissue and become reactivated later upon\nimmunosuppression of the host (846).  \nHealthcare-associated outbreaks of adenovirus infection leading to pneumonia (850;851;861)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 237,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_238",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Healthcare-associated outbreaks of adenovirus infection leading to pneumonia (850;851;861)\nhave occurred in hospital ICUs (860;861), pediatric chronic care facilities (862-864), military\nhospitals (865), and other health-care establishments (850;851).  Infection may be introduced from\nthe community into a hospital setting via staff, patients, or visitors.\nII.   DIAGNOSIS\nClinical signs and symptoms of adenoviral respiratory infections are usually indistinguishable\nfrom those of other viral or bacterial respiratory infections (866).  However, respiratory illness in the\npresence of conjunctivitis is highly suggestive of adenovirus infection.  Adenovirus infection can be\nconfirmed by detecting the virus, its antigens, or its DNA, or by detecting a serologic response to the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 238,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_239",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection.  The virus is most often isolated from respiratory tract specimens (e.g. nasal swabs or\nwashings, throat swabs, sputum, or bronchoalveolar lavage specimens), ocular specimens in patients\nwith conjunctivitis, or stool specimens.  Successful isolation of adenovirus in tissue culture is most\nlikely during the patient’s first week of illness.  Adenovirus antigens can also be demonstrated in the\nabove-noted specimens by enzyme immunoassay, radioimmunoassay, or immunofluorescence, and\nadenovirus DNA, by probe hybridization or PCR assays (867;868).  Antigen or viral DNA detection\nassays have good sensitivity and can be completed in a timely fashion.  Serologically, infection can be\ndemonstrated by detecting a 4-fold rise in complement-fixing, binding (e.g., by immunofluorescence",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 239,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_240",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "demonstrated by detecting a 4-fold rise in complement-fixing, binding (e.g., by immunofluorescence\nor enzyme immunoassays), neutralizing, or hemagglutination-inhibiting antibodies (846;869).  The\ncomplement-fixation and binding assays are not serotype-specific but the neutralization and\nhemagglutination assays are.  Endonuclease restriction, PCR, and sequence studies have been used\nto define distinct strains within adenovirus serotypes and can be used to help confirm linkages\nbetween isolates (868;870-872).\n.III.   MODES OF TRANSMISSION\nThe modes of adenovirus transmission have been studied during outbreaks of\n49\nkeratoconjunctivitis or pharyngoconjunctival fever caused by adenovirus.  In these outbreaks,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 240,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_241",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "49\nkeratoconjunctivitis or pharyngoconjunctival fever caused by adenovirus.  In these outbreaks,\nshedding of adenovirus was demonstrated from 3 days before to 14 days after onset of symptoms\nand viral transmission to contacts was very efficient (873-876).  Transmission appears to occur by\nautoinoculation onto the mucous membranes of the mouth, with hands that have been contaminated\nwith infectious material, such as secretions from the respiratory tract or eye.  The virus can also be\ntransmitted by droplets (851).  Transmission by aerosol, the fecal-oral route, contaminated water,\nand possibly through sexual contact, has been suggested (851;853;877-882), but the exact roles of\nthese modes of transmission in adenovirus respiratory tract infections is unknown.  Since the virus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 241,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_242",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "these modes of transmission in adenovirus respiratory tract infections is unknown.  Since the virus\ncan remain stable on environmental surfaces for prolonged periods of time, fomites are important in\nthe transmission of adenoviruses (883-886).  For example, adenovirus has been reported to retain\nviability up to 49 days on nonporous surfaces such as plastic or metal and 8 to 10 days on cloth and\npaper (883).  Because adenovirus is a non-enveloped virus, it is not inactivated by detergents but can\nbe inactivated by 70%-alcohol or chlorox solutions (887;888).\nIV.   PREVENTION AND CONTROL\nControl of health-care-associated outbreaks of adenovirus infections can be very difficult and\nrequires vigorous infection-control procedures primarily because of the virus’ ability to survive for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 242,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_243",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "long periods in the environment (862;865;873-875;889-891).  A number of infection control\nstrategies have been studied; adherence to contact isolation precautions with careful attention to\npotential transmission by fomites, combined with droplet precautions, have been the key to\nsuccessful control of transmission in health-care settings.  These measures include use of single-dose\ndrug vials of medicines, careful review of procedures to decontaminate medical and other devices to\nensure inactivation of adenovirus, cohorting of patients, use of separate waiting areas in outpatient\nclinics for infected patients, and postponement of elective admissions to the unit(s) where infected\npersons are housed (892;893).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "48\nHEALTH-CARE-ASSOCIATED ADENOVIRUS INFECTION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 243,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_244",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 50\nHEALTH-CARE-ASSOCIATED INFLUENZA]\nI.  EPIDEMIOLOGY\nPneumonia in patients with influenza may be due to the influenza virus itself, a secondary\nbacterial infection, or a combination of both (894-896).  Influenza-associated pneumonia (as well as\nother influenza complications) can occur in any person but are more common in the very young (<24\nmonths of age) or old and in persons in any age group with immunosuppression or certain chronic\nmedical conditions, such as severe underlying heart or lung disease (897-904).\nIn North America, influenza typically occurs annually in the winter from December through\nApril; peak activity in a community usually lasts from 6 to 8 weeks (905;906).  During influenza",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 244,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_245",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "April; peak activity in a community usually lasts from 6 to 8 weeks (905;906).  During influenza\nepidemics in the community, outbreaks in health-care institutions can occur and are often\ncharacterized by abrupt onset and rapid spread of the infection (907-911).  Most reported\ninstitutional outbreaks of influenza have occurred in nursing homes (912-919); however, outbreaks\nalso have been reported on pediatric and chronic care wards, HSCT units, and medical and neonatal\nICUs (755;904;908;920).\nInfluenza is transmitted from person to person primarily via virus-laden large droplets that\nare generated when infected persons cough, sneeze, or talk; these large droplets can then be directly\ndeposited onto the mucosal surfaces of the upper respiratory tracts of susceptible persons who are",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 245,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_246",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "deposited onto the mucosal surfaces of the upper respiratory tracts of susceptible persons who are\nnear the droplet source.  Transmission also may occur by direct (e.g., person-to-person) or indirect\n(person-fomite-person) contact.  Influenza virus can survive for 24-48 hours on nonporous surfaces\nand 8-12 hours on porous surfaces such as paper or cloth and can be transmitted to persons’ hands\nfrom these surfaces (921).  Airborne transmission by droplet nuclei has been suggested, albeit\ninconclusively, in some reports (922-924); however, this route is probably less important than\nperson-to-person spread by either droplet or contact transmission (909).\nThe most important reservoirs of influenza virus are infected persons.  Infected persons are",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 246,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_247",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The most important reservoirs of influenza virus are infected persons.  Infected persons are\nmost infectious during the first 3 days of illness; however, they can shed the virus beginning the day\nbefore and up to 7 or more days after onset of symptoms (765;925;926).  Children and severely\nimmunodeficient persons may shed virus for longer periods (927-930).  In addition, asymptomatic\npersons who are infected with influenza virus can shed the virus and potentially be infectious (931). \nII.  DIAGNOSIS\nClinically, influenza may be difficult to distinguish from febrile respiratory illnesses caused by\nother pathogens.  During periods when influenza viruses are circulating in the community, clinical",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 247,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_248",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "other pathogens.  During periods when influenza viruses are circulating in the community, clinical\ndefinitions that include fever and respiratory symptoms may have positive predictive values ranging\nfrom 30% to 81% (932;933).  In addition, infants can manifest a sepsis-like syndrome and 40% of\nyoung children can have vomiting or diarrhea (925;934).  Clinically defined influenza-like illness,\nhowever, can be useful for evaluating control measures during hospital or nursing-home outbreaks\nwith laboratory-confirmed cases of influenza illness (935).\nInfluenza can be diagnosed by virus isolation from respiratory secretions or by serologic\nconversion; however, recently developed rapid diagnostic tests can allow faster diagnosis and earlier",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 248,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_249",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "treatment of influenza illness and facilitate prompt initiation of antiviral prophylaxis as part of\noutbreak control (936-940).  Because rapid tests are generally less sensitive than viral culture and\nbecause only viral culture can provide information on circulating influenza virus subtypes and strains\n51\n(and allow antiviral-susceptibility testing when needed), a subset of patients with suspected influenza\nillness should be tested by viral culture also (936-939;941).\nIII.  SURVEILLANCE\nAn active surveillance program for influenza-like illness can help health-care facilities identify\nfacility-acquired cases of influenza early in their course and prevent influenza from spreading to\nother patients and health-care personnel (942).  Before the influenza season, health-care personnel",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 249,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_250",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "other patients and health-care personnel (942).  Before the influenza season, health-care personnel\nshould be trained to recognize influenza illness and made aware of the available mechanisms for\nreporting patients with suspected influenza to those in charge of infection control.  In addition, they\nshould learn about the use of diagnostic tests for influenza as well as the use of droplet precautions\n(in addition to standard precautions) for patients with confirmed or suspected influenza.  Infection-\ncontrol personnel should determine the facility-specific threshold levels of influenza or influenza-like\nillness at which laboratory diagnostic testing for influenza and outbreak control measures should be",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 250,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_251",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "initiated.  For example, an investigation that includes performance of diagnostic laboratory tests on\npatients and personnel who have influenza-like illness should be considered upon identification of a\nsingle case of facility-acquired laboratory-confirmed influenza or a cluster (e.g., >3 cases) of facility-\nacquired influenza-like illness detected within a short period (e.g., 48-72 hours) on the same floor or\nunit.  Laboratory testing for influenza in personnel or patients with influenza-like illness can allow\nprompt work exclusion of personnel infected with influenza and early initiation of appropriate patient\nisolation precautions.  In LTCFs, an active surveillance for influenza as well as for pneumonia can\nhelp identify facility-acquired cases of influenza.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 251,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_252",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "help identify facility-acquired cases of influenza.\nIV.  PREVENTION AND CONTROL OF INFLUENZA\nA.  Vaccination of Patients and Health-Care Personnel\nVaccination of persons at high risk for complications of influenza and persons who can\ntransmit influenza to high-risk persons, i.e., health-care personnel and high-risk patients’ household\nmembers, is the most effective measure for reducing the impact of influenza and should be done\nbefore the influenza season each year (941;943-946).  Both an inactivated and a live attenuated\ninfluenza vaccine (LAIV) are now available.  The inactivated vaccine is administered by the\nintramuscular route and is approved for use in persons aged 6 months and older; LAIV is",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 252,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_253",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "intramuscular route and is approved for use in persons aged 6 months and older; LAIV is\nadministered via a nasal spray and is approved for use only in healthy persons aged 5-49  years\n(941).  There are no data assessing the risk of transmission of virus from LAIV recipients to\nimmunosuppressed contacts.  In the absence of such data, use of the inactivated influenza vaccine is\npreferred for vaccinating household members, health-care personnel, and others who have close\ncontact with immunosuppressed individuals because of the theoretical risk that a live attenuated\nvaccine virus could be transmitted to, and cause disease in, the immunosuppressed individual. \nAlthough the risk of transmission of the live attenuated vaccine virus is thought to be low, use of the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 253,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_254",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "inactivated vaccine is preferred for persons (e.g., health-care personnel) exposed to persons at\nincreased  risk of influenza-related complications (947).\nWhen high vaccination rates are achieved in closed or semi-closed settings, the risk of\noutbreaks is reduced because of the induction of herd immunity (948;949).  High-risk groups for\nwhom annual vaccination is recommended include persons >65 years of age; residents of nursing\nhomes and other chronic-care facilities that house persons of any age who have chronic medical\n52\nconditions; adults and children who have chronic disorders of the pulmonary or cardiovascular\ndiseases, including asthma; adults and children who have required medical follow-up or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 254,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_255",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "diseases, including asthma; adults and children who have required medical follow-up or\nhospitalization during the preceding year because of chronic metabolic diseases (including diabetes\nmellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including\nimmunosuppression caused by medications or by HIV infection); children and adolescents (aged 6\nmonths-18 years) who are receiving long-term aspirin therapy and therefore might be at risk for Reye\nsyndrome after influenza infection; and women who will be in the second or third trimester of\npregnancy during the influenza season (941;951-954).  Vaccination of all persons aged 50-64 years\nalso is recommended because of the high prevalence of chronic medical conditions that increase the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 255,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_256",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "also is recommended because of the high prevalence of chronic medical conditions that increase the\nrisk of severe influenza illness in this age group and because of the benefits that healthy persons 50-\n64 years old obtain from vaccination, i.e., decrease in the risk of influenza and its potential sequelae\nsuch as work absenteesim, medical visits, and antibiotic use (941;944;955;956).  Because children\naged 6-23 months are at substantially increased risk for influenza-related hospitalization, influenza\nvaccination for all children in this age group is encouraged when feasible (941).\nHealth-care personnel have been implicated in the transmission of influenza to patients;\nannual vaccination of health-care personnel, as well as others in close contact with persons at high",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 256,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_257",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "risk for influenza complications, is recommended (907;908;941;942;944;957).  Vaccination of\nhealth-care personnel is associated with decreased mortality among nursing home residents\n(945;946) and reduced health-care personnel illness and absenteeism (944;958).\nInfluenza vaccine, however, has been underutilized in institutional settings, even after it\nbecame a covered benefit of Medicare Part B (959).  In order to improve vaccination coverage rates\namong adults, in March 2000, the ACIP published recommendations for the use of SOP, under\nwhich nurses and pharmacists are authorized to administer vaccinations according to an institution-\nor physician-approved protocol, without an examination of the patient by a physician (408).  ACIP",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 257,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_258",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "or physician-approved protocol, without an examination of the patient by a physician (408).  ACIP\nrecommended the use of SOP in LTCFs, inpatient and outpatient facilities, managed-care\norganizations, assisted living facilities, correctional facilities, pharmacies, adult workplaces, and\nhome health care agencies (408) after SOP programs were shown to be the most effective method of\nincreasing adult vaccination rates (960).  To further facilitate the implementation of the SOP to\nMedicare- and Medicaid-eligible patients, in October 2002, the US Department of Health and\nHuman Services Centers for Medicare and Medicaid Services published an interim final rule that\nremoves the physician-signature requirement for the administration of influenza and pneumococcal",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 258,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_259",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "removes the physician-signature requirement for the administration of influenza and pneumococcal\nvaccines to Medicare and Medicaid patients in hospitals, long-term care facilities, and home health\nagencies in states where such is allowed (961). \nB.  Use of Antiviral Drugs \nWhile vaccination of high-risk patients and health-care personnel is the primary focus of\nefforts to prevent and control influenza in health-care settings, the use of antiviral agents can be an\nimportant adjunct (941).  Four licensed agents are available in the United States: amantadine,\noseltamivir, rimantadine, and zanamivir.  Amantadine and rimantadine are chemically related drugs\nwith activity against influenza type A, but not influenza type B (962-964).  Amantadine was",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 259,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_260",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "with activity against influenza type A, but not influenza type B (962-964).  Amantadine was\napproved for influenza A (H2N2) prophylaxis in 1966 and approved for both treatment and\nprophylaxis in 1976.  Rimantadine was approved for treatment and prophylaxis of influenza A in\n1993 (941).  Oseltamivir and zanamivir are neuraminidase inhibitors with activity against both\n53\ninfluenza A and B viruses.  Both drugs were approved in 1999 for the treatment of uncomplicated\ninfluenza infections, and oseltamivir was approved in 2000 for prophylaxis (941).  Zanamivir is\nadministered as an inhaled powder while the other three drugs are ingested.  The four antiviral drugs\ndiffer in age-group indications, pharmacokinetics, side effects, and cost (941).  Additional",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 260,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_261",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "differ in age-group indications, pharmacokinetics, side effects, and cost (941).  Additional\ninformation about the drugs is available in their respective package inserts.\nWhen administered for treatment within 2 days of illness onset, amantadine and rimantadine\ncan reduce the duration of uncomplicated influenza A illness, and zanamivir and oseltamivir can\nreduce the duration of uncomplicated influenza A or B illness, by approximately 1 day\n(941;962;963;965-969).  None of the four drugs has been demonstrated to be effective in\npreventing serious influenza-related complications (e.g., bacterial or viral pneumonia or\nexacerbations of chronic illness).\nWhen administered for prophylaxis before exposure to influenza virus type A, both",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 261,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_262",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "When administered for prophylaxis before exposure to influenza virus type A, both\namantadine and rimantadine are approximately 70-90% effective in preventing illness\n(962;964;970).  These drugs have been studied extensively as components of influenza-outbreak\ncontrol programs in nursing homes (916;962;971-973).\nStudies in community settings suggest that oseltamivir and zanamivir are approximately 82-\n84% effective in preventing febrile influenza illness, although only oseltamivir is currently approved\nby the FDA for use as prophylaxis (974-977).  The experience with prophylactic use of these agents\nin institutional settings or among patients with chronic medical conditions is limited, however\n(915;977-979).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 262,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_263",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(915;977-979).\nAnti-influenza virus agents can be used 1) as short-term prophylaxis for high-risk persons\nwho receive their vaccination late in the season; 2) as prophylaxis for persons for whom vaccination\nis contraindicated; 3) as prophylaxis for immunocompromised persons who may not produce\nprotective levels of antibody in response to vaccination; 4) as prophylaxis, either for the duration of\ninfluenza activity in the community or until immunity develops after vaccination, for unvaccinated\nhealth-care personnel who provide care to high-risk patients; and 5) when vaccine strains do not\nclosely match the epidemic virus strain (941).\nThe decision about which antiviral agent to use as adjunct to vaccination in the prevention",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 263,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_264",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "The decision about which antiviral agent to use as adjunct to vaccination in the prevention\nand control of health-care-related influenza is based in part on virologic and epidemiologic\nsurveillance information from the health-care setting and the community.  An antiviral agent can\nlimit the spread of influenza in the health-care setting if the drug is administered to all or most\npatients once influenza illnesses begin in the facility (916;977;980;981).  Therefore, if an influenza\nantiviral agent is to be given as prophylaxis to high-risk persons and treatment for infected persons,\nit should be administered as early in the outbreak as possible to reduce viral transmission\n(916;941;980).\nSide effects from influenza antiviral agents have been reported.  Both amantadine and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 264,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_265",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Side effects from influenza antiviral agents have been reported.  Both amantadine and\nrimantadine are associated with central nervous system (CNS) side effects such as nervousness,\ninsomnia, impaired concentration, mood changes, and light-headedness; however, amantadine is\nassociated with a higher incidence of adverse CNS reactions (13% of healthy adults taking\namantadine 200 mg/day) than is rimantadine (6% of healthy adults taking rimantadine 200 mg/day)\n(964;982).  Gastrointestinal side effects occur in approximately 1%-3% of persons taking either\ndrug (964).  Serious side effects (e.g., marked behavioral changes, delirium, hallucinations,\nagitation, and seizures) have been observed mostly among persons with renal insufficiency, seizure\n54",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 265,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_266",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "54\ndisorders, or certain psychiatric disorders, and/or in association with high plasma concentrations\n(972;980).  Dose reductions of both amantadine and rimantadine are recommended for certain\npatient groups, such as children <10 years of age, children weighing <40 kg, persons >65 years of\nage, and persons with renal insufficiency.\nIn clinical trials, oseltamivir use was associated with nausea and vomiting although few\npersons discontinued its use because of these symptoms (969;975).  A reduction in the dose of\noseltamivir is recommended for persons with renal insufficiency (941).\nZanamivir was not associated with significantly different side effects compared to inhaled\nlactose placebo in clinical trials (966;968;974).  However,  respiratory-function deterioration has",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 266,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_267",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "lactose placebo in clinical trials (966;968;974).  However,  respiratory-function deterioration has\nbeen reported in persons taking zanamivir, some of whom had underlying airway disease, e.g.,\nasthma or chronic obstructive pulmonary disease.  Because of this risk and the lack of demonstrable\nefficacy in persons with underlying lung disease, zanamivir is generally not recommended for\npersons with underlying lung disease (983).\nC.  Antiviral Drug Resistance\nDrug-resistant viruses can emerge in up to approximately one third of patients who are\ngiven either amantadine or rimantadine for treatment of influenza (963;984;985).  Because of the\npotential risk of transmission of drug-resistant viruses, infected persons taking either amantadine or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 267,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_268",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "rimantadine should avoid contact as much as possible with others during treatment and for 2 days\nafter discontinuing treatment (985-987).  This is particularly important if the contacts involve\nuninfected high-risk persons (986;988).\nDevelopment of viral resistance to oseltamivir and zanamivir during their use for patient\ntreatment has been identified but does not appear to be frequent (989-992).  However, the\nexperience with oseltamivir or zanamivir for use in influenza outbreak control and the number of\ntests conducted for viral resistance to either agent have been considerably less than with amantadine\nor rimantadine (941).  In studies using oseltamivir, 1.3% of post-treatment viral isolates from",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 268,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_269",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "or rimantadine (941).  In studies using oseltamivir, 1.3% of post-treatment viral isolates from\npatients >13 years of age and 8.6% from patients 1-12 years old had decreased susceptibility to\noseltamivir (990).  In clinical trials of zanamivir use, no isolates with reduced susceptibility have\nbeen reported and only one resistant isolate from an immune-compromised child on prolonged\ntherapy has been reported, although only a small number of post-treatment isolates have been tested\n(983;992).\nD.  Isolation Precautions and Other Measures   \nMeasures in addition to vaccination and chemoprophylaxis are recommended for control of\ninfluenza outbreaks in health-care facilities.  During the patient’s infectious stage, droplet",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 269,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_270",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "influenza outbreaks in health-care facilities.  During the patient’s infectious stage, droplet\nprecautions (i.e., placing in private rooms, when possible, or cohorting patients who are potentially\ninfectious with influenza or have influenza-like illness; masking by personnel upon entering the\nroom or when performing an activity within 3 feet of a person with suspected or proven influenza;\nlimiting to only essential purposes the movement or transport of a potentially infectious patient from\nhis/her room; and, if patient movement or transport from the room is necessary, minimizing patient\ndispersal of droplets by making the patient wear a surgical mask, if possible) are recommended in\naddition to standard precautions for personnel (i.e., hand decontamination, gloving when handling",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 270,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_271",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "addition to standard precautions for personnel (i.e., hand decontamination, gloving when handling\nthe patient’s respiratory secretions, and gowning when soiling with the patient’s respiratory\n55\nsecretions is likely) (279).  The added value of placing patients with influenza in rooms for airborne-\ninfection isolation (i.e., negative-pressure rooms) and using N95 respirators, or of using contact\nprecautions, has not been assessed.  In theory, however, contact precautions may be beneficial in\ninfant cases because their secretions are difficult to contain.  Other measures, although not well\nstudied, may be considered, particularly during severe outbreaks: 1) curtailment or elimination of\nelective admissions, both medical and surgical; 2) restriction of cardiovascular and pulmonary",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 271,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_272",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "elective admissions, both medical and surgical; 2) restriction of cardiovascular and pulmonary\nsurgery; 3) restriction of persons with acute respiratory illnesses from visiting patients; and 4) work\nrestriction for health-care personnel with acute respiratory illness (911;993).\nUpdated information regarding prevention and control of influenza, including the use of\ninfluenza vaccine and antiviral medications, is published annually by the ACIP in the Morbidity and\nMortality Weekly Report (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "50\nHEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 272,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_273",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: HEALTH-CARE-ASSOCIATED SARS]\nSARS is an emerging respiratory tract infection apparently linked to a novel corona virus\nthat first appeared in late 2002 in China and spread globally.  In several Asian countries, the\ninfection has caused outbreaks in health-care settings with transmission to large numbers of\npersonnel and patients (994-996).  Although the most important modes of transmission are by\n(large) droplet and contact, airborne transmission has not been ruled out.  High-risk exposures, such\nas those associated with aerosolization of respiratory secretions and exposures to “super-shedders”\nhave been associated with transmission of the disease to health-care personnel outside of the USA.\nCurrent infection-control information about SARS is available at",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 273,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_274",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Current infection-control information about SARS is available at  \nhttp://www.cdc.gov/ncidod/sars/guidance/index.htm.\n56\nPART II.   RECOMMENDATIONS OF THE HEALTHCARE INFECTION CONTROL",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "HEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 274,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_275",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: PRACTICES ADVISORY COMMITTEE]\nCategorization of Recommendations\n    In this document, as in previously published  HICPAC guidelines, each recommendation is\ncategorized on the basis of existing scientific evidence, theoretical rationale, applicability, and\npotential economic impact.  In addition, a new category accommodates recommendations that are\nmade on the basis of existing national or state health regulations.  The following categorization\nscheme is applied in this guideline:\nCategory IA. Strongly recommended for implementation and strongly supported by well-\ndesigned experimental, clinical, or epidemiologic studies.\nCategory IB. Strongly recommended for implementation and supported by some clinical or\nepidemiologic studies and by strong theoretical rationale.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "PRACTICES ADVISORY COMMITTEE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 275,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_276",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "epidemiologic studies and by strong theoretical rationale.\nCategory IC. Required for implementation, as mandated by federal or state regulation or\nstandard.\nCategory II.\nSuggested  for implementation and supported by suggestive clinical or\nepidemiologic studies or by strong theoretical rationale.\nNo Recommendation;  Unresolved Issue.  Practices for which insufficient evidence or no\nconsensus exists about efficacy.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "PRACTICES ADVISORY COMMITTEE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 276,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_277",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 57\nPREVENTION OF\n HEALTH-CARE-ASSOCIATED BACTERIAL PNEUMONIA]\nI.\nStaff Education and Involvement in Infection Prevention\nEducate health-care workers regarding the epidemiology of, and infection control\nprocedures for, preventing health-care-associated bacterial pneumonia to ensure\nworker competency according to the worker’s level of responsibility in the health-\ncare setting, and involve the workers in the implementation of interventions to\nprevent health-care-associated pneumonia by using performance-improvement tools\nand techniques (997-1004).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "57\nPREVENTION OF\n HEALTH-CARE-ASSOCIATED BACTERIAL PNEUMONIA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 277,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_278",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nII.\nInfection and Microbiologic Surveillance\nA.\nConduct surveillance for bacterial pneumonia in ICU patients who are at high risk\nfor health-care-associated bacterial pneumonia (e.g., patients with mechanically\nassisted ventilation or selected postoperative patients) to determine trends and help\nidentify outbreaks and other potential infection-control problems (1005;1006). The\nuse of the new NNIS system’s surveillance definition of pneumonia is recommended\n(1007). Include data on the causative microorganisms and their antimicrobial\nsusceptibility patterns (4). Express data as rates (e.g., number of infected patients or\ninfections per 100 ICU days or per 1,000 ventilator days) to facilitate intrahospital",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 278,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_279",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infections per 100 ICU days or per 1,000 ventilator days) to facilitate intrahospital\ncomparisons and trend determination (1005;1008;1009). Link monitored rates and\nprevention efforts and feed data back to appropriate health-care personnel (1010).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 279,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_280",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nB.\nIn the absence of specific clinical, epidemiologic, or infection-control objectives, do\nnot routinely perform surveillance cultures of patients or of equipment or devices\nused for respiratory therapy, pulmonary-function testing, or delivery of inhalation\nanesthesia (1011-1014).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 280,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_281",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nIII.\nPrevention of Transmission of Microorganisms\nA.\nSterilization or Disinfection and Maintenance of Equipment and Devices\n1.\nGeneral measures\na.\nThoroughly clean all equipment and devices to be sterilized or\ndisinfected (308;310).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 281,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_282",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nWhenever possible, use steam sterilization (by autoclaving) or high-\nlevel disinfection by wet heat pasteurization at >158oF (>70oC) for 30\nminutes for reprocessing semicritical equipment or devices (i.e., items\nthat come into direct or indirect contact with mucous membranes of\nthe lower respiratory tract) that are not sensitive to heat and moisture\n(see examples in Appendix). Use low-temperature sterilization\nmethods (as approved by the Office of Device Evaluation, Center for\nDevices and Radiologic Health, FDA) for equipment or devices that\n58\nare heat- or moisture-sensitive (307;309;310;314;315). After\ndisinfection, proceed with appropriate rinsing, drying, and packaging,\ntaking care not to contaminate the disinfected items in the process\n(308;310).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 282,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_283",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nPreferentially use sterile water for rinsing reusable semicritical\nrespiratory equipment and devices when rinsing is needed after they\nhave been chemically disinfected. If this is not feasible, rinse the\ndevice with filtered water (i.e., water that has been through a 0.2: \nfilter) or tap water, and then rinse with isopropyl alcohol and dry with\nforced air or in a drying cabinet (310).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 283,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_284",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nd.\nAdhere to provisions in the FDA’s enforcement document for single-\nuse devices that are reprocessed by third parties (310;1015).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 284,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_285",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IC]\n2.\nMechanical ventilators\nDo not routinely sterilize or disinfect the internal machinery of\nmechanical ventilators.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IC",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 285,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_286",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nBreathing circuits, humidifiers, and HMEs\na.\nBreathing circuits with humidifiers\n(1)\nDo not change routinely on the basis of duration of use the\nbreathing circuit (i.e., ventilator tubing and exhalation valve\nand the attached humidifier) that is in use on an individual\npatient. Change the circuit when it is visibly soiled or\nmechanically malfunctioning (327-332).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 286,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_287",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n(2)\nBreathing-circuit-tubing condensate\n(a)\nPeriodically drain and discard any condensate that\ncollects in the tubing of a mechanical ventilator, taking\nprecautions not to allow condensate to drain toward\nthe patient (324).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 287,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_288",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(b)\nWear gloves to perform the above procedure or\nhandle the fluid (269;279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 288,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_289",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(c)\nDecontaminate hands with soap and water (if hands\nare visibly soiled) or with an alcohol-based hand rub,\nafter performing the procedure or handling the fluid\n(269;278).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 289,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_290",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n(3)\nNo Recommendation can be made for placing a filter or trap\nat the distal end of the expiratory-phase tubing of the\n59\nbreathing circuit to collect condensate.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 290,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_291",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(4)\nHumidifier fluids \n(a)\nUse sterile (not distilled, nonsterile) water to fill\nbubbling humidifiers (146;291;298;299;324).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 291,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_292",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(b)\nNo recommendation can be made for the preferential\nuse of a closed, continuous-feed humidification\nsystem.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 292,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_293",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nb.\nVentilator breathing circuits with HMEs\n(1)\nNo recommendation can be made for the preferential use of\neither HMEs or heated humidifiers to prevent pneumonia in\npatients receiving mechanically assisted ventilation (341;343-\n346;1016).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 293,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_294",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(2)\nChanging HMEs\n(a)\nChange an HME that is in use on a patient when it\nmalfunctions mechanically or becomes visibly soiled.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 294,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_295",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(b)\nDo not routinely change more frequently than every\n48 hours an HME that is in use on a patient (1017-\n1019).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 295,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_296",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(3)\nDo not change routinely (in the absence of gross\ncontamination or malfunction) the breathing circuit attached\nto an HME while it is in use on a patient (1020).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 296,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_297",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n4.\nOxygen humidifiers\na.\nFollow manufacturers' instructions for use of oxygen humidifiers\n(1015;1021-1023).\nCATEGORIES II and IC\nb.\nChange the humidifier-tubing (including any nasal prongs or mask)\nthat is in use on one patient when it malfunctions or becomes visibly\ncontaminated.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 297,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_298",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n5.\nSmall-volume medication nebulizers: in-line and hand-held nebulizers \na.\nBetween treatments on the same patient: clean, disinfect; rinse with\nsterile water (if rinsing is needed), and dry small-volume in-line or\nhand-held medication nebulizers (292;306;1024).  (See\nrecommendation III-A-1-c if rinsing with sterile water is not feasible.)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 298,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_299",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n60\nb.\nUse only sterile fluid for nebulization, and dispense the fluid into the\nnebulizer aseptically (289;291;298;299;306;316;350).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 299,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_300",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nWhenever possible, use aerosolized medications in single-dose vials.\nIf multidose medication vials are used, follow manufacturers’\ninstructions for handling, storing, and dispensing the medications\n(289;350-354;1025).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 300,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_301",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n6.\nMist-tents\na.\nBetween uses on different patients, replace mist tents and their\nnebulizers, reservoirs, and tubings with those that have been\nsubjected to sterilization or high-level disinfection (1026).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 301,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_302",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nNo Recommendation can be made about the frequency of routinely\nchanging mist-tent nebulizers, reservoirs, and tubings while in use on\none patient.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 302,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_303",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nc.\nSubject mist-tent nebulizers, reservoirs and tubings that are used on\nthe same patient to daily low-level disinfection (e.g., with 2% acetic\nacid) or pasteurization followed by air-drying (1027).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 303,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_304",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n7.\nOther devices used in association with respiratory therapy\na.\nRespirometers and ventilator thermometers\nBetween their uses on different patients, sterilize or subject to high-\nlevel disinfection portable respirometers, and ventilator thermometers\n(294;295;305;364;365).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 304,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_305",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nResuscitation bags\n(1)\nBetween their uses on different patients, sterilize or subject to\nhigh-level disinfection reusable hand-powered resuscitation\nbags (359-363).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 305,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_306",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2)\nNo Recommendation can be made about the frequency of\nchanging hydrophobic filters placed on the connection port of\nresuscitation bags.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 306,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_307",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n8.\nAnesthesia machines and breathing systems or patient circuits\na.\nDo not routinely sterilize or disinfect the internal machinery of\nanesthesia equipment (368).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 307,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_308",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nBetween uses on different patients, clean reusable components of the\nbreathing system or patient circuit (e.g., tracheal tube or face mask;\ninspiratory and expiratory breathing tubing; y-piece; reservoir bag;\n61\nhumidifier; and tubing) and then sterilize or subject them to high-level\nliquid chemical disinfection or pasteurization in accordance with the\ndevice manufacturers' instructions for their reprocessing (310;314).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 308,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_309",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nNo recommendation can be made about the frequency of routinely\ncleaning and disinfecting unidirectional valves and carbon dioxide\nabsorber chambers (371).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 309,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_310",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nd.\nFollow published guidelines and manufacturers' instructions about in-\nuse maintenance, cleaning, and disinfection or sterilization of other\ncomponents or attachments of the breathing system or patient circuit\nof anesthesia equipment (369;370).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 310,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_311",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\ne.\nNo recommendation can be made for placing a bacterial filter in the\nbreathing system or patient circuit of anesthesia equipment (3;372-\n378).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 311,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_312",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n9.\nPulmonary-function testing equipment\na.\nDo not routinely sterilize or disinfect the internal machinery of\npulmonary-function testing machines between uses on different\npatients (379;380).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 312,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_313",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nChange the mouthpiece of a peak flow meter or the mouthpiece and\nfilter of a spirometer between uses on different patients (379;384).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 313,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_314",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n10.\nRoom-air “humidifiers” and faucet aerators\na.\nDo not use large-volume room-air humidifiers that create aerosols\n(e.g., by venturi principle, ultrasound, or spinning disk, and thus\nactually are nebulizers) unless they can be sterilized or subjected to\nhigh-level disinfection at least daily and filled only with sterile water\n(145;288;291).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 314,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_315",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nFaucet aerators\n(1)\nNo recommendation can be made about the removal of faucet\naerators from areas for immunocompetent patients (see also\nsection on Legionnaires Disease, Part II, Section I-C-1-d).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 315,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_316",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(2)\nIf Legionella spp. are detected in the water of a transplant\nunit and until Legionella spp. are no longer detected by\nculture, remove faucet aerators in the unit (see also section on\nLegionnaires Disease, Part II, Section I-C-1-d) (506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 316,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_317",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n62\nB.\nPrevention of Person-to-Person Transmission of Bacteria\n1.  Standard Precautions\na\nHand hygiene\nDecontaminate hands by washing them with either antimicrobial soap\nand water or with nonantimicrobial soap and water (if hands are\nvisibly dirty or contaminated with proteinaceous material or are soiled\nwith blood or body fluids) or by using an alcohol-based antiseptic\nagent (e.g., hand rub) if hands are not visibly soiled after contact with\nmucous membranes, respiratory secretions, or objects contaminated\nwith respiratory secretions, whether or not gloves are worn.\nDecontaminate hands as described previously before and after contact\nwith a patient who has an endotracheal or tracheostomy tube in place,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 317,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_318",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "with a patient who has an endotracheal or tracheostomy tube in place,\nand before and after contact with any respiratory device that is used\non the patient, whether or not gloves are worn (278;279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 318,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_319",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nGloving\n(1)\nWear gloves for handling respiratory secretions or objects\ncontaminated with respiratory secretions of any patient (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 319,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_320",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2)\nChange gloves and decontaminate hands as described\npreviously between contacts with different patients; after\nhandling respiratory secretions or objects contaminated with\nsecretions from one patient and before contact with another\npatient, object, or environmental surface; and between\ncontacts with a contaminated body site and the respiratory\ntract of, or respiratory device on, the same patient (278-\n280;282;283).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 320,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_321",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nGowning\nWhen soiling with respiratory secretions from a patient is\nanticipated, wear a gown and change it after soiling occurs and\nbefore providing care to another patient (279;280).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 321,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_322",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nCare of patients with tracheostomy\na.\nPerform tracheostomy under aseptic conditions.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 322,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_323",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nWhen changing a tracheostomy tube, wear a gown, use aseptic\ntechnique, and replace the tube with one that has undergone\nsterilization or high-level disinfection (279;308;310).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 323,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_324",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nNo recommendation can be made for the daily application of topical\nantimicrobial agent(s) at the tracheostoma (1028).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 324,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_325",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n63\n  \n3.\nSuctioning of respiratory tract secretions\n(See also Section IV-B-1-d.)\na.\nNo recommendation can be made for the preferential use of either\nthe multiuse closed-system suction catheter or the single-use open-\nsystem suction catheter for prevention of pneumonia (343;356-\n358).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 325,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_326",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nb.\nNo recommendation can be made about wearing sterile rather than\nclean gloves when performing endotracheal suctioning.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 326,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_327",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nc.\nNo recommendation can be made about the frequency of routinely\nchanging the in-line suction catheter of a closed-suction system in\nuse on one patient (355).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 327,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_328",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nd.\nIf the open-system suction is employed, use a sterile single-use\ncatheter.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 328,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_329",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\ne.\nUse only sterile fluid to remove secretions from the suction catheter\nif the catheter is to be used for re-entry into the patient's lower\nrespiratory tract.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 329,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_330",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nIV.\nModifying Host Risk For Infection\nA.\nIncreasing Host Defense Against Infection: Administration of Immune\nModulators\n1.\nPneumococcal vaccination. Vaccinate patients at high risk for severe\npneumococcal infections:\na.\nAdminister the 23-valent pneumococcal polysaccharide vaccine to\npersons aged >65 years; persons aged 5-64 years who have chronic\ncardiovascular disease (e.g., congestive heart failure or\ncardiomyopathy), chronic pulmonary disease (e.g., COPD or\nermphysema, but not asthma), diabetes mellitus, alcoholism, chronic\nliver disease (cirrhosis), or cerebro-spinal fluid (CSF) leaks; persons\naged 5-64 years who have functional or anatomic asplenia; persons\naged 5-64 years who are living in special environments or social",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 330,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_331",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "aged 5-64 years who are living in special environments or social\nsettings; immunocompromised persons aged  >5 years with HIV\ninfection, leukemia, lymphoma, Hodgkin’s disease, multiple\nmyeloma, generalized malignancy, chronic renal failure, nephrotic\nsyndrome, or other conditions associated with immunosuppression\n(e.g., receipt of HSCT, solid-organ transplant, or\nimmunosuppressive chemotherapy, including long-term systemic\n64\ncorticosteroids); and persons in long-term care facilities (401;405-\n407;410;1029).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 331,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_332",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nAdminister the 7-valent pneumococcal polysaccharide protein-\nconjugate vaccine to all children aged <2 years and to children aged\n24-59 months who are at increased risk for pneumococcal disease\n(e.g., children with sickle-cell disease and other hemoglobinopathies\nor children who are functionally or anatomically asplenic; children\nwith HIV infection; children who have chronic disease, including\nchronic cardiac or pulmonary disease [except asthma], diabetes\nmellitus, or CSF leak; and children with immunocompromising\nconditions including malignancies, chronic renal failure or nephrotic\nsyndrome, receipt of immunosuppressive chemotherapy, including\nlong-term corticosteroids, and receipt of solid-organ transplant).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 332,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_333",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "long-term corticosteroids, and receipt of solid-organ transplant). \nConsider administering the vaccine to all children aged 24-59\nmonths, with priority given to children aged 24-35 months, children\nwho are American Indians/Alaska Natives or black, and children\nwho attend group child-care centers (407).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 333,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_334",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nIn nursing homes and other long-term care facilities, establish an\nSOP  for the administration of 23-valent vaccine to persons at high\nrisk of acquiring severe pneumococcal infections, including\npneumococcal pneumonia (405;408;409).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 334,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_335",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n2.\nNo recommendation can be made for the routine administration of\npreparations of GCSF or intravenous gamma globulin for prophylaxis\nagainst health-care-associated pneumonia (411-416).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 335,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_336",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n3.\nNo recommendation can be made for the routine enteral administration of\nglutamine for prevention of health-care-associated pneumonia (417;418).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 336,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_337",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nB.\nPrecautions for Prevention of Aspiration\nAs soon as the clinical indications for their use are resolved, remove devices such\nas endotracheal, tracheostomy, or enteral (i.e., oro- or nasogastric, or jejunal)\ntubes from patients (13;16;133;218-220).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 337,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_338",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n1.\nPrevention of aspiration associated with endotracheal intubation\na.\nUse of NIV to reduce the need for and duration of endotracheal\nintubation\n(1)\nWhen feasible and not medically contraindicated, use\nnoninvasive positive-pressure ventilation delivered\ncontinuously by face or nose mask, instead of performing\nendotracheal intubation in patients who are in respiratory\n65\nfailure and are not needing immediate intubation (e.g., those\nwho are in hypercapneic respiratory failure secondary to\nacute exacerbation of COPD or cardiogenic pulmonary\nedema) (254-256;258).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 338,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_339",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(2)\nWhen feasible and not medically contraindicated, use NIV\nas part of the weaning process (from mechanically assisted\nventilation) in order to shorten the period of endotracheal\nintubation (257).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 339,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_340",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nAs much as possible, avoid repeat endotracheal intubation in\npatients who have received mechanically assisted ventilation (149).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 340,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_341",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nc.\nUnless contraindicated by the patient’s condition, perform\norotracheal rather than nasotracheal intubation on patients\n(237;238;343).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 341,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_342",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nd.\nIf feasible, use an endotracheal tube with a dorsal lumen above the\nendotracheal cuff to allow drainage (by continuous or frequent\nintermittent suctioning) of tracheal secretions that accumulate in the\npatient's subglottic area (245-248;343).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 342,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_343",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\ne.\nBefore deflating the cuff of an endotracheal tube in preparation for\ntube removal, or before moving the tube, ensure that secretions are\ncleared from above the tube cuff.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 343,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_344",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nPrevention of aspiration associated with enteral feeding\na.\nIn the absence of medical contraindication(s), elevate at an angle of\n30-45 degrees the head of the bed of a patient at high risk for\naspiration pneumonia (e.g., a person receiving mechanically assisted\nventilation or who has an enteral tube in place) (223;227;228).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 344,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_345",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nNo recommendation can be made for the preferential use of small-\nbore tubes for enteral feeding (229).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 345,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_346",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nd.\nNo recommendation can be made for preferentially administering\nenteral feedings continuously or intermittently (21;210;211;213).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 346,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_347",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\ne.\nNo recommendation can be made for preferentially placing the\nfeeding tubes (e.g., jejunal tubes) distal to the pylorus (230-236).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 347,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_348",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n66\n3.\nPrevention or modulation of oropharyngeal colonization\na.\nOropharyngeal cleaning and decontamination with an antiseptic\nagent \nDevelop and implement a comprehensive oral-hygiene program\n(that might include the use of an antiseptic agent) for patients in\nacute-care settings or residents in long-term care facilities who are\nat high risk of developing health-care-associated pneumonia\n(159;160).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 348,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_349",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nChlorhexidine oral rinse\n(1)\nNo recommendation can be made for the routine use of an\noral chlorhexidine rinse for the prevention of health-care-\nassociated pneumonia in all postoperative or critically ill\npatients or other patients at high risk for pneumonia (161).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 349,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_350",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(2)\nUse an oral chlorhexidine gluconate (0.12%) rinse during\nthe perioperative period on adult patients who undergo\ncardiac surgery (161).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 350,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_351",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nc.\nOral decontamination with topical antimicrobial agents\nNo recommendation can be made for the routine use of topical\nantimicrobial agents for oral decontamination to prevent VAP\n(140).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 351,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_352",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n4.\nPrevention of gastric colonization\na.\nNo recommendation can be made for the preferential use of\nsucralfate, H2-antagonists, or antacids for stress-bleeding\nprophylaxis in patients receiving mechanically assisted ventilation\n(134;197;199;203-205;1031-1033).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 352,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_353",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nb.\nNo recommendation can be made for the routine administration of\nSDD to all critically ill, mechanically ventilated, or ICU patients\n(162-194).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 353,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_354",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nc.\nNo recommendation can be made for routine acidification of gastric\nfeeding (208;209).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 354,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_355",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nC.\nPrevention of Postoperative Pneumonia\n1.\nInstruct preoperative patients, especially those at high risk for contracting\npneumonia, about taking deep breaths and ambulating as soon as medically\nindicated in the postoperative period. Patients at high-risk include those\nwho will have abdominal aortic aneurysm repair, thoracic surgery, or\nemergency surgery; those who will receive general anesthesia; those who\n67\nare aged >60 years; those with totally dependent functional status; those\nwho have had a weight loss >10%; those using steroids for chronic\nconditions; those with recent history of alcohol use, history of COPD, or\nsmoking during the preceding year; those with impaired sensorium, a\nhistory of cerebrovascular accident with residual neurologic deficit, or low",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 355,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_356",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "history of cerebrovascular accident with residual neurologic deficit, or low\n(<8mg/dL) or high (>22 mg/dL) blood urea nitrogen level; and those who\nwill have received more than 4 units of blood before surgery (385-\n387;389).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 356,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_357",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nEncourage all postoperative patients to take deep breaths, move about the\nbed, and ambulate unless these are medically contraindicated (387-389).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 357,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_358",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n3.\nUse incentive spirometry on postoperative patients at high risk for\ndeveloping pneumonia (387-389).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 358,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_359",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n4.\nNo recommendation can be made about the routine use of chest\nphysiotherapy on all postoperative patients at high risk for pneumonia\n(387-389).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 359,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_360",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nD.\nOther Prophylactic Procedures for Pneumonia\n1. \nAdministration of antimicrobial agents other than in SDD \na.\nSystemic antimicrobial prophylaxis\nNo recommendation can be made about the routine administration\nof systemic antimicrobial agent(s) to prevent pneumonia in critically\nill patients and/or in those receiving mechanically-assisted\nventilation (193;420).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 360,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_361",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nb.\nScheduled changes in the class of antimicrobial agents used for\nempiric therapy\nNo recommendation can be made for scheduled changes in the class\nof antimicrobial agents used routinely for empiric treatment of\nsuspected infections in a particular group of patients (421;422).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 361,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_362",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n2.\nTurning or rotational therapy\nNo recommendation can be made for the routine use of turning or\nrotational therapy, either by \"kinetic\" therapy or by continuous lateral\nrotational therapy (i.e., placing patients on beds that turn on their\nlongitudinal axes intermittently or continuously) for prevention of health-\ncare-associated pneumonia in critically ill or immobilized patients\n(343;423;425-427;429;432).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 362,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_363",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 68\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED\n LEGIONNAIRES DISEASE]\nI.\nPrimary Prevention (Preventing health-care-associated Legionnaires disease when\nno cases have been documented)\nA.\nStaff Education\n1.\nEducate physicians to heighten their suspicion for cases of health-care-\nassociated Legionnaires disease and to use appropriate methods for its\ndiagnosis.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "68\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED\n LEGIONNAIRES DISEASE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 363,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_364",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nEducate patient-care, infection-control, and engineering personnel about\nmeasures to prevent and control healthcare-associated legionellosis.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 364,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_365",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nInfection and Environmental Surveillance\n1.\nMaintain a high index of suspicion for the diagnosis of health-care-\nassociated Legionnaires disease and perform laboratory diagnostic tests\n(both culture of appropriate respiratory specimen and the urine antigen\ntest) for legionellosis on suspected cases, especially in patients who are at\nhigh risk of acquiring the disease (e.g., patients who are\nimmunosuppressed, including HSCT or solid-organ-transplant recipients;\npatients receiving systemic steroids; patients aged >65 years; or patients\nwho have chronic underlying disease such as diabetes mellitus, congestive\nheart failure, and COPD) (436;452;454-456;461;463;464;517;518).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 365,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_366",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n2.\nPeriodically review the availability and clinicians’ use of laboratory\ndiagnostic tests for Legionnaires disease in the facility, and if clinicians do\nnot routinely use the tests on patients with diagnosed or suspected\npneumonia, implement measures to enhance clinicians’ use of the tests\n(e.g., by conducting educational programs) (439;457).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 366,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_367",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nRoutine culturing of water systems for Legionella spp.\na.\nNo recommendation can be made about routinely culturing water\nsystems for Legionella spp. in health-care facilities that do not have\npatient-care areas (i.e., transplant units) for persons at high risk for\nLegionella infection\n(317;437;489;494;496;497;499;500;506;525;1034).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 367,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_368",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nb.\nIn facilities with hemopoietic stem-cell- or solid-organ-\ntransplantation programs, periodic culturing for legionellae in water\nsamples from the transplant unit(s) can be performed as part of a\ncomprehensive strategy to prevent Legionnaires disease in\ntransplant recipients (506-508;1035).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 368,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_369",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n69\nc.\nIf such culturing (as in b) is undertaken:\n(1)\nNo recommendation can be made about the optimal\nmethods (i.e., frequency, number of sites) for environmental\nsurveillance cultures in transplant units.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 369,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_370",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(2)\nPerform corrective measures aimed at maintaining\nundetectable levels of Legionella spp. in the unit’s water\nsystem.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 370,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_371",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(3)\nMaintain a high index of suspicion for legionellosis in\ntransplant patients with health-care-associated pneumonia\neven when environmental surveillance cultures do not yield\nlegionellae (439;456).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 371,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_372",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nC.\nUse and Care of Medical Devices, Equipment, and Environment \n1.\nNebulizers and other devices\na.\nPreferentially use sterile water for rinsing nebulization devices and\nother semicritical respiratory-care equipment after they have been\ncleaned or disinfected (306;1036). If this is not feasible, rinse the\ndevice with filtered water (i.e., water that has been through a 0.2: \nfilter) or tap water and then rinse with isopropyl alcohol and dry\nwith forced air or in a drying cabinet (310).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 372,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_373",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nUse only sterile (not distilled, nonsterile) water to fill reservoirs of\ndevices used for nebulization (291;302;306;317;1036).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 373,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_374",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nDo not use large-volume room-air humidifiers that create aerosols\n(e.g., by venturi principle, ultrasound, or spinning disk) and thus are\nreally nebulizers, unless they can be sterilized or subjected to high-\nlevel disinfection at least daily and filled only with sterile water\n(302;1036)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 374,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_375",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nd.\nFaucet aerators\n(1)\nNo recommendation can be made for the removal of faucet\naerators from areas for immunocompetent patients (see also\nBacterial Pneumonia, Part II, section III-A-10-b).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 375,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_376",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n(2)\nIf Legionella spp. are detected in the water of a transplant\nunit and until Legionella spp. are no longer detected by\nculture, remove faucet aerators in areas for severely\nimmmunocompromised patients (506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 376,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_377",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nCooling towers\n70\na.\nWhen a new building is constructed, place cooling towers in such a\nway that the tower drift is directed away from the facility's air-\nintake system and design the cooling towers such that the volume\nof aerosol drift is minimized (482;483;504;506).\nCATEGORIES IB and IC\nb.\nFor cooling towers, install drift eliminators, regularly use an\neffective biocide, maintain the tower according to manufacturers'\nrecommendations, and keep adequate maintenance records\n(482;483;504;506).\nCATEGORIES IB and IC\n3.\nWater-distribution system \na.\nWhere practical and allowed by state law, maintain potable water at\nthe outlet at >51oC (>124oF) or <20oC (<68oF), especially in\nfacilities housing organ-transplant recipients or other patients at",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 377,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_378",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "facilities housing organ-transplant recipients or other patients at\nhigh risk (504;511;513;514;527). If water is maintained at $51oC,\nuse thermostatic mixing valves to prevent scalding (510).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 378,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_379",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nNo recommendation can be made about the treatment of water with\nchlorine dioxide, heavy-metal ions, ozone, or ultraviolet light\n(515;529-543;549). (UNRESOLVED ISSUE).  Hospitals served by\nmunicipalities with monochloramine-treated water have had success\nin controlling legionella (546;548).\n4.\nHealth-care facilities with hemopoietic stem-cell or solid-organ\ntransplantation programs\nIf legionellae are detected in the potable water supply of a transplant unit,\nand until legionellae are no longer detected by culture: \na.\nDecontaminate the water supply as per section II-B-2-b-3)-a)-i to \nII-B-2-b-3)-a)-v.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 379,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_380",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nRestrict severely immunocompromised patients from taking\nshowers (507;509).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 380,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_381",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nUse water that is not contaminated with Legionella spp. for HSCT\npatients’ sponge baths (487;490).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 381,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_382",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nd.\nProvide HSCT patients with sterile water for tooth brushing or\ndrinking, or for flushing nasogastric tubes (490;507).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 382,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_383",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\ne.\nDo not use water from faucets with Legionella-contaminated water\nin patients rooms to avoid creating infectious aerosols (509).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 383,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_384",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n71\nII.\nSECONDARY PREVENTION (Response to identification of laboratory-confirmed\nhealth-care-associated Legionellosis)\nA.\nIn Facilities with HSCT or Solid-Organ Transplant Recipients:\nWhen one inpatient of an HSCT or solid-organ transplant unit develops a case of\nlaboratory-confirmed definite (i.e., after >10 days of continuous inpatient stay) or\npossible (i.e., within 2-9 days of inpatient stay) health-care-associated Legionnaires\ndisease, or when two or more patients develop laboratory-confirmed Legionnaires\ndisease within 6 months of each other and after having visited an outpatient\ntransplant unit during part of the 2-10 day period before illness onset:\n1.\nContact the local or state health department or CDC if the disease is",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 384,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_385",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1.\nContact the local or state health department or CDC if the disease is\nreportable in the state or if assistance is needed.\nCATEGORIES II and IC\n2.\nIn consultation with the facility’s infection control team, conduct a\ncombined epidemiologic and environmental investigation as outlined from\nII-B-2-b-(1) through II-B-2-b-(5) to determine the source(s) of Legionella\nspp. (506;507). Include but not limit the investigation to such potential\nsources as showers, water faucets, cooling towers, hot-water tanks, and\ncarpet-cleaner water tanks (457;471;518). On its identification,\ndecontaminate or remove the source of Legionella spp.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 385,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_386",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nIf the health-care facility’s potable water system is found to be the source\nof  Legionella spp., observe the measures outlined in Section I-C-4-b to e\nabout the nonuse of the facility’s potable water by recipients of HSCT or\nsolid-organ transplants; and decontaminate the water supply as per Section\nII-B-2-b-(3)-(a)-i to v.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 386,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_387",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n4. \nDo not conduct an extensive facility investigation when an isolated case of\npossible health-care-associated Legionnaires disease occurs in a patient\nwho has had little contact with the inpatient transplant unit during most of\nthe incubation period of the disease.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 387,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_388",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nIn Facilities That Do Not House Severely Immunocompromised Patients (e.g.,\nHSCT or Solid-Organ Transplant Recipients):\nWhen a single case of laboratory-confirmed definite health-care-associated\nLegionnaires disease is identified, or when two or more cases of laboratory-\nconfirmed possible health-care-associated Legionnaires disease occur within 6\nmonths of each other:\n1.\nContact the local or state health department or CDC if the disease is\nreportable in the state or if assistance is needed.\nCATEGORIES II and IC\n2.\nConduct an epidemiologic investigation through a retrospective review of\nmicrobiologic, serologic, and postmortem data to identify previous cases,\nand begin an intensive prospective surveillance for additional cases of\n72",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 388,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_389",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "and begin an intensive prospective surveillance for additional cases of\n72\nhealth-care-associated Legionnaires disease.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 389,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_390",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\na.\nIf no evidence of continued nosocomial transmission exists,\ncontinue the intensive prospective surveillance for cases for >2\nmonths after surveillance is begun.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 390,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_391",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nIf evidence of continued transmission exists:\n(1)\nConduct an environmental investigation to determine the\nsource(s) of Legionella spp. by collecting water samples\nfrom potential sources of aerosolized water and saving and\nsubtyping isolates of Legionella spp. obtained from patients\nand the environment (291;306;482-488;519;521;523;524).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 391,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_392",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2) \nIf a source is not identified, continue surveillance for new\ncases for >2 months and, depending on the scope of the\noutbreak, decide to either defer decontamination pending\nidentification of the source(s) of Legionella spp. or proceed\nwith decontamination of the hospital's water distribution\nsystem, with special attention to the specific hospital areas\ninvolved in the outbreak.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 392,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_393",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(3)\nIf a source of infection is identified by the epidemiologic and\nenvironmental investigations, promptly decontaminate the\nsource.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 393,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_394",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(a)\nIf the heated water system is implicated:\ni.\nDecontaminate the heated water system\neither by superheating or by\nhyperchlorination. To superheat, raise the\nhot water temperature to 71°C-77°C (160°F-\n170°F) and maintain at that level while\nprogressively flushing each outlet around the\nsystem. A minimum flush time of 5 minutes\nhas been recommended; however, the\noptimal flush time is not known and longer\nflush times might be required. Post warning\nsigns at each outlet being flushed to prevent\nscald injury to patients, staff, or visitors. If\npossible, perform flushing when the building\nhas the fewest occupants (e.g., nights and\nweekends). For systems on which thermal\nshock treatment is not possible, use shock\nchlorination as an alternative. Add chlorine,\n73",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 394,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_395",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "shock treatment is not possible, use shock\nchlorination as an alternative. Add chlorine,\n73\npreferably overnight, to achieve a free\nchlorine residual of >2 mg/L (>2 ppm)\nthroughout the system. This might require\nchlorination of the water heater or tank to\nlevels of 20-50 mg/L (20-50 ppm).  Maintain\nthe water pH between 7.0 and 8.0 (504;512-\n514;519;525;526;528).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 395,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_396",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nii.\nDepending on local and state regulations\nabout potable water temperature in public\nbuildings (527), circulate potable water at\ntemperatures not conducive to amplification\nof Legionella:  store and distribute cold\nwater at <20oC (<68oF); and store hot water\nat >60oC (>140oF) and circulate it at\nminimum return temperature of 51oC (124oF)\n(506;511;513;514;527).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 396,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_397",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\niii.\nIf the methods described in 3a-i and 3a-ii are\nnot successful in decontaminating the\nhospital’s water, seek expert consultation for\nreview of decontamination procedures and\nassistance with further efforts.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 397,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_398",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\niv.\nNo recommendation can be made for the\ntreatment of water with chlorine dioxide,\nheavy-metal ions, ozone, or ultraviolet light\n(515;529-543;549). (Hospitals have\nreported successful decontamination using\neach of these methods.)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 398,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_399",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nv.\nClean hot-water storage tanks and water\nheaters to remove accumulated scale and\nsediment (506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 399,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_400",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(b)\nIf cooling towers or evaporative condensers are\nimplicated, decontaminate the cooling-tower system\n(482;483;504;506).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 400,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_401",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(4)\nAssess the efficacy of implemented measures in reducing or\neliminating Legionella spp. by collecting specimens for\nculture at 2-week intervals for 3 months.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 401,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_402",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n74\n(a)\nIf Legionella spp. are not detected in cultures during\n3 months of monitoring at 2-week intervals, collect\ncultures monthly for another 3 months.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 402,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_403",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(b)\nIf Legionella spp. are detected in one or more\ncultures, reassess the implemented control measures,\nmodify them accordingly, and repeat\ndecontamination procedures. Options for repeat\ndecontamination include the intensive use of the\nsame technique used for the initial decontamination,\nor a combination of superheating and\nhyperchlorination (528).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 403,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_404",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(5)\nKeep adequate records of all infection control measures,\nincluding maintenance procedures, and of environmental\ntest results for cooling towers and potable-water systems.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 404,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_405",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 75\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED PERTUSSIS]\nI.\nStaff Education\nEducate appropriate personnel in accordance with their level of responsibility in the\nhealthcare setting about the epidemiology, modes of transmission, and means of\npreventing the spread of pertussis (565;567).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "75\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED PERTUSSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 405,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_406",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nII.\nCase-Reporting, Disease Surveillance, and Case-Contact Notification\nA.\nReport to the local and/or state health department all confirmed and suspected\ncases of pertussis (565).\nCATEGORIES II and IC\nB.\nConduct active surveillance for cases of pertussis until 42 days after the onset of\nthe last pertussis case (578).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 406,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_407",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nC.\nNotify persons who have had close contact with a case of pertussis in the health-\ncare setting so that they can be monitored for symptoms of pertussis or\nadministered appropriate chemoprophylaxis. Close contact includes face-to-face\ncontact with a patient who is symptomatic (e.g., in the catarrhal or paroxysmal\nperiod of illness); sharing a confined space in close proximity for a prolonged\nperiod of time (e.g., >1 hour) with a symptomatic patient; or direct contact with\nrespiratory, oral, or nasal secretions from a symptomatic patient (e.g., an explosive\ncough or sneeze on the face, sharing food, sharing eating utensils during a meal,\nkissing, mouth-to-mouth resuscitation, or performing a full medical examination of\nthe nose and throat) (578).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 407,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_408",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nIII.\nPrevention of Pertussis Transmission\nA.\nVaccination for Primary Prevention\n1.\nNo recommendation can be made for routinely vaccinating adults, including\nhealth-care workers, with the acellular pertussis vaccine at regular intervals\n(e.g., every 10 years) (562;578;593;594;1037).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 408,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_409",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n2.\nIn LTCFs for children and for children with prolonged stay in acute-care\nfacilities, follow the recommendations of ACIP for vaccinating children\naccording to their chronologic age (578;589).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 409,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_410",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nB.\nVaccination for Secondary Prevention\n1.\nNo recommendation can be made for vaccinating adults, including health-\ncare workers, during an institutional outbreak of pertussis (578;606).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 410,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_411",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n2.\nDuring an institutional outbreak of pertussis, accelerate scheduled\n76\nvaccinations to infants and children aged <7 years who have not completed\ntheir primary vaccinations, as follows:\na.\nInfants aged <2 months who are receiving their initial vaccination: \n \nAdminister the first dose of the DTaP vaccine as early as age 6\nweeks and the second and third doses at a minimum of 4-week\nintervals between doses. Give the fourth dose on or after age 1 year\nand >6 months after the third dose (578;588;1038).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 411,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_412",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nOther children aged <7 years:\nAdminister DTaP vaccine to all patients who are aged <7 years and\nare not up-to-date with their pertussis vaccinations, as follows:\nadminister a fourth dose of DtaP vaccine if the child has had 3\ndoses of  DTaP or diphtheria, tetanus and pertussis (DTP) vaccine,\nis >12 months old, and >6 months have passed since the third dose\nof DTaP or DTP vaccine; administer a fifth dose of DTaP vaccine if\nthe child has had four doses of DTaP or DTP vaccine, is aged 4-6\nyears, and received the fourth vaccine dose before the fourth\nbirthday (567;578;588;589).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 412,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_413",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n3.\nVaccination of children with a history of well-documented pertussis disease\nNo recommendation can be made for administering additional dose(s) of\npertussis vaccine to children who have a history of well-documented\npertussis disease (i.e., pertussis illness with either a B. pertussis-positive\nculture or epidemiologic linkage to a culture-positive case) (578;589).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 413,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_414",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nC.\nPatient Placement and Management\n1.\nPatients with confirmed pertussis\nPlace a patient with diagnosed pertussis in a private room, or if known not\nto have any other respiratory infection, in a room with other patient(s) with\npertussis until after the first 5 days of a full course of antimicrobial\ntreatment or 21 days after the onset of cough if unable to take antimicrobial\ntreatment for pertussis (278;578).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 414,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_415",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY  IB]\n2.\nPatients with suspected pertussis\na.\nPlace a patient with suspected pertussis in a private room. After\npertussis and no other infection is confirmed, the patient may be\nplaced in a room with other patient(s) who have pertussis until after\nthe first 5 days of a full course of antimicrobial treatment or 21 days\nafter the onset of cough if unable to take antimicrobial treatment for\npertussis (278;578).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY  IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 415,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_416",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY  IB]\nb.\nPerform diagnostic laboratory tests (for confirmation or exclusion of\npertussis) on patients who are admitted with or who develop signs\n77\nand symptoms of pertussis to allow for the earliest possible\ndowngrading of infection-control precautions to the minimum\nrequired for each patient’s specific infection(s)\n(565;569;579;580;582).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY  IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 416,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_417",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nD.\nManagement of Symptomatic Health-Care Personnel\n1.\nIn conjunction with employee health personnel, perform diagnostic\nlaboratory tests for pertussis in health-care personnel with illness suggestive\nof pertussis (i.e., unexplained cough illness of >1week duration, paroxysmal\ncough) (565;567;569;579;580;582).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 417,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_418",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nIn conjunction with employee health personnel, treat symptomatic health-\ncare personnel who are proven to have pertussis or personnel who are\nhighly suspected of having pertussis with the same antimicrobial regimen, as\ndetailed for chemoprophylaxis of case-contacts, in F-1 to F-2 (565;566).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 418,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_419",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n3.\nRestrict symptomatic pertussis-infected health-care workers from work\nduring the first 5 days of their receipt of antimicrobial therapy\n(566;567;578).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 419,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_420",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nE.\nMasking\nIn addition to observing standard precautions, wear a surgical mask when\nwithin three feet of a patient with confirmed or suspected pertussis, when\nperforming procedures or patient-care activities that are likely to generate\nsprays of respiratory secretions, or on entering the room of a patient with\nconfirmed or suspected pertussis (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 420,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_421",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nF.\nUse of a Prophylactic Antibiotic Regimen for Contacts of Persons with\nPertussis\n1.\nAdminister a macrolide to any person who has had close contact with\npersons with pertussis and who does not have hypersensitivity or intolerance\nto macrolides (567;595).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 421,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_422",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\na.\nWith vigilance for IHPS when done in infants aged <2 weeks, use\nerythromycin (i.e., erythromycin estolate, 40-50 mg/kg day for\nchildren and 500 mg four times daily for adults, or erythromycin\ndelayed-release tablets, 333 mg three times daily for adults) for 14\ndays (567;597; 598;600;601).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 422,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_423",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nFor patients who are intolerant to erythromycin, use any of the\nfollowing regimens: azithromycin for 5-7 days (at 10-12 mg/kg/day)\nor for 5 days (at 10 mg/kg on day1 followed by four days at 5\nmg/kg/day) for infants and young children; or clarithromycin for 10-\n78\n14 days (at 500 mg twice a day for adults or 15-20 mg/kg/day in\ntwo divided doses for children) (567;578;602;603).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 423,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_424",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nFor chemoprophylaxis of persons who have hypersensitivity or intolerance\nto erythromycin, use (except in the case of a pregnant woman at term, a\nnursing mother, or an infant aged <2 months) TMP-SMZ for 14 days (at\none double-strength tablet twice a day for adults and 8 mg/kg/day TMP 40\nmg/kg/day SMZ  in 2 divided doses for children) (578;600;605).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 424,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_425",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nG.\nWork Exclusion of Asymptomatic Health-Care Workers Exposed to Pertussis\n1.\nDo not exclude from patient care a health-care worker who remains\nasymptomatic and is receiving chemoprophylaxis after an exposure to a case\nof pertussis (i.e., by direct contact of one’s nasal or buccal mucosa with the\nrespiratory secretions of an untreated person who is in the catarrhal or\nparoxysmal stage of  pertussis) (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 425,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_426",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nIf mandated by state law or where feasible, exclude an exposed,\nasymptomatic health-care worker who is unable to receive\nchemoprophylaxis, from providing care to a child aged <4 years during the\nperiod starting 7 days after the worker’s first possible exposure until 14\ndays after his last possible exposure to a case of pertussis (567).\nCATEGORIES II and IC \n \nH.\nOther measures\n1.\nLimiting patient movement or transport\nLimit the movement and transport of a patient with diagnosed or suspected\npertussis from his room to those for essential purposes only. If the patient is\ntransported out of the room, ensure that precautions are maintained to\nminimize the risk for disease transmission to other patients and\ncontamination of environmental surfaces or equipment (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 426,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_427",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nLimiting visitors\nDo not allow persons who have symptoms of respiratory infection to visit\npediatric, immunosuppressed, or cardiac patients (279;565;1039).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 427,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_428",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 79\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED\nPULMONARY ASPERGILLOSIS]\nI.\nStaff Education and Infection Surveillance\nA.\nStaff Education\nEducate health-care personnel according to their level of responsibility regarding\ninfection-control procedures to decrease the occurrence of health-care-associated\npulmonary aspergillosis.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "79\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED\nPULMONARY ASPERGILLOSIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 428,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_429",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nSurveillance\n1.\nMaintain a high index of suspicion for health-care-associated pulmonary\naspergillosis in severely immunocompromised patients (i.e.,  patients with\nsevere, prolonged neutropenia [ANC <500/mm3 for 2 weeks or <100/mm3\nfor 1 week], most notably HSCT recipients and including recipients of solid-\norgan transplants or patients with hematologic malignancies who are\nreceiving chemotherapy, when they are severely neutropenic as defined\npreviously).and persons receiving prolonged high-dose steroids\n(614;617;618;625;629;649;673;676).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 429,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_430",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n2.\nMaintain surveillance for cases of health-care-associated pulmonary\naspergillosis by establishing a system by which the facility’s infection-control\npersonnel are promptly informed when Aspergillus sp. is isolated from\ncultures of specimens from patient’s respiratory tract and by periodically\nreviewing the hospital's microbiologic, histopathologic, and postmortem\ndata.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 430,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_431",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nSurveillance cultures\na.\nDo not perform routine, periodic cultures of the nasopharynx of\nasymptomatic patients at high risk (1040;1041).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 431,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_432",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nDo not perform routine, periodic cultures of equipment or devices\nused for respiratory therapy, pulmonary function testing, or delivery\nof inhalation anesthesia in the HSCT unit, nor of dust in rooms of\nHSCT recipients (1041).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 432,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_433",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nNo recommendation can be made about routine microbiologic air\nsampling before, during, or after facility construction or renovation,\nor before or during occupancy of areas housing\nimmunocompromised patients (506;1042).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 433,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_434",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n4.\nIn facilities with PEs, perform surveillance of the ventilation status of these\nareas either by continuous monitoring or periodic analysis of the following\nparameters: room air exchanges, pressure relations and filtration efficacy to\n80\nensure that appropriate levels are maintained (506;706).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 434,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_435",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nII.\nPrevention of Transmission of Aspergillus spp. Spores\nA.\nPlanning New Specialized-Care Units for High-Risk Patients\n1.\nPE for allogeneic HSCT recipients\na.\nWhen constructing new specialized-care units with PE for HSCT\nrecipients, ensure that patient rooms have adequate capacity to\nminimize accumulation of fungal spores via 1) HEPA filtration of\nincoming air, 2) directed room airflow, 3) positive air pressure in\npatient's room in relation to the corridor, 4) well-sealed room, and\n5) high (>12) air changes per hour (506;619;700;702;704).\nCATEGORIES IB and IC\nb.\nDo not use LAF routinely in PE (506;507;681;696;707).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 435,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_436",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nUnits for autologous HSCT and solid-organ transplant recipients\nNo recommendation can be made for constructing PE for recipients of\nautologous HSCTs or solid-organ-transplants (e.g., heart, liver, lung,\nkidney) (506;705).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 436,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_437",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nB.\nIn Existing Facilities with HSCT Units and No Cases of Health-Care-\nAssociated Aspergillosis\n1.\nPlacement of patients in PE\na.\nPlace an allogeneic HSCT recipient in a PE that meets the conditions\noutlined in Section II-A-1.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 437,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_438",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nNo recommendation can be made for routinely placing a recipient of\nautologous HSCT or solid-organ transplant in PE.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 438,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_439",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n2.\nMaintain air-handling systems in PE and other high-risk patient-care areas\naccording to published recommendations (506;702;704).\nCATEGORIES IB and IC\n3.\nDevelop a water-damage response plan for immediate execution when water\nleaks, spills, and moisture accumulation occur to prevent fungal growth in\nthe involved areas (506;713).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 439,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_440",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n4.\nUse proper dusting methods for patient-care areas designated for severely\nimmunocompromised (e.g., HSCT recipients) (506;714).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 440,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_441",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\na.\nWet-dust horizontal surfaces daily using cloth that has been\nmoistened with an EPA-registered hospital disinfectant (682).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 441,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_442",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n81\nb.\nAvoid dusting methods that disperse dust (e.g., feather dusting)\n(682).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 442,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_443",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nKeep vacuums in good repair and equip them with HEPA filters for\nuse in areas with patients at high risk (682;714).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 443,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_444",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n5.\nDo not use carpeting in hallways and rooms occupied by severely \nimmunocompromised patients (506;507;1043)",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 444,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_445",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n6.\nAvoid using upholstered furniture or furnishings in rooms occupied by\nseverely immunocompromised patients.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 445,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_446",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n7.\nMinimize the length of time that immunocompromised patients in PEs are\noutside their rooms for diagnostic procedures and other activities.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 446,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_447",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\na.\nInstruct severely immunocompromised patients to wear a high-\nefficiency respiratory-protection device (e.g., an N95 respirator)\nwhen they leave the PE during periods when construction,\nrenovation, and/or other dust-generating activities are ongoing in\nand around the health-care facility (715).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 447,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_448",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nNo recommendation can be made about the specific type of\nrespiratory-protection device (e.g., surgical mask, N95 respirator)\nfor use by a severely immunocompromised patient who leaves the\nPE during periods when there is no construction, renovation or\nother dust-generating activity in progress in or around the health-\ncare facility.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 448,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_449",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n8.\nSystematically review and coordinate infection-control strategies with\npersonnel in charge of the facility’s engineering, maintenance, central supply\nand distribution, and catering services (506;507;685).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 449,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_450",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n9.\nWhen planning construction, demolition, and renovation activities in and\naround the facility, assess whether patients at high-risk for aspergillosis are\nlikely to be exposed to high ambient-air spore counts of Aspergillus spp.\nfrom construction, demolition, and renovation sites, and if so, develop a\nplan to prevent such exposures (506;507;685).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 450,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_451",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n10.\nDuring construction, demolition, or renovation activities, construct\nimpermeable barriers between patient-care and construction areas to prevent\ndust from entering the patient-care areas (506;626).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 451,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_452",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n11.\nDirect pedestrian traffic that come from construction areas away from\n82\npatient-care areas to limit the opening and closing of doors or other barriers\nthat might cause dust dispersion, entry of contaminated air, or tracking of\ndust into patient-care areas (506;507;626;679;685).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 452,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_453",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n12.\nDo not allow fresh or dried flowers or potted plants in patient-care areas for\nseverely immunocompromised patients (695).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 453,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_454",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nC.\nWhen A Case of Aspergillosis Occurs\n1.\nAssess whether the infection is health-care-related or community-acquired.\na.\nObtain and use the following information to help in the investigation:\nbackground rate of disease at the facility; presence of concurrent or\nrecent cases, as determined by a review of the facility’s\nmicrobiologic, histopathologic, and postmortem records; length of\npatient’s stay in the facility prior to the onset of aspergillosis; \npatient’s stay at, visit of, or transfer from, other health-care facilities\nor other locations within the facility; and the period the patient was\nexposed outside the health-care facility after the onset of\nimmunosuppression and before onset of aspergillosis.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 454,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_455",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nIf no evidence exists that the patient’s aspergillosis is facility-acquired,\ncontinue routine maintenance procedures to prevent health-care-associated\naspergillosis, as in Section II-B-1 through II-B-12.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 455,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_456",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n3.\nIf evidence of possible facility-acquired infection with Aspergillus spp.\nexists, conduct an epidemiologic investigation and an environmental\nassessment to determine and eliminate the source of Aspergillus spp. (506).\nCATEGORY IB (If assistance is needed, contact the local or state health\ndepartment.)\n4.\nUse an antifungal biocide (e.g., copper-8-quinolinolate) that is registered\nwith the Environmental Protection Agency for decontamination of structural\nmaterials (506;681;717).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 456,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_457",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CHEMOPROPHYLAXIS]\nA.\nNo recommendation can be made for the routine administration of antifungal agents\nsuch as itraconazole oral solution (5 mg/kg/day) or capsules (500 mg twice a day),\nlow-dose parenteral amphotericin B (0.1 mg/kg/day), lipid-based formulations of\namphotericin B (1 mg/kg/day), or nebulized amphotericin B administered by\ninhalation as prophylaxis for pulmonary aspergillosis in patients at high risk for this\ninfection (507;718-721;723-730).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CHEMOPROPHYLAXIS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 457,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_458",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nB.\nNo recommendation can be made for any specific strategy (e.g., deferral of\n83\nhematopoietic stem-cell transplantation for a particular length of time or routine\nprophylaxis with absorbable or intravenous antifungal medications) to prevent\nrecurrence of pulmonary aspergillosis in patients undergoing hematopoietic stem-\ncell transplantation who have a history of pulmonary aspergillosis (672;731-736).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 458,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_459",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 84\nPREVENTION AND CONTROL OF HEALTH-CARE ASSOCIATED \nRSV, PARAINFLUENZA VIRUS, AND ADENOVIRUS INFECTIONS]\nI.\nStaff Education And Monitoring And Infection Surveillance\nA.\nStaff Education and Monitoring\n1.\nStaff education\na.\nEducate personnel in accordance with their level of responsibility in\nthe health-care setting about the epidemiology, modes of\ntransmission, and means of preventing the transmission of  RSV\nwithin health-care facilities (817).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "84\nPREVENTION AND CONTROL OF HEALTH-CARE ASSOCIATED \nRSV, PARAINFLUENZA VIRUS, AND ADENOVIRUS INFECTIONS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 459,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_460",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nEducate personnel in accordance with their level of responsibility in\nthe health-care setting, about the epidemiology, modes of\ntransmission, and means of preventing the spread of parainfluenza\nvirus and adenovirus within health-care facilities.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 460,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_461",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nIn acute-care facilities, establish mechanisms by which the infection-control\nstaff can monitor personnel compliance with the facility’s infection-control\npolicies about these viruses (817).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 461,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_462",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nSurveillance\n1.\nEstablish mechanisms by which the appropriate health-care personnel are\npromptly alerted to any increase in the activity of RSV, parainfluenza virus,\nadenovirus, or other respiratory viruses in the local community. Establish\nmechanisms by which the appropriate health-care personnel can promptly\ninform the local and state health departments of any increase in the activity\nof the above-named viruses or of influenza-like illness in their facility.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 462,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_463",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nIn acute-care facilities during periods of increased prevalence of symptoms\nof viral respiratory illness in the community or health-care facility, and/or\nduring the RSV and influenza season (i.e., December-March), attempt\nprompt diagnosis of respiratory infections caused by RSV, influenza,\nparainfluenza, or other respiratory viruses. Use rapid diagnostic techniques\nas clinically indicated in patients who are admitted to the health-care facility\nwith respiratory illness and are at high risk for serious complications from\nviral respiratory infections (e.g., pediatric patients, especially infants, and\nthose with compromised cardiac, pulmonary, or immune function)\n(749;764;815;817;897).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 463,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_464",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n3.\nNo recommendation can be made for routinely conducting surveillance\ncultures for RSV or other respiratory viruses in respiratory secretions of\n85\npatients (including immunocompromised patients, such as recipients of\nHSCT) (507).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 464,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_465",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\n4.\nIn LTCFs, establish mechanism(s) for continuing surveillance to allow rapid\nidentification of a potential outbreak in the facility.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 465,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_466",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nII.\nPrevention Of Transmission Of RSV, Parainfluenza Virus, Or Adenovirus\nA.\nPrevention of Person-to-Person Transmission\n \n1.\nStandard and contact precautions for RSV and parainfluenza virus; and\nstandard, contact, and droplet precautions for adenovirus\na.\nHand hygiene\nDecontaminate hands after contact with a patient or after touching\nrespiratory secretions or fomites potentially contaminated with\nrespiratory secretions, whether or not gloves are worn. Use soap\nand water when hands are visibly dirty or contaminated with\nproteinaceous material or are visibly soiled with blood or other body\nfluids, and use an alcohol-based hand rub if hands are not visibly\nsoiled (271;279;284;782;802-804;813;817).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 466,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_467",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nGloving\n(1)\nWear gloves when entering the room of patients with\nconfirmed or suspected RSV, parainfluenza, or adenovirus\ninfection, and/or before handling the patients, their\nrespiratory secretions, or fomites potentially contaminated\nwith the patients’ secretions\n(279;280;782;802;803;810;815;817;819).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 467,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_468",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n(2)\nChange gloves between patients or after handling respiratory\nsecretions or fomites contaminated with secretions from one\npatient before contact with another patient\n(279;280;282;817). Decontanimate hands after removing\ngloves (see II-A-1-a).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 468,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_469",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n(3)\nAfter glove removal and hand decontamination, do not touch\npotentially contaminated environmental surfaces or items in\nthe patient’s room (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 469,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_470",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nGowning\nWear a gown when entering the room of a patient suspected or\nproven to have RSV, parainfluenza virus, or adenovirus infection,\nand when soiling with respiratory secretions from a patient is\nanticipated (e.g., when handling infants with suspected or proven\nRSV, parainfluenza, or adenovirus infection). Change the gown after\n86\nsuch contact and before giving care to another patient or when\nleaving the patient’s room.  After gown removal, ensure that\nclothing does not come into contact with potentially contaminated\nenvironmental surfaces (279;280).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 470,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_471",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nd.\nMasking and wearing eye protection\n(1)\nWear a surgical mask and eye protection or a face shield\nwhen performing procedures or patient-care activities that\nmight generate sprays of respiratory secretions from any\npatient whether or not the patient has confirmed or suspected\nviral respiratory tract infection (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 471,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_472",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2)\nWear a surgical mask and eye protection or a face shield\nwhen within 3 feet of a patient with suspected or confirmed\nadenovirus infection (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 472,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_473",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\ne.\nPatient placement in acute-care facilities\n(1)\nPlace a patient with diagnosed RSV, parainfluenza,\nadenovirus, or other viral respiratory tract infection in a\nprivate room when possible or in a room with other patients\nwith the same infection and no other infection\n(279;749;810;813;815;819).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 473,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_474",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2)\nPlace a patient with suspected RSV, parainfluenza,\nadenovirus, or other viral respiratory tract infection in a\nprivate room.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 474,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_475",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(a)\nPromptly perform rapid diagnostic laboratory tests on\npatients who are admitted with or who have\nsymptoms of RSV infection after admission to the\nhealth-care facility to facilitate early downgrading of\ninfection-control precautions to the minimum\nrequired for each patient’s specific viral infection\n(817;819).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 475,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_476",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(b)\nPromptly perform rapid diagnostic laboratory tests on\npatients who are admitted with or who have\nsymptoms of parainfluenza or adenovirus infection\nafter admission to the health-care facility to facilitate\nearly downgrading of infection-control precautions to\nthe minimum required for each patient’s specific viral\n87\ninfection and early initiation of treatment when\nindicated.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 476,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_477",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nf.\nLimiting patient movement or transport in acute-care facilities \n(1)\nLimit to essential purposes only the movement or transport\nof patients from their rooms when they are diagnosed or\nsuspected to be infected with RSV, parainfluenza virus, or\nadenovirus (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 477,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_478",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(2)\nIf transport or movement from the room is necessary\n (a)\nFor a patient with diagnosed or suspected RSV or\nparainfluenza virus infection, ensure that precautions\nare maintained to minimize the risk for transmission\nof the virus to other patients and contamination of\nenvironmental surfaces or equipment by ensuring that\nthe patient does not touch other persons’ hands or\nenvironmental surfaces with hands that have been\ncontaminated with his/her respiratory secretions\n(279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 478,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_479",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n(b)\nFor a patient with diagnosed or suspected adenovirus\ninfection, minimize patient dispersal of droplets by\nhaving the patient wear a surgical mask, and ensure\nthat contact precautions are maintained to minimize\nthe risk of transmission of the virus to other patients\nand contamination of environmental surfaces or\nequipment (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 479,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_480",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nOther measures in acute-care facilities\na.\nStaffing\n(1)\nRestrict health-care personnel in the acute stages of an upper\nrespiratory tract infection from caring for infants and other\npatients at high risk for complications from viral respiratory\ntract infections (e.g., children with severe underlying cardio-\npulmonary conditions, children receiving chemotherapy for\nmalignancy, premature infants, and patients who are\notherwise immunocompromised) (279;507;813;815;817).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 480,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_481",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(2)\nWhen feasible, perform rapid diagnostic testing on health-\ncare personnel with symptoms of respiratory tract infection,\nespecially those who provide care to patients at high-risk for\nacquiring and/or developing severe complications from RSV,\nparainfluenza, or adenovirus infection, so that their work\n88\nstatus can be determined promptly.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 481,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_482",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nb.\nLimiting visitors\nDo not allow persons who have symptoms of respiratory\ninfection to visit pediatric, immunocompromised, or cardiac\npatients (279;507;810;817;819).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 482,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_483",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nUse of monoclonal antibody (palivizumab) for attenuation of RSV\ninfection\nFollow the recommendations of the American Academy of Pediatrics\nto consider monthly administration of palivizumab, an RSV\nmonoclonal-antibody preparation, to the following infants and\nchildren aged <24 months: 1) those born prematurely at <32 weeks\nof gestational age and have bronchopulmonary dysplasia, and those\nborn prematurely at <32 weeks gestation without chronic lung\ndisease who will be aged <6 months at the beginning of the RSV\nseason, and (2) those born at 32-35 weeks gestation, if two or more\nof the following risk factors are present: child-care attendance,\nschool-aged siblings, exposure to environmental pollutants,\ncongenital abnormalities of the airways, or severe neuromuscular",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 483,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_484",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nControl of outbreaks in acute-care facilities\na.\nPerform rapid screening diagnostic tests for the particular virus(es)\nknown or suspected to be causing the outbreak on patients who are\nadmitted with symptoms of viral respiratory illness. Promptly cohort\nthe patients (according to their specific infections) as soon as the\nresults of the screening tests are available\n(749;764;810;813;815;817;819). In the interim, when possible,\nadmit patients with symptoms of viral respiratory infections to\nprivate rooms.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 484,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_485",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nPersonnel cohorting\n(1)\nDuring an outbreak of health-care-associated RSV infection,\ncohort personnel as much as practical (e.g., restrict personnel\nwho give care to infected patients from giving care to\nuninfected patients) (810;813;815).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 485,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_486",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n(2)\nNo recommendation can be made for routinely cohorting\npersonnel during an outbreak of health-care-associated\nadenovirus or  parainfluenza virus infection.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 486,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_487",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nc.\nUse of  RSV immune globulin or monoclonal antibody\n89\nNo recommendation can be made for the use of RSV\nimmune globulin or monoclonal antibody to control\noutbreaks of RSV infection in the health-care setting (820-\n825;827-829).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 487,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_488",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 90\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED INFLUENZA]\nI.\nStaff Education \nProvide health-care personnel continuing education or access to continuing education\nabout the epidemiology, modes of transmission, diagnosis, and means of preventing the\nspread of influenza, in accordance with their level of responsibility in preventing health-\ncare-associated influenza (1029;1044-1046).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "90\nPREVENTION AND CONTROL OF HEALTH-CARE-ASSOCIATED INFLUENZA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 488,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_489",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nII.\nSurveillance\nA.\nEstablish mechanisms by which facility personnel are promptly alerted about\nincreased influenza activity in the community.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 489,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_490",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nEstablish protocols for intensifying efforts to promptly diagnose cases of facility-\nacquired influenza.\n1.\nDetermine the threshold incidence or prevalence of influenza or influenza-\nlike illness in the facility at which laboratory testing of patients with\ninfluenza-like illness is to be undertaken and outbreak control measures are\nto be initiated (942).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 490,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_491",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nArrange for laboratory tests to be available to clinicians for prompt\ndiagnosis of influenza, especially during November-April (936-939).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 491,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_492",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nIII.\nModifying Host Risk For Infection \nA. \nVaccination\n1.\nIn acute-care settings (including acute-care hospitals, emergency rooms, and\nwalk-in clinics) or ongoing-care facilities (including physicians’ offices,\npublic health clinics, employee health clinics, hemodialysis centers, hospital\nspecialty-care clinics, outpatient rehabilitation programs, or mobile clinics),\noffer vaccine to inpatients and outpatients at high risk for complications\nfrom influenza beginning in September and throughout the influenza season\n(410;941;1047;1048).  Groups at high risk for influenza-related\ncomplications include those aged >65 years; residents of nursing homes and\nother chronic-care facilities that house persons of any age who have chronic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 492,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_493",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "other chronic-care facilities that house persons of any age who have chronic\nmedical conditions; adults and children aged >6 months who have chronic\ndisorders of the pulmonary or cardiovascular system, including asthma;\nadults and children who have required regular medical follow-up or\nhospitalization during the preceding year because of chronic metabolic\ndiseases (including diabetes mellitus), renal dysfunction,\nhemoglobinopathies; or immunosuppression (including immunosuppresssion\ncaused by medications or HIV); children and adolescents (aged 6 months-18\nyears) who are receiving long-term aspirin therapy; and women who will be\nin the second or third trimester of pregnancy during the influenza season\n(941;950-954;957). In addition, offer annual influenza vaccination to all\n91",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 493,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_494",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "(941;950-954;957). In addition, offer annual influenza vaccination to all\n91\npersons aged 50-64 years, close contacts of children aged <24 months, and \nhealthy children aged 6-23 months (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 494,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_495",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n2.\nIn nursing homes and other long-term care facilities, establish an SOP for\ntimely administration of the inactivated influenza vaccine to high-risk\npersons as identified in Section III-A-1 (408;409;941;1029).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 495,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_496",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\na.\nObtain consent for influenza vaccination (if such is required by local\nor state law) from every resident (or his/her guardian) at the time the\nresident is admitted to the facility or anytime afterwards, before the\nnext influenza season (941;1029;1049).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 496,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_497",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nb.\nRoutinely vaccinate all residents, except those with medical\ncontraindication(s) to receipt of influenza vaccine, (under an SOP or\nwith the concurrence of the residents’ respective attending\nphysicians) at one time, annually, before the influenza season. To\nresidents who are admitted during the winter months after\ncompletion of the facility’s vaccination program, offer the vaccine at\nthe time of their admission (941;957;1049;1050).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 497,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_498",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nIn settings not included in sections III-A-1 and -2, where health care\nis given (e.g., in homes visited by personnel from home health-care\nagencies), vaccinate patients for whom vaccination is indicated, as\nlisted in section III-A-1, and refer patient’s household members and\ncare givers for vaccination, before the influenza season (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 498,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_499",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY  IA]\n3.\nPersonnel\na.\nBeginning in October each year, provide inactivated influenza\nvaccine for all personnel including night and weekend staff\n(941;944-946;956;958). Throughout the influenza season, continue\nto make the vaccine available to newly hired personnel and to those\nwho initially refuse vaccination. If vaccine supply is limited, give\nhighest priority to staff caring for patients at greatest risk for severe\ncomplications from influenza infection, as listed in section III-A-1\nabove (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY  IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 499,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_500",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nEducate health-care personnel regarding the benefits of vaccination\nand the potential health consequences of influenza illness for\nthemselves and their patients (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 500,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_501",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nc.\nTake measures to provide all health-care personnel convenient\naccess to inactivated influenza vaccine at the work site, free of\n92\ncharge, as part of employee health program (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 501,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_502",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: PREVENTION OF PERSON-TO-PERSON TRANSMISSION]\nA.\nDroplet Precautions\n1.\nPlace a patient who is diagnosed to have influenza in a private room or in a\nroom with other patients with confirmed influenza, unless there are medical\ncontraindications to doing so (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "PREVENTION OF PERSON-TO-PERSON TRANSMISSION",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 502,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_503",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2\nPlace a patient suspected to have influenza in a private room and promptly\nperform rapid diagnostic laboratory tests to facilitate early downgrading of\ninfection-control precautions to the minimum required for the patient’s\ninfection (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 503,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_504",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nWear a surgical mask upon entering the patient’s room or when working\nwithin 3 feet of the patient (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 504,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_505",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n4.\nLimit the movement and transport of the patient from the room to those for\nessential purposes only.  If patient movement or transport is necessary, have\nthe patient wear a surgical mask, if possible, to minimize droplet dispersal\nby the patient (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 505,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_506",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nB.\nEye Protection\nNo recommendation can be made for wearing eye-protective device upon entering\nthe room of a patient with confirmed or suspected influenza or when working\nwithin 3 feet of the patient.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 506,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_507",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nC.\nContact Precautions\nNo recommendation can be made for observance of contact precautions (in addition\nto droplet precautions) for patients with confirmed or suspected influenza\n(279;921).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 507,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_508",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nD.\nStandard Precautions\n1.\nDecontaminate hands before and after giving care to and/or touching a\npatient or after touching a patient’s respiratory secretions, whether or not\ngloves are worn: if hands are visibly dirty or contaminated with\nproteinaceous material or are visibly soiled with blood or body fluids, wash\nthem with either a nonantimicrobial soap and water or an antimicrobial soap\nand water; and if hands are not visibly soiled, use an alcohol-based hand rub\nfor their decontamination (278).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 508,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_509",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\n2.\nWear gloves if hand contact with patient’s respiratory secretions is expected\n(279;921).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 509,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_510",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 93\nCATEGORY II]\n3.\nWear a gown if soiling of clothes with patient’s respiratory secretions is\nexpected (279).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "93\nCATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 510,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_511",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\nE.\nAir Handling\nNo recommendation can be made for maintaining negative air pressure in rooms of\npatients in whom influenza is suspected or diagnosed, or in placing together persons\nwith influenza-like illness in a hospital area with an independent air-supply and\nexhaust system (909;922;924).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 511,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_512",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nF.\nPersonnel Restrictions\nIn acute-care facilities, utilize the facility’s employee health service or its equivalent\nto evaluate personnel with influenza-like illness and determine whether they should\nbe removed from duties that involve direct patient contact. Use more stringent\ncriteria for personnel who work in certain patient-care areas (e.g., ICUs, nurseries,\nand organ-transplant [especially HSCT] units) where patients who are most\nsusceptible to influenza-related complications are located (920;993;1051).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 512,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_513",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nV.\nControl Of Influenza Outbreaks\n \nA.\nDetermining the Outbreak Strain\nEarly in the outbreak, perform rapid influenza virus testing on nasopharyngeal swab\nor nasal-wash specimens from patients with recent onset of symptoms suggestive of\ninfluenza. In addition, obtain viral cultures from a subset of patients to determine\nthe infecting virus type and subtype (936-939).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 513,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_514",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nB.\nVaccination of Patients and Personnel\nAdminister current inactivated influenza vaccine to unvaccinated patients and\nhealthcare personnel (941;945;946;957).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 514,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_515",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nC.\nAntiviral Agent Administration\n1.\nWhen a facility outbreak of influenza is suspected or recognized:\na.\nAdminister amantadine, rimantadine, or oseltamivir as prophylaxis to\nall patients without influenza illness in the involved unit for whom\nthe antiviral agent is not contraindicated (regardless of whether they\nreceived influenza vaccinations during the previous fall) for a\nminimum of 2 weeks or until approximately 1 week after the end of\nthe outbreak. Do not delay administration of the antiviral agent(s)\nfor prophylaxis unless the results of diagnostic tests to identify the\ninfecting strain(s) can be obtained within 12-24 hours after specimen\ncollection (931;941;964;1050).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 515,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_516",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nb.\nAdminister amantadine, rimantadine, oseltamivir, or zanamivir to\npatients acutely ill with influenza, within 48 hours of illness onset. \n94\nChoose the agent appropriate for the type of influenza virus\ncirculating in the community (931;941;964;967;1050;1052).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 516,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_517",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\nc.\nOffer antiviral agent(s) (amantadine, rimantadine, or oseltamivir) for\nprophylaxis to unvaccinated personnel for whom the antiviral agent\nis not contraindicated and who are in the involved unit or taking care\nof patients at high-risk (931;941;964;975;1050).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 517,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_518",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nd.\nConsider prophylaxis for all healthcare personnel, regardless of their\nvaccination status, if the outbreak is caused by a variant of influenza\nthat is not well matched by the vaccine (941).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 518,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_519",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\ne.\nNo recommendation can be made about the prophylactic\nadministration of zanamivir to patients or personnel\n(915;941;974;977).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 519,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_520",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: UNRESOLVED ISSUE]\nf.\nDiscontinue the administration of influenza antiviral agents to\npatients or personnel if laboratory tests confirm or strongly suggest\nthat influenza is not the cause of the facility outbreak (962).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "UNRESOLVED ISSUE",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 520,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_521",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IA]\ng.\nIf the cause of the outbreak is confirmed or believed to be influenza\nand vaccine has been administered only recently to susceptible\npatients and personnel, continue prophylaxis with an antiviral agent\nuntil 2 weeks after the vaccination (941;1053).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 521,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_522",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\n2.\nTo reduce the potential for transmission of drug-resistant virus, do not\nallow contact between persons at high risk for complications from influenza\nand patients or personnel who are taking an antiviral agent for treatment of\nconfirmed or suspected influenza during and for 2 days after the latter\ndiscontinue treatment (963;984;985;987;988).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 522,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_523",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB]\nD.\nOther Measures in Acute-Care Facilities:\nWhen influenza outbreaks, especially those characterized by high attack rates and\nsevere illness, occur in the community and/or facility:\n1.\nCurtail or eliminate elective medical and surgical admissions (993).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 523,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_524",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n2.\nRestrict cardiovascular and pulmonary surgery to emergency cases only\n(993).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 524,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_525",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n3.\nRestrict persons with influenza or influenza-like illness from visiting patients\nin the health-care facility (993).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 525,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_526",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY II]\n95\n4.\nRestrict personnel with influenza or influenza-like illness from patient care\n(993).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY II",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 526,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_527",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS]\nUpdated information about prevention and control of SARS in health-care facilities is\navailable in a separate document, Public Health Guidance for Community-Level Preparedness and\nResponse to SARS, Version 2. Supplement I: Infection Control in Healthcare Home and\nCommunity Settings, available at (http://www.cdc.gov/ncidod/sars/guidance/index.htm).\nPART III.  PERFORMANCE INDICATORS\n1.   Monitor rates of VAP; can use established benchmarks and definitions of pneumonia (e.g.,\nNNIS definitions and rates) .  Provide feedback to the staff about the facility’s VAP rates and\nreminders about the need for personnel to adhere to infection-control practices that reduce the\nincidence of VAP.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 527,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_528",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "incidence of VAP.\n2..  Establish an SOP for influenza vaccination and monitor the percentage of eligible patients in\nacute-care settings or patients or residents in long-term care settings who receive the vaccine.\n3.  Before and during the influenza season, monitor and record the number of eligible health-care\npersonnel who receive the influenza vaccine and determine the desired unit- and facility-specific\nvaccination rates as recommended by ACIP.\n4.  Monitor the number of cases of health-care-associated RSV infections by geographic location\nwithin the facility and give prompt feedback to appropriate staff members to improve adherence to\nrecommended infection-control precautions.\n5.  Periodically review clinicians’ use of laboratory diagnostic tests (both culture of appropriate",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 528,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_529",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "5.  Periodically review clinicians’ use of laboratory diagnostic tests (both culture of appropriate\nrespiratory specimen and the urine antigen test) for legionellosis, especially in patients who are at\nhigh risk of acquiring the disease (e.g., patients who are immunosuppressed, including recipients of\nHSCT or solid-organ transplant or are receiving systemic steroids; patients aged > 65 years; or\npatients who have chronic underlying disease such as diabetes mellitus, congestive heart failure,\nand COPD). Provide feedback on the utilization of these tests to clinicians.\n6.  During construction or renovation activities in the facility, monitor personnel adherence to\ninfection-control measures (e.g., use of barriers, maintenance of negative room pressure) that are",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 529,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_530",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection-control measures (e.g., use of barriers, maintenance of negative room pressure) that are\naimed at minimizing dust dispersion in patient-care areas. Review all cases of health-care-\nassociated aspergillosis to determine the presence of remediable environmental risks.\n7.  Periodically monitor the frequency of diagnostic testing for pertussis and the time interval\nbetween suspicion of the infection and initiation of isolation precautions for patients in whom\npertussis is suspected.\n96\nReferences\n1. CDC. Guideline for Prevention of Nosocomial Pneumonia. MMWR 1997; 46 (No. RR-\n1).\n2. CDC. Guidelines for Preventing Health-Care-Associated Pneumonia, 2003.\nRecommendations of the CDC and the Healthcare Infection Control Practices Advisory\nCommittee. MMWR 2004; 53(No. RR-3).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 530,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_531",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Committee. MMWR 2004; 53(No. RR-3).\n3. CDC. Guidelines for preventing the transmission of tuberculosis in health-care facilities,\n1994. MMWR 1994; 43(RR-13).\n4. Horan TC, White JW, Jarvis WR, et al. Nosocomial infection surveillance, 1984. MMWR\n1986; 35(SS1):17-29.\n5. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical\nintensive care units in the United States.  National Nosocomial Infections Surveillance System. Crit\nCare Med 1999; 27(5):887-892.\n6. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in coronary\ncare units in the United States.  National Nosocomial Infections Surveillance System. Am J Cardiol\n1998; 82(6):789-793.\n7. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 531,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_532",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "7. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the\nmicrobiology laboratory. Clin Microbiol Rev 1993; 6(4):428-442.\n8. Jarvis WR, Edwards JR, Culver DH, et al. Nosocomial infection rates in adult and\npediatric intensive care units in the United States. Am J Med 1991; 91(supp3B):185S-191S.\n9. Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report, data\nsummary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002;\n30:458-475.\n10. Craven DE, Kunches LM, Lichtenberg DA, et al. Nosocomial infection and fatality in\nmedical and surgical intensive care unit patients. Arch Intern Med 1988; 148(5):1161-1168.\n11. Cross AS, Roup B. Role of respiratory assistance devices in endemic nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 532,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_533",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "11. Cross AS, Roup B. Role of respiratory assistance devices in endemic nosocomial\npneumonia. Am J Med 1981; 70(3):681-685.\n12. Haley RW, Hooton TM, Culver DH, et al. Nosocomial infections in U.S. hospitals, 1975-\n1976: estimated frequencies by selected characteristics of patients. Am J Med 1981; 70(4):947-\n959.\n13. Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Riosin R, Agusti-Vidal A.\nNosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93(2):318-324.\n97\n14. Chevret S, Hemmer M, Carlet J, Langer M. Incidence and risk factors of pneumonia\nacquired in intensive care units. Results from a multicenter prospective study on 996 patients.\nEuropean Cooperative Group on Nosocomial Pneumonia. Intensive Care Med 1993; 19(5):256-\n264.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 533,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_534",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "European Cooperative Group on Nosocomial Pneumonia. Intensive Care Med 1993; 19(5):256-\n264.\n15. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-\nassociated pneumonia in critically ill patients. Ann Intern Med 1998; 129(6):433-440.\n16. Craven DE, Kunches LM, Kilinsky V, Lichtenberg DA, Make BJ, McCabe WR. Risk\nfactors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev\nRespir Dis 1986; 133(5):792-796.\n17. Emori TG, Banerjee SN, Culver DH, et al. Nosocomial infections in elderly patients in\nthe United States, 1986-1990. National Nosocomial Infections Surveillance System. Am J Med\n1991; 91(supp3B):289S-293S.\n18. Garibaldi RA, Britt MR, Coleman ML, Reading JC, Pace NL. Risk factors for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 534,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_535",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "18. Garibaldi RA, Britt MR, Coleman ML, Reading JC, Pace NL. Risk factors for\npostoperative pneumonia. Am J Med 1981; 70(3):677-680.\n19. Gaynes RP, Bizek B, Mowry-Hanley J, et al. Risk factors for nosocomial pneumonia\nafter coronary artery bypass graft operations. Ann Thor Surg 1991; 51:215-218.\n20. Hanson LC, Wever DJ, Rutala WA. Risk factors for nosocomial pneumonia in the\nelderly. Am J Med 1992; 92(2):161-166.\n21. Jacobs S, Chang RW, Lee B, Bartlett FW. Continuous enteral feeding: a major cause of\npneumonia among ventilated intensive care unit patients. J Parenter Enter Nutr 1990; 14(4):353-\n356.\n22. Joshi N, Localio AR, Hamory BH. A predictive risk index for nosocomial pneumonia in\nthe intensive care unit. Am J Med 1992; 93(2):135-142.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 535,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_536",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "the intensive care unit. Am J Med 1992; 93(2):135-142.\n23. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993;\n270(16):1965-1970.\n24. Rello J, Quintana E, Ausina V, Puzo C, Net A, Prats G. Risk factors for Staphylococcus\naureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142(6 Pt 1):1320-\n1324.\n25. Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial\npneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142(3):523-528.\n26. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of\nstay and mortality. Am J Infect Control 1984; 12(4):233-238.\n98\n27. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 536,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_537",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "98\n27. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial\npneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.\nAm J Med 1993; 94(3):281-288.\n28. Leu HS, Kaiser DL, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia.\nAttributable mortality and morbidity. Am J Epidemiol 1989; 129(6):1258-1267.\n29. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy\non the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104(4):1230-1235.\n30. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-\nassociated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 537,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_538",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by\nquantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996;\n23(3):538-542.\n31. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable\nmorbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The\nCanadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-1256.\n32. Rello J, Jubert P, Valles J, Artigas A, Rue M, Niederman MS. Evaluation of outcome for\nintubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996;\n23(5):973-978.\n33. Rello J, Ollendorf DA, Osler G, et al. Epidemiology and outcomes of ventilator-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 538,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_539",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "23(5):973-978.\n33. Rello J, Ollendorf DA, Osler G, et al. Epidemiology and outcomes of ventilator-\nassociated pneumonia in a large US database. Chest 2002; 122:2115-2121.\n34. Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C. Nosocomial\npneumonia and mortality among patients in intensive care units. JAMA 1996; 275(11):866-869.\n35. Freeman J, Rosner BA, McGowan JEJr. Adverse effects of nosocomial infection. J Infect\nDis 1979; 140(5):732-740.\n36. Haley RW, Schaberg DR, Crossley KB, Von Allmen SD, McGowan J.E. Jr. Extra\ncharges and prolongation of stay attributable to nosocomial infections: a prospective interhospital\ncomparison. Am J Med 1981; 70(1):51-58.\n37. Nicolle LE, Strausbaugh LJ, Garibaldi RA. Infections and antibiotic resistance in nursing",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 539,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_540",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "37. Nicolle LE, Strausbaugh LJ, Garibaldi RA. Infections and antibiotic resistance in nursing\nhomes. Clin Microbiol Rev 1996; 9:1-17.\n38. Jackson M, Fierer J, Barrett-Connor E, et al. Intensive surveillance for infections in a\nthree-year study of nursing home patients. Am J Epidemiol 1992; 135(6):685-696.\n39. Crossley KB, Thurn JR. Nursing home-acquired pneumonia. Semin Respir Infect 1989;\n4(1):64-72.\n99\n40. Nicolle LE, McIntyre RN, Zacharias H, MacDonell JA. Twelve-month surveillance of\ninfections in institutionalized elderly men. J Am Geriatr Soc 1984; 32(7):513-519.\n41. Beck-Sague C, Banerjee S, Jarvis WR. Infectious diseases and mortality among US\nnursing home residents. Am J Public Health 1993; 83(12):1739-1742.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 540,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_541",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "nursing home residents. Am J Public Health 1993; 83(12):1739-1742.\n42. Naughton BJ, Mylotte JM, Tayara A. Outcome of nursing home acquired pneumonia:\nderivation and application of a practical model to predict 30 day mortality. J Am Geriatr Soc 2000;\n48:1292.\n43. Loeb M, McGeer A, McArthur M, Peeling RW, Petric M, Simor AE. Surveillance for\noutbreaks of respiratory tract infections in nursing homes. Can Med Assoc J 2000; 162:1133-1137.\n44. Bartlett JG, O'keefe P, Tally FP, Louie TJ, Gorbach SL. Bacteriology of hospital-\nacquired pneumonia. Arch Intern Med 1986; 146(5):868-871.\n45. Johanson WG, Jr., Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory\ninfections with gram-negative bacilli. The significance of colonization of the respiratory tract. Ann\nIntern Med 1972; 77(5):701-706.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 541,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_542",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Intern Med 1972; 77(5):701-706.\n46. Andrews CP, Coalson JJ, Smith JD, Johanson WG, Jr. Diagnosis of nosocomial bacterial\npneumonia in acute, diffuse lung injury. Chest 1981; 80(3):254-258.\n47. Lowy FD, Carlisle PS, Adams A, Feiner C. The incidence of nosocomial pneumonia\nfollowing urgent endotracheal intubation. Infect Control 1987; 8(6):245-248.\n48. Bell RC, Coalson JJ, Smith JD, Johanson WG, Jr. Multiple organ system failure and\ninfection in adult respiratory distress syndrome. Ann Intern Med 1983; 99(3):293-298.\n49. Fagon JY, Chastre J, Hance AJ, Domart Y, Trouillet JL, Gibert C. Evaluation of clinical\njudgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest\n1993; 103(2):547-553.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 542,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_543",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1993; 103(2):547-553.\n50. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management\nof suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;\n132(8):621-630.\n51. Lambert RS, Vereen LE, George RB. Comparison of tracheal aspirates and protected\nbrush catheter specimens for identifying pathogenic bacteria in mechanically ventilated patients.\nAm J Med Sci 1989; 297(6):377-382.\n52. Luna CM, Videla A, Mattera J, et al. Blood cultures have limited value in predicting\nseverity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999;\n116(4):1075-1084.\n100\n53. Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-\nassociated pneumonia. Chest 1992; 102:557S-564S.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 543,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_544",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "associated pneumonia. Chest 1992; 102:557S-564S.\n54. Baselski V, El-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for\nprocessing and interpreting laboratory specimens in patients with suspected ventilator-associated\npneumonia. Chest 1992; 102:571S-579S.\n55. Wunderink RG, Mayhall CG, Gibert C. Methodology for clinical investigation of\nventilator-associated  pneumonia. Epidemiology and therapeutic intervention. Chest 1992;\n102:580S-588S.\n56. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving\ncontinuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected\nspecimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139(4):877-884.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 544,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_545",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139(4):877-884.\n57. Chastre J, Fagon JY, Soler P, et al. Diagnosis of nosocomial bacterial pneumonia in\nintubated patients undergoing ventilation: comparison of the usefulness of bronchoalveolar lavage\nand the protected specimen brush. Am J Med 1988; 85(4):499-506.\n58. Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in\nventilated patients. Use of a protected specimen brush and quantitative culture technique in 147\npatients. Am Rev Respir Dis 1988; 138(1):110-116.\n59. Chastre J, Viau F, Brun P, et al. Prospective evaluation of the protected specimen brush\nfor the diagnosis of pulmonary infections in ventilated patients. Am Rev Respir Dis 1984;\n130(5):924-929.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 545,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_546",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "130(5):924-929.\n60. Rodriguez de Castro F, Sole Violan J, Lafarga Capuz B, Caminero Luna J, Gonzalez\nRodriguez B, Manzano Alonso JL. Reliability of bronchoscopic protected catheter brush in the\ndiagnosis of pneumonia in mechanically ventilated patients. Crit Care Med 1991; 19(2):171-175.\n61. Pham LH, Brun-Buisson C, Legrand P, et al. Diagnosis of nosocomial pneumonia in\nmechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected\nspecimen brush. Am Rev Respir Dis 1991; 143:1055-1061.\n62. Villers D, Derriennic M, Raffi F, et al. Reliability of the broncoscopic protected catheter\nbrush in intubated and ventilated patients. Chest 1985; 88(4):527-530.\n63. Baughman RP, Thorpe JE, Staneck J, Rashkin M, Frame PT. Use of the protected",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 546,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_547",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "63. Baughman RP, Thorpe JE, Staneck J, Rashkin M, Frame PT. Use of the protected\nspecimen brush in patients with endotracheal or tracheostomy tubes. Chest 1987; 91(2):233-235.\n64. Marquette CH, Ramon P, Courcol R, Wallaert B, Tonnel AB, Voisin C. Bronchoscopic\nprotected catheter brush for the diagnosis of pulmonary infections. Chest 1988; 93(4):746-750.\n65. Marik PE, Brown WJ. A comparison of bronchoscopic vs blind protected specimen brush\n101\nsampling in patients with suspected ventilator-associated pneumonia. Chest 1995; 108(1):203-207.\n66. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of\nventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and non-\nbronchoscopic blind bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-1129.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 547,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_548",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "bronchoscopic blind bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-1129.\n67. Torres A, Puig de la Bellacasa J, Xaubet A, et al. Diagnostic value of quantitative\ncultures of bronchoalveolar lavage and telescoping plugged catheters in mechanically ventilated\npatients with bacterial pneumonia. Am Rev Respir Dis 1989; 140(2):306-310.\n68. Kahn FW, Jones JM. Diagnosing bacterial respiratory infection by bronchoalveolar\nlavage. J Infect Dis 1987; 155(5):862-869.\n69. Thorpe JE, Baughman RP, Frame PT, Wesseler TA, Staneck JL. Bronchoalveolar lavage\nfor diagnosing acute bacterial pneumonia. J Infect Dis 1987; 155(5):855-861.\n70. Guerra LF, Baughman RP. Use of bronchoalveolar lavage to diagnose bacterial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 548,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_549",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "70. Guerra LF, Baughman RP. Use of bronchoalveolar lavage to diagnose bacterial\npneumonia in mechanically ventilated patients. Crit Care Med 1990; 18(2):169-173.\n71. Chastre J, Fagon JY, Soler P, et al. Quantification of BAL cells containing intracellular\nbacteria rapidly identifies ventilated patients with nosocomial pneumonia. Chest 1989; 95(3):190S-\n192S.\n72. Valles J, Rello J, Fernandez R, et al. Role of bronchoalveolar lavage in mechanically\nventilated patients with suspected pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13(7):549-\n558.\n73. Meduri GU, Beals DH, Meijub AG, Baselski V. Protected bronchoalveolar lavage. A\nnew bronchoscopic technique to retrieve uncontaminated distal airway secretions. Am Rev Respir\nDis 1991; 143:855-864.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 549,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_550",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Dis 1991; 143:855-864.\n74. Rouby JJ, Rossignon MD, Nicolas MH, et al. A prospective study of protected\nbronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology 1989;\n71(5):679-685.\n75. Torres A, Martos A, Puig de la Bellacasa J, et al. Specificity of endotracheal aspiration,\nprotected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. Am Rev\nRespir Dis 1993; 147(4):952-957.\n76. Torres A, El-ebiary M, Padro L, et al. Validation of different techniques for the diagnosis\nof ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy.\nAm J Respir Crit Care Med 1994; 149:324-331.\n77. Torres A, Puig de la Bellacasa J, Rodriguez-Roisin R, Jimenez de Anta MT, Agusti-Vidal",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 550,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_551",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "77. Torres A, Puig de la Bellacasa J, Rodriguez-Roisin R, Jimenez de Anta MT, Agusti-Vidal\nA. Diagnostic value of telescoping plugged catheters in mechanically ventilated patients with\n102\nbacterial pneumonia using the Metras catheter. Am Rev Respir Dis 1988; 138(1):117-120.\n78. Trouillet JL, Guiget M, Gibert C, et al. Fiberoptic bronchoscopy in ventilated patients.\nEvaluation of cardiopulmonary risk under midazolam sedation. Chest 1990; 97(4):927-933.\n79. Lindholm CE, Ollman B, Snyder JV, Millen EG, Grenvik A. Cardiorespiratory effects of\nflexible fiberoptic bronchoscopy in critically ill patients. Chest 1978; 74(4):362-368.\n80. El-ebiary M, Torres A, Gonzalez J, et al. Quantitative cultures of endotracheal aspirates",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 551,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_552",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "80. El-ebiary M, Torres A, Gonzalez J, et al. Quantitative cultures of endotracheal aspirates\nfor the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993; 148:1552-1557.\n81. Marquette CH, Georges H, Wallet F, et al. Diagnostic efficiency of endotracheal\naspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Am\nRev Respir Dis 1993; 148(1):138-144.\n82. Piperno D, Gaussorgues P, Bachmann P, Jaboulay JM, Robert D. Diagnostic value of\nnonbronchoscopic bronchoalveolar lavage during mechanical ventilation. Chest 1988; 93:223.\n83. Leal-Noval SR, Alfaro-Rodriguez E, Murillo-Cabeza F, Garnacho-Montero J, Rey-Perez\nJ, Munoz-Sanchez MA. Diagnostic value of the blind brush in mechanically ventilated patients with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 552,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_553",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "J, Munoz-Sanchez MA. Diagnostic value of the blind brush in mechanically ventilated patients with\nnosocomial pneumonia. Intensive Care Med 1992; 18(7):410-414.\n84. Papazian L, Martin C, Meric B, Dumon JF, Gouin F. A reappraisal of blind bronchial\nsampling in the microbiologic diagnosis of nosocomial bronchopneumonia. A comparative study in\nventilated patients. Chest 1993; 103(1):236-242.\n85. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology,\nmanagement, and prevention. Am J Med 1998; 105:319-330.\n86. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with\nearly-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117(5):1434-\n1442.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 553,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_554",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117(5):1434-\n1442.\n87. Rouby JJ, Martin de Lasalle E, Poete P, et al. Nosocomial bronchopneumonia in the\ncritically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 146(4):1059-1066.\n88. Schleupner CJ, Cobb DK. A study of the etiologies and treatment of nosocomial\npneumonia in a community-based teaching hospital. Infect Control Hosp Epidemiol 1992;\n13(9):515-525.\n89. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of\nnosocomial infection. Am J Med 1991; 91(3B):72S-75S.\n90. Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial\npneumonia in mechanically ventilated patients. Chest 1991; 100(2):439-444.\n103",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 554,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_555",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pneumonia in mechanically ventilated patients. Chest 1991; 100(2):439-444.\n103\n91. Jimenez P, Torres A, Rodriguez-Roisin R, et al. Incidence and etiology of pneumonia\nacquired during mechanical ventilation. Crit Care Med 1989; 17(9):882-885.\n92. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis,\nassessment of severity, initial antimicrobial therapy and preventive strategies. A consensus\nstatement. Am J Respir Crit Care Med 1995; 153:1711-1725.\n93. Janssens JP, Gauthey L, Herrmann F, Tkatch L, Michel JP. Community-acquired\npneumonia in older patients. J Am Geriat Soc 1996; 44(5):539-544.\n94. Loeb M, et al. Two nursing home outbreaks of respiratory infection with Legionella\nsainthelensi. J Am Geriatr Soc 1999; 47:547-552.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 555,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_556",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "sainthelensi. J Am Geriatr Soc 1999; 47:547-552.\n95. Stout JE, Brennen C, Muder RR. Legionnaires' disease in a newly constructed long-term\ncare facility. J Am Geriatr Soc 2000; 48(12):1589-1592.\n96. Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of\ninfectious outbreaks in nursing homes. JAMA 1997; 277(15):1214-1218.\n97. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the\ninstitutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992; 40(2):115-\n119.\n98. Huxley EJ, Viroslav J, Gray WR, Pierce AK. Pharyngeal aspiration in normal adults and\npatients with depressed consciousness. Am J Med 1978; 64(4):564-568.\n99. Johanson WG, Jr., Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 556,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_557",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "99. Johanson WG, Jr., Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of\nhospitalized patients. Emergence of gram-negative bacilli. N Engl J Med 1969; 281(21):1137-\n1140.\n100. Niederman MS, Merrill WW, Ferranti RD, Pagano KM, Palmer LB, Reynolds HY.\nNutritional status and bacterial binding in the lower respiratory tract in patients with chronic\ntracheostomy. Ann Intern Med 1984; 100(6):795-800.\n101. Reynolds HY. Bacterial adherence to respiratory tract mucosa-- a dynamic interaction\nleading to colonization. Seminars Respir Infect 1987; 2(1):8-19.\n102. Valenti WM, Trudell RG, Bentley DW. Factors predisposing to oropharyngeal\ncolonization with gram-negative bacilli in the aged. N Engl J Med 1978; 298(20):1108-1111.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 557,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_558",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "colonization with gram-negative bacilli in the aged. N Engl J Med 1978; 298(20):1108-1111.\n103. Louria DB, Kaminski T. The effects of four antimicrobial drug regimens on sputum\nsuperinfection in hospitalized patients. Am Rev Respir Dis 1962; 85:649-665.\n104. Rosenthal S, Tager IB. Prevalence of gram negative rods in the nornal pharyngeal flora.\nAnn Intern Med 1975; 83(3):355-357.\n104\n105. Mackowiak PA, Martin RM, Jones SR, Smith JW. Pharyngeal colonization by gram-\nnegative bacilli in aspiration-prone persons. Arch Intern Med 1978; 138(8):1224-1227.\n106. Woods DE, Straus DC, Johanson WG, Jr., Berry VK, Bass JA. Role of pili in adherence\nof Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect Immun 1980; 29(3):1146-\n1151.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 558,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_559",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1151.\n107. Niederman MS. Bacterial adherence as a mechanism of airway colonization. Eur J Clin\nMicrobiol Infect Dis 1989; 8(1):15-20.\n108. Johanson WG, Jr., Higuchi JH, Chaudhuri TR, Woods DE. Bacterial adherence to\nepithelial cells in bacillary colonization of the respiratory tract. Am Rev Respir Dis 1980;\n121(1):55-63.\n109. Abraham SN, Beachey EH, Simpson WA. Adherence of Streptococcus pyogenes,\nEscherichia coli, and Pseudomonas aeruginosa to fibronectin-coated and uncoated epithelial cells.\nInfect Immun 1983; 41(3):1261-1268.\n110. Beachey EH. Bacterial adherence: adhesin-receptor interactions mediating the attachment\nof bacteria to mucosal surfaces. J Infect Dis 1981; 143(3):325-345.\n111. Woods DE, Straus DC, Johanson WG, Jr., Bass JA. Role of fibronectin in the prevention",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 559,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_560",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "111. Woods DE, Straus DC, Johanson WG, Jr., Bass JA. Role of fibronectin in the prevention\nof adherence of Pseudomonas aeruginosa to buccal cells. J Infect Dis 1981; 143(6):784-790.\n112. Woods DE, Straus DC, Johanson WG, Jr., Bass JA. Role of salivary protease activity in\nadherence of gram-negative bacilli to mammalian buccal epithelial cells in vitro. J Clin Invest 1981;\n68(6):1435-1440.\n113. Ramphal R, Small PM, Shands JW, Jr., Fischlschweiger W, Small PA, Jr. Adherence of\nPseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal\nintubation. Infect Immun 1980; 27(2):614-619.\n114. Niederman MS, Merrill WW, Polomski LM, Reynolds HY, Gee JBL. Influence of\nsputum IgA and elastase on tracheal cell bacterial adherence. Am Rev Respir Dis 1986;\n133(2):255-260.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 560,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_561",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "133(2):255-260.\n115. Niederman MS, Raferty TD, Sasaki CT, Merrill WW, Matthay RA, Reynolds HY.\nComparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the \nhuman respiratory tract. Am Rev Respir Dis 1983; 127(1):85-90.\n116. Franklin AL, Todd T, Gurman G, Black D, Mankinen-Irvin PM, Irvin RT. Adherence of\nPseudomonas aeruginosa to cilia of human tracheal epithelial cells. Infect Immun 1987;\n55(6):1523-1525.\n117. Palmer LB, Merrill WW, Niederman MS, Ferranti RD, Reynolds HY. Bacterial\n105\nadherence to respiratory tract cells. Relationships between in vivo and in vitro pH and bacterial\nattachment. Am Rev Respir Dis 1986; 133(5):784-788.\n118. Dal Nogare AR, Toews GB, Pierce AK. Increased salivary elastase precedes gram-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 561,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_562",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "118. Dal Nogare AR, Toews GB, Pierce AK. Increased salivary elastase precedes gram-\nnegative bacillary colonization in post-operative patients. Am Rev Respir Dis 1987; 135(3):671-\n675.\n119. Proctor RA. Fibronectin: a brief overview of its structure, function and physiology. Rev\nInfect Dis 1987; 9:S317-S321.\n120. Niederman MS, Mantovani R, Schoch P, Papas J, Fein AM. Patterns and routes of\ntracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in\ncolonization of the lower airway by Pseudomonas species. Chest 1989; 95(1):155-161.\n121. Atherton ST, White DJ. Stomach as source of bacteria colonising respiratory tract during\nartificial ventilation. Lancet 1978; 2:968-969.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 562,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_563",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "artificial ventilation. Lancet 1978; 2:968-969.\n122. Du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria\nin antacid treated patients: a frequent cause of postoperative colonization of the airway. Lancet\n1982; 2:242-245.\n123. Kappstein I, Schulgen G, Friedrich T, et al. Incidence of pneumonia in mechanically\nventilated patients treated with sucralfate or cimetidine as prophylaxis for stress bleeding: bacterial\ncolonization of the stomach. Am J Med 1991; 91:125S-131S.\n124. Daschner F, Kappstein I, Engels I, et al. Stress ulcer prophylaxis and ventilation\npneumonia: prevention by antibacterial cytoprotective agents? Infect Control 1988; 9(2):59-65.\n125. Torres A, El-ebiary M, Gonzalez J, et al. Gastric and pharyngeal flora in nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 563,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_564",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "125. Torres A, El-ebiary M, Gonzalez J, et al. Gastric and pharyngeal flora in nosocomial\npneumonia acquired during mechanical ventilation. Am Rev Respir Dis 1993; 148(2):352-357.\n126. Mayhall CG. Nosocomial pneumonia. Diagnosis and prevention. Infect Dis Clin N Am\n1997; 11(2):427-457.\n127. Niederman MS, Craven DE. Devising strategies for preventing nososcomial pneumonia--\nshould we ignore the stomach? Clin Infect Dis 1997; 24(3):320-323.\n128. Bonten MJ, Gaillard CA, van Tiel FH, Smeets HGW, van der Geest S, Stobberingh EE.\nThe stomach is not a source for colonization of the upper respiratory tract and pneumonia in ICU\npatients. Chest 1994; 105(3):878-884.\n129. Garrouste-Orgeas M, Chevret S, Arlet G, et al. Oropharyngeal or gastric colonization",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 564,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_565",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "129. Garrouste-Orgeas M, Chevret S, Arlet G, et al. Oropharyngeal or gastric colonization\nand nosocomial pneumonia in adult intensive care unit patients. A prospective study based on\ngenomic DNA analysis. Am J Respir Crit Care Med 1997; 156(5):1647-1655.\n106\n130. Reusser P, Zimmerli W, Scheidegger D, Marbet GA, Buser M, Gyr K. Role of gastric\ncolonization in nosocomial infections and endotoxemia: a prospective study in neurosurgical\npatients on mechanical ventilation. J Infect Dis 1989; 160(3):414-421.\n131. Martin LF, Booth FVM, Karlstadt RG, et al. Continuous intravenous cimetidine\ndecreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit\nCare Med 1993; 21(1):19-30.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 565,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_566",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Care Med 1993; 21(1):19-30.\n132. Inglis TJJ, Sherratt MJ, Sproat LJ, Gibson JS, Hawkey PM. Gastro-duodenal dysfunction\nand bacterial colonisation of the ventilated lung. Lancet 1993; 341:911-913.\n133. Pingleton SK, Hinthorn DR, Liu C. Enteral nutrition in patients receiving mechanical\nventilation. Multiple sources of tracheal colonization include the stomach. Am J Med 1986;\n80(5):827-832.\n134. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given\nsucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization.\nN Engl J Med 1987; 317(22):1376-1382.\n135. Drasar BS, Shiner M, McLeod GM. Studies of the intestinal flora. I.The bacterial flora of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 566,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_567",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "135. Drasar BS, Shiner M, McLeod GM. Studies of the intestinal flora. I.The bacterial flora of\nthe gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology 1969; 56(1):71-79.\n136. Arnold L. The bacterial flora within the stomach and small intestine. The effect of\nexperimental alterations of acid-base balance and the age of the subject. Am J Med Sci 1933;\n186:471-480.\n137. Ruddell WSJ, Axon ATR, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine\non the gastric bacterial flora. Lancet 1980; 1(8170):672-674.\n138. Donowitz LG, Page MC, Mileur BL, Guenthner SH. Alteration of normal gastric flora in\ncritical care patients receiving antacid and cimetidine therapy. Infect Control 1986; 7(1):23-26.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 567,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_568",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "critical care patients receiving antacid and cimetidine therapy. Infect Control 1986; 7(1):23-26.\n139. Bonten MJM, Kullberg BJ, Dalen Rv, et al. Selective digestive decontamination in\npatients in intensive care. J Antimicrob Chemother 2000; 46:351-362.\n140. Bergmans D, Bonten M, Gaillard C, et al. Prevention of ventilator-associated pneumonia\nby oral decontamination: a prospective, randomised, double-blind, placebo-controlled study. Am J\nRespir Crit Care Med 2001; 164:382-388.\n141. Fourrier F, Duvivier B, Boutigny H, et al. Colonization of dental plaque: A source of\nnosocomial infections in intensive care unit patients. Crit Care Med 1998; 26:301-308.\n142. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 568,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_569",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "142. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory\npathogens in medical intensive care patients. Crit Care Med 1992; 20:740-743.\n107\n143. Edmondson EB, Reinarz JA, Pierce AK, Sanford JP. Nebulization equipment: a potential\nsource of infection in gram-negative pneumonias. Am J Dis Child 1966; 111(4):357-360.\n144. Pierce AK, Sanford JP. Bacterial contamination of aerosols. Arch Intern Med 1973;\n131(1):156-159.\n145. Smith PW, Massanari RM. Room humidifiers as the source of Acinetobacter infections.\nJAMA 1977; 237(8):795-797.\n146. Rhame FS, Streifel A, McComb C, Boyle M. Bubbling humidifiers produce\nmicroaerosols which can carry bacteria. Infect Control 1986; 7(8):403-407.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 569,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_570",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "microaerosols which can carry bacteria. Infect Control 1986; 7(8):403-407.\n147. Schulze T, Edmondson EB, Pierce AK, Sanford JP. Studies on a new humidifying device\nas a potential source of bacterial aerosols. Am Rev Respir Dis 1967; 96(3):517-519.\n148. Harkness GA, Bentley DW, Roghmann KJ. Risk factors for nosocomial pneumonia in the\nelderly. Am J Med 1990; 89(4):457-463.\n149. Torres A, Gatell JM, Aznar E, et al. Re-intubation increases the risk of nosocomial\npneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med 1995;\n152(1):137-141.\n150. Vergis EN, Brennen C, Wagener M, Muder RR. Pneumonia in long-term care: a\nprospective case-control study of risk factors and impact on survival. Arch Intern Med 2001;\n161:2378-2381.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 570,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_571",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "161:2378-2381.\n151. Sprunt K, Redman W. Evidence suggesting importance of role of interbacterial inhibition\nin maintaining balance of normal flora. Ann Intern Med 1968; 68(3):579-590.\n152. Sprunt K, Leidy G, Redman W. Abnormal colonization of neonates in an ICU:\nconversion to normal colonization by pharyngeal implantation of alpha hemolytic Streptococcus\nstrain 215. Pediatr Res 1980; 14:308-313.\n153. Klick JM, Du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS.\nPrevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II.\nEffect on the incidence of pneumonia in seriously ill patients. J Clin Invest 1975; 55(3):514-519.\n154. Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 571,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_572",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "154. Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS.\nAerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293(10):471-475.\n155. Wood GC, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. Aerosolized\nceftazidime for prevention of ventilator-associated pneumonia and drug effects on the\nproinflammatory response in critically ill trauma patients. Pharmacotherapy 2002; 22(8):972-982.\n156. Klastersky J, Huysmans E, Weerts D, Hensgens C, Daneau D. Endotracheally\n108\nadministered gentamicin for the prevention of infections of the respiratory tract in patients with\ntracheostomy: a double-blind study. Chest 1974; 65(6):650-654.\n157. Greenfield S, Teres D, Bushnell LS, Hedley-Whyte J, Feingold DS. Prevention of gram-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 572,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_573",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "157. Greenfield S, Teres D, Bushnell LS, Hedley-Whyte J, Feingold DS. Prevention of gram-\nnegative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization\npattern of the upper respiratory tract of seriously ill patients. J Clin Invest 1973; 52(11):2935-\n2940.\n158. Rouby JJ, Poete P, Martin de Lassale E, et al. Prevention of Gram-negative nosocomial\nbronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic\nstudy. Intensive Care Med 1994; 20(3):187-192.\n159. Schleder B, Stott K, Lloyd RC. The effect of a comprehensive oral care protocol on\npatients at risk for ventilator-associated pneumonia. J Advocate Health Care 2002; 4:27-30.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 573,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_574",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients at risk for ventilator-associated pneumonia. J Advocate Health Care 2002; 4:27-30.\n160. Yoneyama T, Yoshida M, Ohrui T, et al. Oral care reduces pneumonia in older patients in\nnursing homes. J Am Geriatr Soc 2002; 50:430-433.\n161. DeRiso AJII, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine\ngluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infections and\nnonprophylactic antibiotic use in patients undergoing heart surgery. Chest 1996; 109(6):1556-\n1561.\n162. Stoutenbeek CP, Van Saene HKF, Miranda DR, Zandstra DF. The effect of selective\ndecontamination of the digestive tract on colonisation and infection rate in multiple trauma\npatients. Intensive Care Med 1984; 10(4):185-192.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 574,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_575",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients. Intensive Care Med 1984; 10(4):185-192.\n163. Unertl K, Ruckdeschel G, Selbmann HK, et al. Prevention of colonization and respiratory\ninfections in long-term ventilated patients by local antimicrobial prophylaxis. Intensive Care Med\n1987; 13(2):106-113.\n164. Kerver JH, Rommes JH, Mevissen-Verhage EAE, et al. Prevention of colonization and\ninfection in critically ill patients: a prospective randomized study. Crit Care Med 1988;\n16(11):1087-1093.\n165. Ledingham IM, Alcock SR, Eastaway AT, McDonald JC, Mckay IC, Ramsay G. Triple\nregimen of selective decontamination of the digestive tract, systemic cefotaxime, and\nmicrobiological surveillance for prevention of acquired infection in intensive care. Lancet 1988;\n1:785-790.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 575,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_576",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1:785-790.\n166. Brun-Buisson C, Legrand P, Rauss A, et al. Intestinal decontamination for control of\nnosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann\nIntern Med 1989; 110(11):873-881.\n167. Ulrich C, Harinck-de Weerd JE, Bakker NC, Jacz K, Doornbos L, de Ridder VA.\n109\nSelective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired\ninfections: a prospective randomized study. Intensive Care Med 1989; 15(7):424-431.\n168. Flaherty J, Nathan C, Kabins SA, Weinstein RA. Pilot trial of selective decontamination\nfor prevention of bacterial infection in an intensive care unit. J Infect Dis 1990; 162(6):1393-1397.\n169. Godard J, Guillaume C, Reverdy ME, et al. Intestinal decontamination in a polyvalent",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 576,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_577",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "169. Godard J, Guillaume C, Reverdy ME, et al. Intestinal decontamination in a polyvalent\nICU. A double-blind study. Intensive Care Med 1990; 16(5):307-311.\n170. McClelland P, Murray AE, Williams PS, et al. Reducing sepsis in severe combined acute\nrenal and respiratory failure by selective decontamination of  the digestive tract. Crit Care Med\n1990; 18(9):935-939.\n171. Rodriguez-Roldan JM, Altuna-Cuesta A, Lopez A, et al. Prevention of nosocomial lung\ninfection in ventilated patients: use of an antimicrobial pharyngeal non-absorbable paste. Crit Care\nMed 1990; 18(11):1239-1242.\n172. Tetteroo GWM, Wagenvoort JHT, Castelein A, Tilanus HW, Ince C, Bruining HA.\nSelective decontamination to reduce gram-negative colonisation and infections after oesophageal\nresection. Lancet 1990; 335:704-707.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 577,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_578",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "resection. Lancet 1990; 335:704-707.\n173. Aerdts SJA, van Daelen R, Clasener HAL, Festen J, Van Lier HJJ, Vollaard EJ.\nAntibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A\nprospective, blinded, randomized trial of the effect of a novel regimen. Chest 1991; 100(3):783-\n791.\n174. Blair P, Rowlands BJ, Lowry K, Webb H, Armstrong P, Smilie J. Selective\ndecontamination of the digestive tract: a stratified, randomized, prospective study in a mixed\nintensive care unit. Surgery 1991; 110(2):303-310.\n175. Fox MA, Peterson S, Fabri BM, Van Saene HKF, Williets T. Selective decontamination\nof the digestive tract in cardiac surgical patients. Crit Care Med 1991; 19(12):1486-1490.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 578,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_579",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of the digestive tract in cardiac surgical patients. Crit Care Med 1991; 19(12):1486-1490.\n176. Hartenauer U, Thulig B, Diemer W, et al. Effect of selective flora suppression on\ncolonization, infection and mortality in critically ill patients: a one-year, prospective, consecutive\nstudy. Crit Care Med 1991; 19(4):463-473.\n177. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases\nincidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind\nclinical trial. JAMA 1991; 265(20):2704-2710.\n178. Vandenbroucke-Grauls CMJE, Vandenbroucke JP. Effect of selective decontamination of\nthe digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet\n1991; 338:859-862.\n110",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 579,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_580",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1991; 338:859-862.\n110\n179. Cockerill FR, Muller SM, Anhalt JP, et al. Prevention of infection on critically ill patients\nby selective decontamination of the digestive tract. Ann Intern Med 1992; 117(7):545-553.\n180. Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S. A controlled trial in intensive\ncare units of selective decontamination of the digestive tract with nonabsorbable antibiotics. N\nEngl J Med 1992; 326(9):594-599.\n181. Hammond JMJ, Potgieter PD, Saunders GL, Forder AA. Double-blind study of selective\ndecontamination of the digestive tract in intensive care. Lancet 1992; 340:5-9.\n182. Rocha LA, Martin MJ, Pita S, et al. Prevention of nosocomial infection in critically ill\npatients by selective decontamination of the digestive tract. A randomized, double-blind, placebo-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 580,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_581",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients by selective decontamination of the digestive tract. A randomized, double-blind, placebo-\ncontrolled study. Intensive Care Med 1992; 18(7):398-404.\n183. Winter R, Humphreys H, Pick A, MacGowan P, Willatts SM, Speller DCE. A controlled\ntrial of selective decontamination of the digestive tract in intensive care and its effect on\nnosocomial infection. J Antimicrob Chemother 1992; 30(1):73-87.\n184. Korinek AM, Laisne MJ, Nicolas MH, Raskine L, Deroin V, Sanson-Lepors MJ.\nSelective decontamination of the digestive tract in neurosurgical intensive care unit patients: a\ndouble-blind, randomized, placebo-controlled study. Crit Care Med 1993; 21(10):1466-1473.\n185. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. Meta-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 581,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_582",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "185. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. Meta-\nanalysis of randomised controlled trials of selective decontamination of the digestive tract. Br Med\nJ 1993; 307:525-532.\n186. Ferrer M, Torres A, Gonzalez J, et al. Utility of selective digestive decontamination in\nmechanically ventilated patients. Ann Intern Med 1994; 120(5):389-395.\n187. Abele-Horn M, Dauber A, Bauernfeind A, et al. Decrease in nosocomial pneumonia in\nventilated patients by selective oropharyngeal decontamination: a prospective, blinded, randomized\ntrial of the effect of a novel regimen. Intensive Care Med 1997; 23(2):187-195.\n188. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 582,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_583",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "188. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of\nantibiotic prophylaxis in critically ill patients: systemic review of randomised controlled trials. Brit\nMed J 1998; 316:1275-1285.\n189. Langlois-Karaga A, Bues-Charbit M, Davignon A, et al. Selective digestive\ndecontamination in multiple trauma patients: cost and efficacy. Pharmacy World and Science 1995;\n17(1):12-16.\n190. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical\npatients: a systematic review of the evidence. Arch Surg 1999; 134(2):170-176.\n191. Quinio B, Albanese J, Bues-Charbit M, Viviand X, Martin C. Selective decontamination\n111\nof the digestive tract in multiple trauma patients. A prospective double-blind, randomized, placebo-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 583,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_584",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "controlled study. Chest 1996; 109(3):765-772.\n192. Sanchez Garcia M, Cambronero Galache JA, Lopez Diaz J, et al. Effectiveness and cost\nof selective decontamination of the digestive tract in crltically ill intubated patients. A randomized,\ndouble-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 1998; 158(3):908-\n916.\n193. Krueger WA, Lenhart FP, Neeser G, Ruckdeschel G, Schreckhase H, Eissner HJ et al.\nInfluence of combined intravenous and topical antibiotic prophylaxis on the incidences of\ninfections, organ dysfunction, and mortality in critically ill surgical patients: a prospective,\nstratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med\n2002; 166:1029-1037.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 584,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_585",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "2002; 166:1029-1037.\n194. Nau R, Ruchel R, Mergerian H, Wegener U, Winkelmann T, Prange HW. Emergence of\nantibiotic-resistant bacteria during selective decontamination of the digestive tract. J Antimicrob\nChemother 1990; 25(5):881-883.\n195. Goularte TA, Lichtenberg DA, Craven DE. Gastric colonization in patients receiving\nantacids and mechanical ventilation: a mechanism for pharyngeal colonization. Am J Infect Control\n1986; 14(2):88.\n196. Daschner F. Stress ulcer prophylaxis and the risk of nosocomial pneumonia in artificially\nventilated patients. Eur J Clin Microbiol 1987; 6(2):129-131.\n197. Messori A, Trippoli Sl, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in\nintensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 585,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_586",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "of randomised controlled trials. Brit Med J 2000; 321:1103-1106.\n198. Prod'hom G, Leuenberger PH, Koerfer J, et al. Nosocomial pneumonia in mechanically\nventilated patients receiving antacid, ranitidine, or sulcralfate as prophylaxis for stress ulcer. A\nrandomized controlled trial. Ann Intern Med 1994; 120(8):653-662.\n199. Tryba M. Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive\ncare unit patients: sucralfate versus antacids. Am J Med 1987; 83(suppl 3B):117-124.\n200. Tryba M, Mantey-Steirs F. Antibacterial activity of sucralfate in human gastric juice. Am\nJ Med 1987; 83(suppl 3B):125-127.\n201. Lacroix J, Infante-Rivard C, Jenicek M, Gauthier M. Prophylaxis of upper",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 586,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_587",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "201. Lacroix J, Infante-Rivard C, Jenicek M, Gauthier M. Prophylaxis of upper\ngastrointestinal bleeding in intensive care units: a meta-analysis. Crit Care Med 1989; 17(9):862-\n869.\n202. Laggner AN, Lenz K, Base W, Druml WC, Schneweiss B, Grimm G. Prevention of\nupper gastrointestinal bleeding in long-term ventilated patients. Sucralfate versus ranitidine. Am J\n112\nMed 1989; 86(suppl 6A):81-84.\n203. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the\nprevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian\nCritical Care Trials Group. N Engl J Med 1998; 338(12):791-797.\n204. Bonten MJM, Gaillard CA, van der Geest S, et al. The role of intragastric acidity and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 587,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_588",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "204. Bonten MJM, Gaillard CA, van der Geest S, et al. The role of intragastric acidity and\nstress ulcer prophylaxis on colonization and infection in mechanically ventilated patients. A\nstratified, ramdomized, double-blind study of sucralfate versus antacids. Am J Respir Crit Care\nMed 1995; 152:1825-1834.\n205. Thomason MH, Payseur ES, Hakenewerth AM, et al. Nosocomial pneumonia in\nventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. J\nTrauma-Injury Infect Crit Care 1996; 41(3):503-508.\n206. Markowicz P, Wolff M, Djedaini K, et al. Multicenter prospective study of ventilator-\nassociated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk\nfactors. Am J Respir Crit Care Med 2000; 161(6):1942-1948.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 588,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_589",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "factors. Am J Respir Crit Care Med 2000; 161(6):1942-1948.\n207. Civil ID, Schwab CW. The effect of enteral feeding on gastric pH. Am Surg 1987;\n53(12):688-690.\n208. Heyland DK, Bradley C, Mandell LA. Effect of acidified enteral feedings on gastric\ncolonization in the critically ill patient. Crit Care Med 1992; 20(10):1388-1394.\n209. Heyland DK, Cook DJ, Schoenfeld PS, Frietag A, Varon J, Wood G. The effect of\nacidified enteral feeds on gastric colonization in critically ill patients: results of a multicenter\nrandomized trial. Crit Care Med 1999; 27(11):2399-2406.\n210. Skiest DJ, Khan N, Feld R, Metersky ML. The role of enteral feeding in gastric\ncolonisation: a randomised controlled trial comparing continuous to intermittent enteral feeding in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 589,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_590",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "colonisation: a randomised controlled trial comparing continuous to intermittent enteral feeding in\nmechanically ventilated patients. Clin Intensive Care 1996; 7:138-143.\n211. Lee B, Chang RWS, Jacobs S. Intermittent nasogastric feeding: a simple and effective\nmethod to reduce pneumonia among ventilated ICU patients. Clin Intensive Care 1990; 1:100-102.\n212. Spilker CA, Hinthorn DR, Pingleton SK. Intermittent enteral feeding in mechanically\nventilated patients. The effect on gastric pH and gastric cultures. Chest 1996; 110(1):243-248.\n213. Bonten MJM, Gaillard CA, van der Hulst R, et al. Intermittent enteral feeding: the\ninfluence on respiratory and digestive tract colonization in mechanically ventilated intensive-care-\nunit patients. Am J Respir Crit Care Med 1996; 154:394-399.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 590,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_591",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "unit patients. Am J Respir Crit Care Med 1996; 154:394-399.\n214. Olivares L, Segovia A, Revuelta R. Tube feeding and lethal aspiration in neurologic\npatients: a review of 720 autopsy cases. Stroke 1974; 5(5):654-657.\n113\n215. Bartlett JG, Gorbach SL. The triple threat of aspiration pneumonia. Chest 1975;\n68(4):560-566.\n216. Winterbauer RH, Durning RB, Jr., Barron E, McFadden MC. Aspirated nasogastric\nfeeding solution detected by glucose strips. Ann Intern Med 1981; 95(1):67-68.\n217. Nair P, Jani K, Sanderson PJ. Transfer of oropharyngeal bacteria into the trachea during\nendotracheal intubation. J Hosp Infect 1986; 8(1):96-103.\n218. Metheny NA, Eisenberg P, Spies M. Aspiration pneumonia in patients fed through\nnasoenteral tubes. Heart Lung 1986; 15(3):256-261.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 591,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_592",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "nasoenteral tubes. Heart Lung 1986; 15(3):256-261.\n219. Kingston GW, Phang PT, Leathley MJ. Increased incidence of nosocomial pneumonia in\nmechanically ventilated patients with subclinical aspiration. Am J Surg 1991; 161(5):589-592.\n220. Treloar DM, Stechmiller J. Pulmonary aspiration of tube-fed patients with artificial\nairways. Heart Lung 1984; 13(6):667-671.\n221. Cheadle WG, Vitale GC, Mackie CR, Cuschiere A. Prophylactic postoperative\nnasogastric decompression. A prospective study of its requirement and the influence of cimetidine\nin 200 patients. Ann Surg 1985; 202(3):361-366.\n222. Ibanez J, Penafiel A, Raurich JM, Marse P, Jorda R, Mata F. Gastroesophageal reflux in\nintubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. J",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 592,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_593",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "intubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. J\nParenter Enter Nutr 1992; 16(5):419-422.\n223. Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from\npulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated\npatients. Am J Respir Crit Care Med 1995; 152:1387-1390.\n224. Anderson KR, Norris DJ, Godfrey LB, Avent CK, Butterworth CE, Jr. Bacterial\ncontamination of the tube feeding formulas. J Parent Enter Nutr 1984; 8(6):673-678.\n225. Schroeder P, Fisher D, Volz M, Paloucek J. Microbial contamination of enteral feeding\nsolutions in a community hospital. J Parent Enter Nutr 1983; 7(4):364-368.\n226. Thurn J, Crossley K, Gerdts A, Maki M, Johnson J. Enteral hyperalimentation as a source",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 593,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_594",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "226. Thurn J, Crossley K, Gerdts A, Maki M, Johnson J. Enteral hyperalimentation as a source\nof nosocomial infection. J Hosp Infect 1990; 15(3):203-217.\n227. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body\nposition as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a\nrandomised trial. Lancet 1999; 354:1851-1858.\n228. Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in\npatients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992;\n114\n116(7):540-543.\n229. Ferrer M, Bauer TT, Torres A, Hernandez C, Piera C. Effect of nasogastric tube size on\ngastroesophageal reflux and microaspiration in intubated patients. Ann Intern Med 1999;\n130(12):991-994.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 594,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_595",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "130(12):991-994.\n230. Heyland DK, Drover JW, MacDonald S, Novak F, Lam M. Effect of postpyloric feeding\non gastroesophageal regurgitation and pulmonary microaspiration. Crit Care Med 2001;\n29(8):1495-1500.\n231. Heyland DK, Drover JW, Dhaliwal R, Greenwood J. Optimizing the benefits and\nminimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding. J Parenter\nEnter Nutr 2002; 26:S51-S57.\n232. Spain DA, DeWeese RC, Reynolds MA, Richardson JD. Transpyloric passage of feeding\ntubes in patients with head injuries does not decrease complications. J Trauma 1995; 39:1000-\n1002.\n233. Strong RM, Condon SC, Solinger MR, Namihas BN, Ito-Wong LA, Leuty JE. Equal\naspiration rates from postpylorus and intragastric-placed small-bore nasoenteric feeding tubes: a",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 595,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_596",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "aspiration rates from postpylorus and intragastric-placed small-bore nasoenteric feeding tubes: a\nrandomized, prospective study. J Parent Enter Nutr 1992; 16(1):59-63.\n234. Kearns PJ, Chin D, Mueller L, Wallace K, Jensen WA, Kirsch CM. The incidence of\nventilator-associated pneumonia and success in nutrient delivery with gastric versus small intestinal\nfeeding: a randomized clinical trial. Crit Care Med 2000; 28(6):1742-1746.\n235. Montecalvo M, Steger KA, Farber HW, et al. Nutritional outcome and pneumonia in\ncritical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research\nTeam. Crit Care Med 1992; 20(10):1377-1387.\n236. Montejo JC, Grau T, Acosta J, et al. Multicenter, prospective, randomized, single-blind",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 596,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_597",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "236. Montejo JC, Grau T, Acosta J, et al. Multicenter, prospective, randomized, single-blind\nstudy comparing the efficacy and gastrointestinal complications of early jejunal feeding with early\ngastric feeding in critically ill patients. Crit Care Med 2002; 30(4):796-800.\n237. Rouby JJ, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial\nmaxillary sinusitis in the critically ill. Am J Respir Crit Care Med 1994; 150(3):776-783.\n238. Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal\nintubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized\nclinical trial. Crit Care Med 1993; 21(8):1132-1138.\n239. Sanderson PJ. Colonisation of the trachea in ventilated patients. What is the bacterial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 597,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_598",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "239. Sanderson PJ. Colonisation of the trachea in ventilated patients. What is the bacterial\npathway? J Hosp Infect 1983; 4(1):15-18.\n240. Sottile FD, Marrie TJ, Prough DS, et al. Nosocomial pulmonary infection: possible\n115\netiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986; 14(4):265-\n270.\n241. Inglis TJJ, Jones JG, Newman SP. Gas-liquid interaction with tracheal tube biofilm: a\nmeans of bacterial colonisation of the lung. Br J Hosp Med 1989; 42:141-142.\n242. Inglis TJJ, Millar MR, Jones JG, Robinson DA. Tracheal tube biofilm as a source of\nbacterial colonisation of the lung. J Clin Microbiol 1989; 27(9):2014-2018.\n243. Rello J, Sonora R, Jubert P, Artigas A, Rue M, Valles J. Pneumonia in intubated patients:",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 598,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_599",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "243. Rello J, Sonora R, Jubert P, Artigas A, Rue M, Valles J. Pneumonia in intubated patients:\nrole of respiratory airway care. Am J Respir Crit Care Med 1996; 154(1):111-115.\n244. Spray SB, Zuidema GD, Cameron JL. Aspiration pneumonia: incidence of aspiration with\nendotracheal tubes. Am J Surg 1976; 131(6):701-703.\n245. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of\nsubglottic secretions in cardiac surgery patients. Chest 1999; 116(5):1339-1346.\n246. Mahul P, Auboyer C, Jospe R, et al. Prevention of nosocomial pneumonia in intubated\npatients: respective role of mechanical subglottic drainage and stress ulcer prophylaxis. Intensive\nCare Med 1992; 18(1):20-25.\n247. Smulders K, van der Hoeven H, Weers-Pothoff I, Vanderbroucke-Grauls C. A",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 599,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_600",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "247. Smulders K, van der Hoeven H, Weers-Pothoff I, Vanderbroucke-Grauls C. A\nrandomized clinical trial of intermittent subglottic secretion drainage in patients receiving\nmechnical ventilation. Chest 2002; 121:858-862.\n248. Valles J, Artigas A, Rello J, et al. Continuous aspiration of subglottic secretions in\npreventing ventilator-associated pneumonia. Ann Intern Med 1995; 122(3):179-186.\n249. Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of\nventilator-associated pneumonia: potential economic implications. Chest 2001; 119(1):228-235.\n250. Brochard L. Noninvasive ventilation for acute respiratory failure. JAMA 2002;\n288(8):932-935.\n251. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 600,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_601",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "251. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in\nacute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341:1555-1557.\n252. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute\nexacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre\nrandomised controlled trial. Lancet 2000; 355:1931-1935.\n253. Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure\nventilation and conventional mechanical ventilation in patients with acute respiratory failure. N\nEngl J Med 1998; 339(7):429-435.\n116\n254. Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard L. Noninvasive versus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 601,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_602",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "116\n254. Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard L. Noninvasive versus\nconventional mechanical ventilation: an epidemiologic survey. Am J Respir Crit Care Med 2001;\n163(4):874-880.\n255. Keenan SP. Noninvasive positive pressure ventilation in acute respiratory failure. JAMA\n2000; 284:2376-2378.\n256. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute\nexacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333(13):817-822.\n257. Nava S, Ambrosino N, Clini E, et al. Noninvasive mechanical ventilation in the weaning\nof patients with respiratory failure due to chronic obstructive pulmonary disease: a randomized,\ncontrolled trial. Ann Intern Med 1998; 128(9):721-728.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 602,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_603",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "controlled trial. Ann Intern Med 1998; 128(9):721-728.\n258. Girou E, Schortgen F, Delcaux C, et al. Association of noninvasive ventilation with\nnosocomial infections and survival in critically ill patients. JAMA 2000; 284(18):2361-2367.\n259. Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A. Noninvasive positive pressure\nventilation in the setting of severe acute exacerbations of chronic obstructive pulmonary disease:\nmore effective and less expensive. Crit Care Med 2000; 28(6):2094-2102.\n260. Nourdine K, Combes P, Carton MJ, Beuret P, Cannamela A, Ducreux JC. Does\nnoninvasive ventilation reduce the ICU nosocomial infection risk? A prospective clinical survey.\nIntensive Care Med 1999; 25(6):567-573.\n261. Kindgen-Milles D, Buhl R, Gabriel A, Bohner H, Muller E. Nasal continuous positive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 603,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_604",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "261. Kindgen-Milles D, Buhl R, Gabriel A, Bohner H, Muller E. Nasal continuous positive\nairway pressure: a method to avoid endotracheal reintubation in postoperative high-risk patients\nwith severe nonhypercapnic oxygenation failure. Chest 2000; 117(4):1106-1111.\n262. Weinstein RA, Nathan C, Gruensfelder R, Kabins SA. Endemic aminoglycoside\nresistance in gram-negative bacilli: epidemiology and mechanisms. J Infect Dis 1980; 141(3):338-\n345.\n263. Maki DG. Control of colonization and transmission of pathogenic bacteria in the hospital.\nAnn Intern Med 1978; 89:777-780.\n264. Larson EL. Persistent carriage of gram-negative bacteria on hands. Am J Infect Control\n1981; 9(4):112-119.\n265. Adams BG, Marrie TJ. Hand carriage of gram-negative rods may not be transient. J Hyg\n1982; 89(1):33-46.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 604,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_605",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1982; 89(1):33-46.\n266. Daschner FD. The transmission of infections in hospitals by staff carriers, methods of\nprevention and control. Infect Control 1985; 6(3):97-99.\n117\n267. Adams BG, Marrie TJ. Hand carriage of aerobic gram-negative rods by health care\npersonnel. J Hyg 1982; 89(1):23-31.\n268. Casewell M, Phillips I. Hands as route of transmission of Klebsiella species. Br Med J\n1977; 2(6098):1315-1317.\n269. Gorman LJ, Sanai L, Notman AW, Grant IS, Masterton RG. Cross infection in an\nintensive care unit by Klebsiella pneumoniae from ventilator condensate. J Hosp Infect 1993;\n23(1):27-34.\n270. Cadwallader HL, Bradley CR, Ayliffe GAJ. Bacterial contamination and frequency of\nchanging ventilator circuitry. J Hosp Infect 1990; 15(1):65-72.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 605,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_606",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "changing ventilator circuitry. J Hosp Infect 1990; 15(1):65-72.\n271. Lowbury EJL, Lilly HA, Bull JP. Disinfection of hands: removal of transient organisms.\nBr Med J 1964; 2:230-233.\n272. Sprunt K, Redman W, Leidy G. Antibacterial effectiveness of routine handwashing.\nPediatrics 1973; 52(2):264-271.\n273. Larson E, Kretzer EK. Compliance with handwashing and barrier precautions. J Hosp\nInfect 1995; 30(suppl):88-106.\n274. Steere AC, Mallison GF. Handwashing practices for the prevention of nosocomial\ninfections. Ann Intern Med 1975; 83(5):683-690.\n275. Albert RK, Condie F. Hand-washing patterns in medical intensive care units. N Engl J\nMed 1981; 304(24):1465-1466.\n276. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 606,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_607",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "276. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-\nwashing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992;\n327(2):88-93.\n277. Simmons B, Bryant J, Neiman K, Spencer L, Arheart K. The role of handwashing in\nprevention of endemic intensive care unit infections. Infect Control Hosp Epidemiol 1990;\n11(11):589-594.\n278. CDC. Guideline for hand hygiene in health-care settings. MMWR 2002; 51(No. RR-16).\n279. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection\nControl Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17(1):53-80.\n280. LeClair JM, Freeman J, Sullivan BF, Crowley CM, Goldmann DA. Prevention of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 607,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_608",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "280. LeClair JM, Freeman J, Sullivan BF, Crowley CM, Goldmann DA. Prevention of\nnosocomial respiratory syncytial virus infections through compliance with glove and gown\nisolation precautions. N Engl J Med 1987; 317(6):329-334.\n118\n281. Klein BS, Perloff WH, Maki DG. Reduction of nosocomial infection during pediatric\nintensive care by protective isolation. N Engl J Med 1989; 320(26):1714-1721.\n282. Doebbeling BN, Pfaller MA, Houston AK, Wenzel RP. Removal of nosocomial\npathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern\nMed 1988; 109(5):394-398.\n283. Patterson JE, Vecchio J, Pantelick EL, et al. Association of contaminated gloves with\ntransmission of Acinetobacter calcoaceticus var. anitratus in an intensive care unit. Am J Med",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 608,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_609",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "transmission of Acinetobacter calcoaceticus var. anitratus in an intensive care unit. Am J Med\n1991; 91(5):479-483.\n284. Korniewicz DM, Laughon BE, Cyr WH, Lytle CD, Larson E. Leakage of virus through\nused vinyl and latex examination gloves. J Clin Microbiol 1990; 28(4):787-788.\n285. Pandit SK, Mehta S, Agarwal SC. Risk of cross infection from inhalation anesthetic\nequipment. Br J Anaesth 1967; 39(11):838-844.\n286. Wheeler PW, Lancaster D, Kaiser AB. Bronchopulmonary cross-colonization and\ninfection related to mycobacterial contamination of suction valves of bronchoscopes. J Infect Dis\n1989; 159(5):954-958.\n287. Fraser VJ, Jones M, Murray PR, Medoff G, Zhang Y, Wallace RJ, Jr. Contamination\nofflexible fiberoptic bronchoscopes with Mycobacterium chelonae linked to an automated",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 609,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_610",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "offlexible fiberoptic bronchoscopes with Mycobacterium chelonae linked to an automated\nbronchoscope disinfection machine. Am Rev Respir Dis 1992; 145:853-855.\n288. Grieble HG, Colton FR, Thomas MS, et al. Fine-particle humidifiers: source of\nPseudomonas aeruginosa infections in a respiratory-disease unit. N Engl J Med 1970;\n282(10):531-533.\n289. Mertz JJ, Scharer L, McClement JH. A hospital outbreak of Klebsiella pneumonia from\ninhalation therapy with contaminated aerosol solutions. Am Rev Respir Dis 1967; 95(3):454-460.\n290. Ringrose RE, McKown B, Felton FG, Barclay BO, Muchmore HG, Rhoades ER. A\nhospital outbreak of Serratia marcescens associated with ultrasonic nebulizers. Ann Intern Med\n1968; 69(4):719-729.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 610,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_611",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1968; 69(4):719-729.\n291. Arnow PM, Chou T, Weil D, Shapiro EN, Kretzschmar C. Nosocomial Legionnaires'\ndisease caused by aerosolized tap water from respiratory devices. J Infect Dis 1982; 146(4):460-\n467.\n292. Craven DE, Lichtenberg DA, Goularte TA, Make BJ, McCabe WR. Contaminated\nmedication nebulizers in mechanical ventilation circuits. Source of bacterial aerosols. Am J Med\n1984; 77(5):834-838.\n293. Babington PCB, Baker AB, Johnson HH. Retrograde spread of organisms from\n119\nventilator to patient via the expiratory limb. Lancet 1971; 1:61-62.\n294. Irwin RS, Demers RR, Pratter MR, et al. An outbreak of Acinetobacter infection\nassociated with the use of a ventilator spirometer. Respir Care 1980; 25(2):232-237.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 611,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_612",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "associated with the use of a ventilator spirometer. Respir Care 1980; 25(2):232-237.\n295. Cunha BA, Klimek JJ, Gracewski J, McLaughlin JC, Quintiliani R. A common source\noutbreak of Acinetobacter  pulmonary infection traced to Wright respirometers. Postgrad Med J\n1980; 56:169-172.\n296. Gough J, Kraak WA, Anderson EC, Nichols WW, Slack MPE, McGhie D. Cross-\ninfection by non-capsulated Haemophilus influenzae. Lancet 1990; 336:159-160.\n297. Hovig B. Lower respiratory tract infections associated with respiratory therapy and\nanesthesia equipment. J Hosp Infect 1981; 2(4):301-315.\n298. Carson LA, Favero MS, Bond WW, Petersen NJ. Morphological, biochemical and\ngrowth characteristics of Pseudomonas cepacia from distilled water. Appl Microbiol 1973;\n25(3):476-483.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 612,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_613",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "25(3):476-483.\n299. Favero MS, Carson LA, Bond WW. Pseudomonas aeruginosa: growth in distilled water\nfrom hospitals. Science 1971; 173:836-838.\n300. Carson LA, Petersen NJ, Favero MS, Aguero SM. Growth characteristics of atypical\nmycobacteria in water and their comparative resistance to disinfectants. Appl Environ Microbiol\n1978; 36(6):839-846.\n301. Pierce AK, Sanford JP, Thomas GD, Leonard JS. Long term evaluation of\ndecontamination of inhalation-therapy equipment and the occurrence of necrotizing pneumonia. N\nEngl J Med 1970; 292(10):528-531.\n302. Zuravleff JJ, Yu VL, Shonnard JW, Rihs JD, Best M. Legionella pneumophila\ncontamination of a hospital humidifier: Demonstration of aerosol transmission and subsequent",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 613,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_614",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "contamination of a hospital humidifier: Demonstration of aerosol transmission and subsequent\nsubclinical infection in exposed guinea pigs. Am Rev Respir Dis 1983; 128(4):657-661.\n303. Gorman GW, Yu VL, Brown A, et al. Isolation of Pittsburgh pneumonia agent from\nnebulizers used in respiratory therapy. Ann Intern Med 1980; 93(4):572-573.\n304. Berthelot P, Grattard F, Mahul P, et al. Ventilator temperature sensors: an unusual\nsource of Pseudomonas cepacia in nosocomial infection. J Hosp Infect 1993; 25(1):33-43.\n305. Weems JJ, Jr. Nosocomial outbreak of Pseudomonas cepacia associated with\ncontamination of reusable electronic ventilator temperature probes. Infect Control Hosp Epidemiol\n1993; 14(10):583-586.\n306. Mastro TD, Fields BS, Breiman RF, Campbell J, Plikaytis BD, Spika JS. Nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 614,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_615",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "306. Mastro TD, Fields BS, Breiman RF, Campbell J, Plikaytis BD, Spika JS. Nosocomial\n120\nLegionnaires' disease and use of medication nebulizers. J Infect Dis 1991; 163(3):667-671.\n307. Cefai C, Richards J, Gould FK, McPeake P. An outbreak of Acinetobacter respiratory\ntract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect 1990;\n15(2):177-182.\n308. Favero MS, Bond WW. Clinical disinfection of medical and surgical materials. In: Block\nS, editor. Disinfection, Sterilization, and Preservation. Philadelphia, Pa.: Lea and Febiger, 1991:\n617-641.\n309. Spaulding EH. Studies on the chemical sterilization of surgical instruments. Surg Gynecol\nObstet 1939; 69:738-744.\n310. Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 615,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_616",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "310. Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee.\nGuideline for disinfection and sterilization in healthcare facilities. MMWR. In press.\n311. Gurevich I, Tafuro P, Ristuccia P, Hermann J, Young AR, Cunha BA. Disinfection of\nrespirator tubing: a comparison of chemical versus hot water machine-assisted processing. J Hosp\nInfect 1983; 4(2):199-208.\n312. Jette LP, Lambert NG. Evaluation of two hot water washer disinfectors for medical\ninstruments. Infect Control Hosp Epidemiol 1988; 9(5):194-199.\n313. Rutala WW, Weber DJ, Gergen MF, Gratta AR. Efficacy of a washer-pasteurizer for\ndisinfection of respiratory-care equipment. Infect Control Hosp Epidemiol 2000; 21:333-336.\n314. Craig DB, Cowan SA, Forsyth W, Parker SE. Disinfection of anesthesia equipment by a",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 616,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_617",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "314. Craig DB, Cowan SA, Forsyth W, Parker SE. Disinfection of anesthesia equipment by a\nmechanized pasteurization method. Can Anaesth Soc J 1975; 22(2):219-223.\n315. McDonald WL, Welch HJ, Keet JE. Antisepsis of endotracheal tubes and face masks.\nAnesthesiology 1955; 16:206-213.\n316. Moffet HL, Williams T. Bacteria recovered from distilled water and inhalation therapy\nequipment. Am J Dis Child 1967; 114(1):7-12.\n317. Alary MA, Joly JR. Factors contributing to the contamination of hospital water\ndistribution systems by Legionellae. J Infect Dis 1992; 165(3):565-569.\n318. Olson BH, Nagy LA. Microbiology of potable water. In: Laskin AI, editor. Advances in\nApplied Microbiology. Orlando, Fl.: Academic Press Inc., 1984: 73-132.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 617,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_618",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Applied Microbiology. Orlando, Fl.: Academic Press Inc., 1984: 73-132.\n319. Alfa MJ, Sitter DL. In-hospital evaluation of contamination of duodenoscopes: a\nquantitative assessment of the effect of drying. J Hosp Infect 1991; 19(2):89-98.\n320. Gerding DN, Peterson LR, Vennes JA. Cleaning and disinfection of fiberoptic\n121\nendoscopes: evaluation of glutaraldehyde exposure time and forced-air drying. Gastroenterology\n1982; 83(3):613-618.\n321. Goularte TA, Manning M, Craven DE. Bacterial colonization in humidifying cascade\nreservoirs after 24 and 48 hours of continuous mechanical ventilation. Infect Control 1987;\n8(5):200-203.\n322. Vesley D, Anderson J, Halbert MM, Wyman L. Bacterial output from three respiratory\ntherapy humidifying devices. Respir Care 1979; 24(3):228-234.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 618,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_619",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "therapy humidifying devices. Respir Care 1979; 24(3):228-234.\n323. Boyce JM, White RL, Spruill EY, Wall M. Cost-effective application of the Centers for\nDisease Control Guideline for Prevention of Nosocomial Pneumonia. Am J Infect Control 1985;\n13(5):228-232.\n324. Craven DE, Goularte TA, Make BJ. Contaminated condensate in mechanical ventilator\ncircuits. A risk factor for nosocomial pneumonia? Am Rev Respir Dis 1984; 129(4):625-628.\n325. Lareau SC, Ryan KJ, Diener CF. The relationship between frequency of ventilator circuit\nchanges and infectious hazard. Am Rev Respir Dis 1978; 118(3):493-496.\n326. Craven DE, Connolly MG, Jr., Lichtenberg DA, Primeau PJ, McCabe WR.\nContamination of mechanical ventilators with tubing changes every 24 or 48 hours. N Engl J Med\n1982; 306(25):1505-1509.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 619,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_620",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1982; 306(25):1505-1509.\n327. Kotilainen HR, Keroack MA. Cost analysis and clinical impact of weekly ventilator\ncircuit changes in patients in intensive care unit. Am J Infect Control 1997; 25:117-120.\n328. Long MN, Wickstrom G, Grimes A, Benton CF, Belcher B, Stamm AM. Prospective,\nrandomised study of ventilator-associated pneumonia in patients with one versus three ventilator\ncircuit changes per week. Infect Control Hosp Epidemiol 1996; 17(1):14-19.\n329. Hess D, Burns E, Romagnoli D, Kacmarek RM. Weekly ventilator circuit changes. A\nstrategy to reduce costs without affecting pneumonia rates. Anesthesiology 1995; 82(4):903-911.\n330. Dreyfuss D, Djedaini K, Weber P, et al. Prospective study of nosocomial pneumonia and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 620,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_621",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "330. Dreyfuss D, Djedaini K, Weber P, et al. Prospective study of nosocomial pneumonia and\nof patient and circuit colonization during mechanical ventilation with circuit changes every 48\nhours versus no change. Am Rev Respir Dis 1991; 143:738-743.\n331. Kollef MH, Shapiro D, Fraser VJ, et al. Mechanical ventilation with or without 7-day\ncircuit changes. A randomized controlled trial. Ann Intern Med 1995; 123(3):168-174.\n332. Fink JB, Krause SA, Barrett L, Schaaff D, Alex CG. Extending ventilator circuit change\ninterval beyond 2 days reduces the likelihood of ventilator-associated pneumonia. Chest 1998;\n113(2):405-411.\n122\n333. Miyao H, Hirokawa T, Miyasaka K, Kawazoe T. Relative humidity, not absolute",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 621,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_622",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "122\n333. Miyao H, Hirokawa T, Miyasaka K, Kawazoe T. Relative humidity, not absolute\nhumidity, is of great importance when using a humidifier with a heating wire. Crit Care Med 1992;\n20(5):674-679.\n334. MacIntyre NR, Anderson HR, Silver RM, Schuler FR, Coleman RE. Pulmonary function\nin mechanically-ventilated patients using 24-hour use of a hygroscopic condenser humidifier. Chest\n1983; 84(5):560-564.\n335. Suzukawa M, Usuda Y, Numata K. The effects on sputum characteristics of combining\nan unheated humidifier with a heat-moisture exchanging filter. Respir Care 1989; 34(11):976-984.\n336. Mebius C. A comparative evaluation of disposable humidifiers. Acta Anaesth Scand\n1983; 27(5):403-409.\n337. Branson RD, Davis K, Jr., Campbell RS, Johnson DJ, Porembka D. Humidification in the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 622,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_623",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "337. Branson RD, Davis K, Jr., Campbell RS, Johnson DJ, Porembka D. Humidification in the\nintensive care unit. Prospective study of a new protocol utilizing heated humidification and a\nhygroscopic condenser humidifier. Chest 1993; 104(6):1800-1805.\n338. Chiaranda M, Verona L, Pinamonti O, Dominioni L, Minoja G, Conti G. Use of heat and\nmoisture exchanging (HME) filters in mechanically ventilated ICU patients: influence on airway\nflow resistance. Intensive Care Med 1993; 19(8):462-466.\n339. Martin C, Perrin G, Gevaudan MJ, Saux P, Gouin F. Heat and moisture exchangers and\nvaporizing humidifiers in the intensive care unit. Chest 1990; 97(1):144-149.\n340. Branson RD, Hurst JM. Laboratory evaluation of moisture output of seven airway heat",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 623,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_624",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "340. Branson RD, Hurst JM. Laboratory evaluation of moisture output of seven airway heat\nand moisture exchangers. Respir Care 1987; 32(9):741-747.\n341. Roustan JP, Kienlen J, Aubas P, Aubas S, du Cailar J. Comparison of hydrophobic heat\nand moisture exchangers with heated humidifier during prolonged mechanical ventilation. Intensive\nCare Med 1992; 18(2):97-100.\n342. Pelosi P, Solca M, Ravagnan I, et al. Effects of heat and moisture exchangers on minute\nventilation, ventilatory drive, and work of breathing during pressure-support ventilation in acute\nrespiratory failure. Crit Care Med 1996; 24:1184-1188.\n343. Cook D, De Jonghe B, Brochard L, Brun-Buisson C. Influence of airway management on\nventilator-associated pneumonia: evidence from randomized trials. JAMA 1998; 279(10):781-787.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 624,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_625",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "ventilator-associated pneumonia: evidence from randomized trials. JAMA 1998; 279(10):781-787.\n344. Kirton OC, DeHaven B, Morgan J, Morejon O, Civetta J. A prospective, randomised\ncomparison of an in-line heat moisture exchange filter and heated wire humidifiers: rates of\nventilator-associated early-onset (community-acquired) or late-onset (hospital-acquired)\npneumonia and incidence of endotracheal tube occlusion. Chest 1997; 112(4):1055-1059.\n345. Hurni JM, Feihl F, Lazor R, Leuenberger P, Perret C. Safety of combined heat and\n123\nmoisture exchanger filters in long-term mechanical ventilation. Chest 1997; 111(3):686-691.\n346. Dreyfuss D, Djedaini K, Gros I, et al. Mechanical ventilation with heated humidifiers or",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 625,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_626",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "346. Dreyfuss D, Djedaini K, Gros I, et al. Mechanical ventilation with heated humidifiers or\nheat and moisture exchangers: effects on patient colonization and incidence of nosocomial\npneumonia. Am J Respir Crit Care Med 1995; 151:986-992.\n347. Kollef MH, Shapiro SD, Boyd V, et al. A randomized clinical trial comparing an\nextended-use hygroscopic condenser humidifier with heated-water humidification in mechanically\nventilated patients. Chest 1998; 113(3):759-767.\n348. Larsson A, Gustafsson A, Svanborg L. A new device for 100 per cent humidification of\ninspired air. Critical Care 2000; 4(1):54-60.\n349. Thomachot L, Viviand X, Boyadjiev I, Vialet R, Martin C. The combination of a heat and\nmoisture exchanger and a Booster: a clinical and bacteriologic evaluation over 96 hours. Intensive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 626,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_627",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "moisture exchanger and a Booster: a clinical and bacteriologic evaluation over 96 hours. Intensive\nCare Med 2002; 28(2):147-153.\n350. Sanders CV, Jr., Luby JP, Johanson WG, Jr., Barnett JA, Sanford JP. Serratia\nmarcescens infections from inhalation therapy medications: nosocomial outbreak. Ann Intern Med\n1970; 73(1):15-21.\n351. Ramsey AH, Skonieczny P, Coolidge DT, Kurzynski TA, Proctor ME, Davis JP.\nBurkholderia cepacia lower respiratory tract infection associated with exposure to a respiratory\ntherapist. Infect Control Hosp Epidemiol 2001; 22(7):423-426.\n352. Hamill RJ, Houston ED, Georghiou PR, et al. An outbreak of Burkholderia (formerly\nPseudomonas) cepacia respiratory tract colonization and infection associated with nebulized\nalbuterol therapy. Ann Intern Med 1995; 122(10):762-766.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 627,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_628",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "albuterol therapy. Ann Intern Med 1995; 122(10):762-766.\n353. Harbarth S, Sudre P, Dharan S, Cadenas M, Pittet D. Outbreak of Enterobacter cloacae\nrelated to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol\n1999; 20(9):598-603.\n354. Sheth NK, Post GT, Wisniewski TR, Uttech BV. Multi-dose vials versus single-dose\nvials: a study in sterility and cost-effectiveness. J Clin Microbiol 1983; 17(2):377-379.\n355. Kollef MH, Prentice D, Shapiro SD, et al. Mechanical ventilation with or without daily\nchanges of in-line suction catheters. Am J Respir Crit Care Med 1997; 156:466-472.\n356. Deppe SA, Kelly JW, Thoi LL, et al. Incidence of colonization, nosocomial pneumonia,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 628,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_629",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "356. Deppe SA, Kelly JW, Thoi LL, et al. Incidence of colonization, nosocomial pneumonia,\nand mortality in critically ill patients using a Trach Care closed-suction system versus open-suction\nsystem: prospective, randomized study. Crit Care Med 1990; 18(12):1389-1393.\n357. Johnson KL, Kearney PA, Johnson SB, Niblett JB, MacMillan NL, McClain RE. Closed\nversus open endotracheal suctioning: costs and physiologic consequences. Crit Care Med 1994;\n124\n22(4):658-666.\n358. Combes P, Fauvage B, Oleyer C. Nosocomial pnemonia in mechanically ventilated\npatients. A prospective randomised evaluation of the Stericath closed suctioning system. Intensive\nCare Med 2000; 26(7):878-882.\n359. Fierer J, Taylor PM, Gezon HM. Pseudomonas aeruginosa epidemic traced to delivery-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 629,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_630",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "359. Fierer J, Taylor PM, Gezon HM. Pseudomonas aeruginosa epidemic traced to delivery-\nroom resuscitators. N Engl J Med 1967; 276(18):991-996.\n360. Stone JW, Das BC. Investigation of an outbreak of infection with Acinetobacter\ncalcoaceticus in a special care baby unit. J Hosp Infect 1986; 7(1):42-48.\n361. Thompson AC, Wilder BJ, Powner DJ. Bedside resuscitation bags: a source of bacterial\ncontamination. Infect Control 1985; 6(6):231-232.\n362. Weber DJ, Wilson MB, Rutala WA, Thomann CA. Manual ventilation bags as a source\nfor bacterial colonization of intubated patients. Am Rev Respir Dis 1990; 142(4):892-894.\n363. Van Der Zwet WC, Parlevliet GA, Savelkoul PH, et al. Outbreak of Bacillus cereus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 630,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_631",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "363. Van Der Zwet WC, Parlevliet GA, Savelkoul PH, et al. Outbreak of Bacillus cereus\ninfections in a neonatal intensive care unit traced to balloons used in manual ventilation. J Clin\nMicrobiol 2000; 38(4):4131-4136.\n364. Kaul R, Burt JA, Cork L, et al. Investigation of a multiyear multiple critical care unit\noutbreak due to relatively drug-sensitive Acinetobacter baumanii: risk factors and attributable\nmortality. J Infect Dis 1996; 174(6):1279-1287.\n365. Rogues AM, Maugein J, Allery A, et al. Electronic ventilator temperature sensors as a\npotential source of respiratory tract colonization with Stenotrophomonas maltophilia. J Hosp\nInfect 2001; 49(4):289-292.\n366. Olds JW, Kisch AL, Eberle BJ, Wilson JN. Pseudomonas aeruginosa respiratory tract",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 631,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_632",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "366. Olds JW, Kisch AL, Eberle BJ, Wilson JN. Pseudomonas aeruginosa respiratory tract\ninfection acquired from a contaminated anesthesia machine. Am Rev Respir Dis 1972; 105(4):629-\n632.\n367. Albrecht WH, Dryden GE. Five-year experience with the development of an individually\nclean anesthesia machine. Anesth Analg 1974; 53(1):24-28.\n368. Du Moulin GC, Sauberman AJ. The anesthesia machine and circle system are not likely\nto be sources of bacterial contamination. Anesthesiology 1977; 47(4):353-358.\n369. American Association of Nurse Anesthetists. Infection Control Guide. 2nd ed. Chicago,\nIL: 1993.\n370. American Society for Anesthesiologists. Prevention of nosocomial infections in patients.\nRecommendations for Infection Control for the Practice of Anesthesiology. Park Ridge, IL:\n125",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 632,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_633",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Recommendations for Infection Control for the Practice of Anesthesiology. Park Ridge, IL:\n125\nAmerican Society of Anesthesiologists, 1991.\n371. Bengtson JP, Brandberg A, Brinkhoff B, Sonander H, Stenqvist O. Low-flow anesthesia\ndoes not increase the risk of microbial contamination through the circle absorber system. Acta\nAnaesth Scand 1989; 33(1):89-92.\n372. Luttropp HH, Berntman L. Bacterial filters protect anaesthetic equipment in a low-flow\nsystem. Anaesthesia 1993; 48(6):520-523.\n373. Shiotani GM, Nicholes P, Ballinger CM, Shaw.L. Prevention of contamination of the\ncircle system and ventilators with a new disposable filter. Anesth Analg 1971; 50(5):844-855.\n374. Vezina DP, Trepanier CA, Lessard MR, Gourdeau M, Tremblay C. Anesthesia breathing",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 633,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_634",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "374. Vezina DP, Trepanier CA, Lessard MR, Gourdeau M, Tremblay C. Anesthesia breathing\ncircuits protected by the DAR Barrierbac S breathing filter have a low bacterial contamination rate.\nCan J Anaesth 2001; 48(8):748-754.\n375. Garibaldi RA, Britt MR, Webster C, Pace NL. Failure of bacterial filters to reduce the\nincidence of pneumonia after inhalation anesthesia. Anesthesiology 1981; 54(5):364-368.\n376. Feeley TW, Hamilton WK, Xavier B, Moyers J, Eger EI. Sterile anesthesia breathing\ncircuits do not prevent postoperative pulmonary infection. Anesthesiology 1981; 54:369-372.\n377. Berry AJ, Nolte FS. An alternative strategy for infection control of anesthesia breathing\ncircuits: a laboratory assessment of the Pall HME Filter. Anesth Analg 1991; 72(5):651-655.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 634,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_635",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "circuits: a laboratory assessment of the Pall HME Filter. Anesth Analg 1991; 72(5):651-655.\n378. Ping FC, Oulton JL, Smith JA, Skidmore AG, Jenkins LC. Bacterial filters--are they\nnecessary on anesthetic machines? Anaesth Soc J 1979; 26(5):415-419.\n379. Rutala DR, Rutala WA, Weber DJ, Thomann CA. Infection risks associated with\nspirometry. Infect Control Hosp Epidemiol 1991; 12(2):89-92.\n380. Hiebert T, Miles J, Okeson GC. Contaminated aerosol recovery from pulmonary function\ntesting equipment. Am J Respir Crit Care Med 1999; 159(2):610-612.\n381. Hazaleus RE, Cole J, Berdischewsky M. Tuberculin skin test conversion from exposure\nto contaminated pulmonary function testing apparatus. Respir Care 1981; 26(1):53-55.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 635,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_636",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "to contaminated pulmonary function testing apparatus. Respir Care 1981; 26(1):53-55.\n382. Kirk YL, Kendall K, Ashworth HA, Hunter PR. Laboratory evaluation of a filter for the\ncontrol of cross-infection during pulmonary function testing. J Hosp Infect 1992; 20(3):193-198.\n383. Leeming JP, Kendrick AH, Pryce-Roberts D, Smith DR, Smith EC. Use of filters for the\ncontrol of cross-infection during pulmonary function testing. J Hosp Infect 1995; 20:245-246.\n384. Ahmed J, Brutus A, D'Amato RF, Glatt AE. Acinetobacter calcoaceticus anitratus\noutbreak in the intensive care unit traced to a peak flow meter. Am J Infect Control 1994;\n126\n22(5):319-321.\n385. Arozullah AM, Khuri SF, Henderson WG, Daley J, Participants in the National Veterans",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 636,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_637",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "385. Arozullah AM, Khuri SF, Henderson WG, Daley J, Participants in the National Veterans\nAffairs Surgical Quality Improvement Program. Development and validation of a multifactorial risk\nindex for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med\n2001; 135(10):847-857.\n386. Brooks-Brunn JA. Predictors of postoperative pulmonary complications following\nabdominal surgery. Chest 1997; 111(3):564-571.\n387. Chumillas S, Ponce JL, Delgado F, Viciano V, Mateu M. Prevention of postoperative\npulmonary complications through respiratory rehabilitation: a controlled clinical study. Arch Phys\nMed Rehab 1998; 79(1):5-9.\n388. Hall JC, Tarala RA, Tapper J, Hall JL. Prevention of respiratory complications after",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 637,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_638",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "388. Hall JC, Tarala RA, Tapper J, Hall JL. Prevention of respiratory complications after\nabdominal surgery: a randomised clinical trial. Br Med J 1996; 312:148-152.\n389. Thomas JA, McIntosh JM. Are incentive spirometry, intermittent positive pressure\nbreathing, and deep breathing exercises effective in the prevention of postoperative pulmonary\ncomplications after upper abdominal surgery?  A systematic overview and meta-analysis. Physical\nTherapy 1994; 74(1):3-10.\n390. Hall JC, Tarala R, Harris J, Tapper J, Christiansen K. Incentive spirometry versus routine\nchest physiotherapy for prevention of respiratory complications after abdominal surgery. Lancet\n1991; 337:953-956.\n391. Roukema JA, Carol EJ, Prins JG. The prevention of pulmonary complications after upper",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 638,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_639",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "391. Roukema JA, Carol EJ, Prins JG. The prevention of pulmonary complications after upper\nabdominal surgery in patients with noncompromised pulmonary status. Arch Surg 1988;\n123(1):30-34.\n392. Morran CG, Finlay IG, Mithieson M, McKay AJ, Wilson N, McArdle CS. Randomized\ncontrolled trial of physiotherapy for postoperative pulmonary complications. Br J Anaesth 1983;\n55:1113-1116.\n393. Castillo R, Haas A. Chest physical therapy: comparative efficacy of preoperative and\npostoperative in the elderly. Arch Phys Med Rehabil 1985; 66:376-379.\n394. Vraciu JK. Effectiveness of breathing exercises in preventing pulmonary complications\nfollowing open heart surgery. Phys Ther 1977; 57:1367-1371.\n395. Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 639,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_640",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "395. Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure\nbreathing, incentive spirometry, and deep breathing exercises in preventing pulmonary\ncomplications after abdominal surgery. Am Rev Respir Dis 1984; 130(4):12-15.\n396. Stock MC, Downs JB, Gauer PK, Alster JM, Imrey PB. Prevention of postoperative\n127\npulmonary complications with CPAP, incentive spirometry, and conservative therapy. Chest 1985;\n87:151-157.\n397. Stein M, Cassara EL. Preoperative pulmonary evaluation and therapy for surgery\npatients. JAMA 1970; 211:787-790.\n398. Gould FK, Magee JG, Ingham HR. A hospital outbreak of antibiotic-resistant\nStreptococcus pneumoniae. J Infect 1987; 15(1):77-79.\n399. Moore EP, Williams EW. Hospital transmission of multiply antibiotic resistant",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 640,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_641",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "399. Moore EP, Williams EW. Hospital transmission of multiply antibiotic resistant\nStreptococcus pneumoniae. J Infect 1988; 16(2):199-200.\n400. Alvarez S, Shell CG, Wooley TW, Berk SL, Smith JK. Nosocomial infections in long-\nterm care facilities. J Gerontol 1988; 43(1):M9-M17.\n401. CDC. Outbreak of pneumococcal pneumonia among unvaccinated residents of a nursing\nhome--New Jersey, April 2001. MMWR 2001; 50(33):707-710.\n402. Gleich S, Morad Y, Echague R, et al. Strepcococcus pneumoniae serotype 4 outbreak in\na home for the aged: report and review of recent outbreaks. Infect Control Hosp Epidemiol 2000;\n21:711-717.\n403. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 641,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_642",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "21:711-717.\n403. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued\nemergence of drug-resistant Steptococcus pneumoniae in the United States: an update from the\nCenters for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect\nDis 1996; 174(5):986-993.\n404. CDC. Geographic variation in penicillin resistance in Streptoccoccus pneumoniae--\nselected sites, United States, 1997. MMWR 1999; 48(30):656-661.\n405. CDC. Prevention of pneumococcal disease: Recommendations of the Advisory\nCommittee on Immunization Practices (ACIP). MMWR 1997; 46(No. RR-8).\n406. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of\npneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 642,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_643",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern\nMed 1984; 101(3):325-330.\n407. CDC. Preventing pneumococcal disease among infants and young children. MMWR\n2000; 49(No. RR-9).\n408. CDC. Use of standing orders programs to increase adult vaccination rates.\nRecommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;\n49(No. RR-1).\n409. Centers for Medicare and Medicaid Services, Department of Health and Human Services.\n128\nMedicare and Medicaid programs; conditions of participation: immunization standards for\nhospitals, long-term care facilities, and home health agencies. Final rule with comment period.\nFederal Register 2002; 67:61808-61814.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 643,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_644",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Federal Register 2002; 67:61808-61814.\n410. Williams WW, Hickson MA, Kane MA, Kendal AP, Spika JS, Hinman AR. Immunization\npolicies and vaccine coverage among adults. The risk for missed opportunities. Ann Intern Med\n1988; 108(4):616-625.\n411. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous\nadministration of standard immune globulin as compared with core-lipopolysaccharide immune\nglobulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327:234-240.\n412. Donta ST, Peduzzi P, Cross AS, et al. Immunoprophylaxis against Klebsiella and\nPseudomonas aeruginosa infections. J Infect Dis 1996; 174(3):537-543.\n413. Gruson D, Hilbert G, Vargas F, et al. Impact of colony-stimulating factor therapy on",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 644,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_645",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "413. Gruson D, Hilbert G, Vargas F, et al. Impact of colony-stimulating factor therapy on\nclinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic\npatients. Crit Care Med 2000; 28(9):3155-3160.\n414. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-\ninduced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;\n121(7):492-501.\n415. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in\nestablished febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997;\n15(3):1163-1170.\n416. Heard SO, Fink MP, Gamelli RL, et al. Effect of prophylactic administration of\nrecombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 645,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_646",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of\nnosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit\nCare Med 1998; 26(4):748-754.\n417. van der Hulst RRWJ, van Kreel BK, Von Meyenfeldt MF, et al. Glutamine and the\npreservation of gut integrity. Lancet 1993; 341:1363-1365.\n418. Houdijk APJ, Rijnsburger ER, Jansen J, et al. Randomised trial of glutamine-enriched\nenteral nutrition on infectious morbidity in patients with multiple trauma. Lancet 1998; 352:772-\n776.\n419. Mandelli M, Mosconi P, Langer M, Cigada M. Prevention of pneumonia in an intensive\ncare unit: a randomized multicenter clinical trial. Crit Care Med 1989; 17(6):501-505.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 646,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_647",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "care unit: a randomized multicenter clinical trial. Crit Care Med 1989; 17(6):501-505.\n420. Sirvent JM, Torres A, El-ebiary M, Castro P, de Batlle J, Bonet A. Protective effect of\nintravenously administered cefuroxime against nosocomial pneumonia in patients with structural\ncoma. Am J Respir Crit Care Med 1997; 155(5):1729-1734.\n129\n421. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of\nantibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J\nRespir Crit Care Med 1997; 156:1040-1048.\n422. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a\nmedical intensive care unit.  Impact on the incidence of ventilator-associated pneumonia caused by",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 647,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_648",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "medical intensive care unit.  Impact on the incidence of ventilator-associated pneumonia caused by\nantibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162:837-843.\n423. Whiteman K, Nachtmann L, Kramer D, Sereika S, Bierman M. Effects of continuous\nlateral rotation therapy on pulmonary complications in liver transplant patients. Am J Crit Care\n1995; 4(2):133-139.\n424. Kelly RE, Vibulsresth S, Bell L, Duncan RC. Evaluation of kinetic therapy in the\nprevention of complications of prolonged bed rest secondary to stroke. Stroke 1987; 18(3):638-\n642.\n425. Gentilello L, Thompson DA, Tonnesen AS, et al. Effect of a rotating bed on the\nincidence of pulmonary complications in critically ill patients. Crit Care Med 1988; 16(8):783-786.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 648,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_649",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "incidence of pulmonary complications in critically ill patients. Crit Care Med 1988; 16(8):783-786.\n426. Summer WR, Curry P, Haponik EF, Nelson S, Elston R. Continuous mechanical turning\nof intensive care unit patients shortens length of stay in some diagnostic-related groups. J Crit Care\n1989; 4(1):45-53.\n427. Fink MP, Helsmoortel CM, Stein KL, Lee PC, Cohn SM. The efficacy of an oscillating\nbed in the prevention of lower respiratory tract infection in critically ill victims of blunt trauma. A\nprospective study. Chest 1990; 97(1):132-137.\n428. Nelson LD, Choi SC. Kinetic therapy in critically ill trauma patients. Clin Intensive Care\n1992; 3(6):248-252.\n429. deBoisblanc BP, Castro M, Everret B, Grender J, Walker CD, Summer WR. Effect of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 649,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_650",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "429. deBoisblanc BP, Castro M, Everret B, Grender J, Walker CD, Summer WR. Effect of\nair-supported, continuous, postural oscillation on the risk of early ICU pneumonia in nontraumatic\ncritical illness. Chest 1993; 103(5):1543-1547.\n430. Zack MB, Pontoppidan H, Kazemi H. The effect of lateral positions on gas exchange in\npulmonary disease. A prospective evaluation. Am Rev Respir Dis 1974; 110(1):49-55.\n431. Becker DM, Gonzalez M, Gentili A, Eismont F, Green BA. Prevention of deep venous\nthrombosis in patients with acute spinal cord injuries: use of rotating treatment tables. Neurosurg\n1987; 20(5):675-677.\n432. Kirschenbaum L, Azzi E, Sfeir T, Tietjen P, Astiz M. Effect of continuous lateral\nrotational therapy on the prevalence of ventilator-associated pneumonia in patients requiring long",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 650,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_651",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "rotational therapy on the prevalence of ventilator-associated pneumonia in patients requiring long\nterm ventilatory care. Crit Care Med 2002; 30(9):1983-1986.\n130\n433. Traver GA, Tyler ML, Hudson LD, Sherrill CL, Quan SF. Continuous oscillation:\noutcome in critically ill patients. J Crit Care 1995; 10(3):97-103.\n434. Hoge CW, Breiman RF. Advances in the epidemiology and control of Legionella\ninfections. Epidemiol Rev 1991; 13:329-340.\n435. Joseph CA, Watson JM, Harrison TG, Bartlett CL. Nosocomial Legionnaires' disease in\nEngland and Wales, 1980-92. Epidemiol Infect 1994; 112(2):329-345.\n436. Brennen C, Vickers RM, Yu VL, Puntereri A, Yee YC. Discovery of occult legionella\npneumonia in a long-stay hospital: results of prospective serologic survey. Br Med J 1987;\n295:306-307.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 651,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_652",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "295:306-307.\n437. Marrie TJ, MacDonald S, Clarke K, Haldane D. Nosocomial Legionnaires' disease:\nlessons from a four year prospective study. Am J Infect Control 1991; 19(2):79-85.\n438. Muder RR, Yu VL, McClure JK, Kroboth FJ, Kominos SD, Lumish RN. Nosocomial\nLegionnaires' disease uncovered in a prospective pneumonia study: implications for\nunderdiagnosis. JAMA 1983; 249(23):3184-3188.\n439. Fiore AE, Butler JC, Emori TG, Gaynes RP. A survey of methods used to detect\nnosocomial legionellosis among participants in the National Nosocomial Infections Surveillance\nSystem. Infect Control Hosp Epidemiol 1999; 20(6):412-416.\n440. Fliermans CB, Cherry WB, Orrison LH, Smith SJ, Tison DL, Pope DH. Ecological\ndistribution of Legionella pneumophila. Appl Environ Microbiol 1981; 41(1):9-16.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 652,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_653",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "distribution of Legionella pneumophila. Appl Environ Microbiol 1981; 41(1):9-16.\n441. Morris GK, Patton CM, Feeley JC, et al. Isolation of the Legionnaires' disease bacterium\nfrom environmental samples. Ann Intern Med 1979; 90(4):664-666.\n442. Hsu SC, Martin R, Wentworth BB. Isolation of Legionella species from drinking water.\nAppl Environ Microbiol 1984; 48(4):830-832.\n443. Tison DL, Seidler RJ. Legionella incidence and density in potable drinking water\nsupplies. App Environ Microbiol 1983; 45(1):337-339.\n444. Farrell ID, Barker JE, Miles EP, Hutchinson JG. A field study of the survival of\nLegionella pneumophila in a hospital hot-water system. Epidemiol Infect 1990; 104(3):381-387.\n445. Stout JE, Yu VL, Best MG. Ecology of Legionella pneumophila within water",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 653,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_654",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "445. Stout JE, Yu VL, Best MG. Ecology of Legionella pneumophila within water\ndistribution systems. Appl Environ Microbiol 1985; 49(1):221-228.\n446. Sanden GN, Fields BS, Barbaree JM, et al. Viability of Legionella pneumophila in\nchlorine-free water at elevated temperatures. Curr Microbiol 1989; 18:61-65.\n131\n447. Schulze-Robbecke R, Rodder M, Exner M. Multiplication and killling temperatures of\nnaturally occurring legionellae. Zbl Bakt Hyg B 1987; 184(6):495-500.\n448. Habicht W, Muller HE. Occurrence and parameters of frequency of Legionella in warm\nwater systems of hospitals and hotels in Lower Saxony. Zbl Bakt Hyg B 1988; 186(1):79-88.\n449. Ciesielski CA, Blaser MJ, Wang WL. Role of stagnation and obstruction of water flow in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 654,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_655",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "449. Ciesielski CA, Blaser MJ, Wang WL. Role of stagnation and obstruction of water flow in\nisolation of Legionella pneumophila from hospital plumbing. Appl Environ Microbiol 1984;\n48(5):984-987.\n450. Rowbotham TJ. Preliminary report on the pathogenicity of Legionella pneumophila for\nfreshwater and soil amoebae. J Clin Pathol 1980; 33(12):1179-1183.\n451. Fields BS, Sanden GN, Barbaree JM, et al. Intracellular multiplication of Legionella\npneumophila in amoebae isolated from hospital hot water tanks. Curr Microbiol 1989; 18:131-\n137.\n452. Le Saux NM, Sekla L, McLeod J, et al. Epidemic of nosocomial Legionnaires' disease in\nrenal transplant recipients: a case-control and environmental study. Can Med Assoc J 1989;\n140(9):1047-1053.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 655,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_656",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "140(9):1047-1053.\n453. Berendt RF, Young HW, Allen RG, Knutsen GL. Dose-response of guinea pigs\nexperimentally infected with aerosols of Legionella pneumophila. J Infect Dis 1980; 141(2):186-\n192.\n454. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease.  Risk\nfactors for morbidity and mortality. Arch Intern Med 1994; 154(21):2417-2422.\n455. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-\nfive nosocomially acquired cases and review of the literature. Medicine 1980; 59(3):188-205.\n456. Chow JW, Yu VL. Legionella: a major opportunistic pathogen in transplant recipients.\nSeminars Respir Infect 1998; 13(2):132-139.\n457. Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of unrecognized nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 656,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_657",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "457. Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of unrecognized nosocomial\ntransmission of Legionnaires' disease among transplant patients. Infect Control Hosp Epidemiol\n1998; 19(12):898-904.\n458. Redd SC, Schuster DM, Quan J, Plikaytis BD, Spika JS, Cohen ML. Legionellosis in\ncardiac transplant recipients: Results of a nationwide survey. J Infect Dis 1988; 158(3):651-653.\n459. Seu P, Winston DJ, Pltkoft KM, et al. Legionnaires' disease in liver transplant recipients.\nInfect Dis Clin Pract 1993; 2:109-113.\n460. Knirsch C.A., Jakob K, Schoonmaker D, et al. An outbreak of Legionella micdadei\n132\npneumonia in transplant patients: evaluation, molecular epidemiology, and control. Am J Med\n2001; 108(4):290-295.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 657,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_658",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "2001; 108(4):290-295.\n461. Bock BV, Kirby BD, Edelstein PH, et al. Legionnaires' disease in renal transplant\nrecipients. Lancet 1978; 1:410-413.\n462. Blatt SP, Dolan MJ, Hendrix CW, Melcher GP. Legionnaires' disease in human\nimmunodeficiency virus-infected patients: eight cases and review. Clin Infect Dis 1994; 18(2):227-\n232.\n463. Jimenez ML, Aspa J, Padilla B, et al. Fiberoptic bronchoscopic diagnosis of pulmonary\ndisease in 151 HIV-infected patients with pneumonitis. Eur J Clin Microbiol Infect Dis 1991;\n10(6):491-497.\n464. Brady MT. Nosocomial Legionnaires' disease in a children's hospital. J Pediatr 1989;\n115(1):46-50.\n465. Levy I, Rubin LG. Legionella pneumonia in the neonate: a literature review. Journal of\nPerinatology 1998; 18(4):287-290.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 658,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_659",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Perinatology 1998; 18(4):287-290.\n466. Holmberg RE, Jr., Pavia AT, Montgomery D, Clark JM, Eggert LD. Nosocomial\nLegionella pneumonia in the neonate. Pediatrics 1993; 92(3):450-453.\n467. Campins M, Ferrer A, Callis L, et al. Nosocomial Legionnaires' disease in a children's\nhospital. Pediatric Infectious Disease Journal 2000; 19(3):228-234.\n468. Benin AL, Benson.R.F., Besser RE. Trends in Legionnaires' disease, 1980-1998:\ndeclining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35:1039-1046.\n469. Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of\npneumococcal, mycoplasma, and Legionnaires' disease pneumonias. Ann Intern Med 1979;\n90(4):543-547.\n470. Yu VL, Kroboth FJ, Shonnard J, Brown A, McDearman S, Magnussen M. Legionnaires'",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 659,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_660",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "90(4):543-547.\n470. Yu VL, Kroboth FJ, Shonnard J, Brown A, McDearman S, Magnussen M. Legionnaires'\ndisease: new clinical perspective from a prospective pneumonia study. Am J Med 1982; 73(3):357-\n361.\n471. Fiore AE, Nuorti JP, Levine OS, et al. Epidemic Legionnaires' disease two decades later:\nold sources, new diagnostic methods. Clin Infect Dis 1998; 26(2):426-433.\n472. Marston B, Plouffe J, File T, et al. Evidence of mixed infection in patients with antibody\nto Chlamydia pneumoniae. Abstracts of the 32nd Interscience Conference on Antimicrobial\nAgents and Chemotherapy 1992;808.\n473. Ussery XT, Butler JC, Breiman R, et al. Outbreak of Legionnaires' disease associated\n133\nwith Mycoplasma infection. Abstracts of the 32nd Interscience Conference on Antimicrobial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 660,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_661",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "133\nwith Mycoplasma infection. Abstracts of the 32nd Interscience Conference on Antimicrobial\nAgents and Chemotherapy 1992;815.\n474. Edelstein PH. The laboratory diagnosis of Legionnaires' disease. Seminars Respir Infect\n1987; 2(4):235-241.\n475. Plouffe JF, File TM, Jr., Breiman RF, et al. Reevaluation of the definition of\nLegionnaires' disease: use of the urinary antigen assay. Clin Infect Dis 1995; 20(5):1286-1291.\n476. Kazandjian D, Chiew R, Gilbert GL. Rapid diagnosis of Legionella pneumophila\nserogroup 1 infection with the Binax immunoassay urinary antigen test. J Clin Microbiol 1997;\n35(4):954-956.\n477. Stout JE. Laboratory diagnosis of Legionnaires' disease: the expanding role of the\nLegionella urinary antigen test. J Clin Microbiol 2000; 22:62-64.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 661,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_662",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Legionella urinary antigen test. J Clin Microbiol 2000; 22:62-64.\n478. Helms CM, Renner ED, Viner JP, Hierholzer WJ, Jr., Wintermeyer LA, Johnson W.\nIndirect immunofluorescence antibodies to Legionella pneumophila: frequency in a rural\ncommunity. J Clin Microbiol 1980; 12(3):326-328.\n479. Wilkinson HW, Reingold AL, Brake BJ, McGiboney DL, Gorman GW, Broome CV.\nReactivity of serum from patients with suspected legionellosis against 29 antigens of\nLegionellaceae and Legionella-like organisms by indirect immunofluorescence assay. J Infect Dis\n1983; 147:23-31.\n480. Nichol KL, Parenti CM, Johnson JE. High prevalence of positive antibodies to\nLegionella pneumophila among outpatients. Chest 1991; 100(3):663-666.\n481. Storch G, Hayes PS, Hill DL, Baine WB. Prevalence of antibody to Legionella",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 662,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_663",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "481. Storch G, Hayes PS, Hill DL, Baine WB. Prevalence of antibody to Legionella\npneumophila in middle-aged and elderly Americans. J Infect Dis 1979; 140(5):784-788.\n482. Dondero TJ, Rendtorff RC, Mallison GF, et al. An outbreak of Legionnaires' disease\nassociated with a contaminated air-conditioning cooling tower. N Engl J Med 1980; 302(7):365-\n370.\n483. Garbe PL, Davis BJ, Weisfeld JS, et al. Nosocomial Legionnaires' disease. Epidemiologic\ndemonstration of cooling towers as a source. JAMA 1985; 254(4):521-524.\n484. O'Mahony MC, Stanwell-Smith RE, Tillett HE, et al. The Stafford outbreak of\nLegionnaires' disease. Epidemiol Infect 1990; 104(3):361-380.\n485. Breiman RF, Fields BS, Sanden GN, Volmer L, Meier A, Spika JS. Association of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 663,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_664",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "485. Breiman RF, Fields BS, Sanden GN, Volmer L, Meier A, Spika JS. Association of\nshower use with Legionnaires' disease: possible role of amoebae. JAMA 1990; 263(21):2924-\n2926.\n134\n486. Hanrahan JP, Morse DL, Scharf VB, et al. A community hospital outbreak of\nlegionellosis: transmission by potable hot water. Am J Epidemiol 1987; 125(4):639-649.\n487. Breiman RF, VanLoock FL, Sion JP, et al. Association of \"sink bathing\" and\nLegionnaires' disease. Abstracts of the 91st Meeting of the American Society for Microbiology\n1991. L18.\n488. Struelens MJ, Maes N, Rost F, et al. Genotypic and phenotypic methods for the\ninvestigation of a nosocomial Legionella pneumophila outbreak and efficacy of control measures.\nJ Infect Dis 1992; 166(1):22-30.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 664,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_665",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "J Infect Dis 1992; 166(1):22-30.\n489. Johnson JT, Yu VL, Best MG, et al. Nosocomial legionellosis in surgical patients with\nhead and neck cancer: implications for epidemiological reservoir and mode of transmission. Lancet\n1985; 2:298-300.\n490. Marrie TJ, Haldane D, MacDonald S, et al. Control of endemic nosocomial Legionnaires'\ndisease by using sterile potable water for high risk patients. Epidemiol Infect 1991; 107(3):591-\n605.\n491. Blatt SP, Parkinson MD, Pace E, et al. Nosocomial Legionnaires' disease: aspiration as a\nprimary mode of disease acquisition. Am J Med 1993; 95(1):16-22.\n492. Venezia RA, Agresta MD, Hanley EM, Urquhart K, Schoonmaker D. Nosocomial\nlegionellosis associated with aspiration of nasogastric feedings diluted in tap water. Infect Control",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 665,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_666",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Hosp Epidemiol 1994; 15(8):529-533.\n493. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an\nepidemic of pneumonia. N Engl J Med 1977; 297(22):1189-1197.\n494. Yu VL, Beam TR, Jr., Lumish RM, et al. Routine culturing for Legionella in the hospital\nenvironment may be a good idea: a three-hospital prospective study. Am J Med Sci 1987;\n294(2):97-99.\n495. Allegheny County Health Department. Approaches to Prevention and Control of\nLegionella Infection in Allegheny County Health Care Facilities. 2nd ed. Pittsburgh, PA: Allegheny\nCounty Health Department, 1997.\n496. Yu VL. Nosocomial legionellosis: current epidemiologic issues. In: Remington JS,\nSwartz MN, editors. Current Clinical Topics in Infectious Diseases. New York,N.Y.: McGraw-\nHill, 1986: 239-253.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 666,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_667",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Hill, 1986: 239-253.\n497. Goetz AM, Yu VL. Screening for nosocomial legionellosis by culture of the water supply\nand targeting of high risk patients for specialized laboratory testing. Am J Infect Control 1991;\n19(2):63-66.\n135\n498. Vickers RM, Yu VL, Hanna SS, et al. Determinants of Legionella pneumophila\ncontamination of water distribution systems: 15-hospital prospective study. Infect Control 1987;\n8(9):357-363.\n499. Tobin JO, Swann RA, Bartlett CLR. Isolation of Legionella pneumophila from water\nsystems: methods and preliminary results. Br Med J 1981; 282:515-517.\n500. Marrie TJ, Haldane D, Bezanson G, Peppard R. Each water outlet is a unique ecologic\nniche for Legionella pneumophila. Epidemiol Infect 1992; 108(2):261-270.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 667,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_668",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "niche for Legionella pneumophila. Epidemiol Infect 1992; 108(2):261-270.\n501. Marrie TJ, Berzcason G, Fox J, Kuehn R, Haldane D, Birbridge S. Dynamics of\nLegionella pneumophila in the potable water of one floor of a hospital. In: Barbaree JM, Breiman\nRF, Dufow AP, editors. Legionella: Current Status and Emerging Perspectives. Washington, D.C.:\nAmerican Society for Microbiology, 1993: 238-240.261-270.\n502. Plouffe JF, Para MF, Maher WE, Hackman B, Webster L. Subtypes of Legionella\npneumophila serogroup 1 associated with different attack rates. Lancet 1983; 2:649-650.\n503. Dournon E, Bibb WF, Rajagopalan P, Desplaces N, McKinney RM. Monoclonal\nantibody reactivity as a virulence marker for  Legionella pneumophila serogroup 1 strain. J Infect\nDis 1988; 157(3):496-501.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 668,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_669",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Dis 1988; 157(3):496-501.\n504. American Society for Heating Refrigerating and Air-Conditioning Engineers. ASHRAE\nGuideline 12-2000: Minimizing the risk of legionellosis associated with building water systems.\nAtlanta, GA: ASHRAE, Inc., 2000.\n505. Kugler JW, Armitage JO, Helms CM, et al. Nosocomial Legionnaires' disease.\nOccurrence in recipients of bone marrow transplants. Am J Med 1983; 74(2):281-288.\n506. CDC. Guidelines for environmental control in health-care facilities. MMWR 2003;\n52(No. RR10).\n507. CDC, Infectious Diseases Society of America, and American Society of Blood and\nMarrow Transplantation. Guidelines for the prevention of opportunistic infections (OIs) in\nhematopoietic stem cell transplant (HSCT) recipients. MMWR 2000; 49(No. RR-10).",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 669,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_670",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hematopoietic stem cell transplant (HSCT) recipients. MMWR 2000; 49(No. RR-10).\n508. Patterson WJ, Hay J, Seal DV, McLuckie JC. Colonization of transplant unit water\nsupplies with Legionella and protozoa: precautions required to reduce the risk of legionellosis. J\nHosp Infect 1997; 37(1):7-17.\n509. Bollin GE, Plouffe JF, Para MF, Hackman B. Aerosols containing Legionella\npneumophila generated by shower heads and hot-water faucets. Appl Environ Microbiol 1985;\n50(5):1128-1131.\n510. Health and Safety Commission. Legionnaires' disease: The control of Legionella bacteria\n136\nin water systems.  Approved code of practice and guidance. 3rd ed ed. United Kingdom: HSA\nBooks, 2000.\n511. Department of Health and Social Security and the Welsh Office. The control of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 670,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_671",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Books, 2000.\n511. Department of Health and Social Security and the Welsh Office. The control of\nLegionellae in health care premises: a code of practice. London: HMSO, 1991.\n512. Helms CM, Massanari RM, Wenzel RP, Pfaller MA, Moyer NP, Hall N. Legionnaires'\ndisease associated with a hospital water system. A five-year progress report on continuous\nhyperchlorination. JAMA 1988; 259(16):2423-2427.\n513. Snyder MB, Siwicki M, Wireman J, et al. Reduction of Legionella pneumophila through\nheat flushing followed by continuous supplemental chlorination of hospital hot water. J Infect Dis\n1990; 162(1):127-132.\n514. Ezzeddine H, Van Ossel C, Delmee M, Wauters G. Legionella spp. in a hospital hot\nwater system: effect of control measures. J Hosp Infect 1989; 13(2):121-131.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 671,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_672",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "water system: effect of control measures. J Hosp Infect 1989; 13(2):121-131.\n515. Mietzner S, Schwille RC, Farley A, et al. Efficacy of thermal treatment and copper-silver\nionization for controlling Legionella pneumophila in high-volume hot water plumbing systems in\nhospitals. Am J Infect Control 1997; 25(6):452-457.\n516. Borau J, Czap RT, Strellrecht KA, Venezia RA. Long-term control of Legionella species\nin potable water after a nosocomial legionellosis outbreak in an intensive care unit. Infect Control\nHosp Epidemiol 2000; 21(9):602-603.\n517. Haley CE, Cohen ML, Halter J, Meyer RD. Nosocomial Legionnaires' disease: a\ncontinuing common-source epidemic at Wadsworth Medical Center. Ann Int Med 1979;\n90(4):583-586.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 672,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_673",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "continuing common-source epidemic at Wadsworth Medical Center. Ann Int Med 1979;\n90(4):583-586.\n518. Lepine LA, Jernigan DB, Butler JC, et al. A recurrent outbreak of nosocomial\nLegionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a\nhospital plumbing system. Infect Control Hosp Epidemiol 1998; 19(12):905-910.\n519. Johnston JM, Latham RH, Meier FA, et al. Nosocomial outbreak of Legionnaires'\ndisease: molecular epidemiology and disease control measures. Infect Control 1987; 8(2):53-58.\n520. Joly JR, McKinney RM, Tobin JO, Bibb WF, Watkins ID, Ramsay D. Development of a\nstandardized subgrouping scheme for Legionella pneumophila serogroup 1 using monoclonal\nantibodies. J Clin Microbiol 1986; 23(4):768-771.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 673,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_674",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "antibodies. J Clin Microbiol 1986; 23(4):768-771.\n521. Schoonmaker D, Heimberger T, Birkhead G. Comparison of ribotyping and restriction\nenzyme analysis using pulsed-field gel electrophoresis for distinguishing Legionella pneumophila\nisolates obtained during a nosocomial outbreak. J Clin Microbiol 1992; 30(6):1491-1498.\n522. Barbaree JM. Selecting a subtyping technique for use in investigations of legionellosis\n137\nepidemics. In: Barbaree JM, Breiman RF, Dufow AP, editors. Legionella: Current Status and\nEmerging Perspectives. Washington, D.C.: American Society for Microbiology, 1993.\n523. Whitney CG, Hofmann J, Pruckler JM, et al. The role of arbitrarily primed PCR in\nidentifying the source of an outbreak of Legionnaires' disease. J Clin Microbiol 1997; 35(7):1800-\n1804.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 674,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_675",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1804.\n524. Pruckler JM, Mermel LA, Benson RF, et al. Comparison of Legionella pneumophila\nisolates by arbitrarily primed PCR and pulsed-field electrophoresis: analysis from seven epidemic\ninvestigations. J Clin Microbiol 1995; 33(1):2872-2875.\n525. Best MG, Yu VL, Stout J, Goetz A, Muder RR, Taylor F. Legionellaceae in the hospital\nwater supply. Epidemiologic link with disease and evaluation of a method for control of\nnosocomial Legionnaires' disease and Pittsburgh pneumonia. Lancet 1983; 2:307-310.\n526. Best MG, Goetz A, Yu VL. Heat eradication measures for control of nosocomial\nLegionnaires' disease. Implementation, education and cost analysis. Am J Infect Control 1984;\n12(1):26-30.\n527. Mandel AS, Sprauer MA, Sniadack DH, Ostroff SM. State regulation of hospital water",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 675,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_676",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "527. Mandel AS, Sprauer MA, Sniadack DH, Ostroff SM. State regulation of hospital water\ntemperature. Infect Control Hosp Epidemiol 1993; 14(11):642-645.\n528. CDC. Sustained transmission of nosocomial Legionnaires' disease - Arizona and Ohio.\nMMWR 1997; 46(19):416-421.\n529. Muraca P, Stout JE, Yu VL. Comparative assessment of chlorine, heat, ozone, and UV\nlight for killing Legionella pneumophila within a model plumbing system. Appl Environ Microbiol\n1987; 53(2):447-453.\n530. Matulonis U, Rosenfield CS, Shadduck RK. Prevention of Legionella infections in a bone\nmarrow transplant unit: multifaceted approach to decontamination of a water system. Infect\nControl Hosp Epidemiol 1993; 14(10):571-575.\n531. Domingue EL, Tyndall RL, Mayberry WR, Pancorbo OC. Effects of three oxidizing",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 676,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_677",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "531. Domingue EL, Tyndall RL, Mayberry WR, Pancorbo OC. Effects of three oxidizing\nbiocides of Legionella pneumophila serogroup 1. Appl Environ Microbiol 1988; 54(3):741-747.\n532. Landeen LK, Yahya MT, Gerba CP. Efficacy of copper and silver ions and reduced levels\nof free chlorine in inactivation of Legionella pneumophila. Appl Environ Microbiol 1989;\n55(12):3045-3050.\n533. Liu Z, Stout JE, Tedesco L, et al. Controlled evaluation of copper-silver ionization in\neradicating Legionella pneumophila from a hospital water distribution system. J Infect Dis 1994;\n169(4):919-922.\n534. Edelstein PH, Whittaker RE, Kreiling RL, Howell CL. Efficacy of ozone in eradication of\n138\nLegionella pneumophila from hospital plumbing fixtures. Appl Environ Microbiol 1982;\n44(6):1330-1333.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 677,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_678",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "44(6):1330-1333.\n535. Goetz AM, Yu VL. Copper-silver ionization: Cautious optimism for Legionella\ndisinfection and implications for environmental culturing. Am J Infect Control 1997; 25(6):449-\n451.\n536. Walker JT, Mackerness C.W., Mallon D, Makin T, Williets T, Keevil CW. Control of\nLegionella pneumophila in a hospital water system by chlorine dioxide. J Indust Microbiol 1995;\n15:384-390.\n537. Stout J, Yu VL. Experiences of the first 16 hospitals using copper-silver ionization for\nLegionella control: Implications for the evaluation of other disinfection modalities. Infect Control\nHosp Epidemiol 2003; 24(8):563-568.\n538. Hall KK, Giannetta ET, Getchell-White SI, Durbin LJ, Farr BM. Ultraviolet light",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 678,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_679",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "538. Hall KK, Giannetta ET, Getchell-White SI, Durbin LJ, Farr BM. Ultraviolet light\ndisinfection of hospital water for preventing nosocomial Legionella infection: a 13-year follow-up.\nInfect Control Hosp Epidemiol 2003; 24(8):580-583.\n539. Srinivasan A, Bova G, Ross T, et al. A 17-month evaluation of a chlorine dioxide water\ntreatment system to control Legionella species in a hospital water supply. Infect Control Hosp\nEpidemiol 2003; 24(8):575-579.\n540. Biurrun A, Caballero M, Pelaz C, Leon E, Gago A. Treatment of a Legionella\npneumophila-colonized water distribution system using copper-silver ionization and continuous\nchlorination. Infect Control Hosp Epidemiol 1999; 20(6):426-428.\n541. Lin YS, Stout JE, Yu VL, Vidic RD. Disinfection of water distribution systems for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 679,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_680",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "541. Lin YS, Stout JE, Yu VL, Vidic RD. Disinfection of water distribution systems for\nLegionella. Seminars Respir Infect 1998; 13(2):147-159.\n542. Stout JE, Lin YS, Goetz AM, Muder RR. Controlling Legionella in hospital water\nsystems: experience with the superheat-and-flush method and copper-silver ionization. Infect\nControl Hosp Epidemiol 1998; 19(12):911-914.\n543. Rohr U, Senger M, Selenka F, Turley R, Wilhelm M. Four years of experience with\nsilver-copper ionization for control of Legionella in a German university hospital hot water\nplumbing system. Clin Infect Dis 1999; 29(6):1507-1511.\n544. Cunliffe DA. Inactivation of Legionella pneumophila by monochloramine. J Appl\nBacteriol 1990; 68(5):453-459.\n545. Kirmeyer G, Foust G, Pierson G, Simmler J, LeChevalier M. Optimizing chloramine",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 680,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_681",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "545. Kirmeyer G, Foust G, Pierson G, Simmler J, LeChevalier M. Optimizing chloramine\ntreatment. Denver, CO: American Water Works Research Foundation, 1993.\n546. Kool JL, Carpenter JC, Fields BS. Effect of monochloramine disinfection of municipal\n139\ndrinking water on risk of nosocomial Legionnaires' disease. Lancet 1999; 353:272-277.\n547. Kool JL, Bergmire-Sweat D, Butler JC, et al. Hospital characteristics associated with\ncolonization of water systems by Legionella and risk of nosocomial legionnaires' disease: a cohort\nstudy of 15 hospitals. Infect Control Hosp Epidemiol 1999; 20(12):798-805.\n548. Heffelfinger JD, Kool JL, Fridkin S, et al. Risk of hospital-acquired Legionnaires' disease\nin cities using monochloramine versus other water disinfectants. Infect Control Hosp Epidemiol",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 681,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_682",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "in cities using monochloramine versus other water disinfectants. Infect Control Hosp Epidemiol\n2003; 24(8):569-574.\n549. Muraca PW, Yu VL, Goetz A. Disinfection of water distribution systems for Legionella:\na review of application procedures and methodologies. Infect Control Hosp Epidemiol 1990;\n11(2):79-88.\n550. Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in\nhospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--\nActive (IMPACT). Clin Infect Dis 1999; 28(6):1238-1243.\n551. Christie CD, Baltimore RS. Pertussis in neonates. Am J Dis Child 1989; 143(10):1199-\n1202.\n552. Black S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16(4 Suppl):S85-S89.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 682,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_683",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1202.\n552. Black S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16(4 Suppl):S85-S89.\n553. Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools,\nMassachusetts, 1996: epidemiologic data supported by  pulse-field gel electrophoresis studies. J\nInfect Dis 2000; 181(1):210-215.\n554. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin\nInfect Dis 1999; 28(suppl 2):S112-S117.\n555. Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella\npertussis infections in adults. Clin Infect Dis 1995; 21(3):639-642.\n556. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the\nUnited States: increasing reported incidence among adolescents and adults. Clin Infect Dis 1999;",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 683,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_684",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "United States: increasing reported incidence among adolescents and adults. Clin Infect Dis 1999;\n28(6):1230-1237.\n557. Hodder SL, Cherry JD, Mortimer EA, Jr., Ford AB, Gornvein J, Papp K. Antibody\nresponses to Bordetella pertussis antigens and clinical correlations in elderly community residents.\nClin Infect Dis 2000; 31(1):7-14.\n558. Jackson LA, Cherry JD, San-Pin W, Grayson JT. Frequency of serological evidence of\nBordetella infections and mixed infections with other respiratory pathogens in university students\nwith cough illnesses. Clin Infect Dis 2000; 31(1):3-6.\n140\n559. Nennig ME, Shinefield HR, Edwards KM, Black SB, Fireman BH. Prevalence and\nincidence of adult pertussis in an urban population. JAMA 1996; 275(21):1672-1674.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 684,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_685",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "incidence of adult pertussis in an urban population. JAMA 1996; 275(21):1672-1674.\n560. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with\npersistent cough. JAMA 1995; 273(13):1044-1046.\n561. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing\nincidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 2000;\n182(5):1409-1416.\n562. Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for\nvaccination. Clin Infect Dis 1999; 28(suppl 2):S147-S150.\n563. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults\nas reservoirs of infection. Am J Dis Child 1978; 132(4):371-373.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 685,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_686",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "as reservoirs of infection. Am J Dis Child 1978; 132(4):371-373.\n564. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and\nadults. J Infect Dis 2000; 182(1):174-179.\n565. Christie CD, Glover AM, Willke MJ, Marx ML, Reising SF, Hutchinson NM.\nContainment of pertussis in the regional pediatric hospital during the Greater Cincinnati epidemic\nof 1993. Infect Control Hosp Epidemiol 1995; 16(10):556-563.\n566. Gehanno JF, Pestel-Caron M, Nouvellon M, Caillard JF. Nosocomial pertussis in\nhealthcare workers from a pediatric emergency unit in France. Infect Control Hosp Epidemiol\n1999; 20(8):549-552.\n567. Haiduven DJ, Hench CP, Simpkins SM, Stevens DA. Standardized management of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 686,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_687",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "567. Haiduven DJ, Hench CP, Simpkins SM, Stevens DA. Standardized management of\npatients and employees exposed to pertussis. Infect Control Hosp Epidemiol 1998; 19(11):861-\n864.\n568. Izurieta HS, Kenyon TA, Strebel PM, Baughman AL, Shulman ST, Wharton M. Risk\nfactors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis 1996;\n22(3):503-507.\n569. Matlow AG, Nelson S, Wray R, Cox P. Nosocomial acquisition of pertussis diagnosed by\npolymerase chain reaction. Infect Control Hosp Epidemiol 1997; 18(10):715-716.\n570. Nouvellon M, Gehanno JF, Pestel-Caron M, Weber C, Lemeland JF, Guiso N. Usefulness\nof pulsed-field gel electrophoresis in assessing nosocomial transmission of pertussis. Infect Control\nHosp Epidemiol 1999; 20(11):758-760.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 687,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_688",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Hosp Epidemiol 1999; 20(11):758-760.\n571. Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. Clinical manifestations of Bordetella\npertussis infection in immunized children and young adults. Chest 1999; 115(5):1254-1258.\n141\n572. Trollfors B, Rabo E. Whooping cough in adults. Brit Med J 1981; 283:696-697.\n573. Preston NW. Technical problems in the laboratory diagnosis and prevention of whooping\n-cough. Lab Pract 1970; 19(5):482-486.\n574. Gilligan PH, Fisher MC. Importance of culture in laboratory diagnosis of Bordetella\npertussis infections. J Clin Microbiol 1984; 20(5):891-893.\n575. Ewanowich CA, Chui LW, Paranchych MG, Peppler MS, Marusyk RG, Albritton WL.\nMajor outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 688,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_689",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-\nantibody and culture results by using polymerase chain reaction methodology. J Clin Microbiol\n1993; 31(7):1715-1725.\n576. Muller FM, Hoppe JE, Wirsing von Konig CH. Laboratory diagnosis of pertussis: state\nof the art 1997. J Clin Microbiol 1997; 35(10):2435-2443.\n577. McNicol P, Giercke SM, Gray M, et al. Evaluation and validation of a monoclonal\nimmunofluorescent reagent for direct detection of Bordetella pertussis. J Clin Microbiol 1995;\n33(11):2868-2871.\n578. CDC. Guidelines for the Control of Pertussis Outbreaks. Atlanta, GA. U.S. Department\nof Health and Human Services, CDC, 2002. Available at\nhttm://www.cdc.gov/nip/publications/pertussis/guide.htm.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 689,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_690",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "httm://www.cdc.gov/nip/publications/pertussis/guide.htm.\n579. Grimprel E, Begue P, Anjak I, Betsou F, Guiso N. Comparison of polymerase chain\nreaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection.\nJ Clin Microbiol 1993; 31(10):2745-2750.\n580. Mastrantonio P, Stefanelli P, Giuliano M. Polymerase chain reaction for the detection of\nBordetella pertussis in clinical nasopharyngeal aspirates. J Med Microbiol 1996; 44(4):261-266.\n581. Edelman K, Nikkari S, Ruuskanen O, He Q, Viljanen M, Mertsola J. Detection of\nBordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-\ntreated infants with pertussis. Ped Infect Dis J 1996; 15(1):54-57.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 690,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_691",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "treated infants with pertussis. Ped Infect Dis J 1996; 15(1):54-57.\n582. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of\nBordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with\nculture and serology using samples from patients with suspected whooping cough from a highly\nimmunized population. J Infect Dis 1996; 174(1):89-96.\n583. Lievano FA, Reynolds MA, Waring AL, et al. Issues associated with and\nrecommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 2002;\n40(8):2801-2805.\n584. Meade BD, Bollen A. Recommendations for use of the polymerase chain reaction in the\n142\ndiagnosis of Bordetella pertussis infections. J Med Microbiol 1994; 41(1):51-55.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 691,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_692",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "142\ndiagnosis of Bordetella pertussis infections. J Med Microbiol 1994; 41(1):51-55.\n585. Wirsing von Konig CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a\nsingle-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin\nMicrobiol Infect Dis 1999; 18(5):341-345.\n586. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991:\nIncidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169(6):1297-1305.\n587. Aintablian N, Walpita P, Sawyer MH. Detection of Bordetella pertussis and respiratory\nsyncytial virus in air samples from hospital rooms. Infect Control Hosp Epidemiol 1998;\n19(12):918-923.\n588. CDC. Recommended childhood immunization schedule--United States, 2002. MMWR\n2002; 51:574.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 692,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_693",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "588. CDC. Recommended childhood immunization schedule--United States, 2002. MMWR\n2002; 51:574.\n589. CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young\nchildren.  Recommendations of the Advisory Committtee on Immunization Practices (ACIP).\nMMWR 1997; 46(No. RR-7).\n590. Edwards KM, Decker MD, Graham BS, Mezzatesta J, Scott J, Hackett J. Adult\nimmunization with acellular pertussis vaccine. JAMA 1993; 269(1):53-56.\n591. Aoyama T, Harashima M, Nishimura K, Saito Y. Outbreak of pertussis in highly\nimmunized adolescents and its secondary spread to their families. Acta Paediatrica Japonica 1995;\n37(3):321-324.\n592. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10-year\ncommunity study. Brit Med J 1988; 296:612-614.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 693,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_694",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "community study. Brit Med J 1988; 296:612-614.\n593. Gardner P. Indications for acellular pertussis vaccines in adults: the case for selective,\nrather than universal, recommendations. Clin Infect Dis 1999; 28(suppl 2):S131-S135.\n594. Linnemann CC, Jr., Ramundo N, Perlstein PH, Minton SD, Englender GS. Use of\npertussis vaccine in an epidemic involving hospital staff. Lancet 1975; 2:540-543.\n595. Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized,\nplacebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of\nchildren with culture-positive Bordetella pertussis infection. (Abstract). Pediatrics 1999;\n104(4):953.\n596. Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 694,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_695",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "104(4):953.\n596. Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the\nmanagement of persons exposed to pertussis. Epidemiology & Infection 1998; 120(2):143-149.\n597. Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis\n143\nafter pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999;\n354:2101-2105.\n598. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early\nexposures to erythromycin and infantile hypertrophic pyloric stenosis. Arch Ped Adol Med 2002;\n156(7):647-650.\n599. American Academy of Pediatrics. Pertussis. Red Book: Report of the Committee on\nInfectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 472-486.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 695,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_696",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 472-486.\n600. CDC. Diphtheria, tetanus, and pertussis: recommendations for vaccine and other\npreventive measures. Recommendations of the Advisory Committee on Immunization Practices.\nMMWR 1991; 40(No. RR-10):1-28.\n601. Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of\nerythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis\ninfection. Pediatrics 1997; 100(1):65-71.\n602. Hoppe JE, Bryskier A. In vitro susceptibilities of Bordetella pertussis and Bordetella\nparapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin,\nclarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 696,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_697",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and\nrifapentine). Antimicrob Agents Chemother 1998; 42(4):965-966.\n603. Aoyama T, Sumakawa K, Iwata S, Takeuchi Y, Fuji R. Efficacy of short-term treatment\nof pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129(5):761-764.\n604. Bace A, Zrnic T, Begovac J, Kuzmanovic N, Culig J. Short-term treatment of pertussis\nwith azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999; 18(4):296-\n298.\n605. Hoppe JE, Halm U, Hagedorn HJ, Kraminer-Hagedorn A. Comparison of erythromycin\nethylsuccinate and co-trimoxazole for treatment of pertussis. Infection 1989; 17(4):227-231.\n606. Shefer A, Dales L, Nelson M, Werner B, Baron R, Jackson R. Use and safety of acellular",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 697,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_698",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "606. Shefer A, Dales L, Nelson M, Werner B, Baron R, Jackson R. Use and safety of acellular\npertussis vaccine among adult hospital staff during an outbreak of pertussis. J Infect Dis 1995;\n171(4):1053-1056.\n607. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital\nepidemiology, diagnosis and treatment. Eur J Epidemiol 1989; 5(2):131-142.\n608. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered\nfrom a hospital water system: a three-year prospective study. Clin Infect Dis 2002; 34(6):780-789.\n609. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8(5):413-\n437.\n144\n610. Brown RS, Jr., Lake JR, Katzman BA, et al. Incidence and significance of Aspergillus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 698,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_699",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "437.\n144\n610. Brown RS, Jr., Lake JR, Katzman BA, et al. Incidence and significance of Aspergillus\ncultures following liver and kidney transplantation. Transplantation 1996; 61(4):666-669.\n611. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma\npatients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp\nEpidemiol 1993; 14(3):131-139.\n612. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of\ninvasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC\nInvasive Fungal Infections Cooperative Group. J Infect 1998; 37(2):173-180.\n613. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 699,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_700",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "613. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in\npatients with leukemia over a twenty-year period. Infect Control Hosp Epidemiol 1989; 10(7):299-\n305.\n614. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious\ncomplications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993;\n153(17):2010-2016.\n615. Lortholary O, Ascioglu S, Moreau P, et al. Invasive aspergillosis as an opportunistic\ninfection in nonallografted patients with multiple myeloma. A European Organization for Research\nand Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe\nFrancais du Myelome. Clin Infect Dis 2000; 30(1):41-46.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 700,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_701",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Francais du Myelome. Clin Infect Dis 2000; 30(1):41-46.\n616. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive\ndisease in AIDS: review of 342 cases. Chest 1998; 114(1):251-262.\n617. Pannuti CS, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in\npatients having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992;\n69(11):2653-2662.\n618. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;\n78(2):123-138.\n619. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial\nAspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987;\n83(4):709-718.\n620. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 701,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_702",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "83(4):709-718.\n620. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive\nAspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis 1993; 12(8):673-\n682.\n621. Williamson ECM, Millar MR, Steward CG, et al. Infections in adults undergoing\nunrelated bone marrow transplantation. Br J Haematol 1999; 104(3):560-568.\n145\n622. Woitas RP, Rockstroh JK, Theisen A, Leutner C, Sauerbruch T, Spengler U. Changing\nrole of invasive aspergillosis in AIDS--a case control study. J Infect 1998; 37(2):116-122.\n623. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis: the spectrum\nof the disease in 98 patients. Medicine 1970; 49(2):147-173.\n624. Mouy R, Fischer A, Vilner E, Seger R, Griscelli C. Incidence, severity, and prevention of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 702,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_703",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "624. Mouy R, Fischer A, Vilner E, Seger R, Griscelli C. Incidence, severity, and prevention of\ninfections in chronic granulomatous disease. J Pediatr 1989; 114(4 Pt 1):555-560.\n625. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH, Jr.\nInvasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect\nDis 1983; 148(2):230-238.\n626. Arnow PM, Anderson RL, Mainous PD, Smith EJ. Pulmonary aspergillosis during\nhospital renovation. Am Rev Respir Dis 1978; 118(1):49-53.\n627. Hopkins CC, Weber DJ, Rubin RH. Invasive aspergillosis infection: possible non-ward\ncommon source within the hospital environment. J Hosp Infect 1989; 13(1):19-25.\n628. Leenders A, van Belkum A, Janssen S, et al. Molecular epidemiology of apparent",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 703,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_704",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "628. Leenders A, van Belkum A, Janssen S, et al. Molecular epidemiology of apparent\noutbreak of invasive aspergillosis in a hematology ward. J Clin Microbiol 1996; 34(2):345-351.\n629. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic\nstem cell tansplant recipients: changes in epidemiology and risk factors. Blood 2002;\n100(13):4358-4366.\n630. Rhame FS. Lessons from the Roswell Park bone marrow transplant aspergillosis\noutbreak. Infect Control 1985; 6(9):345-346.\n631. Rotstein C, Cummings KM, Tidings J, et al. An outbreak of invasive aspergillosis among\nallogeneic bone marrow transplants: a case-control study. Infect Control 1985; 6(9):347-355.\n632. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 704,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_705",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "632. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac\ntransplantation. Report of five cases. Arch Intern Med 1971; 128(4):541-545.\n633. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS.\nAspergillosis in 25 renal transplant patients. Epedemiology, clinical presentation, diagnosis, and\nmanagement. Ann Surg 1983; 198(5):622-629.\n634. Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious\ncomplications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern\nMed 1987; 106(2):209-216.\n635. Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. Respiratory\ncomplications of cardiac transplantation. Am J Med Sci 1988; 296(1):10.\n146",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 705,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_706",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "complications of cardiac transplantation. Am J Med Sci 1988; 296(1):10.\n146\n636. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients\nin the 1990s. Transplantation 1997; 64(5):716-720.\n637. Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients.\nTransplantation 1985; 40(4):347-353.\n638. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis:\nreview of 2,121 published cases. Rev Infect Dis 1990; 12(6):1147-1201.\n639. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult\npatients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991; 9(1):77-84.\n640. Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 706,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_707",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "640. Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic\nanemia and the emergence of Aspergillus as a major cause of death. Medicine 1992; 71(1):24-43.\n641. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8(5):413-\n437.\n642. Orr DP, Myerowitz RL, Dubois PJ. Patho-radiologic correlation of invasive pulmonary\naspergillosis in the compromised host. Cancer 1978; 41(5):2028-2039.\n643. Meyer RD, Young LS, Armstrong D, Yu V. Aspergillosis complicating neoplastic\ndisease. Am J Med 1973; 54(1):6-15.\n644. Aisner J, Murillo J, Schimpff SC, Steere AC. Invasive aspergillosis in acute leukemia:\ncorrelation with nose cultures and antibiotic use. Ann Intern Med 1979; 90(1):4-9.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 707,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_708",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "correlation with nose cultures and antibiotic use. Ann Intern Med 1979; 90(1):4-9.\n645. Martino P, Raccah R, Gentile G, Venditti M, Girmenia C, Mandelli F. Aspergillus\ncolonization of the nose and pulmonary aspergillosis in neutropenic patients: a retrospective study.\nHaematologica 1989; 74(3):263-265.\n646. Richet HM, McNeil MM, Davis BJ, et al. Aspergillus fumigatus sternal wound infections\nin patients undergoing open heart surgery. Am J Epidemiol 1992; 135(1):48-58.\n647. Paradowski LJ. Saprophytic fungal infections and lung transplantation--revisited. J Heart\nLung Trransplantation 1997; 16(5):524-531.\n648. Latge JP. Apergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12(2):310-\n350.\n649. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 708,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_709",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "350.\n649. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged\ngranulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute\nleukemia. Ann Intern Med 1984; 100(3):345-351.\n650. Logan PM, Primack SL, Staples C, Miller RR, Muller NL. Acute lung disease in the\n147\nimmunocompromised host.  Diagnostic accuracy of the chest radiograph. Chest 1995;\n108(5):1283-1287.\n651. Kahn FW, Jones JM, England DM. The role of bronchoalveolar lavage in the diagnosis of\ninvasive pulmonary aspergillosis. Am J Clin Pathol 1986; 86(4):518-523.\n652. Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ. The value of\nbronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary\naspergillosis. Respir Med 1992; 86(3):243-248.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 709,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_710",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "aspergillosis. Respir Med 1992; 86(3):243-248.\n653. Pepys J, Riddell RW, Citron KM, Clayton YM, Short EI. Clinical and immunologic\nsignificance of Aspergillus fumigatus in the sputum. Am Rev Respir Dis 1959; 80:167-180.\n654. Karam GH, Griffin FMJr. Invasive pulmonary aspergillosis in nonimmunocompromised,\nnon-neutropenic hosts. Rev Infect Dis 1986; 8(3):357-363.\n655. Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the\nrespiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year\nprospective study. Am J Med 1986; 81(2):249-254.\n656. Kammer RB, Utz JP. Aspergillus species endocarditis. The new face of a not so rare\ndisease. Am J Med 1974; 56(4):506-521.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 710,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_711",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "disease. Am J Med 1974; 56(4):506-521.\n657. Graham NJ, Muller NL, Miller RR, Sheperd JD. Intrathoracic complications following\nallogeneic bone marrow transplantation: CT findings. Radiology 1991; 181(1):153-156.\n658. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary\naspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.\nJ Clin Oncol 1997; 15(1):139-147.\n659. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute\nleukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.\nRadiology 1985; 157(3):611-614.\n660. Pasmans HLM, Loosveld OJL, Schouten HC, Thunnissen F, van Engelshoven JM.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 711,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_712",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "660. Pasmans HLM, Loosveld OJL, Schouten HC, Thunnissen F, van Engelshoven JM.\nInvasive aspergillosis in immunocompromised patients: findings on plain film and (HR)CT. Eur J\nRadiol 1992; 14(1):37-40.\n661. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. CT of invasive pulmonary\naspergillosis in children with cancer. Pediatr Radiol 1993; 23(3):177-180.\n662. Tomee JF, Mannes GP, van der Bij W, et al. Serodiagnosis and monitoring of Aspergillus\ninfections after lung transplantation. Ann Intern Med 1996; 125(3):197-201.\n663. Dupont B, Huber M, Kim SJ, Bennett JE. Galactomannan antigenemia and antigenuria in\n148\naspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 1987; 155(1):1-\n11.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 712,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_713",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "11.\n664. Fujita S, Matsubara F, Matsuda T. Demonstration of antigenemia in patients with\ninvasive aspergillosis by biotin-streptavidin enzyme-linked immunosorbent assay. J Lab Clin Med\n1988; 112(4):464-470.\n665. Patterson TF, Miniter P, Patterson JE, Rappeport JM, Andriole VT. Aspergillus antigen\ndetection in the diagnosis of invasive aspergillosis. J Infect Dis 1995; 171(6):1553-1558.\n666. Bretagne S, Marmorat-Khuong A, Kuentz M, Latge JP, Bart-Delabesse E, Cordonnier C.\nSerum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic\npatients. J Infect 1997; 35(1):7-15.\n667. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked\nimmunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 713,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_714",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive\naspergillosis. Pediatr Infect Dis J 1996; 15(3):232-237.\n668. Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and\nlatex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis.\nEur J Clin Microbiol Infect Dis 1996; 15(2):139-145.\n669. Verweij PE, Stynen D, Rijs AJMM, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF.\nSandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for\ndiagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995;\n33(7):1912-1914.\n670. Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 714,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_715",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "670. Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one\nantigen test for the diagnosis of invasive aspergillosis. Mycoses 1996; 39:13-23.\n671. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology\nlaboratory. Transplant Infect Dis 2002; 4(Suppl 3):32-37.\n672. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and\nmanagement of aspergillosis in bone marrow transplantations: 13 years' experience. Clin Infect Dis\n1993; 17(3):397-404.\n673. Wingard JR, Beals SU, Santos GW, Mertz WG, Saral R. Aspergillus infections in bone\nmarrow transplant recipients. Bone Marrow Transplant 1987; 2(2):175-181.\n674. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 715,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_716",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "674. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive\naspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28(2):322-330.\n675. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone\nmarrow transplant patients at a university hospital. Bone Marrow Transpl 2002; 29(1):15-19.\n149\n676. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus\ninfections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;\n175(6):1459-1466.\n677. Nunley DR, Ohori NP, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung\ntransplant recipients. Chest 1998; 114(5):1321-1329.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 716,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_717",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "transplant recipients. Chest 1998; 114(5):1321-1329.\n678. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar\nair-flow isolation. J Hosp Infect 1989; 14(2):89-94.\n679. Krasinski K, Holzman RS, Hanna B, Greco MA, Graff M, Bhogal M. Nosocomial fungal\ninfection during hospital renovation. Infect Control 1985; 6(7):278-282.\n680. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial\naspergillosis: a retrospective review of airborne disease secondary to road construction and\ncontaminated air conditioners. Am J Epidemiol 1982; 116(3):430-437.\n681. Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial\naspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17(6):360-\n364.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 717,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_718",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17(6):360-\n364.\n682. Rhame FS, Streifel A, Kersey JH, Jr., McGlave PB. Extrinsic risk factors for pneumonia\nin the patient at high risk of infection. Am J Med 1984; 76:42-52.\n683. Sarubbi FA, Jr., Kopf HB, Brejetta Wilson M, McGinnis MR, Rutala WA. Increased\nrecovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev\nRespir Dis 1982; 125(1):33-38.\n684. Streifel AJ, Lauer JL, Vesley D, Juni B, Rhame FS. Aspergillus fumigatus and other\nthermotolerant fungi generated by hospital building demolition. Appl Environ Microbiol 1983;\n46(2):375-378.\n685. Weems JJ, Jr., Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 718,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_719",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "685. Weems JJ, Jr., Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an\nindependent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic\nmalignancy. Infect Control 1987; 8(2):71-75.\n686. Gage AA, Dean DC, Schimert G, Minsley M. Aspergillus infection after cardiac surgery.\nArch Surg 1970; 101(3):384-387.\n687. Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus\ncompared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998;\n36(3):165-168.\n688. Leenders AC, van Belkum A, Behrendt M, Luijendijk AD, Verbrugh HA. Density and\nmolecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection.\n150\nJ Clin Microbiol 1999; 37(6):1752-1757.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 719,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_720",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "150\nJ Clin Microbiol 1999; 37(6):1752-1757.\n689. Buffington J, Reporter R, Lasker BA, et al. Investigation of an epidemic of invasive\naspergillosis: utility of molecular typing with the use of random amplified polymorphic DNA\nprobes. Pediatr Infect Dis J 1994; 13(5):386-393.\n690. Debeaupuis JP, Sarfati J, Chazalet V, Latge JP. Genetic diversity among clinical and\nenvironmental isolates of Aspergillus fumigatus. Infect Immun 1997; 65(8):3080-3085.\n691. Keller NP, Cleveland TE, Bhatnagar D. Variable electrophoretic karyotypes of members\nof Aspergillus flavi.  Curr Genet 1992; 21:371-375.\n692. Chazalet V, Debeaupuis JP, Sarfati J, et al. Molecular typing of environmental and\npatient isolates of Aspergillus fumigatus from various hospital settings. J Clin Microbiol 1998;\n36(6):1494-1500.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 720,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_721",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "36(6):1494-1500.\n693. Denning DW, Clemons KV, Hanson LH, Stevens DA. Restriction endonuclease analysis\nof total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically\ndiverse origin. J Infect Dis 1990; 162(5):1151-1158.\n694. VanderBergh MF, Verweij PE, Voss A. Epidemiology of nosocomial fungal infections:\ninvasive aspergillosis and the environment. Diag Microbiol Infect Dis 1999; 34(3):221-227.\n695. Lass-Flörl C, Rath P, Niederwieser D, et al. Aspergillus terreus infections in\nhaematological malignancies: Molecular epidemiology suggests association with in-hospital plants.\nJ Hosp Infect 2000; 46:31-35.\n696. Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 721,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_722",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "696. Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant\nrecipients. A prospective study. Ann Intern Med 1978; 89(6):893-901.\n697. Hahn T, Cummings KM, MIchaels AM, Lipman BJ, Segal BH, McCarthy PLJ. Efficacy\nof high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised\npatients with hematologic malignancies. Infect Control Hosp Epidemiol 2002; 23:525-531.\n698. Levine AS, Siegel SE, Schreiber AD, et al. Protected environments and prophylactic\nantibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl\nJ Med 1973; 288(10):477-483.\n699. Murray WA, Streifel AJ, O'Dea TJ, Rhoades ER, Rhame FS. Ventilation for protection",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 722,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_723",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "699. Murray WA, Streifel AJ, O'Dea TJ, Rhoades ER, Rhame FS. Ventilation for protection\nof immune compromised patients. ASHRAE Transactions 1988; 94:1185-1191.\n700. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in\nneutropenic patients during hospital construction: before and after chemoprophylaxis and\ninstitution of HEPA filters. Am J Hematol 2001; 66(4):257-262.\n151\n701. Perry S, Penland WZ. The portable laminar flow isolator: new unit for patient protection\nin a germ-free environment. In: Mathe G, editor. Recent Results in Cancer Research. New York,\nN.Y.: Springer-Verlag, 1970: 35-40.\n702. Rice N, Streifel A, Vesley D. An evaluation of hospital special-ventilation-room\npressures. Infect Control Hosp Epidemiol 2001; 22(1):19-23.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 723,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_724",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pressures. Infect Control Hosp Epidemiol 2001; 22(1):19-23.\n703. Streifel AJ, Vesley D, Rhame FS, Murray B. Control of airborne fungal spores in a\nuniversity hospital. Environment International 1989; 12:441-444.\n704. Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an\noutbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit.\nInfect Control Hosp Epidemiol 2000; 21(1):18-23.\n705. Walsh TR, Guttendorf J, Dummer S, et al. The value of protective isolation procedures in\ncardiac transplant recipients. Ann Thorac Surg 1989; 47(4):539-544.\n706. Streifel AJ. Design and maintenance of hospital ventilation systems and the prevention of\nairborne nosocomial infections. In: Mayhall CG, editor. Hospital Epidemiology and Infection",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 724,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_725",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "airborne nosocomial infections. In: Mayhall CG, editor. Hospital Epidemiology and Infection\nControl. Philadelphia, PA.: Lippincott Williams & Wilkins, 1999: 1211-1221.\n707. Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis\nClin N Am 1995; 9(4):823-847.\n708. Petersen FB, Buckner CD, Clift RA, et al. Infectious complications in patients\nundergoing marrow transplantation: a prospective randomized study of the additional effect of\ndecontamination and laminar air flow isolation among patients receiving prophylactic systemic\nantibiotics. Scand J Infect D 1987; 19(5):559-567.\n709. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in\npatients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 725,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_726",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial\neffect of a protected environment. N Engl J Med 1983; 308(6):302-307.\n710. Streifel AJ, Marshall JW. Parameters for ventilation controlled environments in hospitals.\nIn: Design, Construction and Operation of Healthy Buildings Conference. IAQ/1997.  1998.\nAtlanta,GA., ASHRAE Press. 1998. \n711. Rhame FS. Nosocomial aspergillosis: how much protection for which patients? Infect\nControl Hosp Epidemiol 1989; 10(7):296-298.\n712. Carter CD, Barr BA. Infection control issues in construction and renovation. Infect\nControl Hosp Epidemiol 1997; 18(8):587-596.\n713. Vesley D, Streifel AJ. Environmental Services. In: Mayhall CG, editor. Hospital",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 726,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_727",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "713. Vesley D, Streifel AJ. Environmental Services. In: Mayhall CG, editor. Hospital\nEpidemiology and Infection Control. Philadelphia, PA.: Lippincott Williams & Wilkins, 1999:\n152\n1047-1053.\n714. Anderson K, Morris G, Kennedy H, et al. Aspergillosis in immunocompromised\npaediatric patients: associations with building hygiene, design, and indoor air. Thorax 1996;\n51(3):256-261.\n715. Raad I, Hanna H, Osting C, et al. Masking of neutropenic patients on transport from\nhospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect\nControl Hosp Epidemiol 2002; 23(1):41-43.\n716. Centers for Disease Control and Prevention. Laboratory performance evaluation of N95\nfiltering facepiece respirators, 1996. MMWR 1998; 47(48):1045-1049.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 727,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_728",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "filtering facepiece respirators, 1996. MMWR 1998; 47(48):1045-1049.\n717. Opal SM, Asp AA, Cannady PB, Jr., Morse PL, Burton LJ, Hammer PG. Efficacy of\ninfection control measures during a nosocomial outbreak of disseminated aspergillosis associated\nwith hospital construction. J Infect Dis 1986; 153(3):634-637.\n718. Gubbins PO, Bowman JL, Penzak SR. Antifungal prophylaxis to prevent invasive\nmycoses among bone marrow transplantation recipients. Pharmacotherapy 1998; 18(3):549-564.\n719. Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized placebo-controlled trial of\nitraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000;\n30(2):300-305.\n720. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 728,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_729",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "30(2):300-305.\n720. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis\nagainst invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;\n91(5):484-492.\n721. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid\norgan transplant recipients and implications for prophylaxis in lung transplants. Transplant Infect\nDis 2002; 4(4):195-200.\n722. Riley DK, Pavia ST, Beatty PG, Petersen FB, Spruance JL, stokes R et al. The\nprophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;\n97:509-514.\n723. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the\nprophylaxis of fungal infection in neutropenic patients: a randomised, double-blind, placebo-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 729,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_730",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "prophylaxis of fungal infection in neutropenic patients: a randomised, double-blind, placebo-\ncontrolled study. Bone Marrow Transplant 1999; 23(2):163-168.\n724. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin\nB as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transpl\n1990; 5(6):403-406.\n725. Tsourounis C, Guglielmo BJ. Aerosolized amphotericin B in prophylaxis of pulmonary\n153\naspergillosis. Ann Pharmacother 1996; 30(10):1175-1176.\n726. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as\nprophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a\nprospective randomized multicenter trial. Blood 1999; 93(11):3654-3661.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 730,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_731",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "prospective randomized multicenter trial. Blood 1999; 93(11):3654-3661.\n727. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for\nprimary prophylaxis of fungal infections in patients with hematological malignancy and profound\nneutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole\nand amphoteticin B. Antimicrob Agents Chemother 2000; 44(7):1887-1893.\n728. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A\nrandomized controlled trial of itraconazole versus fluconazole for the prevention of fungal\ninfections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis\nStudy Group. Br J Haematol 1999; 105(4):901-911.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 731,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_732",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Study Group. Br J Haematol 1999; 105(4):901-911.\n729. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal\nprophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-\ncontrolled clinical trials. Cancer 2002; 94(12):3230-3246.\n730. Gotzsche PC, Krogh Johansen H. Meta-analysis of prophylactic or empirical antifungal\ntreatment versus placebo or no treatment in patients with cancer complicated by neutropenia. Brit\nMed J 1997; 314:1238-1244.\n731. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the\noutcome of bone marrow transplantation. Clin Infect Dis 1998; 26(5):1098-1103.\n732. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A. Risk of reactivation of a",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 732,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_733",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "732. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A. Risk of reactivation of a\nrecent invasive fungal infection in patients with hematological malignancies undergoing further\nintensive chemo-radiotherapy. A single-center experience and review of the literature.\nHaematologica 1997; 82(3):297-304.\n733. Michailov G, Laporte JP, Lesage S, et al. Autologous bone-marrow transplantation is\nfeasible in patients with prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant\n1996; 17(4):569-572.\n734. Richard C, Romon I, Baro J, et al. Invasive pulmonary aspergillosis prior to BMT in\nacute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 1993;\n12(3):237-241.\n735. Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 733,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_734",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "735. Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients\nwith previous invasive aspergillosis. Am J Med 1988; 85(2):203-206.\n736. Lupinetti FM, Behrendt DM, Giller RH, Trigg ME, de Alarcon P. Pulmonary resection\nfor fungal infection in children undergoing bone marrow transplantation. J Thoracic Cardiovasc\n154\nSurg 1992; 104(3):684-687.\n737. Welliver RC, McLaughlin S. Unique epidemiology of nosocomial infections in a\nchildren's hospital. Am J Dis Child 1984; 138(2):131-135.\n738. Valenti WM, Hall CB, Douglas RG, Jr., Menegus MA, Pincus PH. Nosocomial viral\ninfections: I. Epidemiology and significance. Infect Control 1980; 1:33-37.\n739. Goldwater PN, Martin AJ, Ryan B, et al. A survey of nosocomial respiratory viral",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 734,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_735",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "739. Goldwater PN, Martin AJ, Ryan B, et al. A survey of nosocomial respiratory viral\ninfections in a children's hospital: occult respiratory infection in patients admitted during an\nepidemic season. Infect Control Hosp Epidemiol 1991; 12(4):231-238.\n740. Raymond JT, Aujard Y, European Study Group. Nosocomial infections in pediatric\npatients: a European, multicenter prospective study. Infect Control Hosp Epidemiol 2000;\n21(4):260-263.\n741. Krasinski K. Severe respiratory syncytial virus infection: clinical features, nosocomial\nacquisition and outcome. Pediatr Infect Dis 85 A.D.; 4(3):250-257.\n742. Meissner HC, Murray SA, Kiernan MA, Snydman DR, McIntosh K. A simultaneous\noutbreak of respiratory syncytial virus and Parainfluenza virus type 3 in a newborn nursery. J",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 735,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_736",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "outbreak of respiratory syncytial virus and Parainfluenza virus type 3 in a newborn nursery. J\nPediatr 1984; 104(5):680-684.\n743. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial virus infection in\nchildren with compromised immune function. N Engl J Med 1986; 315(2):77-81.\n744. Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and Influenza A\ninfections in the institutionalized elderly and chronically ill. Ann Intern Med 980; 93(1):49-52.\n745. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory\nsyncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307(7):397-\n400.\n746. Drescher J, Zink P, Verhagen W, Flik J., Milbradt H. Recent Influenza virus A infections",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 736,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_737",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "400.\n746. Drescher J, Zink P, Verhagen W, Flik J., Milbradt H. Recent Influenza virus A infections\nin forensic cases of sudden unexplained death. Virology 1987; 92(1-2):63-76.\n747. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial\nvirus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach\nand review of the literature. Medicine 1989; 68(5):269-281.\n748. Baron RC, Dicker RC, Bussell KE, Herndon JL. Assessing trends in mortality in 121\nU.S. cities, 1970-1979, from all causes and from pneumonia and influenza. Public Health Rep\n1988; 103(2):120-128.\n749. Krasinski K, LaCouture R, Holzman RS, Waithe E, Bonk S, Hanna B. Screening for\n155\nrespiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 737,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_738",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "155\nrespiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial\ntransmission. J Pediatr 1990; 116(6):894-898.\n750. Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in\nthe immunocompromised host. Am J Med 1997; 102(3A):48-52.\n751. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the\nelderly: an assessment of disease burden. J Infect Dis 1999; 179(1):25-30.\n752. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia\nin the hospital setting: length of stay, charges, and mortality. J Pediatr 2000; 137:227-232.\n753. Todd J, Bertoch D, Dolan S. Use of a large national database for comparative evaluation",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 738,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_739",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "753. Todd J, Bertoch D, Dolan S. Use of a large national database for comparative evaluation\nof the effect of a bronchiolitis/viral pneumonia clinical care guideline on patient outcome and\nresource utilization. Arch Pediatr 2002; 156(11):1086-1090.\n754. Hall CB. Nosocomial respiratory syncytial virus infections: the \"Cold War\" has not\nended. Clin Infect Dis 2000; 31(2):590-596.\n755. Hall CB. Nosocomial viral respiratory infections: perennial weeds on pediatric wards. Am\nJ Med 1981; 70(3):670-676.\n756. Glezen WP. Viral pneumonia as a cause and result of hospitalization. J Infect Dis 1983;\n147(4):765-770.\n757. Wenzel RP, Deal EC, Hendley JO. Hospital-acquired viral respiratory illness on a\npediatric ward. Pediatrics 1977; 60(3):367-371.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 739,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_740",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pediatric ward. Pediatrics 1977; 60(3):367-371.\n758. Hall CB. Hospital-acquired pneumonia in children: the role of respiratory viruses.\nSeminars Respir Infect 1987; 2(1):48-56.\n759. Glezen WP, Loda FA, Clyde WA, Jr., et al. Epidemiologic patterns of acute lower\nrespiratory diseases in pediatric group practice. J Pediatr 1971; 78(3):397-406.\n760. Finger R, Anderson LJ, Dicker RC, et al. Epidemic infections caused by respiratory\nsyncytial virus in institutionalized young adults. J Infect Dis 1987; 155(6):1335-1339.\n761. Hall WJ, Hall CB, Speers DM. Respiratory syncytial virus infection in adults: clinical,\nvirologic, and serial pulmonary function studies. Ann Intern Med 1978; 88(2):203-205.\n762. Englund JA, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 740,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_741",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "762. Englund JA, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial\nvirus infection in immunocompromised adults. J Clin Microbiol 1991; 29(1):115-119.\n763. Falsey AR, Walsh EE, Betts RF. Serologic evidence of respiratory syncytial virus\ninfection in nursing home patients. J Infect Dis 1990; 162(2):568-569.\n156\n764. Beekmann SE, Engler HD, Collins AS, Canosa J, Henderson DK, Freifeld A. Rapid\nidentification of respiratory viruses: impact on isolation practices and transmission among\nimmunocompromised pediatric patients. Infect Control Hosp Epidemiol 1996; 17(9):581-586.\n765. Hall CB, Douglas R.G. Jr. Nosocomial influenza infection as a cause of intercurrent\nfevers in infants. Pediatrics 1975; 55(5):673-677.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 741,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_742",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "fevers in infants. Pediatrics 1975; 55(5):673-677.\n766. Hall CB, Kopelman AE, Douglas RG, Jr., Geiman JM, Meagher MP. Neonatal\nrespiratory syncytial virus infection. N Engl J Med 1979; 300(8):393-396.\n767. Hall CB, Douglas RG, Jr., Geiman JM, Messner MK. Nosocomial respiratory syncytial\nvirus infections. N Engl J Med 1975; 293(26):1343-1346.\n768. Centers for Disease Control. Para-influenza outbreaks in extended-care facilities.\nMMWR 1978; 27:475-476.\n769. DeFabritus AM, Riggio RR, David DS, David DS, Senterfit LB, Cheigh JS et al.\nParainfluenza type 3 in a transplant unit. JAMA 1979; 241(4):384-386.\n770. Mufson MA, Mocega HE, Krause HE. Acquisition of Parainfluenza 3 virus infection by\nhospitalized children.  I. Frequencies, rates, and temporal data. J Infect Dis 1973; 128(2):141-147.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 742,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_743",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "771. Meyers JD, MacQuarrie MB, Merigan TC, Jennison MH. Nosocomial varicella. Part I:\noutbreak in oncology patients at a children's hospital. West J Med 1979; 130(3):196-199.\n772. Atkinson WL, Markowitz LE, Adams NC, Seastrom GR. Transmission of measles in\nmedical setting-- United States, 1985-1989. Am J Med 1991; 91(3B):320S-324S.\n773. Graman PS, Hall CB. Epidemiology and control of nosocomial viral infections. Infect Dis\nClin N Am 1989; 3(4):815-841.\n774. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations.\nPediatr Infect Dis J 2002; 21(7):629-632.\n775. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection\nwith respiratory syncytial virus. J Infect Dis 1991; 163(4):693-698.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 743,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_744",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "with respiratory syncytial virus. J Infect Dis 1991; 163(4):693-698.\n776. Henderson FW, Collier AM, Clyde WA, Jr., Denny FW. Respiratory syncytial virus\ninfections, reinfections and immunity: a prospective longitudinal study in young children. N Engl J\nMed 1979; 300(10):530-534.\n777. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus\ninfection in Washington, D.C. II. Infection and disease with respect to age, immunologic status,\nrace and sex. Am J Epidemiol 1973; 98(4):289-300.\n157\n778. Rabella N, Rodriguez P, Labeaga R, et al. Conventional respiratory viruses recovered\nfrom immunocompromised patients: clinical considerations. Clin Infect Dis 1999; 28(5):1043-\n1048.\n779. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 744,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_745",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1048.\n779. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections\namong hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22(5):778-782.\n780. Anderson LJ, Parker RA, Strikas RL. Association between respiratory syncytial virus\noutbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 1990;\n161(4):640-646.\n781. Brandt CD, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus in\nWashington, D.C. 3.Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol\n1973; 98(5):355-364.\n782. Hall CB. The nosocomial spread of respiratory syncytial viral infections. Ann Rev Med\n1983; 34:311-319.\n783. Kim HW, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncytial virus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 745,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_746",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "783. Kim HW, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncytial virus\ninfection in Washington, D.C. I. Importance of the virus in different respiratory tract disease\nsyndromes and temporal distribution of infection. Am J Epidemiol 1973; 98(3):216-225.\n784. Yun BY, Kim MR, Park JY, Choi EH, Lee HJ, Yun CK. Viral etiology and epidemiology\nof acute lower respiratory tract infections in Korean children. Pediatr Infect Dis 1995;\n14(12):1054-1059.\n785. Forster J, Schumacher RF. The clinical picture presented by premature neonates infected\nwith the respiratory syncytial virus. Eur J Pediatr 1995; 154(11):901-905.\n786. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza\nA infections in the hospitalized elderly. J Infect Dis 1995; 172(2):389-394.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 746,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_747",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "A infections in the hospitalized elderly. J Infect Dis 1995; 172(2):389-394.\n787. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent\nand immunocompromised persons. Am J Med 1997; 102(3A):2-9.\n788. Falsey AR, Walsh EE. Humoral immunity to respiratory syncytial virus infection in the\nelderly. J Med Virol 1992; 36(1):39-43.\n789. Falsey AR, McCann RM, Hall WJ, Criddle MM. Evaluation of four methods for the\ndiagnosis of respiratory syncytial virus infection in older adults. J Am Geriatric Soc 1996;\n44(1):71-73.\n790. Richardson LS, Yolken RH, Belshe RB, Camargo E, Kim HW, Chanock RM. Enzyme-\nlinked immunosorbent assay for measurement of serological response to respiratory syncytial virus\ninfection. Infect Immun 1978; 20(3):660-664.\n158",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 747,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_748",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "infection. Infect Immun 1978; 20(3):660-664.\n158\n791. Meurman O, Ruuskanen O, Sarkkinen H, Hanninen P, Halonen P. Immunoglobulin class-\nspecific antibody response in respiratory syncytial virus infection measured by enzyme\nimmunoassay. J Med Virol 1984; 14(1):67-72.\n792. Henkel JH, Aberle SW, Kundi M, Popow-Kraupp T. Improved detection of respiratory\nsyncytial virus in nasal aspirates by seminested RT-PCR. J Med Virol 1997; 53(4):366-371.\n793. Freymuth F, Vabret A, Galateau-Salle F, et al. Detection of respiratory syncytial virus,\nparainfluenza virus 3, adenovirus and rhinovirus sequences in respiratory tract of infants by\npolymerase chain reaction and hybridization. Clin Diagnostic Virol 1997; 8(1):31-40.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 748,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_749",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "polymerase chain reaction and hybridization. Clin Diagnostic Virol 1997; 8(1):31-40.\n794. vanElden LJ, van Kraaij MG, Nijhuis M, et al. Polymerase chain reaction is more snsitive\nthan viral culture and antigen testing in the detection of respiratory viruses in adults with\nhematological cancer and pneumonia. Clin Infect Dis 2002; 34(2):177-183.\n795. Navarro-Mari JM, Sanbonmatsu-Gamez S, Perez-Ruiz M, de la Rosa-Fraile M. Rapid\ndetection of respiratory viruses by shell vial assay using simultaneous culture of HEp-2, LLC-\nMK2, and MDCK cells in a single vial. J Clin Microbiol 1999; 37(7):2346-2347.\n796. Smith MC, Creutz C, Huang YT. Detection of respiratory syncytial virus in\nnasopharyngeal secretions by shell vial technique. J Clin Microbiol 1991; 29(3):463-465.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 749,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_750",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "nasopharyngeal secretions by shell vial technique. J Clin Microbiol 1991; 29(3):463-465.\n797. Kellogg JA. Culture vs direct antigen assays for detection of microbial pathogens from\nlower respiratory tract specimens suspected of containing the respiratory syncytial virus. Arch\nPathol Lab Med 1991; 115(5):451-458.\n798. Lipson SM, Popiolek D, Hu QZ, Falk LH, Bornfreund M, Krilov LR. Efficacy of\nDirectigen RSV testing in patient management following admission from a pediatric emergency\ndepartment. J Hosp Infect 1999; 41(4):323-329.\n799. Popow-Kraupp T, Kern G, Binder C, Tuma W, Kundi M, Kunz C. Detection of\nrespiratory syncytial virus in nasopharyngeal secretions by enzyme-linked immunosorbent assay,\nindirect immunofluorescence and virus isolation: a comparative study. J Med Virol 1986;",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 750,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_751",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "indirect immunofluorescence and virus isolation: a comparative study. J Med Virol 1986;\n19(2):123-134.\n800. Ray CG, Minnich LL. Efficiency of immunofluorescence for rapid detection of common\nrespiratory viruses. J Clin Microbiol 1987; 25(2):355-357.\n801. Waner JL, Whitehurst NJ, Todd SJ, Shalaby H, Wall LV. Comparison of directigen RSV\nwith viral isolation and direct immunofluorescence for the identification of respiratory syncytial\nvirus. J Clin Microbiol 1990; 28(3):480-483.\n802. Hall CB, Douglas RG, Jr. Modes of transmission of respiratory syncytial virus. J Pediatr\n1981; 99(1):100-103.\n159\n803. Hall CB, Douglas RG, Jr., Geiman JM. Possible transmission by fomites of respiratory\nsyncytial virus. J Infect Dis 1980; 141(1):98-102.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 751,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_752",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "syncytial virus. J Infect Dis 1980; 141(1):98-102.\n804. Hall CB, Douglas RG, Jr., Schnabel KC, Geiman JM. Infectivity of respiratory syncytial\nvirus by various routes of inoculation. Infect Immun 1981; 33(3):779-783.\n805. Mazzulli T, Peret TC, McGeer A, et al. Molecular characterization of a nosocomial\noutbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. J Infect Dis\n1999; 180(5):1686-1689.\n806. Storch GA, Park CS, Dohner DE. RNA fingerprinting of respiratory syncytial virus using\nribonuclease protection. Application to molecular epidemiology. J Clin Invest 1989; 83(6):1894-\n1902.\n807. Dowell SF, Anderson LJ, Gary HE, Jr., et al. Respiratory syncytial virus is an important",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 752,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_753",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1902.\n807. Dowell SF, Anderson LJ, Gary HE, Jr., et al. Respiratory syncytial virus is an important\ncause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis\n1996; 174(3):456-462.\n808. Hall CB, Douglas RG, Jr., Geiman JM. Respiratory syncytial virus infections in infants:\nquantitation and duration of shedding. J Pediatr 1976; 89(1):11-15.\n809. Hall CB, Douglas RG, Jr. Nosocomial respiratory syncytial viral infections. Should\ngowns and masks be used? Am J Dis Child 1981; 135(6):512-515.\n810. Snydman DR, Greer C, Meissner HC, McIntosh K. Prevention of nosocomial\ntransmission of respiratory syncytial virus in a newborn nursery. Infect Control Hosp Epidemiol\n1988; 9(3):105-108.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 753,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_754",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1988; 9(3):105-108.\n811. Murphy D, Todd JK, Chao RK, Orr I, McIntosh K. The use of gowns and masks to\ncontrol respiratory illness in pediatric hospital personnel. J Pediatr 1981; 99(5):746-750.\n812. Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection\nrate in personnel caring for children with RSV infections. Routine isolation procedure vs routine\nprocedure supplemented by use of masks and gowns. Am J Dis Child 1987; 141(6):695-697.\n813. Hall CB, Geiman JM, Douglas RG, Jr., Meagher MP. Control of nosocomial respiratory\nsyncytial viral infections. Pediatrics 1978; 62(5):728-732.\n814. Itano A, Sorvillo F. Infection control practices for Respiratory Syncytial Virus (RSV)\namong acute care hospitals in Los Angeles County. Am J Infect Control 1991; 19(2):107.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 754,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_755",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "among acute care hospitals in Los Angeles County. Am J Infect Control 1991; 19(2):107.\n815. Madge P, Paton JY, McColl JH, Mackie PL. Prospective controlled study of four\ninfection-control procedures to prevent nosocomial infection with respiratory syncytial virus.\nLancet 1992; 340:1079-1083.\n160\n816. Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial RSV infection in Canadian\npediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada study.\nPediatrics 1997; 100(6):943-946.\n817. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial\nrespiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control.\nPediatrics 2000; 106(3):520-526.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 755,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_756",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Pediatrics 2000; 106(3):520-526.\n818. Mackie PL, Joannidis PA, Beattie J. Evaluation of an acute point-of-care system\nscreening for respiratory syncytial virus infection. J Hosp Infect 2001; 48(1):66-71.\n819. Garcia R, Raad I, Abi-said D, et al. Nosocomial respiratory syncytial virus infections:\nprevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 1997;\n18(6):412-416.\n820. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, editor.\nThe Red Book 2003. Report of the Committee on Infectious Diseases. Elk Grove, IL: American\nAcademy of Pediatrics, 2003: 523-528.\n821. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 756,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_757",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "821. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection\nin high-risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis\nChild 2000; 83(4):313-316.\n822. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of RSVIG to high\nrisk infants and young children. N Engl J Med 1993; 329(21):1524-1530.\n823. Anonymous. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody,\nreduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-\nRSV Study Group. Pediatrics 1998; 102(3):531-537.\n824. Anonymous. Reduction of RSV hospitalization among premature infants and infants with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 757,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_758",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "824. Anonymous. Reduction of RSV hospitalization among premature infants and infants with\nbronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The\nPREVENT Study Group. Pediatrics 1997; 99(1):93-99.\n825. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of\nrespiratory syncytial virus infections: indications for the use of palivizumab and update on the use\nof RSV-IGIV. Pediatrics 1998; 102:1211-1216.\n826. Cox RA, Rao P, Brandon-Cox C. The use of palivizumab monoclonal antibody to control\nan outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect 2001;\n48 (3):186-192.\n827. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 758,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_759",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "827. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus\nimmunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;\n156(10):1034-1041.\n161\n828. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-\nneeded-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent\nhospitalization. Arch Pediatr Adolesc Med 1998; 152(4):358-366.\n829. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial\nvirus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Therapeutics 2000;\n22(11):1357-1369.\n830. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM,",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 759,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_760",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "830. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM,\nHowley PM, et al, editors. Virology. Philadelphia: Lippincott-Raven Publishers, 1996: 1205.\n831. Denny FW, Clyde WA, Jr. Acute lower respiratory tract infections in nonhospitalized\nchildren. J Pediatr 1986; 108(5):635-646.\n832. Holzel A, Parker L, Patterson W, et al. Virus isolations from throats of children admitted\nto hospital with respiratory and other diseases, Manchester 1962-4. Br Med J 1965; 1:614-619.\n833. Clarke SK. Parainfluenza virus infections. Postgrad Med J 1973; 49(577):792-797.\n834. Gardner PS, McQuillin J, McGuckin R, Ditchburn RK. Observations on clinical and\nimmunofluorescent dignosis of parainfluenza virus infections. Br Med J 1971; 2(752):7-12.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 760,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_761",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "immunofluorescent dignosis of parainfluenza virus infections. Br Med J 1971; 2(752):7-12.\n835. Marx A, Gary HE, Jr., Marston BJ, et al. Parainfluenza virus infection among adults\nhospitalized for lower respiratory tract infection. Clin Infect Dis 1999; 29(1):134-140.\n836. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical\nimpact of parainfluenza virus infections in otherwise healthy infants and young children <5 years\nold. J Infect Dis 1997; 175(4):807-813.\n837. Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson LJ. Pediatric hospitalizations for\ncroup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1\nepidemics. J Infect Dis 1997; 176(6):1423-1427.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 761,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_762",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "epidemics. J Infect Dis 1997; 176(6):1423-1427.\n838. Banatvala JE, Anderson TB, Reiss BB. Parainfluenza infections in the community. Br\nMed J 1964; 1:537-540.\n839. Fedova D, Novotny J, Kubinova I. Serological diagnosis of parainfluenza virus infections:\nverification of the sensitivity and specificity of the haemagglutination-inhibition (HI), complement\nfixation (CF), immunofluorescence (IFA) tests and enzyme immunoassay (ELISA). Acta Virol\n1992; 36(3):304-312.\n840. Korppi M, Halonen P, Kleemola M, Launiala K. Viral findings in children under the age\nof two years with expiratory difficulties. Acta Paediatr Scand 1986; 75(3):457-464.\n841. Karron RA, Froehlich JL, Bobo L, Belshe RB, Yolken RH. Rapid detection of\n162",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 762,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_763",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "841. Karron RA, Froehlich JL, Bobo L, Belshe RB, Yolken RH. Rapid detection of\n162\nParainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme\nimmunoassay. J Clin Microbiol 1994; 32(2):484-488.\n842. van Elden LJ, van Kraaij MG, Nijhuis M, et al. Polymerase chain reaction is more\nsensitive than viral culture and antigen testing in the detection of respiratory viruses in adults with\nhematological cancer and pneumonia. Clin Infect Dis 2002; 34(2):177-183.\n843. Foy HM. Adenoviruses. In: Evans AS, Kaslow RA, editors. Viral infections of humans:\nepidemiology and control. New York: Plenum, 1997: 119-138.\n844. Fox JP, Brandt CD, Wasserman FE, et al. The virus watch program: a continuing",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 763,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_764",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "844. Fox JP, Brandt CD, Wasserman FE, et al. The virus watch program: a continuing\nsurveillance of viral infections in metropolitan New York families. VI. Observations of adenovirus\ninfections: virus excretion patterns, antibody response, efficacy of surveillance, patterns of\ninfection, and relation to illness. Am J Epidemiol 1969; 89(1):25-50.\n845. Ruuskanen O, Meurman O, Akusjarvi G. Adenoviruses. In: Richman DD, Whitley RJ,\nHayden FG, editors. Clinical Virology. New York: Churchill Livingstone, 1997: 525-547.\n846. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM,\nHowley PM, editors. Fields Virology. Philadelphia: Lippincott-Raven, 1996: 2111.\n847. Larsen RA, Jacobson JT, Jacobson JA, Strikas JA, Hierholzer JC. Hospital-associated",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 764,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_765",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "847. Larsen RA, Jacobson JT, Jacobson JA, Strikas JA, Hierholzer JC. Hospital-associated\nepidemic of pharyngitis and conjunctivitis caused by Adenovirus (21/H21+35). J Infect Dis 1986;\n154(4):706-709.\n848. Herbert FA, Wilkinson D, Burchak E, Morgante O. Adenovirus type 3 pneumonia\ncausing lung damage in childhood. Can Med Assoc J 1977; 116(3):274-276.\n849. James AG, Lang WR, Liang AY, et al. Adenovirus type 21 bronchopneumonia in infants\nand young children. J Pediatr 1979; 95(4):530-533.\n850. Klinger JR, Sanchez MP, Curtin LA, Durkin M, Matyas B. Multiple cases of life-\nthreatening adenovirus pneumonia in a mental health care center. Am J Respir Crit Care Med\n1998; 157(2):645-649.\n851. Sanchez MP, Erdman DD, Torok TJ, Freeman CJ, Matyas BT. Outbreak of Adenovirus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 765,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_766",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "851. Sanchez MP, Erdman DD, Torok TJ, Freeman CJ, Matyas BT. Outbreak of Adenovirus\n35 pneumonia among adult residents and staff of a chronic care psychiatric facility. J Infect Dis\n1997; 176(3):760-763.\n852. Morris CA, Flewett TH, Bryden AS, Davies H. Epidemic viral enteritis in a long-stay\nchildren's ward. Lancet 1975; 1:4-5.\n853. Levandowski RA, Rubenis M. Nosocomial conjunctivitis caused by Adenovirus type 4. J\nInfect Dis 1981; 143(1):28-31.\n163\n854. Tabery HM. Two outbreaks of Adenovirus type 8 keratoconjunctivitis with different\noutcome. Acta Ophthalmol Scand 1995; 73(4):358-360.\n855. Greenberg SB. Viral pneumonia. Infect Dis Clin N Am 1991; 5(3):603-621.\n856. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992;\n5(3):262-274.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 766,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_767",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "5(3):262-274.\n857. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in\nimmunocompromised and immunocompetent children. Clin Infect Dis 1998; 27(5):1194-1200.\n858. Whimbey E, Bodey GP. Viral pneumonia in the immunocompromised adult with\nneoplastic disease: the role of common community respiratory viruses. Sem Resp Infect 1992;\n7(2):122-131.\n859. Graham NM. The epidemiology of acute respiratory infections in children and adults: a\nglobal perspective. Epidemiol Rev 1990; 12:149-178.\n860. Holladay RC, Campbell GD, Jr. Nosocomial viral pneumonia in the intensive care unit.\nClin Chest Med 1995; 16(1):121-133.\n861. Pingleton SK, Pingleton WW, Hill RH, Dixon A, Sobonya RE, Gertzen J. Type 3",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 767,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_768",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "861. Pingleton SK, Pingleton WW, Hill RH, Dixon A, Sobonya RE, Gertzen J. Type 3\nadenoviral pneumonia occuring in a respiratory intensive care unit. Chest 1978; 73(4):554-555.\n862. Alpert G, Charney E, Fee M, Plotkin SA. Outbreak of fatal adenoviral type 7a respiratory\ndisease in a children's long-term care inpatient facility. Am J Infect Control 1986; 14(4):188-190.\n863. Fee MA, Charney E, Plotkin SA, et al. Adenovirus type 7 outbreak in a pediatric chronic-\ncare facility- Pennsylvania, 1982. MMWR 1983; 32(19):258-260.\n864. Porter JD, Teter M, Traister V, Pizzutti W, Parkin WE, Farrell J. Outbreak of adenoviral\ninfections in a long-term paediatric facility, New Jersey, 1986/87. J Hosp Infect 1991; 18(3):201-\n210.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 768,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_769",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "210.\n865. Feikin DR, Moroney JF, Talkington DF, et al. An outbreak of acute respiratory disease\ncaused by Mycoplasma pneumonia and adenovirus at a federal service training academy: new\nimplications from an old scenario. Clin Infect Dis 1999; 29(6):1545-1550.\n866. Benenson AS, Chin J. Control of communicable diseases manual. Benenson AS, Chin J,\neditors. 16th, 109-111. 1995. Washington,D.C., American Public Health Association.\n867. Lehtomaki K, Julkunen I, Sandelin K, et al. Rapid diagnosis of respiratory adenovirus\ninfections in young adult men. J Clin Microbiol 1986; 24(1):108-111.\n868. Raty R, Kleemola M, Melen K, Stenvik M, Julkunen I. Efficacy of PCR and other\n164\ndiagnostic methods for the detection of respiratory adenovirus infections. J Med Virol 1999;\n59(1):66-72.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 769,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_770",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "59(1):66-72.\n869. Wigand R. Pitfalls in the identification of adenoviruses. J Virol Methods 1987;\n16(3):161-169.\n870. Elnifro EM, Cooper RJ, Klapper PE, Bailey AS. PCR and restriction endonuclease\nanalysis for rapid identification of human Adenovirus subgenera. J Clin Microbiol 2000;\n38(6):2055-2061.\n871. Venard V, Carret A, Corsaro D, Bordigoni P, Le Faou A. Genotyping of adenoviruses\nisolated in an outbreak in a bone marrow transplant unit shows that diverse strains are involved. J\nHosp Infect 2000; 44(1):71-74.\n872. Singh-Naz N, Brown M, Ganeshananthan M. Nosocomial adenovirus infection:\nmolecular epidemiology of an outbreak. Pediatr Infect Dis 1993; 12(11):922-925.\n873. Buehler JW, Finton RJ, Goodman RA, et al. Epidemic keratoconjunctivitis: report of an",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 770,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_771",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "873. Buehler JW, Finton RJ, Goodman RA, et al. Epidemic keratoconjunctivitis: report of an\noutbreak in an ophthalmology practice and recommendations for prevention. Infect Control 1984;\n5(8):390-394.\n874. Insler MS, Kern MD. Keratoconjunctivitis due to Adenovirus type 8: a local outbreak.\nSouth Med J 1989; 82(2):159-160.\n875. Keenlyside RA, Hierholzer JC, D'Angelo LJ. Keratoconjunctivitis associated with\nAdenovirus type 37: an extended outbreak in an ophthalmologist's office. J Infect Dis 1983;\n147(2):191-198.\n876. Koo D, Courtwright P, Reingold AL, et al. Epidemiologic Notes and Reports Epidemic\nkeratoconjunctivitis in an ophthalmology clinic--California. MMWR 1990; 39(35):598-601.\n877. Couch RB, Cate TR, Fleet WF, Gerone PJ, Knight V. Aerosol-induced adenovirus illness",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 771,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_772",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "877. Couch RB, Cate TR, Fleet WF, Gerone PJ, Knight V. Aerosol-induced adenovirus illness\nresembling the naturally occurring illness in military recruits. Am Rev Respir Dis 1966; 93(4):529-\n535.\n878. D'Angelo LJ, Hierholzer JC, Keenlyside RA, Anderson LJ, Martone WJ.\nPharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related\noutbreak with recovery of virus from pool water. J Infect Dis 1979; 140(1):42-47.\n879. Harnett GB, Newnham WA. Isolation of Adenovirus type 19 from the male and female\ngenital tracts. Br J Venereal Dis 1981; 57(1):55-57.\n880. Nakanishi AK, Soltau JB. Common viral infections of the eye. Pediatr Ann 1996;\n25(10):542,546,550-544,547.\n165\n881. Rubin BA. Clinical picture and epidemiology of adenovirus infections (a review). Acta",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 772,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_773",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "165\n881. Rubin BA. Clinical picture and epidemiology of adenovirus infections (a review). Acta\nMicrobiol Hung 1993; 40(4):303-323.\n882. Wright SA, Bieluch VM. Selected nosocomial viral infections. Heart Lung 1993;\n22(2):183-187.\n883. Gordon YJ, Gordon RY, Romanowski EG, Araullo-Cruz TP. Prolonged recovery of\ndessicated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro.\nOphthalmology 1993; 100(12):1839-1840.\n884. Nauheim RC, Romanowski EG, Araullo-Cruz TA, et al. Prolonged recoverability of\ndessicated Adenovirus type 19 from various surfaces. Ophthalmology 1990; 97(11):1450-1453.\n885. Kowalski RP, Romanowski EG, Waikhom B, Gordon YJ. The survival of adenovirus in\nmultidose bottles of topical fluorescein. Am J Ophthalmol 1998; 126(6):835-836.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 773,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_774",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "multidose bottles of topical fluorescein. Am J Ophthalmol 1998; 126(6):835-836.\n886. Mueller AJ, Klauss V. Main sources of infection in 145 cases of epidemic\nkeratoconjunctivitis. Ger J Ophthalmol 1993; 2(4-5):224-227.\n887. Wood RM. Prevention of infection during tonometry. Arch Ophthalmol 1962; 68:202-\n218.\n888. Caven ER, Butler SL, McCulley JP, Luby JP. Applanation tonometer tip sterilization for\nadenovirus type 8. Ophthalmology 1987; 94(12):1538-1540.\n889. Laungani SG, Escalante E, Kauffman SL, Rudolph N, Glass L. Adenovirus infection in a\nneonatal intensive care unit. NY State J Med 1991; 91(4):162-163.\n890. Ford E, Nelson KE, Warren D. Epidemiology of epidemic keratoconjunctivitis.\nEpidemiol Rev 1978; 9:244-261.\n891. Warren D, Nelson KE, Farrar JA, et al. A large outbreak of epidemic",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 774,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_775",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "891. Warren D, Nelson KE, Farrar JA, et al. A large outbreak of epidemic\nkeratoconjunctivitis: problems in controlling nosocomial spread. J Infect Dis 1989; 160(6):938-\n943.\n892. Buffington J, Chapman LE, Stobierski MG, et al. Epidemic keratoconjunctivitis in a\nchronic care facility: risk factors and measures for control. J Am Geriatr Soc 1993; 41(11):1177-\n1181.\n893. Clarke SK, Hart JC, Barnard DL. The disinfection of instruments and hands during\noutbreaks of epidemic keratoconjunctivitis. Trans Ophthalmol Soc UK 1972; 92:613-618.\n894. Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in\nthe pandemic of 1957-58. II. Pulmonary complications of influenza. J Clin Invest 1959; 38:213-\n265.\n166",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 775,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_776",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "265.\n166\n895. Lindsay MI, Jr., Herrman EC, Jr., Morrow GW, Jr., Brown AL, Jr. Hong Kong\ninfluenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA 1970;\n214(10):1825-1832.\n896. Schwarzmann SW, Adler JL, Sullivan RJ, Jr., Marine W.N. Bacterial pneumonia during\nthe Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971; 127(6):1037-1041.\n897. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus\ninfections on persons with chronic underlying conditions. JAMA 2000; 283(4):499-505.\n898. Izurieta HS, Thompson WW, Kramarz, ., et al. Influenza and the rates of hospitalization\nfor respiratory disease among infants and young children. N Engl J Med 2000; 342(4):232-239.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 776,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_777",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "for respiratory disease among infants and young children. N Engl J Med 2000; 342(4):232-239.\n899. Neuzil KM, Mellen BG, Wright PF, Mitchell EF, Jr., Griffin MR. The effect of influenza\non hospitalizations, outpatient visits, and courses of antibiotics on children. N Engl J Med 2000;\n342(4):225-231.\n900. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N\nEngl J Med 1973; 288(10):498-505.\n901. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications\nfor prevention. Arch Intern Med 1982; 142(1):85-89.\n902. Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study.\nAm J Public Health 1982; 72(9):1008-1016.\n903. Eickhoff TC, Sherman IL, Serfling IE. Observations on excess mortality associated with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 777,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_778",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "903. Eickhoff TC, Sherman IL, Serfling IE. Observations on excess mortality associated with\nepidemic influenza. JAMA 1961; 176:104-110.\n904. Munoz FM, Campbell JR, Atmar RL, et al. Influenza A virus outbreak in a neonatal\nintensive care unit. Pediatr Infect Dis J 1999; 18(9):811-815.\n905. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, editor. Basic\nand Applied Influenza Research. Boca Raton, FL.: CRC Press, 1982: 11-50.\n906. Monto AS, Kioumehr F. The Tecumseh study of respiratory illness, IX. Occurrence of\ninfluenza in the community, 1966-1971. Am J Epidemiol 1975; 102(6):553-563.\n907. Pachucki CT, Pappas SA, Fuller GF, Krause SL, Lentino JR, Schaaff DM. Influenza A",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 778,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_779",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "907. Pachucki CT, Pappas SA, Fuller GF, Krause SL, Lentino JR, Schaaff DM. Influenza A\namong hospital personnel and patients. Implications for recognition, prevention, and control. Arch\nIntern Med 1989; 149(1):77-80.\n908. Evans ME, Hall KL, Berry SE. Influenza control in acute care hospitals. Am J Infect\nControl 1997; 25(4):357-362.\n167\n909. Blumenfeld HL, Kilbourne ED, Louria DB, et al. Studies on influenza in the pandemic of\n1957-1958, I. An epidemiologic, clinical, and serologic investigation of an intra-hospital epidemic,\nwith a note on vaccine efficacy. J Clin Invest 1959; 38:199-212.\n910. Bean B, Rhame FS, Hughes RS, Weiler MD, Peterson LR, Gerding DN. Influenza B:\nhospital activity during a community epidemic. Diag Microbiol Infect Dis 1983; 1(3):177-183.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 779,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_780",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "hospital activity during a community epidemic. Diag Microbiol Infect Dis 1983; 1(3):177-183.\n911. Hoffman PC, Dixon RE. Control of influenza in the hospital. Ann Intern Med 1977;\n87(6):725-728.\n912. Drinka PJ, Gravenstein S, Krause P, Schilling M, Miller BA, Shult P. Outbreaks of\nInfluenza A and B in a highly immunized nursing home population. J Family Practice 1997;\n45(6):509-514.\n913. CDC. Influenza A outbreaks--Louisiana, August 1993. MMWR 1993; 42(36):689-692.\n914. CDC. Update: influenza activity--New York and United States, 1994-95 Season.\nMMWR 1995; 44(07):132-134.\n915. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of\nnursing home influenza outbreaks. Vaccine 1998; 16(18):1771-1774.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 780,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_781",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "nursing home influenza outbreaks. Vaccine 1998; 16(18):1771-1774.\n916. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine\nprophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med\n1988; 148(4):865-868.\n917. Arroyo JC, Postic B, Brown A, Harrison K, Birgenheier R, Dowda H. Influenza\nA/Philippines/2/82 outbreak in a nursing home: limitations of influenza vaccination in the aged. Am\nJ Infect Control 1984; 12(6):329-334.\n918. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes.\nReduction in illness and complications during an Influenza A (H3N2) epidemic. JAMA 1985;\n253(8):1136-1139.\n919. Saah AJ, Neufeld R, Rodstein M, et al. Influenza vaccine and pneumonia mortality in a",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 781,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_782",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "919. Saah AJ, Neufeld R, Rodstein M, et al. Influenza vaccine and pneumonia mortality in a\nnursing home population. Arch Intern Med 1986; 146(12):2353-2357.\n920. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized\nadult bone marrow transplant recipients. Bone Marrow Transpl 1994; 13(4):437-440.\n921. Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH, Jr. Survival of\ninfluenza viruses on environmental surfaces. J Infect Dis 1982; 146(1):47-51.\n922. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol\ninhalation. Proc Soc Exp Biol Med 1966; 122(3):800-804.\n168\n923. Henle W, Henle G, Stokes J, Maris EP. Experimental exposure of human subjects to\nviruses of influenza. J Immunol 1946; 52:145-165.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 782,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_783",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "viruses of influenza. J Immunol 1946; 52:145-165.\n924. Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of\ninfluenza aboard a commercial airliner. Am J Epidemiol 1979; 110(1):1-6.\n925. Kilbourne ED. Influenza. New York: Plenum Publishing, 1987.\n926. Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive\nmutants of influenza virus. III. Further characterization of the ts-1[E] Influenza A recombinant\n(H3N2) virus in man. J Infect Dis 1973; 128(4):479-487.\n927. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding\nof myxoviruses and paramyxoviruses in children. J Infect Dis 1981; 144(5):433-441.\n928. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 783,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_784",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "928. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with\nleukemia. Clin Infect Dis 1997; 24(6):1095-1099.\n929. Evans KD, Kline MW. Prolonged Influenza A infection responsive to rimantadine therapy\nin a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995; 14(4):332-334.\n930. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding\nof amantadine-resistant Influenza A viruses by immunodeficient patients: Detection by polymerase\nchain reaction-restriction analysis. J Infect Dis 1995; 172(5):1352-1355.\n931. Welliver R, Monto AS, Carewicz O, Oseltamivir Post Exposure Prophylaxis Investigator\nGroup. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 784,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_785",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized\ncontrolled trial. JAMA 2001; 285(6):748-754.\n932. Carrat F, Tachet A, Rouzioux C, Housset B, Valleron AJ. Evaluation of clinical case\ndefinitions of influenza: detailed investigation of patients during the 1995-96 epidemic in France.\nClin Infect Dis 1999; 28(2):283-290.\n933. Monto AS, Gravenstein S, Elliot M, Colopy M, Schweinle J. Clinical signs and symptoms\npredicting influenza infection. Arch Intern Med 2000; 160(21):3243-3247.\n934. Dagan R, Hall CB. Influenza A virus infection imitating bacterial sepsis in early infancy.\nPediatr Infect Dis 1984; 3(3):218-221.\n935. Glezen WP, Decker M, Joseph SW, Mercready RG, Jr. Acute respiratory disease",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 785,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_786",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "935. Glezen WP, Decker M, Joseph SW, Mercready RG, Jr. Acute respiratory disease\nassociated with influenza epidemics in Houston, 1981-1983. J Infect Dis 1987; 155(6):1119-1126.\n936. Anonymous. Rapid diagnostic tests for influenza. Medical Letter on Drugs &\nTherapeutics 1999; 41(1068):121-122.\n169\n937. Covalciuc KA, Webb KH, Carlson CA. Comparison of four clinical specimen types for\ndetection of Influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture\nmethods. J Clin Microbiol 1999; 37(12):3971-3974.\n938. Leonardi GP, Leib H, Birkhead GS, Smith C, Costello P, Conron W. Comparison of\nrapid detection methods for Influenza A  virus and their value in health-care management of\ninstitutionalized geriatric patients. J Clin Microbiol 1994; 32(1):70-74.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 786,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_787",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "institutionalized geriatric patients. J Clin Microbiol 1994; 32(1):70-74.\n939. Noyola DE, Clark B, O'Donnell FT, Atmar RL, Greer J, Demmler.G.J. Comparison of a\nnew neuraminidase detection assay with an enzyme immunoassay, immmunofluorescence, and\nculture for rapid detection of Influenza A and B viruses in nasal wash specimens. J Clin Microbiol\n2000; 38(3):1161-1165.\n940. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically\nuseful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003; 22(2):164-177.\n941. CDC. Prevention and control of influenza: Recommendations of the Advisory Committee\non Immunization Practices (ACIP). MMWR 2003; 52(No. RR-8).\n942. Weingarten S, Friedlander M, Rascon D, Ault M, Morgan M, Meyer RD. Influenza",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 787,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_788",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "942. Weingarten S, Friedlander M, Rascon D, Ault M, Morgan M, Meyer RD. Influenza\nsurveillance in an acute-care hospital. Arch Intern Med 1988; 148(1):113-116.\n943. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost\neffectiveness of vaccination against influenza among elderly persons living in the community. N\nEngl J Med 1994; 331(12):778-784.\n944. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness\nof influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281(10):908-\n913.\n945. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care\nworkers on mortality of elderly people in long-term care: a randomized controlled trial. Lancet\n2000; 355:93-97.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 788,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_789",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "2000; 355:93-97.\n946. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in\nlong-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175(1):1-6.\n947. Advisory Committee on Immunization Practices. Using live, attenuated influenza vaccine\nfor prevention and control of influenza. MMWR 2003; 52(RR13):1-8.\n948. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in\nnursing homes. A case control study. Am J Epidemiol 1986; 124(1):114-119.\n949. Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E. Herd immunity: basic concept\nand relevance to public health immunization practices. Am J Epidemiol 1971; 94(3):179-189.\n170\n950. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 789,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_790",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "170\n950. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza\nvaccination in heart transplant recipients. J Heart Lung Trransplantation 1999; 18(3):220-225.\n951. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of\ninfluenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med\n1995; 123(7):518-527.\n952. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on\nacute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148(11):1094-\n1102.\n953. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient\nvisits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med\n1999; 130(5):397-403.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 790,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_791",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1999; 130(5):397-403.\n954. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in\nHIV-infected persons.  A randomized, double-blind, placebo-controlled trial. Ann Intern Med\n1999; 131(6):430-433.\n955. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of\ninfluenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000;\n284(13):1655-1663.\n956. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza\nin healthy, working adults. N Engl J Med 1995; 333(14):889-893.\n957. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among\nnursing home residents during an Influenza type A (H3N2) epidemic. J Am Geriat Soc 1999;\n47(2):165-171.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 791,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_792",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "47(2):165-171.\n958. Saxen H, Virtanen M. Randomized placebo-controlled double blind study on the efficacy\nof influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999;\n18(9):779-783.\n959. CDC. Missed opportunities for pneumococcal and influenza vaccination of Medicare\npneumonia inpatients--12 western states, 1995. MMWR 1997; 46(39):919-923.\n960. Anonymous. Recommendations regarding interventions to improve vaccination coverage\nin children, adolescents, and adults. Task Force on Community Preventive Services. Am J Prev\nMed 2000; 18(1 Suppl):92-96.\n961. Centers for Medicare and Medicaid Services H. Medicare and Medicaid programs;\nconditions of participation: immunization standards for hospitals, long-term care facilities, and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 792,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_793",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "conditions of participation: immunization standards for hospitals, long-term care facilities, and\nhome health agencies. Final rule with comment period. Federal Register 2002; 67:61808-61814.\n171\n962. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use\nin Influenza A virus infections. Infect Dis Clin N Am 1987; 1(2):459-478.\n963. Hall CB, Dolin R, Gala CL, et al. Children with Influenza A infection: treatment with\nrimantadine. Pediatrics 1987; 80(2):275-282.\n964. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A\ncontrolled trial of amantadine and rimantadine prophylaxis of influenza A infection. N Engl J Med\n1982; 307(10):580-584.\n965. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 793,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_794",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "965. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza\nin healthy adults. Vaccine 2000; 18(11):957-1030.\n966. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase\ninhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N\nEngl J Med 1997; 337(13):874-880.\n967. The MIST (Management of influenza in the Southern Hemisphere Trialists) Study Group.\nRandomized trial of efficacy and safety of inhaled zanamivir in teatment of influenza A and B virus\ninfections. Lancet 1998; 352:1877-1881.\n968. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase\ninhibitor zanamivir in the treatment of Influenza A and B virus infections. J Infect Dis 1999;\n180(2):254-261.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 794,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_795",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "180(2):254-261.\n969. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase\ninhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA 2000;\n283(8):1016-1024.\n970. Douglas RG, Jr. Prophylaxis and treatment of influenza. N Engl J Med 1990; 322(7):443-\n450.\n971. Nicholson KG. Use of antivirals in influenza in the elderly: prophylaxis and therapy.\nGerontology 1996; 42(5):280-289.\n972. Guay DR. Amantadine and rimantadine prophylaxis of Influenza A in nursing homes: a\ntolerability perspective. Drugs Aging 1994; 5(1):8-19.\n973. Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK. Safety of\nprolonged administration of rimantadine hydrochloride in the prophylaxis of Influenza A virus",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 795,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_796",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "prolonged administration of rimantadine hydrochloride in the prophylaxis of Influenza A virus\ninfections in nursing homes. Antimicrob Agents Chemother 1984; 26(1):101-103.\n974. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Jr., Elliott MJ, Crisp A. Zanamivir\nin the prevention of influenza among healthy adults: a randomized  controlled trial. JAMA 1999;\n282(1):31-35.\n172\n975. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase\ninhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341(18):1336-1343.\n976. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a\nnursing home Influenza B outbreak. Canada Comm Dis Report 2001; 27(5):37-40.\n977. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 796,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_797",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "977. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-\nresistant Influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21(11):700-704.\n978. McGeer AJ, Lee W, McArthur M, et al. Use of zanamivir to control an outbreak of\ninfluenza A in a nursing home. Clin Infect Dis 2000; 31(1):318.\n979. Peters PH, Jr., Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the\nprophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49(8):1025-\n1031.\n980. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui KJ, Gohd R. Amantadine\nprophylaxis during an institutional outbreak of type A(H1N1) influenza. Arch Intern Med 1986;\n146(9):1751-1756.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 797,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_798",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "146(9):1751-1756.\n981. O'Donoghue JM, Ray CG, Terry DW, Jr., Beaty HN. Prevention of nosocomial influenza\ninfection with amantadine. Am J Epidemiol 1973; 97(4):276-282.\n982. Keyser LA, Karl M, Nafziger AN, Bertino JS, Jr. Comparison of central nervous system\nadverse events of amantadine and rimantadine used as sequential prophylaxis of Influenza A in\nelderly nursing home patients. Arch Intern Med 2000; 160(10):1485-1488.\n983. Glaxo Wellcome Inc. Relenza (zanamivir for inhalation) [package insert].  2000.\nResearch Triangle, North Carolina, Glaxo Wellcome Inc.\n984. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-\nresistant Influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother\n1991; 35(9):1741-1747.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 798,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_799",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1991; 35(9):1741-1747.\n985. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of\namantadine-resistant viruses during nursing home outbreaks of Influenza A(H3N2). Am J\nEpidemiol 1991; 134(9):988-997.\n986. Hayden FG, Belshe RB, Clover RD, Hey AJ, Oakes MG, Soo W. Emergence and\napparent transmission of rimantadine-resistant Influenza A virus in families. N Engl J Med 1989;\n173\n 321(25):1696-1702.\n987. Hayden FG, Couch RB. Clinical and epidemiological importance of Influenza A viruses\nresistant to amantadine and rimantadine. Rev Med Virol 1992; 2:89-96.\n988. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of\nInfluenza A. Clin Infect Dis 1992; 15(2):362-367.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 799,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_800",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Influenza A. Clin Infect Dis 1992; 15(2):362-367.\n989. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled\nneuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind,\nplacebo-controlled European study. J Infect 2000; 40(1):42-48.\n990. Roche Laboratories I. Tamiflu TM (oseltamivir phosphate) capsules [package insert]. \n2000. Nutley,N.J., Roche Laboratories Inc. \n991. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and\ncharacterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.\nAntimicrob Agents Chemother 2000; 44(1):78-87.\n992. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 800,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_801",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "992. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for\nzanamivir resistance in an immunocompromised child infected with Influenza B virus. J Infect Dis\n1998; 178(5):1257-1262.\n993. Valenti WM, Betts RF, Hall CB, Hruska JF, Douglas RG, Jr. Nosocomial viral\ninfections: II. Guidelines for prevention and control of respiratory viruses, herpesviruses and\nhepatitis viruses. Infect Control 1980; 1(3):165-178.\n994. CDC. Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR 2003;\n52(11):226-228.\n995. CDC. Preliminary clinical description of severe acute respiratory syndrome. MMWR\n2003; 52(12):255-256.\n996. CDC. Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003.\nMMWR 2003; 52(12):241-246.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 801,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_802",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "MMWR 2003; 52(12):241-246.\n997. Brooks K, Whitten S, Quigley D. Reducing the incidence of ventilator-related\npneumonia. J Health Qual 1998; 20(1):14-19.\n998. Halm EA, Atlas SJ, Borowsky LH, et al. Understanding physician adherence with a\npneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med\n2000; 160(1):98-104.\n999. Katz DA. Barriers between guidelines and improved patient care: an analysis of AHCPR's\n174\n Unstable Angina Clinical Practice Guideline. Agency for Health Care Policy and Research. Health\nServ Res 1999; 34:(1):377-389.\n1000. Kaye J, Ashline V, Erickson D, et al. Critical care bug team: a multidisciplinary team\napproach to reducing ventilator-associated pneumonia. Am J Infect Control 2000; 28(2):197-201.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 802,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_803",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "approach to reducing ventilator-associated pneumonia. Am J Infect Control 2000; 28(2):197-201.\n1001. Kelleghan SI, Salemi C, Padilla S, et al. An effective continuous quality improvement\napproach to the prevention of ventilator-associated pneumonia. Am J Infect Control 1993;\n21(6):322-330.\n1002. Joiner GA, Salisbury D, Bollin GE. Utilizing quality assurance as a tool for reducing the\nrisk of nosocomial ventilator-associated pneumonia. Am J Med Qual 1996; 11(2):100-103.\n1003. Nicotra D, Ulrich C. Process improvement plan for the reduction of nosocomial\npneumonia in patients on ventilators. J Nurs Care Qual 1996; 10:18-23.\n1004. Zack JE, Garrison T, Trovillion E, et al. Effect of an education program aimed at",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 803,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_804",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1004. Zack JE, Garrison T, Trovillion E, et al. Effect of an education program aimed at\nreducing the occurrence of ventilator-associated pneumonia. Crit Care Med 2002; 30(11):2407-\n2412.\n1005. Haley RW, Culver DH, White J.W., et al. The efficacy of infection surveillance and\ncontrol programs in preventing nosocomial infections in U.S. hospitals. Am J Epidemiol 1985;\n121(2):182-205.\n1006. Haley RW, Morgan WM, Culver DH, et al. Update from the SENIC project. Hospital\ninfection control: recent progress and opportunities under prospective payment. Am J Infect\nControl 1985; 13(3):97-108.\n1007. CDC. NNIS criteria for determining nosocomial pnemonia.  2003. Atlanta, GA, U.S.\nDepartment of Health and Human Services, CDC. Available at",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 804,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_805",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Department of Health and Human Services, CDC. Available at\nhttp://www.cdc.gov.ncid/hip/nnis/members/pneumonia/pneumonia_final.htm.\n1008. Gaynes RP, Solomon S. Improving hospital-acquired infection rates: the CDC\nexperience. Jt Comm J Qual Improv 1996; 22(7):457-467.\n1009. Josephson A, Karanfil L, Alonso H, Watson A, Blight J. Risk-specific nosocomial\ninfection rates. Am J Med 1991; 91(3B):131S-137S.\n1010. Gaynes R, Richards C, Edwards J, et al. Feeding back surveillance data to prevent\nhospital-acquired infections. Emerging Infect Dis 2001; 7(2):295-298.\n1011. American Hospital Association Committee on Infection within Hospitals. Statement on\nmicrobiologic sampling in the hospital. Hospitals 1974; 48:125-126.\n1012. Eickhoff TC. Microbiologic sampling. Hospitals 1970; 44:86-87.\n175",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 805,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_806",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1012. Eickhoff TC. Microbiologic sampling. Hospitals 1970; 44:86-87.\n175\n1013. Finelli L, Livengood JR, Saiman L. Surveillance of pharyngeal colonization: detection\nand control of serious bacterial illness in low birth weight infants. Pediatr Infect Dis J 1994;\n13(10):854-859.\n1014. Glupczynski Y. Usefuness of bacteriologic surveillance cultures for monitoring infection\nin hospitalized patients. Acta Clin Belg 2001; 56:38-45.\n1015. Food and Drug Administration. Enforcement priorities for single-use devices reprocessed\nby third parties and hospitals. Rockville, MD. US Department of Health and Human Services,\nFDA, 2000.\n1016. Thomachot L, Viviand X, Arnaud S, Boisson C, Martin CD. Comparing two heat and",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 806,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_807",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "FDA, 2000.\n1016. Thomachot L, Viviand X, Arnaud S, Boisson C, Martin CD. Comparing two heat and\nmoisture exchangers, one hydrophobic and one hygroscopic, on humidifying efficacy and the rate\nof nosocomial pneumonia. Chest 1998; 114(5):1383-1389.\n1017. Boisson C, Viviand X, Arnaud S, Thomachot L, Miliani Y, Martin C. Changing a\nhydrophobic heat and moisture exchanger after 48 hours rather than 24 hours: a clinical and\nmicrobiologic evaluation. Intensive Care Med 1999; 25(11):1237-1243.\n1018. Daumal F, Colpart E, Manoury B, Mariani M, Daumal M. Changing heat and moisture\nexchangers every 48 hours does not increase the incidence of nosocomial pneumonia. Infect\nControl Hosp Epidemiol 1999; 20(5):347-349.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 807,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_808",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Control Hosp Epidemiol 1999; 20(5):347-349.\n1019. Thomachot L, Vialet R, Viguier JM, Sidier B, Roulier P, Martin C. Efficacy of heat and\nmoisture exchangers after changing every 48 hours rather than 24 hours. Crit Care Med 1998;\n26(3):477-481.\n1020. Salemi C, Padilla S, Canola T, Reynolds D. Heat-and-moisture exchangers used with\nbiweekly circuit tubing changes: effect on costs and pneumonia rates. Infect Control Hosp\nEpidemiol 2000; 21(11):737-739.\n1021. Golar SD, Sutherland LLA, Ford GT. Multipatient use of prefilled disposable oxygen\nhumidifiers for up to 30 days: patient safety and cost analysis. Respir Care 1993; 38(4):343-347.\n1022. Henderson E, Ledgerwood D, Hope KM, et al. Prolonged and multipatient use of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 808,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_809",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1022. Henderson E, Ledgerwood D, Hope KM, et al. Prolonged and multipatient use of\nprefilled disposable oxygen humidifier bottles: safety and cost. Infect Control Hosp Epidemiol\n1993; 14(8):463-468.\n1023. Seto WH, Ching TY, Yuen KY, Lam WK. Evaluating the sterility of disposable wall\noxygen humidifiers, during and between use on patients. Infect Control 1990; 11(11):604-605.\n1024. Reboli AC, Koshinski R, Arias K, Marks-Austin K, Stieritz D, Stull TL. An outbreak of\nBurkholderia cepacia lower respiratory tract infection associated with contaminated abuterol\nnebulization solution. Infect Control Hosp Epidemiol 1996; 17(11):741-743.\n176\n1025. Longfield R, Longfield J, Smith LP, Hyams KC, Strohmer ME. Multidose medication",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 809,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_810",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "176\n1025. Longfield R, Longfield J, Smith LP, Hyams KC, Strohmer ME. Multidose medication\nvial sterility: an in-use study and a review of literature. Infect Control 1984; 5(4):165-169.\n1026. Moffet HL, Allan D. Survival and dissemination of bacteria in nebulizers and incubators.\nAm J Dis Child 1967; 114:13-20.\n1027. Jakobsson B, Hjelte L, Nystrom B. Low level of bacterial contamination of mist tents\nused in home treatment of cystic fibrosis patients. J Hosp Infect 2000; 44(1):37-41.\n1028. Morar P, Makura Z, Jones A, et al. Topical antibiotics on tracheostoma prevents\nexogenous colonization and infection of lower airways in children. Chest 2000; 117(2):513-518.\n1029. Nichol KL, Grimm MB, Peterson DC. Immunizations in long-term care facilities: policies",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 810,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_811",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "1029. Nichol KL, Grimm MB, Peterson DC. Immunizations in long-term care facilities: policies\nand practice. J Am Geriat Soc 1996; 44(4):349-355.\n1030. Hand RW, Kempster M, Levy JH, Rogol PR, Spirn P. Inadvertent transbronchial\ninsertion of narrow-bore feeding tubes into the pleural space. JAMA 1984; 251(18):2396-2397.\n1031. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients.\nResolving discordant meta-analyses. JAMA 1996; 275(4):308-314.\n1032. Simms HH, DeMaria E, McDonald L, Peterson D, Robinson A, Burchard KW. Role of\ngastric colonization in the development of pneumonia in critically ill trauma patients: results of a\nprospective randomized trial. J Trauma 1991; 31(4):531-536.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 811,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_812",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "prospective randomized trial. J Trauma 1991; 31(4):531-536.\n1033. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia\nin mechanically ventilated pediatric intensive care patients during stress ulcer propohylaxis with\nsucralfate, ranitidine, and omeprazole. J Crit Care 2002; 17(4):240-245.\n1034. Redd SC, Cohen ML. Legionella in water: what should be done? JAMA 1987;\n257(9):1221-1222.\n1035. Pannuti CS. Hospital environment for high-risk patients. In: Wenzel RP, editor.\nPrevention of nosocomial infections. Baltimore: Williams & Wilkins, 1997: 463-489.\n1036. Woo AH, Yu VL, Goetz A. Potential in-hospital modes of transmission of Legionella\npneumophila. Demonstration experiments for dissemination by showers, humidifiers, and rinsing of",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 812,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_813",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "pneumophila. Demonstration experiments for dissemination by showers, humidifiers, and rinsing of\nventilation bag apparatus. Am J Med 1986; 80(4):567-573.\n1037. Wright SW, Decker MD, Edwards KM. Incidence of pertussis infection in healthcare\nworkers. Infect Control Hosp Epidemiol 1999; 20(2):120-123.\n1038. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules\ninitiated from birth to 12 weeks of age. Bull WHO 1985; 63(6):1151-1169.\n177\n1039. Valenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible spread by a\nhospital visitor. Am J Dis Child 1980; 134(5):520-521.\n1040. Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone\nmarrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant 1995; 15(3):469-\n473.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 813,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_814",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "marrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant 1995; 15(3):469-\n473.\n1041. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections.\nNCI Monogr 1990; 9:43-45.\n1042. Richardson MD, Rennie S, Marshall I, et al. Fungal surveillance of an open haematology\nward. J Hosp Infect 2000; 45(4):288-292.\n1043. Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet\ncontamination. Infect Control Hosp Epidemiol 1994; 15:221-223.\n1044. Kim CS, Kristopaitis RJ, Stone E, Pelter M, Sandhu M, Weingarten SR. Physician\neducation and report cards: do they make the grade? Results from a randomized controlled trial.\nAm J Med 1999; 107(6):566-560.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 814,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_815",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Am J Med 1999; 107(6):566-560.\n1045. Nichol KL. Preventing influenza: the physician's role. Seminars Respir Infect 1992;\n7(1):71-77.\n1046. Pachucki CT, Lentino JR, Jackson GG. Attitudes and behavior of health care personnel\nregarding the use and efficacy of influenza vaccine. J Infect Dis 1985; 151(6):1170-1171.\n1047. Arden N, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated\nvaccines in nursing homes. In: Kendal AP, Patriarca PA, editors. Options for the Control Of\nInfluenza. New York, N.Y.: Alan Liss, 1985: 155-168.\n1048. Fedson DS. Immmunizations for health care workers and patients in hospitals. In: Wenzel\nRP, editor. Prevention and Control of Nosocomial Infection. Baltimore, MD.: Williams and\nWilkins, 1987: 116-174.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 815,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_816",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "Wilkins, 1987: 116-174.\n1049. McArthur MA, Simor AE, Campbell B, McGreer A. Influenza vaccination in long-term\ncare facilities: structuring programs for success. Infect Control Hosp Epidemiol 1999; 20(7):499-\n503.\n1050. Libow LS, Neufeld RR, Olson E, Breuer B, Starer P. Sequential outbreak of Influenza A\nand B in a nursing home: efficacy of vaccine and amantadine. J Am Geriat Soc 1996; 44(10):1153-\n1157.\n1051. Berlinberg CD, Weingarten SR, Bolton LB, Waterman SH. Occupational exposure to\ninfluenza--introduction of an index case to a hospital. Infect Control Hosp Epidemiol 1989;\n10(2):70-73.\n178\n1052. Hayden FG, Treanor JJ, Fritz RS, et al. Use of oral neuraminidase inhibitor oseltamivir in\nexperimental human influenza: randomized controlled trials for prevention and treatment. JAMA",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 816,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_817",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "experimental human influenza: randomized controlled trials for prevention and treatment. JAMA\n1999; 282(13):1240-1246.\n1053. Askonas BA, McMichael AJ, Webster RG. The immune response to influenza viruses and\nthe problem of protection against infection. In: Beare AS, editor. Basic and Applied Influenza\nResearch. Boca Raton, FL: CRC Press, 1982: 159-182.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "CATEGORY IB \nHEALTH-CARE-ASSOCIATED SARS",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 817,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_818",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "[Section: 179\nAPPENDIX]\nEXAMPLES OF SEMICRITICAL ITEMS* USED ON THE RESPIRATORY TRACT\nAnesthesia device or equipment including:\nface mask or tracheal tube\ninspiratory and expiratory tubing\nY-piece\nreservoir bag\nhumidifier\nBreathing circuits of mechanical ventilators\nBronchoscopes and their accessories,\n    except for biopsy forceps ** and specimen brush **\n \n \nEndotracheal and endobronchial tubes\nLaryngoscope blades\nMouthpieces and tubing of pulmonary-function testing equipment\nNebulizers and their reservoirs\nOral and nasal airways\nProbes of CO2 analyzers, air-pressure monitors\nResuscitation bags\nStylets \nSuction catheters\nTemperature sensors\n   *\nItems that directly or indirectly contact mucous membranes of the respiratory tract.  They should be",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "179\nAPPENDIX",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 818,
      "total_chunks": 820
    }
  },
  {
    "chunk_id": "Guideline-Healthcare-Associated-Pneumonia-H_chunk_819",
    "document_id": "Guideline-Healthcare-Associated-Pneumonia-H",
    "text": "sterilized or subjected to high-level disinfection before reuse.\n **\nConsidered critical items; they should be sterilized before reuse.",
    "metadata": {
      "disease_type": "pneumonia",
      "year": 2003,
      "guideline_name": "Healthcare-Associated Pneumonia Guideline 2003",
      "section_header": "179\nAPPENDIX",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 819,
      "total_chunks": 820
    }
  }
]